uric acid has been researched along with Cardiovascular Diseases in 958 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Obesity, lipids, glucose tolerance and insulin resistance are risk factors for numerous cardiovascular diseases and are often accompanied by a considerable increase in serum uric acid (SUA) concentrations." | 9.94 | Insights into the relationship between serum uric acid and pulmonary hypertension (Review). ( Chen, M; He, Y; Lei, W; Luo, H; Shui, X; Zheng, J; Zhou, Y, 2024) |
| " One hundred and ninety-seven adults with gout and SUA levels ≥8 mg/dL were randomized to febuxostat or allopurinol in a 1:1 ratio for 36 weeks." | 9.51 | Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. ( Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK, 2022) |
| "A direct relationship between serum uric acid levels and hypertension, cardiovascular, renal and metabolic diseases has been reported in many basic and epidemiological studies." | 9.41 | Update in uric acid, hypertension, and cardiovascular diseases. ( Ae, R; Andres-Hernando, A; Borghi, C; Hisatome, I; Kanbay, M; Kodama, T; Kuwabara, M; Lanaspa, MA, 2023) |
| "Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout." | 9.34 | Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. ( De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020) |
| "We previously reported that febuxostat was more effective for hyperuricemia than allopurinol." | 9.24 | Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial). ( Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A, 2017) |
| "Since uric acid is associated with cardiovascular and renal disease, a treatment to maintain blood uric acid level may be required in patients with hyperuricemia." | 9.24 | Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. ( Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N, 2017) |
| "Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy." | 9.24 | Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017) |
| "Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases." | 9.22 | Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022) |
| "Uric acid is the final product of purine metabolism, and its increased serum levels have been directly involved in the pathogenesis and natural history of hypertension." | 9.22 | Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk. ( Agnoletti, D; Borghi, C; Cicero, AFG; Lurbe, E; Virdis, A, 2022) |
| "The study included two age-, weight-, lipid-, and prolactin level-matched groups of premenopausal women with hypecholesterolemia and a history of hyperprolactinemia: patients treated with bromocriptine (5." | 9.20 | The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2015) |
| "To date uric acid (UA) is not considered a cardiovascular risk factor, although evidence about a relationship between UA and cardiovascular diseases has been reported." | 9.17 | Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction. ( Franzosi, MG; Levantesi, G; Maggioni, AP; Marchioli, R; Marfisi, RM; Nicolosi, GL; Schweiger, C; Silletta, MG; Tavazzi, L; Tognoni, G, 2013) |
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 9.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| "To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia." | 9.12 | The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021) |
| "Studies on the association of uric acid with mortality and cardiovascular outcomes in patients with hypertension have produced contradictory results." | 9.12 | Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis. ( Jin, Z; Yang, Y; Zhang, X; Zhao, Q, 2021) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "We examined the relation of serum creatinine and uric acid to mortality and cardiovascular disease in older (aged >/=60 years) Chinese patients with isolated systolic hypertension (systolic/diastolic blood pressure >/=160/<95 mm Hg)." | 9.09 | Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. ( Birkenhäger, WH; Fagard, RH; Gong, L; Liu, L; Staessen, JA; Wang, JG, 2001) |
| "Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure." | 8.93 | Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016) |
| "Elevated serum uric acid concentration is a common laboratory finding in subjects with metabolic syndrome/obesity, hypertension, kidney disease and cardiovascular events." | 8.89 | Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? ( Kapusta, DR; Rasheed, K; Reisin, E; Soltani, Z, 2013) |
| " Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality." | 8.89 | Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013) |
| "Elevated uric acid levels are a common finding in patients with metabolic syndrome and in those with cardiovascular and renal disease, but the meaning of this elevation is still unclear." | 8.88 | Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? ( Di Giorgio, C; Gesualdo, L; Morrone, LF; Stellato, D, 2012) |
| "This article critically evaluates the clinical evidence regarding the influence of uric acid on hypertension, cardiovascular disease, and kidney disease." | 8.82 | Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: a statistical modeling perspective. ( Short, RA; Tuttle, KR, 2005) |
| "The association between serum uric acid (SUA) and mortality from cardiovascular diseases (CVDs) in nonalcoholic fatty liver disease (NAFLD) participants remains uncertain." | 8.31 | Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease. ( He, P; Li, H; Liu, C; Liu, M; Qin, X; Wu, Q; Yang, S; Ye, Z; Zhang, Y; Zhang, Z; Zhou, C, 2023) |
| "Associations between body mass index (BMI)- standard deviation score (SDS)/waist-to-height ratio (WHtR) were studied with (i) serum uric acid (sUA)/gamma-glutamyl-transferase (GGT) and (ii) cardiometabolic risk markers in children with obesity, considering sex, pubertal development, and degree of weight loss/type of patient care." | 8.31 | Uric acid and gamma-glutamyl-transferase in children and adolescents with obesity: Association to anthropometric measures and cardiometabolic risk markers depending on pubertal stage, sex, degree of weight loss and type of patient care: Evaluation of the ( Bergjohann, L; Dannemann, A; Holl, RW; Leipold, G; Prinz, N; Reinehr, T; Weghuber, D; Weihe, P; Weihrauch-Blüher, S; Wiegand, S, 2023) |
| "Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored." | 8.31 | Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023) |
| "We compared two matched groups of euthyroid women with hypercholesterolemia receiving atorvastatin treatment: subjects with autoimmune (Hashimoto's) thyroiditis (group A, n = 29) and subjects without thyroid pathology (group B, n = 29)." | 8.31 | Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis. ( Kowalcze, K; Krysiak, R; Okopień, B, 2023) |
| " The aim of this study was to investigate whether autoimmune thyroiditis determines cardiometabolic effects of cabergoline." | 8.31 | Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2023) |
| "This cohort study intended to elucidate the association between serum uric acid (SUA) levels and cardiovascular disease events in Japanese patients with obesity." | 8.31 | Novel pathological implications of serum uric acid with cardiovascular disease risk in obesity. ( Kasahara, M; Kasama, S; Kato, H; Kato, S; Kusakabe, T; Ozu, N; Satoh-Asahara, N; Tanaka, M; Wakabayashi, D; Yamakage, H, 2023) |
| "Background Serum uric acid (UA) is correlated closely with traditional cardiovascular risk factors, which might interfere with the action of UA, in patients with coronary artery disease." | 8.31 | Uric Acid Levels, Number of Standard Modifiable Cardiovascular Risk Factors, and Prognosis in Patients With Coronary Artery Disease: A Large Cohort Study in Asia. ( Cui, K; Dong, Q; Dou, K; Feng, L; Fu, R; Jia, L; Lu, Y; Song, C; Song, W; Song, Y; Wang, H; Yang, Y; Yin, D; Zhang, D; Zhu, C, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) and serum uric acid (SUA) levels are risk factors for developing cardiovascular disease (CVD)." | 8.12 | The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients. ( Hwang, J; Kang, K; Kim, K; Lee, JM; Sheol, H; Shin, J; Sim, Y; Yang, T, 2022) |
| "Little research has been conducted into the effects of the combined manifestation of hyperuricemia and hyperhomocysteinemia on cardiometabolic risk factors and markers in young subjects." | 8.12 | The Presence of Hyperhomocysteinemia Does Not Aggravate the Cardiometabolic Risk Imposed by Hyperuricemia in Young Individuals: A Retrospective Analysis of a Cross-Sectional Study. ( Gurecká, R; Koborová, I; Podracká, Ľ; Repiská, G; Šebeková, K, 2022) |
| " Anthropometric measurements, fasting glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), HOMA- β (%), lipids profile, monocyte to lymphocyte ratio (MLR), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), uric acid, gamma glutamyl transpeptidase (GGT), AST/ALT ratio and total bilirubin were assessed." | 8.12 | Association Between Total Bilirubin Levels and Cardio-Metabolic Risk Factors Related to Obesity. ( Asar, M; El-Eshmawy, MM; Elsehely, I; Mahsoub, N, 2022) |
| "Asymptomatic hyperuricemia patients exposed to a higher level of uric acid (>=428 mmol/L) could significantly increase the incidence risk of CHD and stroke, with or without hyperuricemia-related comorbidities." | 8.02 | High-level uric acid in asymptomatic hyperuricemia could be an isolated risk factor of cardio-cerebrovascular diseases: A prospective cohort study. ( Bai, Y; Cheng, Z; Hu, X; Li, J; Li, N; Ren, X; Shi, D; Wang, M; Yang, J; Yin, C; Zhang, D; Zheng, S; Zheng, T, 2021) |
| "BACKGROUND Serum uric acid (UA) is involved in the development of hypertension." | 8.02 | U-Shaped Relationship Between Cardiovascular Mortality and Serum Uric Acid May Be Attributed to Stroke- and Heart-Specific Mortality, Respectively, Among Hypertensive Patients: A Nationally Representative Cohort Study. ( Chen, K; Han, P; You, H; Yue, C; Zhao, X, 2021) |
| "Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis." | 8.02 | The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. ( Barbagallo, CM; Bombelli, M; Borghi, C; Bruno, B; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Dell'Oro, R; Desideri, G; Ferri, C; Galletti, F; Georgiopoulos, G; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Lippa, L; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Pugliese, NR; Rattazzi, M; Rivasi, G; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2021) |
| "We aimed to investigate the association between serum uric acid (SUA) and all-cause or cardiovascular mortality among participants with obesity." | 7.96 | Relationship between serum uric acid level and all-cause and cardiovascular mortality in population with obesity. ( Chen, CL; Feng, YQ; Huang, JY; Huang, YQ; Li, J; Liu, L; Lo, K; Sun, S; Zhang, B, 2020) |
| "For 40 years many studies have been conducted to verify the connection between serum uric acid concentration and cardiovascular diseases, such as myocardial infarction." | 7.96 | The differential role of uric acid - The purpose or cause of cardiovascular diseases? ( Siemińska, E; Sikora, J; Skibińska, N; Sobczak, P, 2020) |
| "To observe the changes in blood pressure (BP) over 10 years and to investigate current BP association to serum uric acid (SUA) levels and cardiovascular risk factors in the epidemiological data of a target group of patients with prehypertension in 2007." | 7.96 | Association of serum uric acid, morning home blood pressure and cardiovascular risk factors in a population with previous prehypertension: a cross-sectional study. ( Bawazier, LA; Irijanto, F; Kholiq, A; Sja'bani, M; Tomino, Y; Widiatmoko, A; Zulaela, Z, 2020) |
| "Serum uric acid (UA) levels are one of the determinants of the cardiovascular disease and metabolic syndrome but none of criteria for that syndrome include serum UA." | 7.96 | Uric acid alterations by consumption of gluten-free bakery products in relation to cardiovascular and metabolic syndrome risk factors. ( Gažarová, M; Mečiarová, L, 2020) |
| "Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI." | 7.91 | Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. ( Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019) |
| "The aim of this study was to assess the association between serum uric acid concentration (SUAC) and the parameters of the metabolic syndrome (MetS) and insulin resistance (IR)." | 7.91 | Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children ( Ersoy, B; Özalp Kızılay, D; Şen, S, 2019) |
| "We studied 12 women with NC-CAH, 6 of whom because of coexisting hypercholesterolemia received atorvastatin (20-40 mg daily)." | 7.91 | The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. ( Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B, 2019) |
| "We indicated that uric acid, AIP, and proteinuria are closely related." | 7.88 | Relationship Between Uric Acid, Proteinuria, and Atherogenic Index of Plasma in Renal Transplant Patients. ( Biyik, Z; Guney, I, 2018) |
| "Studies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a clinical history of gout and has not been studied in large patient cohorts." | 7.85 | An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. ( Akerblom, A; Clare, RM; Held, C; Hess, CN; James, S; Keenan, RT; Klein, AB; Mahaffey, KW; Pagidipati, NJ; Roe, MT; Tricoci, P; Wallentin, L; Wojdyla, D, 2017) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 7.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| "Aims of this study were 1) to evaluate early cardiovascular abnormalities in a large population of obese children and adolescents compared with a normal weight counterpart, 2) to investigate their potential association with insulin resistance (IR), serum uric acid (sUA) and metabolic syndrome (MetS)." | 7.85 | Insulin resistance, serum uric acid and metabolic syndrome are linked to cardiovascular dysfunction in pediatric obesity. ( Aronici, M; Bellone, S; Bona, G; Castagno, M; Di Mario, C; Genoni, G; Grossini, E; Martelli, M; Menegon, V; Monzani, A; Prodam, F; Ricotti, R; Secco, GG; Sonzini, M, 2017) |
| "We aim to explore the associations between serum uric acid (SUA) and obesity and cardio-cerebrovascular events (CCEs) in Chinese inpatients with type 2 diabetes mellitus (T2DM)." | 7.85 | Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Yu, TP; Zhao, CC; Zhu, Y, 2017) |
| "Elevated serum uric acid levels and increased arginase activity are risk factors for cardiovascular diseases (CVD)." | 7.83 | Effects of serum uric acid levels on the arginase pathway in women with metabolic syndrome. ( Demirci, F; Demirustu, C; Ergun, B; Kebapci, N; Ozcelik, E; Temel, HE; Uslu, S, 2016) |
| "This study examined the relationship between serum levels of uric acid and insulin resistance and metabolic syndrome in nondiabetic patients with schizophrenia." | 7.83 | Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia. ( Cimpeanu, C; Fan, X; Harrington, A; Rajan, S; Song, X; Zalpuri, I, 2016) |
| "Although high uric acid levels have been reported to be a risk factor for cardiovascular disease and stroke, the relationship between serum uric acid (SUA) levels and cardioembolic stroke (CES) has not been fully elucidated." | 7.83 | Association of serum uric acid and cardioembolic stroke in patients with acute ischemic stroke. ( Jung, S; Kim, CK; Kim, TJ; Kim, Y; Lee, SH; Yang, XL, 2016) |
| "Serum uric acid (SUA) is associated with many cardiovascular risk factors such as hypertension (HTN) and metabolic syndrome (MetS)." | 7.81 | Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Dong, XH; Jia, WP; Li, LX; Li, MF; Li, TT; Shen, J; Zhang, R, 2015) |
| "Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population." | 7.81 | Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. ( Babio, N; Basora, J; Becerra-Tomás, N; Corella, D; Estruch, R; Fitó, M; Martínez-González, MA; Ortega-Calvo, M; Recondo, J; Ros, E; Salas-Salvadó, J; Serra-Majem, L; Wärnberg, J, 2015) |
| "We tested the hypothesis that uric acid levels are higher in subjects with schizophrenia treated with clozapine than in healthy control and they correlate with anthropometric measurements, laboratory tests and results of bioimpedance analysis of body composition." | 7.81 | Uric acid levels in patients with schizophrenia on clozapine monotherapy. ( Kłoszewska, I; Wysokiński, A, 2015) |
| "The purpose of this study was to evaluate associations among hypertension (HTN) and uric acid (UA) with cardiovascular autonomic neuropathy (CAN), and to estimate the extent to which synergistic effects of HTN and UA affect the outcome in a Chinese population." | 7.81 | The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy. ( Liao, XP; Tang, ZH; Zeng, F; Zhu, HW, 2015) |
| "To explore the association between serum uric acid (SUA) levels, metabolic syndrome (MetS) and cardiovascular disease (CVD) in patients treated with lipid-lowering agents from multiple centers in China." | 7.81 | The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. ( Chen, K; Fang, Y; Hu, D; Mu, Y; Nie, Y; Tian, Y; Wang, H; Xie, Z, 2015) |
| "To determine whether women who had a hypertensive pregnancy disorder (HPD) have elevated uric acid concentrations decades after pregnancy as compared with women who had normotensive pregnancies." | 7.81 | Uric Acid: A Missing Link Between Hypertensive Pregnancy Disorders and Future Cardiovascular Disease? ( Asad, RA; Garovic, VD; Hanis, CL; Kardia, SL; Milic, NM; Mosley, TH; Turner, ST; Weissgerber, TL, 2015) |
| "Serum uric acid (UA) is now beginning to be considered a risk predictor for cardiovascular diseases." | 7.80 | Serum uric acid as a risk predictor for erectile dysfunction. ( Heydari, R; Mehrsai, A; Pourmand, G; Salem, S, 2014) |
| "Elevated albuminuria as well as an increased serum uric acid concentration is associated with poor cardiovascular outcome." | 7.80 | The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. ( Bakker, SJ; de Jong, PE; Gansevoort, RT; Joosten, MM; Scheven, L, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 7.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "The aims of this study were to investigate (i) associations between uric acid and prevalent cardiovascular disease (CVD), ankle-arm blood pressure index (AAIx) and carotid intima-media thickness (CIMT) in the total population and in predefined subgroups according to glucose metabolism status and (ii) the extent to which these associations are explained by low-grade inflammation." | 7.80 | The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: the CODAM study. ( Arts, IC; Boonen, A; Dagnelie, PC; Ferreira, I; Feskens, EJ; Schalkwijk, CG; Stehouwer, CD; van der Kallen, CJ; van der Linden, S; van Greevenbroek, MM; Wijnands, JM, 2014) |
| "Hyperuricemia is related to Metabolic Syndrome (MetS) and cardiovascular diseases, but the use of serum uric acid (UA) to diagnose MetS is currently ignored in clinical practices." | 7.80 | The impact of serum uric acid on the diagnostic of metabolic syndrome in apparently healthy brazilian middle-aged men. ( Azevedo Novello, A; Bressan, J; Cardoso dos Santos, E; de Oliveira, A; Guedes Cocate, P; Hermsdorff, HHM; José Natali, A, 2014) |
| "While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid." | 7.80 | Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014) |
| "The predictive value of serum uric acid (SUA) for adverse cardiovascular events among obese and overweight patients is not known, but potentially important because of the relation between hyperuricaemia and obesity." | 7.79 | Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. ( Andersson, C; Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Sharma, AM; Skak-Nielsen, H; Torp-Pedersen, C; Van Gaal, L, 2013) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 7.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "The objective of this study was to examine the association between uric acid, GGT, obesity and the individual components of metabolic syndrome in children and adolescents." | 7.79 | Associations of uric acid and gamma-glutamyltransferase (GGT) with obesity and components of metabolic syndrome in children and adolescents. ( Chan, CW; Chan, JC; Chan, MH; Choi, KC; Ho, CS; Kong, AP; Ozaki, R, 2013) |
| "Although various kinds of cardiovascular risk factors have been reported to be associated with atrial fibrillation (AF), the relationship between serum uric acid level and AF has not been fully examined." | 7.78 | Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012) |
| "Serum uric acid (SUA) is a suggested biomarker for established coronary artery disease, but the role of SUA in early phases of atherosclerosis is controversial." | 7.78 | Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. ( Hutri-Kähönen, N; Huupponen, R; Jula, A; Juonala, M; Kähönen, M; Lehtimäki, T; Loo, BM; Lyytikäinen, LP; Oikonen, M; Raitakari, OT; Saarikoski, L; Seppälä, I; Siitonen, N; Viikari, JS; Wendelin-Saarenhovi, M, 2012) |
| "Uric acid (UA) is considered to be a powerful predictor of cardiovascular risk and hyperuricemia might be involved in the metabolic syndrome (MS)." | 7.76 | Relation of uric acid levels to aortic root dilatation in hypertensive patients with and without metabolic syndrome. ( Chen, XF; Du, YX; Fang, CF; Jiang, JJ; Lin, XF; Pu, ZX; Tang, LJ; Wang, JA, 2010) |
| " Mortality from all causes, total cardiovascular disease (CVD), ischemic stroke, congestive heart failure, hypertensive disease, and coronary heart disease were compared according to increasing serum uric acid levels." | 7.75 | Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. ( Chen, HJ; Chen, JH; Chuang, SY; Pan, WH; Yeh, WT, 2009) |
| "The association of elevated serum uric acid (UA) with cardiovascular events in patients with severe coronary artery stenosis was examined." | 7.75 | Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. ( Hayashi, D; Higaki, J; Irita, J; Kohro, T; Kurata, M; Miyoshi, K; Nagai, R; Okura, T; Yamazaki, T, 2009) |
| " Several substances (such as leptin and adiponectin) are secreted from adipocytes, which may contribute to regulate energy homeostasis and the development of cardiovascular diseases." | 7.74 | Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. ( Caliumi, C; Cavallaro, G; Cotesta, D; D' Erasmo, E; De Toma, G; Delfini, E; Diacinti, D; Letizia, C; Mazzuoli, GF; Minisola, S; Panzironi, G; Petramala, L, 2007) |
| "The purpose of this study was to assess whether increasing serum uric acid (UA) levels are related to cardiovascular disease (CVD) mortality, all-cause mortality, and incident (fatal and nonfatal) myocardial infarction (MI) in men from the general population taking into account C-reactive protein (CRP), a sensitive marker of systemic inflammation." | 7.74 | Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. ( Baumert, J; Döring, A; Koenig, W; Meisinger, C, 2008) |
| " The present study examined a Korean adult population with respect to the relationships between serum uric acid concentrations and hypertension, insulin resistance, and the risk factors of metabolic syndrome." | 7.73 | Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. ( Kang, JH; Keum, DG; Kim, BJ; Kim, BS; Kim, H; Kim, SW; Lee, MH; Lee, WY; Park, JR; Rhee, EJ; Ryu, SH; Shin, HS; Sung, KC; Yoo, TW, 2005) |
| "Elevated serum uric acid (UA) is frequently encountered in individuals with hypertension, but whether the relationship between UA and cardiovascular events is circumstantial or causal remains to be answered." | 7.73 | Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. ( Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Ogihara, T; Rakugi, H, 2006) |
| "The role of uric acid as a risk factor for myocardial infarction is controversial, and little is known about its role as a risk factor for stroke." | 7.73 | Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. ( Bos, MJ; Breteler, MM; Hofman, A; Koudstaal, PJ; Witteman, JC, 2006) |
| " Besides alcohol consumption and the use of antihypertensive therapy, mainly diuretics, serum uric acid is markedly associated with parameters of the metabolic syndrome, in particular serum triglycerides." | 7.72 | Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. ( Bovet, P; Burnier, M; Conen, D; Paccaud, F; Riesen, W; Shamlaye, C; Wietlisbach, V, 2004) |
| "Comparison of the serum uric acid levels of healthy people (n=71) and patients with cardiovascular diseases (CVD) (n=62)." | 7.70 | Serum uric acid levels in cardiovascular diseases. ( Burgaz, S; Simsek, B; Torun, M; Yardim, S, 1998) |
| "Because previous findings have been inconsistent, we explored the association of serum concentrations of uric acid with all-cause and cardiovascular disease mortality and myocardial infarction prospectively." | 7.70 | Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. ( Döring, A; Hense, HW; Keil, U; Liese, AD; Löwel, H; Tietze, M, 1999) |
| "The question of serum uric acid as an independent risk factor in subjects with essential hypertension remains controversial." | 7.70 | Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. ( Brunetti, P; Porcellati, C; Reboldi, G; Santeusanio, F; Schillaci, G; Verdecchia, P, 2000) |
| "To examine the relationships of serum uric acid concentration with several risk factors of cardiovascular diseases (CVD)." | 7.69 | Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. ( Bonora, E; Branzi, P; Cacciatori, V; Muggeo, M; Saggiani, F; Santi, L; Targher, G; Tosi, F; Travia, D; Zenere, MB; Zenti, MG, 1996) |
| "Serum uric acid concentrations and the fractional excretion of uric acid were determined in 31 children from 3 1/2 to 18 years of age with essential hypertension." | 7.66 | Uric acid in childhood essential hypertension. ( Baluarte, HJ; Gruskin, AB; Polinsky, MS; Prebis, JW, 1981) |
| "Hyperuricemia is a recognized risk factor for cardiovascular diseases." | 6.80 | Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension. ( Chen, YM; Ho, CS; Liu, ZM; Woo, J, 2015) |
| "Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout." | 6.79 | Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. ( Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S, 2014) |
| "Atorvastatin was titrated from 10-80 mg/day aiming at a low density lipoprotein cholesterol (LDL-C) target of <100 mg/dl (group A) or an LDL-C target of <130 mg/dl (group B)." | 6.76 | Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. ( Alexandrides, T; Athyros, VG; Bacharoudis, G; Ganotakis, ES; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Tziomalos, K, 2011) |
| "Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy." | 6.52 | Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015) |
| "Uric acid is a waste product of purine catabolism." | 6.49 | Uric acid as a danger signal in gout and its comorbidities. ( Kataoka, H; Lai, JJ; Rock, KL, 2013) |
| "Hyperuricemia is a prevalent finding in patients presenting metabolic syndrome, although its clinical meaning is still controversial and often underestimated." | 6.46 | Uric acid as a factor in the metabolic syndrome. ( Batista, MC; Borges, RL; Ribeiro, AB; Zanella, MT, 2010) |
| "Calcium antagonists are used in the treatment of hypertension and angina." | 6.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| "Hyperuricemia is associated with hypertension, vascular disease, renal disease, and cardiovascular events." | 6.42 | Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? ( Feig, D; Herrera-Acosta, J; Johnson, RJ; Kanellis, J; Kang, DH; Kivlighn, S; Mazzali, M; Rodriguez-Iturbe, B; Tuttle, KR; Watanabe, S, 2003) |
| "Uric acid has been suggested as a risk factor in cardiovascular disease since the beginning of the twentieth century." | 6.42 | [Role of uric acid in cardiovascular diseases]. ( Adamiec, R; Bednarska-Chabowska, D; Wdowczyk, M, 2003) |
| " Obesity, lipids, glucose tolerance and insulin resistance are risk factors for numerous cardiovascular diseases and are often accompanied by a considerable increase in serum uric acid (SUA) concentrations." | 5.94 | Insights into the relationship between serum uric acid and pulmonary hypertension (Review). ( Chen, M; He, Y; Lei, W; Luo, H; Shui, X; Zheng, J; Zhou, Y, 2024) |
| "Both hyperprolactinemia and early-onset androgenic alopecia are associated with increased cardiometabolic risk." | 5.91 | Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia. ( Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W, 2023) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 5.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| " One hundred and ninety-seven adults with gout and SUA levels ≥8 mg/dL were randomized to febuxostat or allopurinol in a 1:1 ratio for 36 weeks." | 5.51 | Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. ( Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK, 2022) |
| "As uric acid levels increase there is a relevant clustering of metabolic risk factors, whereas elevated blood pressure is the risk factor less frequently present." | 5.48 | Uric acid is linked to cardiometabolic risk factors in overweight and obese youths. ( Alvarez-Pitti, J; Borghi, C; Lurbe, E; Redon, J; Redon, P; Torro, MI, 2018) |
| "Hyperuricemia is associated with incident cardiovascular events in different settings of patients." | 5.46 | Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. ( Addesi, D; Baggetta, R; Cimellaro, A; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tripepi, G, 2017) |
| "67) and also revealed a dose-response relationship in this subgroup." | 5.43 | Association of cognitive function and serum uric acid: Are cardiovascular diseases a mediator among women? ( Brenner, H; Mons, U; Perna, L; Schöttker, B, 2016) |
| "Metabolic syndrome was defined according to the Adult Treatment Panel III criteria modified for children and adolescents." | 5.43 | Association of Serum Uric Acid With Cardiometabolic Risk Factors and Metabolic Syndrome in Iranian Adolescents: the CASPIAN-III Study. ( Asayesh, H; Djalalinia, S; Eslami Shahr Babaki, A; Heshmat, R; Kelishadi, R; Motlagh, ME; Qorbani, M; Safari, O; Safiri, S; Tajadini, MH; Tajbakhsh, R, 2016) |
| "The aim of the present study is to present a historical and unified perspective on the association of serum uric acid (SUA) in the cause of cardiovascular diseases (CVDs)." | 5.41 | Association of hyperuricemia with cardiovascular diseases: current evidence. ( Chrysant, SG, 2023) |
| "A direct relationship between serum uric acid levels and hypertension, cardiovascular, renal and metabolic diseases has been reported in many basic and epidemiological studies." | 5.41 | Update in uric acid, hypertension, and cardiovascular diseases. ( Ae, R; Andres-Hernando, A; Borghi, C; Hisatome, I; Kanbay, M; Kodama, T; Kuwabara, M; Lanaspa, MA, 2023) |
| "Adults with type 1 diabetes have lower serum uric acid levels compared with nondiabetic adults." | 5.40 | Serum uric acid and hypertension in adults: a paradoxical relationship in type 1 diabetes. ( Bjornstad, P; Chonchol, MB; Jalal, D; Johnson, RJ; Maahs, DM; McFann, K; Paul Wadwa, R; Rewers, M; Rivard, CJ; Sirota, JC; Snell-Bergeon, JK, 2014) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 5.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "Uric acid has been known to exert neuroprotective effects by acting as a free radical scavenger; however, several observational studies indicated that high levels of serum uric acid increased the risk of cardiovascular events or stroke." | 5.36 | High levels of serum uric acid are associated with silent brain infarction. ( Heo, SH; Lee, SH, 2010) |
| "Uric acid is a risk factor of cardiovascular disease, as well as a major natural antioxidant, prohibiting the occurrence of cellular damage." | 5.35 | Serum uric acid and cognitive function and dementia. ( Breteler, MM; Euser, SM; Hofman, A; Westendorp, RG, 2009) |
| "Hyperuricemia is common after kidney transplantation." | 5.35 | Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. ( Bandukwala, F; Huang, M; Nash, MM; Prasad, GV; Zaltzman, JS, 2009) |
| "Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout." | 5.34 | Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. ( De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J, 2020) |
| "Hyperuricemia is part of the "metabolic syndrome"." | 5.32 | Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. ( Debatin, KM; Denzer, C; Heinze, E; Mayer, H; Muche, R; Wabitsch, M, 2003) |
| "We previously reported that febuxostat was more effective for hyperuricemia than allopurinol." | 5.24 | Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial). ( Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A, 2017) |
| "Since uric acid is associated with cardiovascular and renal disease, a treatment to maintain blood uric acid level may be required in patients with hyperuricemia." | 5.24 | Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. ( Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N, 2017) |
| "Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy." | 5.24 | Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017) |
| "Hyperuricemia is caused by reduced renal/extrarenal excretion and overproduction of uric acid." | 5.22 | Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. ( Maeda, N; Nishizawa, H; Shimomura, I, 2022) |
| "Increased serum uric acid (SUA) levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension, gout, non-alcoholic fatty liver disease, chronic kidney disease (CKD), and cardiovascular diseases." | 5.22 | Uric acid in metabolic syndrome: Does uric acid have a definitive role? ( Copur, S; Demiray, A; Kanbay, M, 2022) |
| "Uric acid is the final product of purine metabolism, and its increased serum levels have been directly involved in the pathogenesis and natural history of hypertension." | 5.22 | Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk. ( Agnoletti, D; Borghi, C; Cicero, AFG; Lurbe, E; Virdis, A, 2022) |
| "The study included two age-, weight-, lipid-, and prolactin level-matched groups of premenopausal women with hypecholesterolemia and a history of hyperprolactinemia: patients treated with bromocriptine (5." | 5.20 | The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2015) |
| "To date uric acid (UA) is not considered a cardiovascular risk factor, although evidence about a relationship between UA and cardiovascular diseases has been reported." | 5.17 | Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction. ( Franzosi, MG; Levantesi, G; Maggioni, AP; Marchioli, R; Marfisi, RM; Nicolosi, GL; Schweiger, C; Silletta, MG; Tavazzi, L; Tognoni, G, 2013) |
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 5.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| "Hyperuricemia is prevalent in patients with chronic kidney disease (CKD); however, data are limited about the relationship of uric acid levels with long-term outcomes in this patient population." | 5.14 | Uric acid and long-term outcomes in CKD. ( Beck, GJ; Collins, AJ; Greene, T; Kusek, JW; Levey, AS; Madero, M; Menon, V; Sarnak, MJ; Wang, X, 2009) |
| "To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia." | 5.12 | The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. ( Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T, 2021) |
| "Uric acid, the end-product of purine metabolism in humans, is not only a cause of gout, but also may play roles in developing cardiovascular diseases such as hypertension, atrial fibrillation, chronic kidney disease, heart failure, coronary artery disease, and cardiovascular death." | 5.12 | Uric acid and cardiovascular disease: A clinical review. ( Kobayashi, Y; Node, K; Saito, Y; Tanaka, A, 2021) |
| " Results of multiple studies have demonstrated independent associations between increased levels of uric acid and risk of arterial hypertension, cardiovascular diseases, and chronic kidney disease." | 5.12 | [Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events]. ( Kobalava, ZD; Troitskaya, EA, 2021) |
| "Despite the high incidence and mortality of cardiovascular events in hyperuricemia patients, the role of serum uric acid in cardiovascular diseases is still controversial." | 5.12 | Carotid intima-media thickness in patients with hyperuricemia: a systematic review and meta-analysis. ( Chen, J; He, CS; He, Y; Liu, M; Luo, X; Peng, LH; Xu, WD; Zhao, ZX, 2021) |
| "Studies on the association of uric acid with mortality and cardiovascular outcomes in patients with hypertension have produced contradictory results." | 5.12 | Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis. ( Jin, Z; Yang, Y; Zhang, X; Zhao, Q, 2021) |
| "The role of uric acid (UA) in the process of atherothrombosis is controversial." | 5.12 | Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. ( Bandinelli, S; Cherubini, A; Ferrucci, L; Lauretani, F; Maggio, M; Miller, E; Najjar, SS; Ruggiero, C; Senin, U, 2007) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "We examined the relation of serum creatinine and uric acid to mortality and cardiovascular disease in older (aged >/=60 years) Chinese patients with isolated systolic hypertension (systolic/diastolic blood pressure >/=160/<95 mm Hg)." | 5.09 | Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. ( Birkenhäger, WH; Fagard, RH; Gong, L; Liu, L; Staessen, JA; Wang, JG, 2001) |
| "We included randomized controlled trials (RCTs) investigating the isocaloric effect of substituting dietary sugars (fructose, glucose, sucrose) with other sugars or starch on cardiometabolic risk markers, including LDL cholesterol, triacylglycerol (TG), fasting glucose (FG), glycated hemoglobin (HbA1c), insulin resistance (HOMA-IR), uric acid, C-reactive protein (CRP), alanine transaminase (ALT), aspartate transaminase (AST), and liver fat content." | 5.05 | Dietary sugars and cardiometabolic risk factors: a network meta-analysis on isocaloric substitution interventions. ( Buyken, AE; Hoffmann, G; Neuenschwander, M; Schlesinger, S; Schwingshackl, L, 2020) |
| "Uric acid, the metabolic mediator of gout and urate renal stones, is associated with increased cardiovascular risk burden." | 5.05 | Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. ( Borghi, C; Cosentino, E; Landolfo, M; Palazzuoli, A, 2020) |
| " In the present review, we summarize experimental data on the potential biological mechanisms linking fructose and uric acid in the development of insulin resistance, metabolic syndrome, obesity, diabetes, hypertension, non-alcoholic fatty liver disease and chronic renal disease, thereby contributing to an increase in cardiovascular risk at pediatric age." | 5.05 | Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age. ( Esposito, P; Garibotto, G; Leoncini, G; Pontremoli, R; Russo, E; Viazzi, F, 2020) |
| "Hyperuricemia is a state in which the serum levels of uric acid are elevated." | 5.05 | Hyperuricemia, the heart, and the kidneys - to treat or not to treat? ( Bevc, S; Ekart, R; Hojs, R; Petreski, T, 2020) |
| " Cardioprotective benefits of allopurinol, a first-line agent for the treatment of gout, have been demonstrated to potentially prevent myocardial infarction, stroke, atrial fibrillation, and other cardiovascular diseases in observational studies in select populations." | 5.01 | Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. ( Gupta, MK; Singh, JA, 2019) |
| "Purine metabolism in the circulatory system yields uric acid as its final oxidation product, which is believed to be linked to the development of gout and kidney stones." | 5.01 | Hyperuricemia and Cardiovascular Disease. ( Cheng, J; Huangfu, N; Wang, Y; Xu, Z; Zhang, D; Zhang, F; Zhang, S; Zhao, R; Zheng, W, 2019) |
| " The current obesity epidemic has in fact made it relatively frequent even among children and adolescents to find some cardiovascular risk factors known in adults such as arterial hypertension, dyslipidemia, glucose metabolism disorders and increased of uric acid values." | 5.01 | Prevention of Cardiovascular Diseases in Children and Adolescents. ( Battaglino, MG; Genovesi, S; Giussani, M; Nava, E; Orlando, A; Parati, G, 2019) |
| " When compared with other combinations, the combination of ACEIs/ARBs and CCBs had comparable WMD of systolic as well as diastolic BP (73 study arms) but provided better benefits on metabolic parameters, such as HDL, FBS, HbA1C, and serum uric acid; renal functions, including serum creatinine and estimated glomerular filtration rate; and cardiovascular diseases, including reduction of all cardiovascular events, myocardial infarction, and syncope/hypotension." | 4.98 | The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. ( Eiam-Ong, S; Pitakpaiboonkul, P; Pongpanich, P; Praditpornsilpa, K; Susantitaphong, P; Takkavatakarn, K, 2018) |
| "Gout is the most common form of inflammatory arthropathy and is caused by an excess of uric acid in the blood (hyperuricemia)." | 4.95 | Change gout: the need for a new approach. ( Punzi, L, 2017) |
| "Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure." | 4.93 | Uric acid lowering therapy in cardiovascular diseases. ( Iellamo, F; Romeo, F; Sposato, B; Volterrani, M, 2016) |
| "Besides the well accepted need to treat hyperuricemia associated with gout, some large observational studies and small prospective therapeutic trials have suggested that treating asymptomatic hyperuricemia, especially by xanthine oxidase inhibition, the enzyme producing uric acid, could be beneficial for cardiovascular and renal risk prevention." | 4.93 | [HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES]. ( Krzesinski, JM; Schils, R, 2016) |
| " Although several studies reported serum uric acid as a marker of an underlying pathophysiological process, other studies hypothesis a potential causal link between serum uric acid and cardiovascular diseases." | 4.90 | Serum uric acid and cardiovascular risk: state of the art and perspectives. ( Blacher, J; Fenech, G; Mazighi, M; Rajzbaum, G, 2014) |
| "Elevated serum uric acid concentration is a common laboratory finding in subjects with metabolic syndrome/obesity, hypertension, kidney disease and cardiovascular events." | 4.89 | Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? ( Kapusta, DR; Rasheed, K; Reisin, E; Soltani, Z, 2013) |
| "Traditionally, serum uric acid (SUA) has been implicated in acute gouty arthritis or chronic gouty arthropathy." | 4.89 | Hyperuricaemia: more than just a cause of gout? ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2013) |
| " Concordantly, recent studies have revived the controversy over the role of circulating uric acid, hyperuricemia, and gout as an independent prognostic factor for cardiovascular morbidity and mortality." | 4.89 | Chronic hyperuricemia, uric acid deposit and cardiovascular risk. ( Cheli, P; Del Pinto, R; Desideri, G; Di Giosia, P; Ferri, C; Ferri, L; Grassi, D; Properzi, G, 2013) |
| "Elevated uric acid levels are a common finding in patients with metabolic syndrome and in those with cardiovascular and renal disease, but the meaning of this elevation is still unclear." | 4.88 | Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? ( Di Giorgio, C; Gesualdo, L; Morrone, LF; Stellato, D, 2012) |
| "A number of epidemiological studies have reported an association between serum uric acid levels and a wide variety of high-risk conditions including hypertension, insulin resistance, and kidney and cerebro-cardiovascular disease." | 4.88 | Cardiovascular and renal effects of hyperuricaemia and gout. ( Leoncini, G; Pontremoli, R; Viazzi, F, 2012) |
| "With considering serum concentration of the uric acid in humans we are observing hyperuricemia and possible gout development." | 4.88 | Uric acid as one of the important factors in multifactorial disorders--facts and controversies. ( Feher-Turkovic, L; Marinkovic, N; Pasalic, D, 2012) |
| "To review and interpret the recently published data on hyperuricemia and cardiovascular disease to present an opinion on the nature of link between serum uric acid concentration and the risk for cardiovascular outcomes, and to comment on its implications for clinical practice." | 4.87 | Uric acid in heart disease: a new C-reactive protein? ( Krishnan, E; Sokolove, J, 2011) |
| "Both elevated levels of uric acid and non-alcoholic fatty liver disease (NAFLD) have been associated with increased vascular risk." | 4.87 | Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2011) |
| " However, emerging data suggest that elevated uric acid (UA) is actually one of the most important factors for cardiovascular disease and that it also plays a significant role in the development of renal disease and metabolic syndrome." | 4.87 | Uric acid as a cardiometabolic risk factor: to be or not to be. ( Afsar, B; Covic, A; Kanbay, M, 2011) |
| "High uric acid (UA) levels can cause gout, urolithiasis and acute and chronic nephropathy, all of which are due to the deposit of urate crystals." | 4.87 | Is there anything good in uric acid? ( Alvarez-Lario, B; Macarrón-Vicente, J, 2011) |
| " Early markers of CVD such as microalbuminuria and uric acid levels need to be added to the routine annual evaluation, particularly among high-risk individuals such as diabetics, hypertensives, smokers, and the elderly." | 4.85 | Chronic kidney disease: a marker of cardiovascular disease. ( Nguyen, PT; Olivero, JJ, 2009) |
| " Specifically, we review newly discovered mechanisms of uric acid-induced inflammation, uric acid's putative role as a "danger signal" in innate immunity, the possible link between hyperuricemia and cardiovascular disease, and evolutionary evidence suggesting that hyperuricemia conferred a survival advantage in primates (when the gene for uricase was lost) several million years ago." | 4.84 | Update on gout: pathophysiology and potential treatments. ( Abeles, AM; Cronstein, BN; Park, JY; Pillinger, MH, 2007) |
| "The association of elevated serum uric acid (hyperuricemia, gout) with the presence of classical coronary risk factors and coronary artery disease (CAD) or myocardial infarction (MI) has been analysed in many epidemiological studies." | 4.83 | [Is hyperuricemia a cardiovascular risk factor?]. ( Chizyński, K; Rózycka, M, 2006) |
| "This article critically evaluates the clinical evidence regarding the influence of uric acid on hypertension, cardiovascular disease, and kidney disease." | 4.82 | Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: a statistical modeling perspective. ( Short, RA; Tuttle, KR, 2005) |
| "Treatment of asymptomatic hyperuricemia is not necessary in most patients, unless perhaps they have very high levels of uric acid or are otherwise at risk of complications, such as those with a personal or strong family history of gout, urolithiasis, or uric acid nephropathy." | 4.81 | Asymptomatic hyperuricemia: to treat or not to treat. ( Dincer, AP; Dincer, HE; Levinson, DJ, 2002) |
| "The association between serum uric acid (SUA) and mortality from cardiovascular diseases (CVDs) in nonalcoholic fatty liver disease (NAFLD) participants remains uncertain." | 4.31 | Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease. ( He, P; Li, H; Liu, C; Liu, M; Qin, X; Wu, Q; Yang, S; Ye, Z; Zhang, Y; Zhang, Z; Zhou, C, 2023) |
| "Menopause may be a crucial factor related to changes in serum total cholesterol, non-high-density lipoprotein cholesterol, triglycerides, uric acid, hemoglobin, and liver enzymes." | 4.31 | Changes in cardiovascular disease risk factors during menopausal transition in Japanese women: the Circulatory Risk in Communities Study (CIRCS). ( Cui, R; Hayama-Terada, M; Imano, H; Iso, H; Kihara, T; Kitamura, A; Kiyama, M; Muraki, I; Ohira, T; Okada, T; Sankai, T; Shimizu, Y; Tanaka, M; Teramura, S; Umesawa, M; Yamagishi, K, 2023) |
| "Associations between body mass index (BMI)- standard deviation score (SDS)/waist-to-height ratio (WHtR) were studied with (i) serum uric acid (sUA)/gamma-glutamyl-transferase (GGT) and (ii) cardiometabolic risk markers in children with obesity, considering sex, pubertal development, and degree of weight loss/type of patient care." | 4.31 | Uric acid and gamma-glutamyl-transferase in children and adolescents with obesity: Association to anthropometric measures and cardiometabolic risk markers depending on pubertal stage, sex, degree of weight loss and type of patient care: Evaluation of the ( Bergjohann, L; Dannemann, A; Holl, RW; Leipold, G; Prinz, N; Reinehr, T; Weghuber, D; Weihe, P; Weihrauch-Blüher, S; Wiegand, S, 2023) |
| "Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored." | 4.31 | Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis. ( Dang, W; Liu, J; Wang, J; Xu, D; You, L; Zhao, L, 2023) |
| "We compared two matched groups of euthyroid women with hypercholesterolemia receiving atorvastatin treatment: subjects with autoimmune (Hashimoto's) thyroiditis (group A, n = 29) and subjects without thyroid pathology (group B, n = 29)." | 4.31 | Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis. ( Kowalcze, K; Krysiak, R; Okopień, B, 2023) |
| " The aim of this study was to investigate whether autoimmune thyroiditis determines cardiometabolic effects of cabergoline." | 4.31 | Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2023) |
| "Patients with metabolic syndrome We can observe that the Blood urea level showed positive correlation with uric acid level (p value 0." | 4.31 | Endocrinology. ( Konan, V; Swamy, N, 2023) |
| "Elevated serum uric acid (SUA) is regarded as a risk factor for the development of cardiovascular diseases." | 4.31 | The synergistic effect of the triglyceride-glucose index and serum uric acid on the prediction of major adverse cardiovascular events after coronary artery bypass grafting: a multicenter retrospective cohort study. ( Chen, S; Cheng, C; Guo, D; Liu, L; Liu, X; Sun, X; Wang, J; Wu, Z; Yang, J; Zhang, C; Zhang, Y, 2023) |
| "Pathophysiologic processes promoted by uric acid, including inflammation and oxidative stress, play a key role in the pathogenesis of several cardiovascular diseases." | 4.31 | [ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach]. ( Aquilani, S; Castello, L; Colivicchi, F; Di Fusco, SA; Flori, M; Gabrielli, D; Gulizia, MM; Marino, G; Nardi, F; Oliva, F; Riccio, C, 2023) |
| "This cohort study intended to elucidate the association between serum uric acid (SUA) levels and cardiovascular disease events in Japanese patients with obesity." | 4.31 | Novel pathological implications of serum uric acid with cardiovascular disease risk in obesity. ( Kasahara, M; Kasama, S; Kato, H; Kato, S; Kusakabe, T; Ozu, N; Satoh-Asahara, N; Tanaka, M; Wakabayashi, D; Yamakage, H, 2023) |
| "This study aimed to examine the association of serum uric acid levels with incident cardiovascular disease and mortality in Korean adults without gout." | 4.31 | Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study. ( Chang, TI; Kim, JY; Lim, H; Pak, H; Seo, C, 2023) |
| "Background Serum uric acid (UA) is correlated closely with traditional cardiovascular risk factors, which might interfere with the action of UA, in patients with coronary artery disease." | 4.31 | Uric Acid Levels, Number of Standard Modifiable Cardiovascular Risk Factors, and Prognosis in Patients With Coronary Artery Disease: A Large Cohort Study in Asia. ( Cui, K; Dong, Q; Dou, K; Feng, L; Fu, R; Jia, L; Lu, Y; Song, C; Song, W; Song, Y; Wang, H; Yang, Y; Yin, D; Zhang, D; Zhu, C, 2023) |
| " The clinical evaluation included lipid and glycid profile, platelets, leukocytes, lymphocytes, monocytes, uric acid and blood pressure, as well as the presence of metabolic syndrome (MS) and its components." | 4.12 | Cardiometabolic risk in adolescents with normal weight obesity. ( Cota, BC; de Faria, ER; de Faria, FR; Juvanhol, LL; Pereira, PF; Priore, SE; Ribeiro, SAV, 2022) |
| " We aim to investigate the effect of overweight and/or obesity on high blood pressure (HBP), dyslipidemia, elevated serum uric acid (SUA) and their clustering among children and adolescents in an island in South China." | 4.12 | Body mass index was linked with multi-cardiometabolic abnormalities in Chinese children and adolescents: a community-based survey. ( Du, J; He, H; Jia, P; Jin, Y; Pan, L; Shan, G, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) and serum uric acid (SUA) levels are risk factors for developing cardiovascular disease (CVD)." | 4.12 | The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients. ( Hwang, J; Kang, K; Kim, K; Lee, JM; Sheol, H; Shin, J; Sim, Y; Yang, T, 2022) |
| " Potential factors associated with reduced renal function including age, ethnicity, educational level, history of diabetes, hypertension, gout, hydronephrosis, serum uric acid level, and type of renal stone were evaluated using univariable and multivariable analyses." | 4.12 | Cardiovascular risk factors, ethnicity and infection stone are independent factors associated with reduced renal function in renal stone formers. ( Choy, SH; J R, S; Kamaruzaman, S; Lim, J; Malek, R; Md Yusoff, NA; Nagappan, P; Nyanatay, SA; Ong, TA; Sothilingam, S; Sundram, M; Toh, CC; Yeoh, WS, 2022) |
| " 113 patients fulfilled the criteria for central obesity with the mean uric acid level of 8." | 4.12 | A Clinical Profile of Patients with Hyperuricemia and the Relationship between Hyperuricemia and Metabolic Syndrome: A Cross-sectional Study at a Tertiary Hospital in the Indian Population. ( Ingawale, S; Raghorte, N; Rajadhyaksha, A; Sarate, N, 2022) |
| " Plasma lipids, insulin sensitivity, and levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine, and 25-hydroxyvitamin D were measured before and after 14-week treatment with atorvastatin (20 mg daily)." | 4.12 | Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "The uric acid serum level is higher in people with hypertension and overweight/obesity." | 4.12 | Hyperuricaemia and its association with other risk factors for cardiovascular diseases: A population-based study. ( Baniasad, A; Najafipour, H; Najafzadeh, MJ; Shakibi, MR; Sistani, S; Yazdi, F, 2022) |
| "Little research has been conducted into the effects of the combined manifestation of hyperuricemia and hyperhomocysteinemia on cardiometabolic risk factors and markers in young subjects." | 4.12 | The Presence of Hyperhomocysteinemia Does Not Aggravate the Cardiometabolic Risk Imposed by Hyperuricemia in Young Individuals: A Retrospective Analysis of a Cross-Sectional Study. ( Gurecká, R; Koborová, I; Podracká, Ľ; Repiská, G; Šebeková, K, 2022) |
| "Hyperuricemia is prevalent and associated with individual cardiometabolic diseases, highlighting the potential role of serum uric acid (SUA) in the development and progression of cardiometabolic multimorbidity (CMM, the coexistence of diabetes, heart disease, or stroke)." | 4.12 | Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study. ( Dai, X; Li, D; Ni, Y; Wang, D; Xu, X, 2022) |
| " Anthropometric measurements, fasting glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), HOMA- β (%), lipids profile, monocyte to lymphocyte ratio (MLR), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), uric acid, gamma glutamyl transpeptidase (GGT), AST/ALT ratio and total bilirubin were assessed." | 4.12 | Association Between Total Bilirubin Levels and Cardio-Metabolic Risk Factors Related to Obesity. ( Asar, M; El-Eshmawy, MM; Elsehely, I; Mahsoub, N, 2022) |
| "The association between serum uric acid (SUA) and the all-cause and cardiovascular diseases (CVD) mortality remains controversial, but few studies based on the community population in Shanghai have been reported." | 4.02 | Serum uric acid level and all-cause and cardiovascular mortality in Chinese elderly: A community-based cohort study in Shanghai. ( Chen, J, 2021) |
| "Self-reported gout or hyperuricemia and uric acid level." | 4.02 | Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1). ( Engel, B; Freitag, MH; Hoffmann, F; Jacobs, H, 2021) |
| "Asymptomatic hyperuricemia patients exposed to a higher level of uric acid (>=428 mmol/L) could significantly increase the incidence risk of CHD and stroke, with or without hyperuricemia-related comorbidities." | 4.02 | High-level uric acid in asymptomatic hyperuricemia could be an isolated risk factor of cardio-cerebrovascular diseases: A prospective cohort study. ( Bai, Y; Cheng, Z; Hu, X; Li, J; Li, N; Ren, X; Shi, D; Wang, M; Yang, J; Yin, C; Zhang, D; Zheng, S; Zheng, T, 2021) |
| "BACKGROUND Serum uric acid (UA) is involved in the development of hypertension." | 4.02 | U-Shaped Relationship Between Cardiovascular Mortality and Serum Uric Acid May Be Attributed to Stroke- and Heart-Specific Mortality, Respectively, Among Hypertensive Patients: A Nationally Representative Cohort Study. ( Chen, K; Han, P; You, H; Yue, C; Zhao, X, 2021) |
| "Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis." | 4.02 | The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. ( Barbagallo, CM; Bombelli, M; Borghi, C; Bruno, B; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Dell'Oro, R; Desideri, G; Ferri, C; Galletti, F; Georgiopoulos, G; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Lippa, L; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Pugliese, NR; Rattazzi, M; Rivasi, G; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2021) |
| "In addition to the controversy regarding the association of hyperuricemia with mortality, uncertainty also remains regarding the association between low serum uric acid (SUA) and mortality." | 3.96 | U-Shaped Association of Serum Uric Acid With All-Cause and Cause-Specific Mortality in US Adults: A Cohort Study. ( Bao, H; Cheng, X; Hu, G; Hu, L; Wang, T; Xu, BP; Zhou, W; Zhu, L, 2020) |
| "We aimed to investigate the association between serum uric acid (SUA) and all-cause or cardiovascular mortality among participants with obesity." | 3.96 | Relationship between serum uric acid level and all-cause and cardiovascular mortality in population with obesity. ( Chen, CL; Feng, YQ; Huang, JY; Huang, YQ; Li, J; Liu, L; Lo, K; Sun, S; Zhang, B, 2020) |
| "For 40 years many studies have been conducted to verify the connection between serum uric acid concentration and cardiovascular diseases, such as myocardial infarction." | 3.96 | The differential role of uric acid - The purpose or cause of cardiovascular diseases? ( Siemińska, E; Sikora, J; Skibińska, N; Sobczak, P, 2020) |
| "To observe the changes in blood pressure (BP) over 10 years and to investigate current BP association to serum uric acid (SUA) levels and cardiovascular risk factors in the epidemiological data of a target group of patients with prehypertension in 2007." | 3.96 | Association of serum uric acid, morning home blood pressure and cardiovascular risk factors in a population with previous prehypertension: a cross-sectional study. ( Bawazier, LA; Irijanto, F; Kholiq, A; Sja'bani, M; Tomino, Y; Widiatmoko, A; Zulaela, Z, 2020) |
| "Serum uric acid (UA) levels are one of the determinants of the cardiovascular disease and metabolic syndrome but none of criteria for that syndrome include serum UA." | 3.96 | Uric acid alterations by consumption of gluten-free bakery products in relation to cardiovascular and metabolic syndrome risk factors. ( Gažarová, M; Mečiarová, L, 2020) |
| "Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI." | 3.91 | Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. ( Baumgartner, S; Goldfarb, DS; Jalal, D; Pillinger, M; Saag, KG; Schechter, BM; Terkeltaub, R; Valiyil, R; White, WB, 2019) |
| "The aim of this study was to assess the association between serum uric acid concentration (SUAC) and the parameters of the metabolic syndrome (MetS) and insulin resistance (IR)." | 3.91 | Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children ( Ersoy, B; Özalp Kızılay, D; Şen, S, 2019) |
| " The levels of leptin, fibrinogen, homocysteine, high-sensitivity C-reactive protein (hs-CRP), triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), fasting blood glucose and insulin, glycated hemoglobin, and uric acid of the obese patients who were put on calorie restricted diet were evaluated retrospectively and compared before and after weight loss." | 3.91 | Does weight loss affect the parameters that are metabolically related to cardiovascular diseases? ( Persil-Ozkan, O; Yigit, E; Yigit, Z, 2019) |
| "We studied 12 women with NC-CAH, 6 of whom because of coexisting hypercholesterolemia received atorvastatin (20-40 mg daily)." | 3.91 | The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. ( Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B, 2019) |
| " This review discussed the non-glycemic effects of SGLT-2is in patients with T2D and renal impairment, including reductions in systolic and diastolic blood pressure, decreases in albuminuria and plasma uric acid, changes in estimated glomerular filtration rate, and minimal changes in electrolytes." | 3.91 | Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. ( Weir, MR, 2019) |
| " Serum uric acid (SUA) has been associated with cardiovascular diseases (CVD), but no conclusive findings are available nowadays in patients suffering from hypoglycaemia." | 3.88 | Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality. ( Bonaventura, A; Carbone, F; Cordera, R; Dallegri, F; Gallo, F; Liberale, L; Maggi, D; Montecucco, F; Sacchi, G, 2018) |
| "Hyperuricemia is a risk factor for causing end-stage kidney disease and cardiovascular disease in the general population; however, several aspects, such as the site of kidney damaged by hyperuricemia and the threshold levels of serum uric acid for the development of renal damage, have not been fully clarified." | 3.88 | The Association between Serum Uric Acid and Renal Damage: The Takahata Study - New Insights. ( Ichikawa, K; Kamei, K; Kayama, T; Konta, T; Kubota, I, 2018) |
| "In addition to the controversy regarding the association of hyperuricemia with cardiovascular disease (CVD) mortality, few studies have examined the impact of a low uric acid level on mortality." | 3.88 | U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study. ( Chang, Y; Cho, SK; Kim, I; Ryu, S, 2018) |
| " Blood levels of creatinine, glucose, potassium, urea, and uric acid were measured during pregnancy." | 3.88 | Routine blood tests during pregnancy for predicting future increases in risk of cardiovascular morbidity. ( Sergienko, R; Shefer, A; Sheiner, E; Shoham-Vardi, I; Wolak, A; Wolak, T; Yuval Bar-Asher, S, 2018) |
| " The aim of this analysis was to describe the relationship of maternal serum uric acid (SUA) and cystatin C with maternal and neonatal cardiometabolic risk markers and with birth weight and risk of small-for-gestational age (SGA) as well as large-for gestational age (LGA)." | 3.88 | Association of maternal uric acid and cystatin C serum concentrations with maternal and neonatal cardiovascular risk markers and neonatal body composition: The Ulm SPATZ Health Study. ( Braig, S; Feike, G; Genuneit, J; Koenig, W; Logan, CA; Müller, M; Reister, F; Rothenbacher, D, 2018) |
| "We indicated that uric acid, AIP, and proteinuria are closely related." | 3.88 | Relationship Between Uric Acid, Proteinuria, and Atherogenic Index of Plasma in Renal Transplant Patients. ( Biyik, Z; Guney, I, 2018) |
| "Studies have suggested a relationship between higher baseline serum uric acid (sUA) levels and an elevated risk of subsequent ischemic cardiovascular outcomes among acute coronary syndrome (ACS) patients; this relationship may be modified by a clinical history of gout and has not been studied in large patient cohorts." | 3.85 | An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. ( Akerblom, A; Clare, RM; Held, C; Hess, CN; James, S; Keenan, RT; Klein, AB; Mahaffey, KW; Pagidipati, NJ; Roe, MT; Tricoci, P; Wallentin, L; Wojdyla, D, 2017) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 3.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| "Aims of this study were 1) to evaluate early cardiovascular abnormalities in a large population of obese children and adolescents compared with a normal weight counterpart, 2) to investigate their potential association with insulin resistance (IR), serum uric acid (sUA) and metabolic syndrome (MetS)." | 3.85 | Insulin resistance, serum uric acid and metabolic syndrome are linked to cardiovascular dysfunction in pediatric obesity. ( Aronici, M; Bellone, S; Bona, G; Castagno, M; Di Mario, C; Genoni, G; Grossini, E; Martelli, M; Menegon, V; Monzani, A; Prodam, F; Ricotti, R; Secco, GG; Sonzini, M, 2017) |
| "Hyperuricemia and angiotensin II (Ang II) may have a pathogenetic role in the development of hypertension and atherosclerosis as well as cardiovascular disease (CVD) and its prognosis." | 3.85 | Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. ( Çetin, A; Kırça, M; Oğuz, N; Uzuner, F; Yeşilkaya, A, 2017) |
| " Correlations between SA and atherosclerosis indicators, such as CIMT, LDL, hs-CRP, and uric acid, in hypothyroid individuals suggest that SA may be an indicator of atherogenesis in these patients." | 3.85 | Serum Total Sialic Acid Level is Elevated in Hypothyroid Patients as an Atherosclerotic Risk Factor. ( Aktürk, M; Altay, M; Arslan, M; Ateş, İ; Bukan, N; Çakır, N; Cerit, ET; Karakoç, MA; Yılmaz Demirtaş, C, 2017) |
| "We aim to explore the associations between serum uric acid (SUA) and obesity and cardio-cerebrovascular events (CCEs) in Chinese inpatients with type 2 diabetes mellitus (T2DM)." | 3.85 | Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Yu, TP; Zhao, CC; Zhu, Y, 2017) |
| "The role of serum uric acid (SUA), an inflammatory agent and potential mediator of cardiovascular diseases, in endothelial function (EF) has been tested only in middle-aged subjects affected by specific diseases." | 3.85 | Uric acid and endothelial function in elderly community-dwelling subjects. ( Aloe, R; Ceda, GP; Cederholm, T; Ferrucci, L; Larsson, A; Lauretani, F; Lind, L; Maggio, M; Meschi, T; Ruggiero, C; Ticinesi, A, 2017) |
| "Elevated serum uric acid levels and increased arginase activity are risk factors for cardiovascular diseases (CVD)." | 3.83 | Effects of serum uric acid levels on the arginase pathway in women with metabolic syndrome. ( Demirci, F; Demirustu, C; Ergun, B; Kebapci, N; Ozcelik, E; Temel, HE; Uslu, S, 2016) |
| " Uric acid levels, insulin resistance (homeostasis model assessment insulin resistance; HOMA-IR), C-reactive protein (CRP), triacylglycerol (TG), systolic blood pressure (SBP), abdominal fat and cIMT (both by ultrasound) were assessed." | 3.83 | Uric acid, carotid intima-media thickness and body composition in prepubertal children. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz-Roldán, F; Ibáñez, L; López-Bermejo, A; Martínez-Calcerrada, JM; Osiniri, I; Prats-Puig, A; Riera-Pérez, E, 2016) |
| "This study examined the relationship between serum levels of uric acid and insulin resistance and metabolic syndrome in nondiabetic patients with schizophrenia." | 3.83 | Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia. ( Cimpeanu, C; Fan, X; Harrington, A; Rajan, S; Song, X; Zalpuri, I, 2016) |
| "Serum uric acid level is regulated by gender, dietary habit, genetic predisposition, and renal function, and is associated with the development of renal and cardiovascular diseases." | 3.83 | Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study. ( Hirayama, A; Ichikawa, K; Kabasawa, A; Kamei, K; Kato, T; Kayama, T; Konta, T; Kubota, I; Sato, H; Shibata, Y; Suzuki, K; Suzuki, N; Ueno, Y; Watanabe, T, 2016) |
| " Variables included were waist circumference (WC), glucose, high-density lipoprotein (HDL), triglycerides (TGL), blood pressure, insulin resistance (by homeostatic model assessment HOMA-index), acanthosis nigricans (AN), uric acid, serum glutamic oxaloacetic transaminase (GOT) and alanine transaminase, and hepatic sonogram." | 3.83 | Models Predictive of Metabolic Syndrome Components in Obese Pediatric Patients. ( Barrera-de Leon, JC; Colunga Rodríguez, C; Hurtado López, EF; López Beltrán, AL; Ortega-Cortes, R; Tlacuilo-Parra, A; Trujillo, X, 2016) |
| "Although high uric acid levels have been reported to be a risk factor for cardiovascular disease and stroke, the relationship between serum uric acid (SUA) levels and cardioembolic stroke (CES) has not been fully elucidated." | 3.83 | Association of serum uric acid and cardioembolic stroke in patients with acute ischemic stroke. ( Jung, S; Kim, CK; Kim, TJ; Kim, Y; Lee, SH; Yang, XL, 2016) |
| " Hence, we aimed to compare the prevalence of elevated lipoprotein (a), apolipoprotein B, and uric acid (UA) levels, apolipoprotein B/apolipoprotein A1 ratio, and visceral adiposity index (VAI) scores, and low apolipoprotein A1 levels among 6 body size phenotypes (normal weight with and without metabolic abnormalities, overweight with and without metabolic abnormalities, and obese with or without metabolic abnormalities)." | 3.81 | Nontraditional risk factors for cardiovascular disease and visceral adiposity index among different body size phenotypes. ( Du, T; Liu, Z; Sun, X; Yu, X; Yuan, G; Zhang, J; Zhang, M; Zhou, X, 2015) |
| " The variables of the diagnostic rule (male sex, previous arthritis attack, onset <1 day, joint redness, involvement of the first MTP joint, hypertension or one or more cardiovascular disease, and serum uric acid >5." | 3.81 | The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. ( Fransen, J; Janssen, M; Janssens, HJ; Kienhorst, LB, 2015) |
| "Serum uric acid (SUA) is associated with many cardiovascular risk factors such as hypertension (HTN) and metabolic syndrome (MetS)." | 3.81 | Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Dong, XH; Jia, WP; Li, LX; Li, MF; Li, TT; Shen, J; Zhang, R, 2015) |
| "Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population." | 3.81 | Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. ( Babio, N; Basora, J; Becerra-Tomás, N; Corella, D; Estruch, R; Fitó, M; Martínez-González, MA; Ortega-Calvo, M; Recondo, J; Ros, E; Salas-Salvadó, J; Serra-Majem, L; Wärnberg, J, 2015) |
| " Measurements included clinical and ambulatory blood pressure monitoring, ultrasound-measured flow-mediated dilatation (FMD), microalbuminuria, carotid intima-media thickness (CIMT) and serum uric acid, as well as clinical and demographic features." | 3.81 | Persistence of cardiovascular risk factors in women with previous preeclampsia: a long-term follow-up study. ( Acmaz, G; Afsar, B; Aykas, F; Bulut, K; Covic, A; Dogan, S; Erden, A; Johnson, RJ; Kanbay, M; Sarli, B; Sharma, S; Siriopol, D; Solak, Y, 2015) |
| "Obesity and diets rich in uric acid-raising components appear to account for the increased prevalence of hyperuricemia in Westernized populations." | 3.81 | Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. ( Delgado, G; Grammer, TB; Huang, J; Kleber, ME; Krämer, BK; März, W; Ritz, E; Silbernagel, G, 2015) |
| "We tested the hypothesis that uric acid levels are higher in subjects with schizophrenia treated with clozapine than in healthy control and they correlate with anthropometric measurements, laboratory tests and results of bioimpedance analysis of body composition." | 3.81 | Uric acid levels in patients with schizophrenia on clozapine monotherapy. ( Kłoszewska, I; Wysokiński, A, 2015) |
| "The purpose of this study was to evaluate associations among hypertension (HTN) and uric acid (UA) with cardiovascular autonomic neuropathy (CAN), and to estimate the extent to which synergistic effects of HTN and UA affect the outcome in a Chinese population." | 3.81 | The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy. ( Liao, XP; Tang, ZH; Zeng, F; Zhu, HW, 2015) |
| "To explore the association between serum uric acid (SUA) levels, metabolic syndrome (MetS) and cardiovascular disease (CVD) in patients treated with lipid-lowering agents from multiple centers in China." | 3.81 | The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. ( Chen, K; Fang, Y; Hu, D; Mu, Y; Nie, Y; Tian, Y; Wang, H; Xie, Z, 2015) |
| "To determine whether women who had a hypertensive pregnancy disorder (HPD) have elevated uric acid concentrations decades after pregnancy as compared with women who had normotensive pregnancies." | 3.81 | Uric Acid: A Missing Link Between Hypertensive Pregnancy Disorders and Future Cardiovascular Disease? ( Asad, RA; Garovic, VD; Hanis, CL; Kardia, SL; Milic, NM; Mosley, TH; Turner, ST; Weissgerber, TL, 2015) |
| "Elevated serum uric acid concentration was strongly associated with obesity and hyperlipidemia in both men and women." | 3.81 | Relationship Between Hyperuricemia and Cardiovascular Disease Risk Factors in a Chinese Population: A Cross-Sectional Study. ( Hong, L; Li, L; Su, P; Sun, H; Zhao, Y, 2015) |
| "The main purpose of the present supplement, which is based on a symposium held in Bologna, 6-8 November 2014, is twofold: first of all, to reinforce the role of uric acid in the pathogenesis of gout and gout-related non-rheumatic diseases including renal involvement; second, to provide an updated review of the evidence supporting the relevant role of elevated uric acid as a risk factor for cardiovascular diseases." | 3.81 | The role of uric acid in the development of cardiovascular disease. ( Borghi, C, 2015) |
| " The changes of BMI-SDS in the time period of 1-year were related to baseline fasting insulin resistance index HOMA, blood pressure, waist circumference, waist-to-height ratio, lipids, uric acid, and HbA1c." | 3.80 | Components of the metabolic syndrome are negative predictors of weight loss in obese children with lifestyle intervention. ( Knop, C; Reinehr, T; Uysal, Y; Wolters, B, 2014) |
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| "A link between uric acid (UA) levels and cardiovascular diseases has been previously reported." | 3.80 | Association between serum uric acid levels and cardiovascular disease in middle-aged and elderly Chinese individuals. ( Gu, H; Li, R; Li, X; Lu, S; Ning, G; Qin, L; Shi, Q; Su, Q; Xing, Y; Yang, Z, 2014) |
| "Serum uric acid (UA) is now beginning to be considered a risk predictor for cardiovascular diseases." | 3.80 | Serum uric acid as a risk predictor for erectile dysfunction. ( Heydari, R; Mehrsai, A; Pourmand, G; Salem, S, 2014) |
| "Elevated albuminuria as well as an increased serum uric acid concentration is associated with poor cardiovascular outcome." | 3.80 | The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. ( Bakker, SJ; de Jong, PE; Gansevoort, RT; Joosten, MM; Scheven, L, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 3.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "cross-sectional and prospective multivariate analysis of the relation between tertiles of serum uric acid and individual traditional CV risk factors in a cohort of gouty arthritis (GA, n=172), rheumatoid arthritis (RA, n=480) and osteoarthritis (OA, n=206) patients." | 3.80 | Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort. ( Meek, IL; van de Laar, MA; Vonkeman, HE, 2014) |
| "The aims of this study were to investigate (i) associations between uric acid and prevalent cardiovascular disease (CVD), ankle-arm blood pressure index (AAIx) and carotid intima-media thickness (CIMT) in the total population and in predefined subgroups according to glucose metabolism status and (ii) the extent to which these associations are explained by low-grade inflammation." | 3.80 | The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: the CODAM study. ( Arts, IC; Boonen, A; Dagnelie, PC; Ferreira, I; Feskens, EJ; Schalkwijk, CG; Stehouwer, CD; van der Kallen, CJ; van der Linden, S; van Greevenbroek, MM; Wijnands, JM, 2014) |
| "There was direct relationship between level of CV risk and presence of additional risk factors (hyperglycemia, hyperuricemia, hyperfibrinogenemia, left ventricular hypertrophy)." | 3.80 | [Detection of early markers of atherosclerosis in men with various levels of risk of cardiovascular complications]. ( Badeĭnikova, KK; Didigova, RT; Mamedov, MN; Mazaev, AP; Toguzova, ZA, 2014) |
| "Hyperuricemia is related to Metabolic Syndrome (MetS) and cardiovascular diseases, but the use of serum uric acid (UA) to diagnose MetS is currently ignored in clinical practices." | 3.80 | The impact of serum uric acid on the diagnostic of metabolic syndrome in apparently healthy brazilian middle-aged men. ( Azevedo Novello, A; Bressan, J; Cardoso dos Santos, E; de Oliveira, A; Guedes Cocate, P; Hermsdorff, HHM; José Natali, A, 2014) |
| "While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid." | 3.80 | Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. ( Conca, A; Corrao, S; Djade, CD; Franchi, C; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2014) |
| " Hyperuricemia was defined as serum uric acid >6." | 3.79 | Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. ( Gelber, AC; Juraschek, SP; Kovell, LC; Miller, ER, 2013) |
| "The predictive value of serum uric acid (SUA) for adverse cardiovascular events among obese and overweight patients is not known, but potentially important because of the relation between hyperuricaemia and obesity." | 3.79 | Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. ( Andersson, C; Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Sharma, AM; Skak-Nielsen, H; Torp-Pedersen, C; Van Gaal, L, 2013) |
| "Gout and serum uric acid are associated with mortality but their simultaneous contributions have not been fully evaluated in the general population." | 3.79 | Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. ( Abdalla, AA; Casserly, LF; Cronin, CJ; Hanley, A; Hannigan, A; Hegarty, A; Kiernan, TJ; Murthy, BV; Nguyen, HT; Stack, AG, 2013) |
| "Parameters were correlated with homeostasis model assessment for insulin resistance, fasting insulin, blood pressure, transaminases, lipids and uric acid, applying adjusted regression models, with age group, pubertal stage and gender as covariates." | 3.79 | Body mass index, waist circumference, and waist-to-height ratio as predictors of cardiometabolic risk in childhood obesity depending on pubertal development. ( Blüher, S; Holl, RW; Kiess, W; L'Allemand-Jander, D; Molz, E; Otto, KP; Sergeyev, E; Tuschy, S; Wiegand, S, 2013) |
| "Whether uric acid (UA) serves as risk factor for cardiovascular diseases or as antioxidant defense has not yet been completely clarified." | 3.79 | Higher uric acid levels are associated with better functional recovery in elderly patients receiving cardiac rehabilitation. ( Cecchi, F; Luisi, ML; Macchi, C; Molino-Lova, R; Paperini, A; Pasquini, G; Prisco, D; Vannetti, F; Zipoli, R, 2013) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 3.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| " The higher CRP group was discriminated by the above variables in addition to lower VO(2max), serum metabolic syndrome components (triglycerides, glucose, and HDL cholesterol), higher insulin, homeostasis assessment of insulin resistance, uric acid, gamma-GT, and homocysteine." | 3.79 | Pathological and behavioral risk factors for higher serum C-reactive protein concentrations in free-living adults--a Brazilian community-based study. ( Burini, RC; de Oliveira, EP; Manda, RM; Michelin, E; Moreto, F; Teixeira, O; Torezan, GA, 2013) |
| " Blood pressure, lipids, glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR) and uric acid levels were compared across BMI groups." | 3.79 | Association between WHO cut-offs for childhood overweight and obesity and cardiometabolic risk. ( Brines, J; de Onis, M; Martínez-Costa, C; Montal, A; Nguefack-Tsague, G; Núñez, F, 2013) |
| "The objective of this study was to examine the association between uric acid, GGT, obesity and the individual components of metabolic syndrome in children and adolescents." | 3.79 | Associations of uric acid and gamma-glutamyltransferase (GGT) with obesity and components of metabolic syndrome in children and adolescents. ( Chan, CW; Chan, JC; Chan, MH; Choi, KC; Ho, CS; Kong, AP; Ozaki, R, 2013) |
| "High plasma uric acid (UA) is a prerequisite for gout and is also associated with the metabolic syndrome and its components and consequently risk factors for cardiovascular diseases." | 3.79 | Dietary, anthropometric, and biochemical determinants of uric acid in free-living adults. ( Burini, RC; de Oliveira, EP; Moreto, F; Silveira, LV, 2013) |
| " Hyperuricemia was defined by uric acid ≥458." | 3.78 | Relationship between serum uric acid and cerebral white matter lesions in the elderly. ( Chen, CY; Kuo, HK; Liu, HM; Shih, CY; Wen, CJ, 2012) |
| "Overweight, obesity, higher blood pressure, unfavorable blood lipid profile, and especially higher uric acid levels are connected with greater TAC of blood serum across an adult man's life." | 3.78 | Physical activity and total antioxidant capacity across an adult lifespan of men. ( Chrzczanowicz, J; Drygas, W; Gawron-Skarbek, A; Jegier, A; Kostka, J; Kostka, T; Nowak, D, 2012) |
| "Although various kinds of cardiovascular risk factors have been reported to be associated with atrial fibrillation (AF), the relationship between serum uric acid level and AF has not been fully examined." | 3.78 | Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012) |
| "Baseline levels of serum uric acid were negatively correlated with HbA1c, were higher in men and in the elderly and were independently associated with components of the metabolic syndrome." | 3.78 | Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. ( Barutta, F; Bruno, G; Cavallo-Perin, P; Fornengo, P; Ghezzo, G; Greco, E; Gruden, G; Panero, F; Perotto, M; Runzo, C, 2012) |
| "Uric acid is associated with cardiovascular disease and cardiovascular disease risk factors in adults, including chronic kidney disease, coronary artery disease, stroke, diabetes mellitus, preeclampsia, and hypertension." | 3.78 | Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006. ( Brady, TM; Fadrowski, JJ; Loeffler, LF; Miller, ER; Navas-Acien, A, 2012) |
| "Serum uric acid (SUA) is a suggested biomarker for established coronary artery disease, but the role of SUA in early phases of atherosclerosis is controversial." | 3.78 | Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. ( Hutri-Kähönen, N; Huupponen, R; Jula, A; Juonala, M; Kähönen, M; Lehtimäki, T; Loo, BM; Lyytikäinen, LP; Oikonen, M; Raitakari, OT; Saarikoski, L; Seppälä, I; Siitonen, N; Viikari, JS; Wendelin-Saarenhovi, M, 2012) |
| " Elevated serum uric acid levels, hypoadiponectinemia and arterial stiffness are strongly associated with cardiovascular diseases." | 3.78 | Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women. ( Ahn, CW; Cha, BS; Kang, S; Kim, KR; Lee, HC; Park, JS, 2012) |
| " Blood pressure and uric acid was most strongly correlated with body weight and height (heavier and taller boys)." | 3.77 | Differential relationships between anthropometry measures and cardiovascular risk factors in boys and girls. ( Beilin, LJ; de Klerk, N; Hands, B; Huang, RC; Landau, LI; Mori, TA; Newnham, JP; Oddy, WH; Stanley, FJ, 2011) |
| "In both men and women, we observed positive linearity between GGT quartiles and body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides, uric acid, high-sensitive C-reactive protein (hsCRP) and homeostatic model assessment of insulin resistance (HOMA-IR) score (P for trends < 0·001)." | 3.77 | Serum gamma-glutamyltransferase is associated with arterial stiffness in healthy individuals. ( Bae, SJ; Jung, CH; Kim, HK; Kim, MS; Koh, EH; Lee, WJ; Park, JY; Yu, JH, 2011) |
| " Hyperuricemia (serum uric acid >7 mg/dL) was found in 15." | 3.77 | Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. ( Dukes, J; Hinyard, LJ; Lentine, KL; Neri, L; Pinsky, B; Rocca Rey, LA; Schnitzler, MA; Xiao, H, 2011) |
| " It specifically addressed the hypotheses that renal dysfunction in these patients may associate with the presence of insulin resistance, dyslipidaemia, uric acid levels and/or current levels of systemic inflammation." | 3.76 | Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis. ( Antonopoulos, I; Daoussis, D; Douglas, KM; John, H; Kitas, GD; Nightingale, P; Panoulas, VF; Toms, TE; Wong, P, 2010) |
| "Little is known about the interrelationships between metabolic syndrome (MS), uric acid, and early carotid atherosclerosis with diet in adolescents." | 3.76 | Carotid intima-media thickness, dietary intake, and cardiovascular phenotypes in adolescents: relation to metabolic syndrome. ( Barth, JD; Croymans, DM; Roberts, CK; Sanchez, A, 2010) |
| " Recently, serum uric acid (SUA) was shown to be an independent predictor of long-term mortality in patients with cardiovascular diseases." | 3.76 | Prognostic significance of serum uric acid in patients admitted to the Department of Medicine. ( Boursi, B; Guzner-Gur, H; Shnell, M; Wasserman, A, 2010) |
| "High serum uric acid levels are associated with gout, atherosclerosis and cardiovascular disease." | 3.76 | Sex and age interaction with genetic association of atherogenic uric acid concentrations. ( Adams, TD; Brandstätter, A; Coassin, S; Hunt, SC; Kedenko, L; Kiechl, S; Kramer, F; Kronenberg, F; Lamina, C; Paulweber, B; Summerer, M; Willeit, J, 2010) |
| " The cut-off point varied in subjects with various cardiovascular risk profiles such as serum uric acid level, gender or hypertension." | 3.76 | Very low-grade albuminuria reflects susceptibility to chronic kidney disease in combination with cardiovascular risk factors. ( Ahn, JM; Chae, DW; Chin, HJ; Heo, NJ; Kim, S; Lee, TW; Na, KY, 2010) |
| "Uric acid (UA) is considered to be a powerful predictor of cardiovascular risk and hyperuricemia might be involved in the metabolic syndrome (MS)." | 3.76 | Relation of uric acid levels to aortic root dilatation in hypertensive patients with and without metabolic syndrome. ( Chen, XF; Du, YX; Fang, CF; Jiang, JJ; Lin, XF; Pu, ZX; Tang, LJ; Wang, JA, 2010) |
| " Mortality from all causes, total cardiovascular disease (CVD), ischemic stroke, congestive heart failure, hypertensive disease, and coronary heart disease were compared according to increasing serum uric acid levels." | 3.75 | Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. ( Chen, HJ; Chen, JH; Chuang, SY; Pan, WH; Yeh, WT, 2009) |
| "The association of elevated serum uric acid (UA) with cardiovascular events in patients with severe coronary artery stenosis was examined." | 3.75 | Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. ( Hayashi, D; Higaki, J; Irita, J; Kohro, T; Kurata, M; Miyoshi, K; Nagai, R; Okura, T; Yamazaki, T, 2009) |
| " Several substances (such as leptin and adiponectin) are secreted from adipocytes, which may contribute to regulate energy homeostasis and the development of cardiovascular diseases." | 3.74 | Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. ( Caliumi, C; Cavallaro, G; Cotesta, D; D' Erasmo, E; De Toma, G; Delfini, E; Diacinti, D; Letizia, C; Mazzuoli, GF; Minisola, S; Panzironi, G; Petramala, L, 2007) |
| "Elevated serum uric acid level is associated with obesity, insulin resistance, diabetes, nephropathy, and hypertension." | 3.74 | Genome scan for determinants of serum uric acid variability. ( Abboud, HE; Arar, NH; Bauer, R; Blangero, J; Comuzzie, AG; Lopez-Alvarenga, JC; MacCluer, JW; Nath, SD; Thameem, F; Voruganti, VS, 2007) |
| "The role of serum uric acid (SUA) as an independent risk factor for cardiovascular disease (CVD) remains controversial, and little is known about its prognostic importance for mortality from congestive heart failure (CHF) and stroke." | 3.74 | Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. ( Brant, L; Concin, H; Diem, G; Kelleher, C; Klenk, J; Pfeiffer, K; Ruttmann, E; Strasak, A; Ulmer, H, 2008) |
| "The purpose of this study was to assess whether increasing serum uric acid (UA) levels are related to cardiovascular disease (CVD) mortality, all-cause mortality, and incident (fatal and nonfatal) myocardial infarction (MI) in men from the general population taking into account C-reactive protein (CRP), a sensitive marker of systemic inflammation." | 3.74 | Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. ( Baumert, J; Döring, A; Koenig, W; Meisinger, C, 2008) |
| " The present study examined a Korean adult population with respect to the relationships between serum uric acid concentrations and hypertension, insulin resistance, and the risk factors of metabolic syndrome." | 3.73 | Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. ( Kang, JH; Keum, DG; Kim, BJ; Kim, BS; Kim, H; Kim, SW; Lee, MH; Lee, WY; Park, JR; Rhee, EJ; Ryu, SH; Shin, HS; Sung, KC; Yoo, TW, 2005) |
| "Elevated serum uric acid (UA) is frequently encountered in individuals with hypertension, but whether the relationship between UA and cardiovascular events is circumstantial or causal remains to be answered." | 3.73 | Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. ( Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Ogihara, T; Rakugi, H, 2006) |
| " After adjustment for the degree of obesity, subjects with MS had significantly higher uric acid (6." | 3.73 | Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors. ( Gilardini, L; Girola, A; Invitti, C; Maffeis, C; Mazzilli, G; Morabito, F; Pontiggia, B; Sartorio, A; Viberti, GC, 2006) |
| "The role of uric acid as a risk factor for myocardial infarction is controversial, and little is known about its role as a risk factor for stroke." | 3.73 | Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. ( Bos, MJ; Breteler, MM; Hofman, A; Koudstaal, PJ; Witteman, JC, 2006) |
| "0001) differences, and correlated significantly in a beneficial manner to measures of obesity (body mass index, waist circumference, and abdominal height), mean arterial blood pressure, lipoprotein variables (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), measures of glucose homeostasis (insulin, glucose, homeostasis model assessment of insulin resistance [HOMA-IR]), and uric acid, after adjusting for age, race, sex, and cigarette smoking." | 3.73 | Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study. ( Berenson, GS; Chen, W; Patel, DA; Srinivasan, SR; Xu, JH, 2006) |
| " The degree of obesity did not relate to insulin resistance but was independently correlated with inflammatory proteins, uric acid, and systolic BP, variables that were often abnormal in this population." | 3.72 | Prevalence and concomitants of glucose intolerance in European obese children and adolescents. ( Gilardini, L; Guzzaloni, G; Invitti, C; Morabito, F; Viberti, G, 2003) |
| " Besides alcohol consumption and the use of antihypertensive therapy, mainly diuretics, serum uric acid is markedly associated with parameters of the metabolic syndrome, in particular serum triglycerides." | 3.72 | Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. ( Bovet, P; Burnier, M; Conen, D; Paccaud, F; Riesen, W; Shamlaye, C; Wietlisbach, V, 2004) |
| "Anthropometric parameters, blood lipid spectrum, levels of glucose, uric acid (UA), immunoreactive insulin, HOMA index were studied in 55 male patients with gout (mean age 50." | 3.72 | [Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Nasonov, EL; Zilov, AV, 2004) |
| "A population sample of 2469 men and women aged 35-74 years, free from major cardiovascular diseases and in whom serum uric acid was measured in 1983 along with other standard risk factors, were followed up for 6 years and the incidence of coronary heart disease (CHD) and all cardiovascular atherosclerotic (CVD) events, both fatal and non-fatal, was computed." | 3.71 | Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population Study. ( Angeletti, M; Cirillo, M; Lanti, M; Mancini, M; Menotti, A; Panarelli, W; Puddu, PE; Zanchetti, A, 2001) |
| "Comparison of the serum uric acid levels of healthy people (n=71) and patients with cardiovascular diseases (CVD) (n=62)." | 3.70 | Serum uric acid levels in cardiovascular diseases. ( Burgaz, S; Simsek, B; Torun, M; Yardim, S, 1998) |
| "Because previous findings have been inconsistent, we explored the association of serum concentrations of uric acid with all-cause and cardiovascular disease mortality and myocardial infarction prospectively." | 3.70 | Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. ( Döring, A; Hense, HW; Keil, U; Liese, AD; Löwel, H; Tietze, M, 1999) |
| "The question of serum uric acid as an independent risk factor in subjects with essential hypertension remains controversial." | 3.70 | Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. ( Brunetti, P; Porcellati, C; Reboldi, G; Santeusanio, F; Schillaci, G; Verdecchia, P, 2000) |
| "To examine the relationships of serum uric acid concentration with several risk factors of cardiovascular diseases (CVD)." | 3.69 | Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. ( Bonora, E; Branzi, P; Cacciatori, V; Muggeo, M; Saggiani, F; Santi, L; Targher, G; Tosi, F; Travia, D; Zenere, MB; Zenti, MG, 1996) |
| "To assess the relationship between obesity and body fat distribution with cardiovascular risk factors in children, various measures of obesity and waist-to-hip circumference ratio (WHR) were related to serum lipids, lipoproteins, apolipoproteins, glucose, insulin, uric acid, systolic (SBP) and diastolic blood pressure (DBP)." | 3.68 | Cardiovascular risk factors in obese children in relation to weight and body fat distribution. ( Mueller, T; Pakosta, R; Widhalm, K; Zwiauer, KF, 1992) |
| "The relationships of serum uric acid to mortality from all causes, the cardiovascular diseases, and cancer were evaluated in 6797 white women age 35-64 years followed for an average of 11." | 3.67 | Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. ( Dyer, AR; Levine, W; Schoenberger, JA; Shekelle, RB; Stamler, J, 1989) |
| " The following significant differences were observed in the study group versus the controls: high systolic and diastolic blood pressure, longer duration of hypertension before renal allografting, higher serum concentrations of cholesterol, triglycerides and uric acid, and an increased incidence of left ventricular hypertrophy and preexisting cardiovascular disease." | 3.66 | [Cardiovascular diseases after kidney transplantation: an analysis of predisposing factors]. ( Binswanger, U; Heule, H; Keusch, G; Largiadèr, F; Uhlschmid, G, 1981) |
| "To clarify the role of the serum urate level and its change as a potential marker for severe tissue hypoxia, we have measured serum urate levels and urine uric acid excretion in 16 patients with acute cardiovascular disease." | 3.66 | Hyperuricemia in acute illness: a poor prognostic sign. ( Colfer, H; Fox, IH; Woolliscroft, JO, 1982) |
| "Serum uric acid concentrations and the fractional excretion of uric acid were determined in 31 children from 3 1/2 to 18 years of age with essential hypertension." | 3.66 | Uric acid in childhood essential hypertension. ( Baluarte, HJ; Gruskin, AB; Polinsky, MS; Prebis, JW, 1981) |
| "A critical survey of the literature suggests that elevated serum uric acid is definitely associated with hypertension and may function as an independent risk factor in the development of this disease." | 3.66 | Elevated serum uric acid. A cardiovascular risk factor? ( Fodor, JG; Tweeddale, MG, 1979) |
| "A total of 7020 patients with type 2 diabetes (T2D) were randomized to either empagliflozin (10 or 25 mg) or placebo." | 3.11 | Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. ( Ferreira, JP; Inzucchi, SE; Mattheus, M; Meinicke, T; Steubl, D; Wanner, C; Zinman, B, 2022) |
| " However, other cardiometabolic markers were not improved by magnesium supplementation at the above dosage and duration." | 3.11 | Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial. ( Amini, M; Aminorroaya, A; Feizi, A; Salehidoost, R; Taghipour Boroujeni, G, 2022) |
| " In this review, we discuss recent advances and novel insights into the effects exerted by HUA conditions in ED and related underlying mechanisms focusing on impaired UA metabolism, reduction in the synthesis and bioavailability of nitric oxide, endothelial cell injury, the endothelial-to-mesenchymal transition, insulin resistance, procoagulant activity, and acquisition of an inflammatory phenotype." | 3.01 | Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases. ( He, Y; Huang, S; Lan, X; Lei, W; Luo, H; Wei, X; Zhang, M; Zheng, J, 2023) |
| "Patients with type 2 diabetes and CV disease received empagliflozin or placebo." | 2.94 | Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. ( Al-Omran, M; Bhatt, DL; Fitchett, D; George, JT; Inzucchi, SE; Ji, Q; Mazer, CD; Ofstad, AP; Verma, S; Wanner, C; Zinman, B; Zwiener, I, 2020) |
| "Aspirin treatment for two weeks showed no hyperuricaemic effect in people over 60." | 2.94 | Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial. ( Chen, XH; Liang, WY; Liu, ML; Liu, WW; Wang, H; Zhang, P, 2020) |
| "AZD4831 was generally well tolerated, rapidly absorbed, had a long plasma half-life and lowered uric acid concentrations after single oral doses in healthy men." | 2.90 | Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers. ( Ericsson, H; Fuhr, R; Gan, LM; Heijer, M; Kjaer, M; Lagerström-Fermér, M; Lindstedt, EL; Michaëlsson, E; Nelander, K; Whatling, C, 2019) |
| "Treatment with febuxostat resulted in a significant decrease in the serum ADMA level from 1." | 2.84 | Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study. ( Alshahawey, M; Elsaid, TW; Sabri, NA; Shahin, SM, 2017) |
| "Insulin sensitivity was assessed by hyperinsulinaemic-euglycaemic clamps and cardiovascular variables were measured." | 2.84 | Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes: A randomized clinical trial. ( Hornemann, S; Markova, M; Pfeiffer, AFH; Pivovarova, O; Rohn, S; Rudovich, N; Schneeweiss, R; Sucher, S; Thomann, R, 2017) |
| " Dose-response analysis suggested a nonlinear association between SUA and all-cause mortality risk (Pnonlinearity = 0." | 2.82 | Serum uric acid level and all-cause and cardiovascular mortality in peritoneal dialysis patients: A systematic review and dose-response meta-analysis of cohort studies. ( Amoah, AN; Hu, Y; Huang, X; Kang, T; Lyu, Q, 2022) |
| "Hyperuricemia is a recognized risk factor for cardiovascular diseases." | 2.80 | Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension. ( Chen, YM; Ho, CS; Liu, ZM; Woo, J, 2015) |
| "We determined the dose-response effects of consuming beverages sweetened with high-fructose corn syrup (HFCS) at zero, low, medium, and high proportions of energy requirements (Ereq) on circulating lipid/lipoprotein risk factors for CVD and uric acid in adults [age: 18-40 y; body mass index (in kg/m(2)): 18-35]." | 2.80 | A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. ( Bremer, AA; Chen, GX; Havel, PJ; Keim, NL; Lam, HD; Lee, V; Medici, V; Nunez, MV; Stanhope, KL, 2015) |
| "Allopurinol is a potent xanthine oxidase inhibitor used in hyperuricemic patients." | 2.80 | Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease. ( Burata, A; Ruangkanchanasetr, P; Satirapoj, B; Supasyndh, O; Wirajit, O, 2015) |
| "Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout." | 2.79 | Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. ( Hasegawa, K; Hiramitsu, S; Ishiguro, Y; Ishii, J; Kani, A; Kato, H; Kato, K; Kato, Y; Kimura, H; Matsubara, S; Matsubara, Y; Matsuyama, H; Mori, K; Noba, M; Shino, K; Tokuda, M; Uchiyama, T; Uemura, A; Yamada, K; Yoshida, S, 2014) |
| "Soy protein with isoflavones or isoflavones alone at the provided dosage showed no significantly beneficial effects on measured cardiovascular risk factors in postmenopausal Chinese women with early hyperglycaemia." | 2.77 | The effects of isoflavones combined with soy protein on lipid profiles, C-reactive protein and cardiovascular risk among postmenopausal Chinese women. ( Chen, YM; Ho, SC; Ho, YP; Liu, ZM, 2012) |
| "Atorvastatin was titrated from 10-80 mg/day aiming at a low density lipoprotein cholesterol (LDL-C) target of <100 mg/dl (group A) or an LDL-C target of <130 mg/dl (group B)." | 2.76 | Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. ( Alexandrides, T; Athyros, VG; Bacharoudis, G; Ganotakis, ES; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Tziomalos, K, 2011) |
| "Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use." | 2.75 | Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. ( Ampuero, J; Arroyo, D; de Vinuesa, SG; Goicoechea, M; Luño, J; Rincón, A; Ruiz-Caro, C; Verdalles, U, 2010) |
| "Hyperuricemia is defined as an abnormally high level of uric acid (UA; i." | 2.72 | Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. ( Sun, D; Waheed, Y; Yang, F, 2021) |
| " The three outcomes used to assess the safety of uric acid lowering medications were treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE)." | 2.72 | The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials. ( Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L, 2021) |
| " Hence, a reduction in CsA dosage in kidney transplant recipients (KTR) may improve long-term outcomes." | 2.71 | Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. ( Cardarelli, F; Cosimi, AB; Delmonico, FL; Farrell, ML; Pascual, M; Saidman, SL; Shih, V; Tolkoff-Rubin, N; Winkelmayer, WC; Wong, W, 2004) |
| "However, whether treating hyperuricemia and gout with ULTs modifies cardiovascular risks remains controversial." | 2.66 | Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis. ( Cao, L; Wan, WG; Xue, Y; Yang, X; Zhao, L; Zhao, TY; Zhu, XX; Zou, HJ, 2020) |
| " Dose-response analysis was also carried out." | 2.61 | Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. ( Bellissimo, N; Hekmatdoost, A; Maroofi, M; Rahimi-Sakak, F; Rahmani, J, 2019) |
| "Gout is one of the most prevalent inflammatory rheumatic disease." | 2.61 | Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review. ( de Vries, R; Gerritsen, M; Heslinga, M; Nurmohamed, M; van Schaardenburg, D; Vedder, D; Walrabenstein, W, 2019) |
| "Gout is associated with the risk of cardiovascular morbidity and mortality, but the biological relationship between the two remains uncertain." | 2.61 | Gout and cardiovascular disease: crystallized confusion. ( Abeles, AM; Pillinger, MH, 2019) |
| "This has been ascribed, in part, to haemodynamic changes, body weight reduction and several possible effects on myocardial, endothelial and tubulo-glomerular functions, as well as to reduced glucotoxicity." | 2.61 | Uric acid and the cardio-renal effects of SGLT2 inhibitors. ( Bailey, CJ, 2019) |
| "Uric acid (UA) is an end product of purine metabolism in humans and great apes." | 2.58 | Uric acid and cardiovascular disease. ( Ndrepepa, G, 2018) |
| " In the process of purine metabolism, reactive oxygen species, including superoxide, are generated concomitantly with uric acid production, which may deteriorate endothelial function through the reaction of superoxide with nitric oxide (NO), leading to decreased NO bioavailability and increased production of peroxynitrite, a reactive oxidant." | 2.58 | Hyperuricemia and endothelial function: From molecular background to clinical perspectives. ( Higashi, Y; Hisatome, I; Kihara, Y; Maruhashi, T, 2018) |
| "Gout is both an inflammatory and a metabolic disease." | 2.55 | Gout and Metabolic Syndrome: a Tangled Web. ( Krasnokutsky, S; Pillinger, MH; Thottam, GE, 2017) |
| "Hyperuricemia has long been known to cause gout, and has recently been correlated with cardiovascular disease, hypertension, and renal disease." | 2.55 | The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies. ( Pontremoli, R, 2017) |
| "If hyperuricemia is an independent risk factor in blood-pressure control, urate-lowering therapy should be used to reduce cardiovascular risk." | 2.55 | Effects of serum uric acid on blood-pressure lowering treatment. ( Grassi, G, 2017) |
| "Diabetic nephropathy is a long-standing microvascular complication of diabetes mellitus and is the leading cause of end stage renal disease in developed countries." | 2.52 | Uric acid as a biomarker and a therapeutic target in diabetes. ( Cherney, DZ; Lytvyn, Y; Perkins, BA, 2015) |
| "Uric acid has a stimulating effect on the cerebral cortex, and this could have allowed humans, compared with other animals, to develop higher brain mass volume, better intellectual performances, and maybe evolutionary supremacy." | 2.52 | Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple". ( De Giorgi, A; Fabbian, F; Manfredini, R; Misurati, E; Pala, M; Parisi, C; Tiseo, R, 2015) |
| "Hyperuricemia is one of the many metabolic changes that occur during the course of chronic kidney disease (CKD)." | 2.52 | [Uric acid, the kidney and cardiovascular mortality]. ( Mandreoli, M; Santoro, A, 2015) |
| "Allopurinol, which has been used in clinical practice for almost 50 years, is the drug of first choice for long-term control of gout." | 2.52 | [The role of uric acid and allopurinol therapy in cardiovascular disease]. ( Linhart, A; Rob, D, 2015) |
| "Hypertension is an established risk factor of cardiovascular morbidity and mortality." | 2.52 | [The First Step Aiming at the Prevention of Hypertension and Atherosclerosis. Identification of Individuals at High Risk of Hypertension]. ( Dohi, Y, 2015) |
| "Gout is defined as an arthritic condition resulting from the deposition of monosodium urate (MSU) crystals in and/or around joints, following long-standing hyperuricemia." | 2.50 | Definition of hyperuricemia and gouty conditions. ( Bardin, T; Richette, P, 2014) |
| "Hyperphosphatemia is a major problem in these patients especially at advanced stages of CKD, and it is associated with cardiovascular and mineral complications in these patients." | 2.50 | [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent]. ( Maizel, J; Massy, ZA, 2014) |
| "Hyperuricemia is considered to be a component of cardiovascular continuum, risk factor of chronic heart failure and marker of its unfavourable outcome." | 2.49 | [Hyperuricemia and cardiovascular continuum]. ( Bart, BIa; Donskov, AS; Larin, VG; Larina, VN, 2013) |
| "Uric acid is a waste product of purine catabolism." | 2.49 | Uric acid as a danger signal in gout and its comorbidities. ( Kataoka, H; Lai, JJ; Rock, KL, 2013) |
| "Uric acid has been formerly considered a major antioxidant in human plasma with possible beneficial anti-atherosclerotic effects." | 2.48 | Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. ( Cravero, E; Muscari, A; Puddu, GM; Puddu, P; Vizioli, L, 2012) |
| "Hypocitraturia and hypercalciuria are risk factors for calcium stone disease." | 2.47 | Diet-induced metabolic acidosis. ( Adeva, MM; Souto, G, 2011) |
| "The definition of hyperuricemia is currently arbitrary." | 2.47 | Allopurinol, uric acid, and oxidative stress in cardiorenal disease. ( Covic, A; Goldsmith, D; Riegersperger, M, 2011) |
| "Hyperuricemia is a specific risk factor for cardiovascular morbidity and mortality." | 2.47 | [Hyperuricemia and uro-nephrological disorders]. ( Hurtes, X; Meria, P, 2011) |
| "Proteinuria is the most sensitive marker of CKD progression in clinical practice, especially when combined with eGFR, but these have limitations." | 2.47 | Biomarkers in chronic kidney disease: a review. ( Coombes, JS; Cooper, MA; Fassett, RG; Gobe, GC; Hoy, WE; Venuthurupalli, SK, 2011) |
| "Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms." | 2.46 | [Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers]. ( Hamada, T; Hisatome, I; Igawa, O; Mizuta, E; Shigemasa, C, 2010) |
| "Hyperuricemia is a prevalent finding in patients presenting metabolic syndrome, although its clinical meaning is still controversial and often underestimated." | 2.46 | Uric acid as a factor in the metabolic syndrome. ( Batista, MC; Borges, RL; Ribeiro, AB; Zanella, MT, 2010) |
| "Gout and hyperuricemia have long been suspected to be risk factors for cardiovascular disease." | 2.46 | Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? ( Keenan, RT; Shah, A, 2010) |
| "Gout is an acute inflammatory arthritis with the potency to fully destroy the integrity of the joint leading to severe disability." | 2.46 | Gout: a clinical syndrome illustrated and discussed. ( Bhansing, KJ; Janssen, M; Radstake, TR; van Bon, L, 2010) |
| "Uric acid has previously been viewed as a benign solute in serum until it exceeds its saturation level." | 2.45 | The role of hyperuricemia in vascular disorders. ( Edwards, NL, 2009) |
| "Calcium antagonists are used in the treatment of hypertension and angina." | 2.44 | The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension. ( Coca, A; Sierra, C, 2008) |
| "Hyperuricemia has also been found to be an independent risk factor for cardiovascular disease and hypertension." | 2.44 | The role of hyperuricemia and gout in kidney and cardiovascular disease. ( Edwards, NL, 2008) |
| "Gout is a crystal deposition disease." | 2.44 | [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. ( Fujimori, S, 2008) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "Metabolic syndrome is a cluster of cardiovascular risk factors such as hypertriglyceridemia, hypertension, insulin resistance, based on visceral fat accumulation." | 2.44 | [Relationship between hyperuricemia and metabolic syndrome]. ( Tomita, K; Yamasaki, T, 2008) |
| "Allopurinol has been the archetypal XO inhibitor for over 40 years." | 2.44 | The role of urate and xanthine oxidase inhibitors in cardiovascular disease. ( George, J; Struthers, AD, 2008) |
| "Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed." | 2.43 | Overview of hyperuricaemia and gout. ( Agudelo, C; Liu-Bryan, R; Masseoud, D; Rott, K, 2005) |
| "Hyperuricemia is a frequent finding in diseases in which the clinical manifestations are thought to be secondary to a state of generalized vascular endothelial dysfunction and related to the cardiovascular disease present in conditions associated with the metabolic syndrome, such as hypertension or diabetes." | 2.43 | Uric acid and the vasculature. ( Corry, DB; Tuck, ML, 2006) |
| "Hyperuricemia is commonly associated with traditional risk factors such as abnormalities in glucose metabolism, dyslipidemia, and hypertension." | 2.43 | Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived. ( Leoncini, G; Pontremoli, R; Ratto, E; Viazzi, F, 2006) |
| "Hyperuricemia is associated with hypertension, vascular disease, renal disease, and cardiovascular events." | 2.42 | Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? ( Feig, D; Herrera-Acosta, J; Johnson, RJ; Kanellis, J; Kang, DH; Kivlighn, S; Mazzali, M; Rodriguez-Iturbe, B; Tuttle, KR; Watanabe, S, 2003) |
| "In the treatment of hypertension, especially with hyperuricemia, it might be important to select the drug, which does not influence or reduce the concentration of uric acid." | 2.41 | [Hyperuricemia in hypertension]. ( Saito, Y; Tatsuno, I, 2001) |
| "Uric acid has long been associated with cardiovascular disease." | 2.41 | Uric acid and cardiovascular risk. ( Alderman, MH, 2002) |
| "One hundred sixty NIDDM patients who had undergone the clamp study were stratified into 5 groups according to the serum uric acid level." | 2.39 | [Hyperuricemia and insulin resistance]. ( Iwatani, M; Katsumori, K; Saeki, A; Wasada, T, 1996) |
| "Both hyperprolactinemia and early-onset androgenic alopecia are associated with increased cardiometabolic risk." | 1.91 | Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia. ( Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W, 2023) |
| " We emulated a hypothetical trial comparing the rate of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) among seven different strategies over 24 months." | 1.91 | Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach. ( Desai, RJ; Glynn, RJ; Kim, SC; Liu, J; Solomon, DH; Yoshida, K, 2023) |
| " However, information on the dose-response relationship between SUA and CVD is limited in the Chinese population." | 1.91 | U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults. ( Bi, M; Feng, A; Liu, Y; Tian, S, 2023) |
| " The association between low SUA and mortality and the dose-response analysis on the non-linearity of SUA-mortality relationship were not statistically significant." | 1.91 | Association of serum uric acid levels with cardiovascular and all-cause mortality in hypertensive patients in China: a cohort study. ( Chen, JY; Feng, YQ; Lo, K; Tang, ST; Yu, YL; Zhang, SX, 2023) |
| "Dyslipidemia is the most common risk factor for cardiovascular disease, causing more than 4 million deaths each year worldwide." | 1.91 | Dyslipidemia and its associated factors among adult cardiac patients at Ambo university referral hospital, Oromia region, west Ethiopia. ( Addisu, B; Bekele, S; Cheneke, W; Hirigo, AT; Wube, TB, 2023) |
| "Insulin sensitivity was assessed using Homeostatic Model Assessment of Insulin Resistance and the Matsuda Insulin Sensitivity Index." | 1.72 | Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. ( Dufour, S; Li, F; Petersen, KF; Rothman, DL; Shulman, GI, 2022) |
| "Uric acid (UA) is a product of the catabolism of purines, and its increase in blood may be related to the development of cardiometabolic diseases." | 1.72 | Uricaemia and associated health determinants in a paediatric population in Mexico. ( Aradillas-García, C; Cossío-Torres, PE; Lares-Villaseñor, E; Portales-Pérez, DP; Salazar-García, S; Vargas-Morales, JM, 2022) |
| "In conclusion, Hyperuricemia is prevalent among Chinese adults." | 1.72 | Association of Hyperuricemia with 10-Year Atherosclerotic Cardiovascular Disease Risk among Chinese Adults and Elders. ( Chen, F; Han, S; Liu, J; Xu, T; Yuan, L, 2022) |
| "Hyperuricemia is an independent risk factor for high AIP level." | 1.72 | Association of hyperuricemia with apolipoprotein AI and atherogenic index of plasma in healthy Chinese people: a cross-sectional study. ( An, Y; Chang, X; Ding, X; Duan, Y; Liu, J; Wang, G, 2022) |
| "Results indicated significant increases in body weight, BMI, Lee index, food consumption, systolic and diastolic pressure and decrease in serum nitric oxide bioavailability in the 8-hr sedentary rats." | 1.72 | Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers. ( Akomolafe, RO; Alabi, QK, 2022) |
| "Hyperuricemia is an important problem also in healthy subjects and its prevalence could further increase if lower cut-off will be used." | 1.62 | Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. ( Bombelli, M; Brambilla, P; Cartella, I; Casati, M; Giannattasio, C; Grassi, G; Grasso, E; Maloberti, A; Milani, M; Occhi, L; Qualliu, E; Signorini, S; Sun, J; Tavecchia, G; Tognola, C; Vallerio, P, 2021) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 1.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| "Hyperuricemia is associated with cardiovascular mortality, but the association of the age at hyperuricemia onset with cardiovascular disease (CVD) and mortality is still unclear." | 1.62 | Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk. ( Chen, S; Cui, L; Li, L; Wang, C; Wu, S; Xue, H; Yun, C; Zhang, S; Zhao, M, 2021) |
| "Uric acid (UA) levels were significantly higher in the intensive care patients (6." | 1.56 | Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care. ( Asai, K; Asano, K; Goda, H; Hata, N; Kiuchi, K; Kobayashi, N; Matsushita, M; Murase, T; Nakamura, T; Okazaki, H; Shibata, Y; Shigihara, S; Shimizu, W; Shirakabe, A; Tani, K, 2020) |
| "Patients with cancer were older and more often former smokers, had lower body mass index, lower left ventricular ejection fraction (LVEF), less implanted devices, lower glucose and haemoglobin and higher uric acid levels than those without cancer." | 1.56 | Cancer in chronic heart failure patients in the GISSI-HF trial. ( Ameri, P; Canepa, M; Latini, R; Luigi Nicolosi, G; Maggioni, AP; Marchioli, R; Tavazzi, L, 2020) |
| "Nevertheless, gout is a "curable disease" by ULT, a treatment which in adequate doses may also have positive effect on several associated co-morbidities." | 1.56 | [Consequences of Gout and Hyperuricemia]. ( Bengtsson Boström, K; Dehlin, M; Forsblad d'Elia, H; Jacobsson, L; Kapetanovic, M; Sigurdardottir, V; Svärd, A; Wändell, P, 2020) |
| "The prevalence of gout has increased in recent decades." | 1.51 | Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. ( Bellmann-Weiler, R; Feuchtner, G; Gruber, J; Halpern, EJ; Jaschke, W; Klauser, AS; Stofferin, H; Strobl, S; Weiss, G, 2019) |
| "Uric acid has been reported to activate Nod-like receptor protein 3 (NLRP3)-inflammasome and alter vascular smooth muscle cells (VSMC)." | 1.51 | Elevated Uric Acid Levels Promote Vascular Smooth Muscle Cells (VSMC) Proliferation via an Nod-Like Receptor Protein 3 (NLRP3)-Inflammasome-Dependent Mechanism. ( Li, H; Liu, H; Qian, F; Zhang, Z, 2019) |
| "Hyperuricemia is an important potential pathogenic factor for hypertension, cardiovascular disease and stroke." | 1.51 | Risk Factors For Hyperuricemia In Chinese Centenarians And Near-Centenarians. ( Cai, GY; Chen, XM; Han, QX; Li, J; Liu, DW; Liu, L; Liu, ZS; Luan, FX; Zhang, D; Zhang, F; Zhao, YL; Zhu, HY, 2019) |
| "Whether hyperuricemia affects biological response to acute stress remains largely unknown, suggesting a need to clarify this potential connection." | 1.51 | Salivary uric acid: Associations with resting and reactive blood pressure response to social evaluative stress in healthy African Americans. ( Granger, DA; Lucas, T; Pierce, J; Riis, JL; Woerner, J, 2019) |
| "The study included ADPKD patients and control group, who carried out uroflowmetry, an assessment of renal function, metabolic and nutritional parameters and an evaluation of endothelial dysfunction and atherosclerotic markers, such as Renal Resistive Index (RRI), Intima-Media Thickness (IMT) and Flow-Mediated Dilation (FMD)." | 1.51 | Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease. ( Cianci, R; Ciccariello, M; Lai, S; Mastroluca, D; Mazzaferro, S; Mittherhofer, AP; Ricciuti, GP; Riviello, L; Salciccia, S; Vocaturi, M; Von Heland, M, 2019) |
| "People with gout are at an increased risk of readmission for heart failure and have longer hospital stays." | 1.51 | Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. ( Doughty, RN; Drake, J; Frampton, C; Richards, AM; Stamp, LK; Troughton, RW, 2019) |
| "Hyperuricemia was frequently noted in subjects with a high risk of cardiovascular disease (CVD)." | 1.48 | Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors. ( Ahn, JY; Hur, KY; Jin, SM; Jun, JE; Kang, MR; Kim, G; Kim, JH; Lee, MK; Lee, SE; Lee, YB, 2018) |
| "The magnitude of undiagnosed COPD in our population with cardiovascular risk factors (CVRF) is unknown." | 1.48 | Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors. ( Alsedà, M; Barbé, F; Betriu, À; Castañ, MT; Godoy, P; Lecube, A; Marsal, JR; Montserrat-Capdevila, J; Ortega, M; Portero, M; Pujol, J; Purroy, F; Seminario, MA; Valdivielso, JM, 2018) |
| "Gout is associated with higher cardiovascular risk that increases with disease severity." | 1.48 | The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient. ( Budzik, JF; Capon, B; Ducoulombier, V; Godart, C; Grandjean, A; Houvenagel, E; Legrand, J; Luraschi, H; Motte, M; Namane, N; Norberciak, L; Pascart, T; Vandecandelaere, M, 2018) |
| "As uric acid levels increase there is a relevant clustering of metabolic risk factors, whereas elevated blood pressure is the risk factor less frequently present." | 1.48 | Uric acid is linked to cardiometabolic risk factors in overweight and obese youths. ( Alvarez-Pitti, J; Borghi, C; Lurbe, E; Redon, J; Redon, P; Torro, MI, 2018) |
| "Metabolic syndrome was considered a proxy for overall cardiometabolic risk." | 1.48 | Association between serum activin A and metabolic syndrome in older adults: Potential of activin A as a biomarker of cardiometabolic disease. ( Chen, LK; Chou, MY; Kojima, T; Lee, WJ; Liang, CK; Lin, MH; Loh, CH; Peng, LN, 2018) |
| "Hyperuricemia is associated with incident cardiovascular events in different settings of patients." | 1.46 | Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. ( Addesi, D; Baggetta, R; Cimellaro, A; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tripepi, G, 2017) |
| " Furthermore, there was a dose-response association between the number of CVD risk factors clustering and hyperuricemia." | 1.46 | Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. ( Cheng, Q; Cheng, XQ; Guo, XZ; Liu, L; Liu, Q; Qiu, L; Wu, J; Wu, W; Xu, CL; Xu, T; Ye, YC; Zeng, XJ; Zhu, GJ, 2017) |
| "Uric acid (UA) levels were dichotomized using 6." | 1.46 | Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study. ( Baggio, G; Corti, MC; Crepaldi, G; Manzato, E; Musacchio, E; Perissinotto, E; Punzi, L; Ramonda, R; Sartori, L; Veronese, N; Zambon, S, 2017) |
| "Hyperuricemia is associated with cardiovascular disease and its prevalence is unknown in black Africans." | 1.46 | Distribution of Serum Uric Acid in Black Africans and Its Association With Cardiovascular Risk Factors. ( Baldo, MP; Capingana, DP; Luchi, WM; Magalhães, P; Mill, JG; Moulin, SR; Souza, JB, 2017) |
| "Hyperuricemia is significantly associated with hypertension, renal dysfunction, MACE, and independently confers a higher risk of mortality in patients with AMI." | 1.46 | Association Between Hyperuricemia and Major Adverse Cardiac Events in Patients with Acute Myocardial Infarction. ( Mayise, C; Myeni, NN; Ranjith, N; Sartorius, B, 2017) |
| "Hyperuricemia has been shown to be associated with increased risks of gout and cardiovascular diseases." | 1.43 | Ideal Cardiovascular Health Metrics and Incident Hyperuricemia. ( Chen, S; Cong, H; Cui, L; Gao, J; Gao, X; Huang, Z; Li, W; Li, Z; Meng, L; Wang, Z; Wu, S; Zhang, G; Zhang, R; Zheng, X; Zhou, J, 2016) |
| " It remains to be seen whether allopurinol has a dose-response relationship with cardiovascular events at higher doses." | 1.43 | Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. ( Hallas, J; Lindegaard, HM; Pottegård, A; Søltoft Larsen, K, 2016) |
| "Uric acid is a powerful determinant of blood pressure over time, independent of lifestyle modifications." | 1.43 | Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk. ( Antolini, L; Genovesi, S; Giussani, M; Orlando, A; Pontremoli, R; Rebora, P; Stella, A; Valsecchi, MG; Viazzi, F, 2016) |
| "Prevalence of hyperuricemia is high in patients with hypertension." | 1.43 | Hyperuricemia and Cardiovascular Disease in Patients with Hypertension. ( Acevedo, A; Benavides, J; Chowdhury, M; Lievano, M; Lombo, B; Lopez, M; Montenegro, A; Pena, L, 2016) |
| "67) and also revealed a dose-response relationship in this subgroup." | 1.43 | Association of cognitive function and serum uric acid: Are cardiovascular diseases a mediator among women? ( Brenner, H; Mons, U; Perna, L; Schöttker, B, 2016) |
| "Metabolic syndrome was defined according to the Adult Treatment Panel III criteria modified for children and adolescents." | 1.43 | Association of Serum Uric Acid With Cardiometabolic Risk Factors and Metabolic Syndrome in Iranian Adolescents: the CASPIAN-III Study. ( Asayesh, H; Djalalinia, S; Eslami Shahr Babaki, A; Heshmat, R; Kelishadi, R; Motlagh, ME; Qorbani, M; Safari, O; Safiri, S; Tajadini, MH; Tajbakhsh, R, 2016) |
| "Hyperuricemia is characterized by inhibited nitric oxide system and enhanced synthesis of reactive oxygen species." | 1.42 | Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. ( Barbieri, L; Cassetti, E; De Luca, G; Marino, P; Schaffer, A; Suryapranata, H; Verdoia, M, 2015) |
| "Uric acid (UA) has been reported to be associated with cardiovascular disease (CVD) in caucasians." | 1.42 | Serum Uric Acid, Gender, and Low Ankle Brachial Index in Adults With High Cardiovascular Risk. ( Dong, Y; Hu, D; Tang, Z; Yu, J; Zhan, Y; Zhang, F, 2015) |
| "Uric acid was not significantly associated with stiffness of the aorta, or the carotid or femoral artery among adults aged 40-75 years without and with type 2 diabetes mellitus." | 1.42 | Association between serum uric acid, aortic, carotid and femoral stiffness among adults aged 40-75 years without and with type 2 diabetes mellitus: The Maastricht Study. ( Arts, IC; Boonen, A; Dagnelie, PC; Henry, RM; Koster, A; Schram, MT; Sep, SJ; Stehouwer, CD; van der Kallen, CJ; van der Linden, S; van Sloten, TT; Wijnands, JM, 2015) |
| "Uric acid (UA) is a risk factor for cardiovascular (CV) disease." | 1.42 | Uric acid is an independent predictor of cardiovascular events in post-menopausal women. ( Cimellaro, A; Maio, R; Miceli, S; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tassone, EJ, 2015) |
| "Metabolic syndrome is characterized by a cluster of atherosclerotic cardiovascular risk factors." | 1.42 | Association of Metabolic Syndrome with the Cardioankle Vascular Index in Asymptomatic Korean Population. ( Kang, SG; Lee, YA; Nam, SH; Rho, JS; Song, SW, 2015) |
| "Uric acid was not predictive of events." | 1.42 | Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels. ( Berland, Y; Brunet, P; Burtey, S; Cerini, C; Dou, L; Dussol, B; Gondouin, B; Guieu, R; Jourde-Chiche, N; Loundou, A; Morange, S; Sallee, M, 2015) |
| "Mean uric acid level was 7." | 1.40 | Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis. ( He, F; Huang, F; Peng, F; Wu, X; Xia, X; Yu, X, 2014) |
| "Uric acid was not associated with death-censored graft loss." | 1.40 | Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients. ( Dahle, DO; Hartmann, A; Holdaas, H; Jenssen, T; Leivestad, T; Mjøen, G; Reisaeter, AV; Toft, I; Vårdal, M, 2014) |
| "The pandemic of obesity is a global public health concern." | 1.40 | Overweight and obesity among low-income Muslim Uyghur women in far western China: correlations of body mass index with blood lipids and implications in preventive public health. ( Amanguli, A; Chen, C; Cong, L; Gu, Y; Hao, XL; Jing, MX; Li, F; Li, L; Li, SG; Ma, ZP; Mohemaiti, M; Saimaiti, A; Simayi, D; Tao, L; Wang, W; Wang, YH; Yang, L; Zhan, JQ; Zhang, HY; Zhang, W; Zhang, WJ; Zhao, J; Zou, XG, 2014) |
| "Adults with type 1 diabetes have lower serum uric acid levels compared with nondiabetic adults." | 1.40 | Serum uric acid and hypertension in adults: a paradoxical relationship in type 1 diabetes. ( Bjornstad, P; Chonchol, MB; Jalal, D; Johnson, RJ; Maahs, DM; McFann, K; Paul Wadwa, R; Rewers, M; Rivard, CJ; Sirota, JC; Snell-Bergeon, JK, 2014) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 1.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "Uric acid was significantly higher in those who had a cardiovascular event even in the mild, moderate and severe OSA groups." | 1.40 | Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. ( Erden, A; Inonu, H; Johnson, RJ; Kanbay, A; Kanbay, M; McFann, K; Ozturk, MA; Solak, Y; Uslu, E; Yuksel, SA, 2014) |
| "Uric acid levels were correlated with eGFR(cr-cys) (r = -0." | 1.40 | Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. ( Amadu, AR; Lo, L; Odden, MC; Peralta, CA; Smit, E, 2014) |
| "Hyperuricemia has been shown to be a strong correlate of hypertension in children." | 1.39 | Serum uric acid and blood pressure in children at cardiovascular risk. ( Antolini, L; Brambilla, P; Galbiati, S; Genovesi, S; Giussani, M; Mastriani, S; Pontremoli, R; Stella, A; Valsecchi, MG; Viazzi, F, 2013) |
| "Hyperuricemia is an independent risk factor for mortality, cardiovascular disease, and renal disease in general population." | 1.38 | Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. ( Chang, JM; Chen, HC; Chen, SC; Chiu, YW; Hung, CC; Hwang, SJ; Kuo, MC; Lin, MY; Liu, WC; Yeh, SM, 2012) |
| "Early-onset hyperuricemia is a significant predictor of cardiovascular complications and graft survival independently of graft function." | 1.37 | Clinical significance of early-onset hyperuricemia in renal transplant recipients. ( Choi, BS; Chung, BH; Hwang, HS; Kang, SH; Kim, JI; Kim, YS; Moon, IS; Park, CW; Yang, CW, 2011) |
| "Uric acid level was associated with lower all-cause mortality (HR: 0." | 1.37 | Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. ( Arrington, CJ; Karaboyas, A; Kleophas, W; Latif, W; Levin, NW; Marshall, MR; Pisoni, RL; Robinson, BM; Saran, R; Sen, A; Tong, L; Winchester, JF, 2011) |
| "Prehypertension was defined as a systolic blood pressure of 120-139 mmHg and/or diastolic blood pressure of 80-89 mmHg, and prediabetes was defined as a fasting blood glucose of 5." | 1.37 | High prevalence of coexisting prehypertension and prediabetes among healthy adults in northern and northeastern China. ( Chen, XQ; Ding, HT; Guo, XZ; Han, SM; Liu, YH; Qin, XZ; Qiu, L; Wu, J; Wu, W; Xia, LY; Xu, CL; Yan, WH; Zhu, GJ, 2011) |
| "Asymptomatic hyperuricemia affects one in five adults in the general population and is associated with elevated cardiovascular risk." | 1.37 | [Contribution of the CoLaus study to decipher the determinants of serum uric acid]. ( Bochud, M; Vollenweider, P; Waeber, G, 2011) |
| "Women with type 2 diabetes had higher S-Ca and lower S-Mg than non-diabetes women." | 1.37 | A structural equation model for assessment of links between changes in serum triglycerides, -urate, and -glucose and changes in serum calcium, -magnesium and -phosphate in type 2 diabetes and non-diabetes metabolism. ( Bäckman, L; Håglin, L; Törnkvist, B, 2011) |
| "Uric acid has been known to exert neuroprotective effects by acting as a free radical scavenger; however, several observational studies indicated that high levels of serum uric acid increased the risk of cardiovascular events or stroke." | 1.36 | High levels of serum uric acid are associated with silent brain infarction. ( Heo, SH; Lee, SH, 2010) |
| "Hyperuricemia is a significant factor in a variety of diseases, including gout and cardiovascular diseases." | 1.35 | Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. ( Anzai, N; Babu, E; Endou, H; Hisatome, I; Ichida, K; Jin, CJ; Jutabha, P; Kimura, T; Kitamura, K; Sakurai, H; Srivastava, S, 2008) |
| "We documented 1215 new cases of type 2 diabetes." | 1.35 | Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. ( Choi, HK; De Vera, MA; Krishnan, E, 2008) |
| "Uric acid is a risk factor of cardiovascular disease, as well as a major natural antioxidant, prohibiting the occurrence of cellular damage." | 1.35 | Serum uric acid and cognitive function and dementia. ( Breteler, MM; Euser, SM; Hofman, A; Westendorp, RG, 2009) |
| "Hyperuricemia is common after kidney transplantation." | 1.35 | Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. ( Bandukwala, F; Huang, M; Nash, MM; Prasad, GV; Zaltzman, JS, 2009) |
| "Hyperuricemia is a common finding in hypertensive patients, especially among those who are on diuretic therapy." | 1.35 | Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. ( Batista, MC; Borges, RL; Hirota, AH; Quinto, BM; Ribeiro, AB; Zanella, MT, 2009) |
| "The prevalence of hyperuricemia is low in Uygurs, who have a high prevalence of cardiovascular risk factors such as hypertension, overweight-obesity, dyslipidemia, hyperglycemia, and insulin resistance (IR)." | 1.35 | Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population. ( Hong, J; Li, NF; Wang, HM; Yang, J; Yao, XG; Zhou, L, 2009) |
| "0001), showing a clear dose-response relationship; the adjusted hazard ratio (95%CI) in comparison to the lowest SUA quartile was 1." | 1.35 | Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. ( Brant, LJ; Concin, H; Diem, G; Kelleher, CC; Pfeiffer, KP; Rapp, K; Ruttmann, E; Strasak, AM; Ulmer, H, 2008) |
| "Uric acid is a product of the activity of xanthine oxidase, an enzyme linked to oxidative stress, endothelial dysfunction, and heart failure." | 1.35 | Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. ( Brennan, DM; Hazen, SL; Hoar, BM; Hoogwerf, BJ; Ioachimescu, AG, 2008) |
| "Hypertension is an independent risk factor for peripheral arterial disease." | 1.34 | Prevalence of and risk factors for peripheral arterial disease in the patients with hypertension among Han Chinese. ( Hui, R; Sun, K; Wu, H; Yang, X; Zhang, H; Zhang, W, 2007) |
| "Hyperuricemia is associated with hypertension, vascular disease and cardiovascular (CV) disease." | 1.34 | Association between serum uric acid levels and coronary flow reserve in hypertensive patients without concomitant risk factors. ( Caliskan, M; Erdogan, D; Gullu, H; Muderrisoglu, H; Ozer, I; Yildirim, I; Yildirir, A, 2007) |
| "Thus, cancer cells can no longer divide and cancer activity is inhibited." | 1.34 | Anatomical relationship between traditional acupuncture point ST 36 and Omura's ST 36 (True ST 36) with their therapeutic effects: 1) inhibition of cancer cell division by markedly lowering cancer cell telomere while increasing normal cell telomere, 2) im ( Chen, Y; Duvvi, H; Lu, DP; Ohki, M; Omura, Y; Shimotsura, Y, 2007) |
| "Metabolic syndrome is associated with subclinical organ damage in nondiabetic, essential hypertensive patients." | 1.33 | Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. ( Deferrari, G; Falqui, V; Leoncini, G; Parodi, A; Parodi, D; Pontremoli, R; Ratto, E; Tomolillo, C; Vaccaro, V; Viazzi, F, 2005) |
| "Uric acid is a metabolic product synthesized from nucleic acids, amino acids and the Krebs cycle, reflecting a multiple metabolic associations in humans." | 1.33 | The serum uric acid and related cardiovascular risk factors in south Taiwan. ( Chang, YY; Chen, SS; Chen, WH; Huang, CC; Liu, JS; Peng, MC; Tsai, WC, 2005) |
| "Uric acid has been shown to be heritable; however, genome-wide linkage analyses have not been reported." | 1.33 | Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. ( Cupples, LA; Fox, CS; Guo, CY; Levy, D; Wilson, PW; Yang, Q, 2005) |
| "All patients had never been treated for hyperuricemia, were on no medications, and were free of any other known diseases." | 1.33 | Status of endothelial dependent vasodilation in patients with hyperuricemia. ( Hisatome, I; Igawa, O; Ishida, K; Kato, M; Kinugawa, T; Kotani, K; Ogino, K; Shigemasa, C; Somers, VK; Tomikura, Y, 2005) |
| "Hyperuricemia is part of the "metabolic syndrome"." | 1.32 | Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. ( Debatin, KM; Denzer, C; Heinze, E; Mayer, H; Muche, R; Wabitsch, M, 2003) |
| "Underexcretory hyperuricemia is strongly related to hypertensive organ damage and this relationship does not seem to be mediated by a decreased renal function." | 1.32 | Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. ( Campo, C; Garcia-Puig, J; García-Robles, R; Rodicio, JL; Ruilope, LM; Segura, J, 2003) |
| "Deaths due to ischemic heart disease in both men and women increased when serum uric acid levels were in the highest quartile compared with the lowest quartile (men, >416 vs <321 micromol/L; risk ratio, 1." | 1.31 | Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. ( Alderman, MH; Fang, J, 2000) |
| "To know the prevalence of phenotypic dyslipidemias and their clinical and metabolic characteristics in recently diagnosed hypertensive patients." | 1.31 | [Prevalence of dyslipidemia and its phenotypes in recently diagnosed essential arterial hypertension]. ( García-Morillo, S; Miranda, ML; Montilla, C; Pamies, E; Stiefel, P; Villar, J, 2000) |
| "To determine if obstructive sleep apnea (OSA) is independently associated with cardiovascular risk factors and health status in subjects with severe obesity." | 1.29 | Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. ( Grunstein, RR; Hedner, J; Sjöström, L; Stenlöf, K, 1995) |
| "Epidemiologically, diabetes mellitus affects men by 64% and women by 36%." | 1.29 | [Diabetes mellitus at the National Hospital Center of Ouagadougou (Burkina Faso)]. ( Drabo, PY; Ilboudo, PD; Kabore, J; Lengani, A, 1996) |
| "163 patients suffering from sudden hearing loss were examined with regard to their cardiovascular risk factors (hypertension, hyperlipaemia, cigarette smoking, hyperglycaemia, hyperuricaemia and obesity)." | 1.27 | [Etiology and pathogenesis of sudden deafness]. ( Friedrich, G, 1985) |
| " Each patient was allocated, according to his/her baseline values of serum uric acid or serum creatinine to four different sulphinpyrazone incremental dosage schedules." | 1.27 | Sulphinpyrazone dose schedule in hyperuricemic patients with cardiovascular diseases: tolerability assessment. ( Bertoli, L; Borghi, C; Busnardo, I; Zagnoni, P, 1985) |
| "Post-operative care of cancer patients has to take into consideration additional diseases not related to the basic disease, too." | 1.26 | [Secondary diseases complicating cancer]. ( Kirsch, JJ; Müller, J; Pitule-Schödel, H, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (8.14) | 18.7374 |
| 1990's | 49 (5.11) | 18.2507 |
| 2000's | 184 (19.21) | 29.6817 |
| 2010's | 459 (47.91) | 24.3611 |
| 2020's | 188 (19.62) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 4 |
| Zhang, Y | 18 |
| Zhang, M | 8 |
| Li, H | 7 |
| Wen, C | 1 |
| Zhao, T | 2 |
| Xie, Z | 2 |
| Sun, J | 3 |
| Bao, F | 1 |
| Cui, M | 2 |
| Shi, X | 2 |
| Ju, S | 1 |
| Cong, H | 2 |
| Kawamoto, R | 4 |
| Kikuchi, A | 1 |
| Akase, T | 1 |
| Ninomiya, D | 1 |
| Kumagi, T | 1 |
| Ferreira, JP | 1 |
| Inzucchi, SE | 2 |
| Mattheus, M | 1 |
| Meinicke, T | 1 |
| Steubl, D | 1 |
| Wanner, C | 2 |
| Zinman, B | 2 |
| Katsiki, N | 7 |
| Kouvari, M | 3 |
| Panagiotakos, DB | 4 |
| Borghi, C | 26 |
| Chrysohoou, C | 3 |
| Mikhailidis, DP | 10 |
| Pitsavos, C | 3 |
| Fiorini, G | 1 |
| Chen, J | 6 |
| Piani, F | 1 |
| Engel, B | 1 |
| Hoffmann, F | 1 |
| Freitag, MH | 1 |
| Jacobs, H | 1 |
| Cheng, Z | 1 |
| Zheng, T | 1 |
| Zhang, D | 6 |
| Yang, J | 8 |
| Hu, X | 5 |
| Yin, C | 1 |
| Ren, X | 3 |
| Li, J | 15 |
| Shi, D | 1 |
| Li, N | 2 |
| Zheng, S | 1 |
| Bai, Y | 1 |
| Xue, X | 1 |
| Lu, CL | 1 |
| Jin, XY | 1 |
| Liu, XH | 1 |
| Yang, M | 2 |
| Wang, XQ | 1 |
| Cheng, H | 1 |
| Yuan, J | 1 |
| Liu, Q | 5 |
| Zheng, RX | 1 |
| Robinson, N | 1 |
| Liu, JP | 1 |
| Cota, BC | 1 |
| Priore, SE | 1 |
| Ribeiro, SAV | 1 |
| Juvanhol, LL | 1 |
| de Faria, ER | 1 |
| de Faria, FR | 1 |
| Pereira, PF | 1 |
| Wang, A | 5 |
| Tian, X | 5 |
| Wu, S | 8 |
| Zuo, Y | 2 |
| Chen, S | 11 |
| Mo, D | 1 |
| Luo, Y | 6 |
| Wang, Y | 12 |
| Wang, C | 5 |
| Zhao, M | 2 |
| Li, Y | 15 |
| Yao, S | 1 |
| Xue, H | 2 |
| He, H | 2 |
| Pan, L | 2 |
| Du, J | 2 |
| Jin, Y | 1 |
| Jia, P | 2 |
| Shan, G | 2 |
| Nishizawa, H | 1 |
| Maeda, N | 1 |
| Shimomura, I | 1 |
| Drosos, GC | 1 |
| Vedder, D | 2 |
| Houben, E | 1 |
| Boekel, L | 1 |
| Atzeni, F | 1 |
| Badreh, S | 1 |
| Boumpas, DT | 1 |
| Brodin, N | 1 |
| Bruce, IN | 1 |
| González-Gay, MÁ | 1 |
| Jacobsen, S | 1 |
| Kerekes, G | 1 |
| Marchiori, F | 1 |
| Mukhtyar, C | 1 |
| Ramos-Casals, M | 1 |
| Sattar, N | 1 |
| Schreiber, K | 1 |
| Sciascia, S | 1 |
| Svenungsson, E | 1 |
| Szekanecz, Z | 1 |
| Tausche, AK | 2 |
| Tyndall, A | 1 |
| van Halm, V | 1 |
| Voskuyl, A | 1 |
| Macfarlane, GJ | 1 |
| Ward, MM | 1 |
| Nurmohamed, MT | 2 |
| Tektonidou, MG | 1 |
| Singhal, R | 1 |
| Hechanova, LA | 1 |
| Kim, K | 1 |
| Kang, K | 1 |
| Sheol, H | 1 |
| Shin, J | 1 |
| Sim, Y | 1 |
| Yang, T | 7 |
| Hwang, J | 1 |
| Lee, JM | 1 |
| Petersen, KF | 1 |
| Dufour, S | 1 |
| Li, F | 4 |
| Rothman, DL | 1 |
| Shulman, GI | 1 |
| Mengozzi, A | 3 |
| Virdis, A | 8 |
| Kang, T | 1 |
| Hu, Y | 1 |
| Huang, X | 2 |
| Amoah, AN | 1 |
| Lyu, Q | 1 |
| Lares-Villaseñor, E | 1 |
| Salazar-García, S | 1 |
| Cossío-Torres, PE | 1 |
| Aradillas-García, C | 1 |
| Portales-Pérez, DP | 1 |
| Vargas-Morales, JM | 1 |
| Sekizuka, H | 1 |
| Cai, R | 1 |
| Dong, Y | 5 |
| Zhou, J | 4 |
| Bai, L | 1 |
| Jia, L | 2 |
| Ding, W | 1 |
| Liu, L | 9 |
| Zhang, X | 12 |
| Peng, L | 1 |
| Ma, N | 2 |
| Nie, C | 1 |
| Zhang, L | 5 |
| Xu, Z | 3 |
| Tang, X | 3 |
| Zheng, L | 2 |
| Zhang, T | 3 |
| Hong, F | 1 |
| Yang, Y | 9 |
| Hong, X | 1 |
| Xie, M | 1 |
| Zou, Z | 1 |
| Zheng, C | 1 |
| Reichetzeder, C | 1 |
| Krämer, BK | 3 |
| Lv, Y | 1 |
| Hocher, B | 1 |
| Longo, GZ | 1 |
| Ordaz, KD | 1 |
| da Silva, DCG | 1 |
| Hinnig, PF | 1 |
| Roberto, DMT | 1 |
| Reinert, C | 1 |
| Pot, GK | 1 |
| Palla, L | 1 |
| Choy, SH | 1 |
| Nyanatay, SA | 1 |
| Sothilingam, S | 1 |
| Malek, R | 1 |
| J R, S | 1 |
| Toh, CC | 1 |
| Sundram, M | 1 |
| Md Yusoff, NA | 1 |
| Nagappan, P | 1 |
| Kamaruzaman, S | 1 |
| Yeoh, WS | 1 |
| Ong, TA | 1 |
| Lim, J | 1 |
| Corso, LML | 1 |
| Wing, RR | 1 |
| Tate, DF | 1 |
| Espeland, MA | 1 |
| Blanchard, BE | 1 |
| McCaffery, JM | 1 |
| Copur, S | 1 |
| Demiray, A | 1 |
| Kanbay, M | 10 |
| Bragina, АЕ | 1 |
| Osadchiy, KK | 1 |
| Rodionova, JN | 1 |
| Bayutina, DА | 1 |
| Cherepanov, АG | 1 |
| Podzolkov, VI | 1 |
| Najafi, S | 1 |
| Bahrami, M | 1 |
| Butler, AE | 1 |
| Sahebkar, A | 3 |
| Weisshaar, S | 1 |
| Litschauer, B | 1 |
| Reichardt, B | 1 |
| Gruber, F | 1 |
| Leitner, S | 1 |
| Sibinovic, S | 1 |
| Kossmeier, M | 1 |
| Wolzt, M | 1 |
| Rajadhyaksha, A | 1 |
| Sarate, N | 1 |
| Raghorte, N | 1 |
| Ingawale, S | 1 |
| Agnoletti, D | 1 |
| Cicero, AFG | 8 |
| Lurbe, E | 2 |
| Zhang, Q | 7 |
| Ren, P | 1 |
| Pan, Y | 2 |
| Liu, Y | 7 |
| Li, C | 3 |
| Fan, Z | 1 |
| Han, F | 1 |
| Chen, F | 2 |
| Yuan, L | 1 |
| Xu, T | 3 |
| Liu, J | 6 |
| Han, S | 1 |
| Vallée, A | 1 |
| Tsai, KZ | 1 |
| Liu, PY | 2 |
| Huang, WC | 1 |
| Lima, JAC | 1 |
| Lavie, CJ | 1 |
| Lin, GM | 2 |
| Gruszka, K | 1 |
| Terlecki, M | 1 |
| Klocek, M | 1 |
| Drożdż, T | 1 |
| Rajzer, M | 2 |
| Dewi, IP | 1 |
| Putra, KNS | 1 |
| Dewi, KP | 1 |
| Wardhani, LFK | 1 |
| Julario, R | 1 |
| Dharmadjati, BB | 1 |
| Di Bonito, P | 1 |
| Rosanio, FM | 1 |
| Marcovecchio, ML | 1 |
| Cherubini, V | 1 |
| Delvecchio, M | 1 |
| Di Candia, F | 1 |
| Iafusco, D | 1 |
| Zanfardino, A | 1 |
| Iovane, B | 1 |
| Maffeis, C | 2 |
| Maltoni, G | 1 |
| Ripoli, C | 1 |
| Piccinno, E | 1 |
| Piona, CA | 1 |
| Ricciardi, MR | 1 |
| Schiaffini, R | 1 |
| Franzese, A | 1 |
| Mozzillo, E | 1 |
| Dalbeth, N | 3 |
| Mihov, B | 1 |
| Stewart, A | 1 |
| Gamble, GD | 1 |
| Merriman, TR | 3 |
| Mount, D | 1 |
| Reid, IR | 1 |
| Stamp, LK | 2 |
| Horne, A | 1 |
| Krysiak, R | 12 |
| Kowalcze, K | 7 |
| Okopień, B | 12 |
| Jatuworapruk, K | 1 |
| Rivasi, G | 4 |
| Masi, S | 5 |
| Ungar, A | 4 |
| Duan, Y | 1 |
| Chang, X | 3 |
| Ding, X | 1 |
| An, Y | 1 |
| Wang, G | 1 |
| Yang, S | 4 |
| Ye, Z | 1 |
| Liu, M | 2 |
| Wu, Q | 4 |
| Zhou, C | 1 |
| Zhang, Z | 2 |
| He, P | 1 |
| Liu, C | 5 |
| Qin, X | 2 |
| Pangiotakos, DB | 1 |
| Cimmino, G | 1 |
| Conte, S | 1 |
| Marra, L | 1 |
| Morello, A | 1 |
| Morello, M | 1 |
| De Rosa, G | 1 |
| Pepe, M | 2 |
| Sugraliyev, A | 1 |
| Golino, P | 1 |
| Cirillo, P | 4 |
| Pradwipa, RY | 1 |
| Hustrini, NM | 1 |
| Hidayat, R | 1 |
| Shatri, H | 1 |
| Nilsson, S | 1 |
| Smurthwaite, K | 1 |
| Aylward, LL | 1 |
| Kay, M | 1 |
| Toms, LM | 1 |
| King, L | 1 |
| Marrington, S | 1 |
| Kirk, MD | 1 |
| Mueller, JF | 1 |
| Bräunig, J | 1 |
| Rubín-García, M | 1 |
| Vitelli-Storelli, F | 1 |
| Álvarez-Álvarez, L | 1 |
| Martínez-González, MÁ | 3 |
| Salas-Salvadó, J | 3 |
| Corella, D | 4 |
| Hernáez, Á | 1 |
| Martínez, JA | 1 |
| Alonso-Gómez, ÁM | 2 |
| Wärnberg, J | 3 |
| Vioque, J | 2 |
| Romaguera, D | 2 |
| López-Miranda, J | 1 |
| Estruch, R | 3 |
| Tinahones, FJ | 2 |
| Serra-Majem, LI | 1 |
| Cano-Ibañez, N | 1 |
| Tur, JA | 2 |
| Marcos-Delgado, A | 1 |
| Tresserra-Rimbau, A | 1 |
| Pintó, X | 2 |
| Delgado-Rodríguez, M | 2 |
| Matía-Martín, P | 2 |
| Vidal, J | 2 |
| Vázquez, C | 2 |
| Daimiel, L | 2 |
| Ros, E | 3 |
| Vázquez-Ruiz, Z | 1 |
| Babio, N | 3 |
| Barragán, R | 1 |
| Castañer-Niño, O | 1 |
| Razquin, C | 1 |
| Tojal-Sierra, L | 1 |
| Gómez-Gracia, E | 1 |
| González-Palacios, S | 1 |
| Morey, M | 2 |
| García-Rios, A | 2 |
| Castro-Barquero, S | 1 |
| Bernal-López, MR | 1 |
| Santos-Lozano, JM | 2 |
| Ruiz-Canela, M | 2 |
| Castro-Salomó, A | 1 |
| Pascual-Castelló, EC | 1 |
| Moldon, V | 1 |
| Bullón-Vela, V | 1 |
| Sorto-Sanchez, C | 1 |
| Cenoz-Osinaga, JC | 2 |
| Gutiérrez, L | 1 |
| Mengual, M | 1 |
| Lamuela-Raventós, RM | 1 |
| Martín-Sánchez, V | 1 |
| Basiak, M | 2 |
| Szkróbka, W | 3 |
| Gicchino, MF | 1 |
| Marzuillo, P | 1 |
| Zarrilli, S | 1 |
| Melone, R | 1 |
| Guarino, S | 1 |
| Miraglia Del Giudice, E | 1 |
| Olivieri, AN | 1 |
| Di Sessa, A | 1 |
| Yazdi, F | 2 |
| Shakibi, MR | 1 |
| Baniasad, A | 1 |
| Najafzadeh, MJ | 1 |
| Najafipour, H | 1 |
| Sistani, S | 1 |
| Šebeková, K | 1 |
| Gurecká, R | 1 |
| Repiská, G | 1 |
| Koborová, I | 1 |
| Podracká, Ľ | 1 |
| Salehidoost, R | 1 |
| Taghipour Boroujeni, G | 1 |
| Feizi, A | 1 |
| Aminorroaya, A | 1 |
| Amini, M | 1 |
| Sawada, S | 1 |
| Kajiyama, K | 1 |
| Shida, H | 1 |
| Kimura, R | 1 |
| Nakazato, Y | 1 |
| Iguchi, T | 1 |
| Oniyama, Y | 1 |
| Ishiguro, C | 1 |
| Uyama, Y | 1 |
| Teramura, S | 1 |
| Sankai, T | 1 |
| Yamagishi, K | 1 |
| Umesawa, M | 1 |
| Hayama-Terada, M | 1 |
| Muraki, I | 1 |
| Tanaka, M | 2 |
| Kihara, T | 1 |
| Ohira, T | 1 |
| Imano, H | 1 |
| Cui, R | 1 |
| Shimizu, Y | 1 |
| Okada, T | 1 |
| Kitamura, A | 1 |
| Kiyama, M | 1 |
| Iso, H | 3 |
| Weihrauch-Blüher, S | 1 |
| Wiegand, S | 2 |
| Weihe, P | 1 |
| Prinz, N | 1 |
| Weghuber, D | 2 |
| Leipold, G | 1 |
| Dannemann, A | 1 |
| Bergjohann, L | 1 |
| Reinehr, T | 2 |
| Holl, RW | 2 |
| Moshkovits, Y | 3 |
| Tiosano, S | 3 |
| Kaplan, A | 3 |
| Kalstein, M | 3 |
| Bayshtok, G | 3 |
| Kivity, S | 4 |
| Segev, S | 4 |
| Grossman, E | 3 |
| Segev, A | 3 |
| Maor, E | 4 |
| Fardman, A | 3 |
| Li, D | 7 |
| Wang, D | 4 |
| Dai, X | 3 |
| Ni, Y | 3 |
| Xu, X | 4 |
| Zhang, A | 4 |
| Qi, L | 3 |
| Ren, Z | 3 |
| Zhao, C | 4 |
| Wang, Q | 7 |
| Ren, K | 3 |
| Bai, J | 3 |
| Cao, N | 3 |
| Zou, YW | 3 |
| Li, QH | 3 |
| Zhu, YY | 3 |
| Pan, J | 3 |
| Gao, JW | 3 |
| Lin, JZ | 3 |
| Wu, T | 5 |
| Zheng, HW | 3 |
| Mo, YQ | 3 |
| Ma, JD | 3 |
| Dai, L | 3 |
| Alabi, QK | 3 |
| Akomolafe, RO | 3 |
| Li, B | 4 |
| Chen, L | 7 |
| Tan, T | 2 |
| Bao, W | 2 |
| Rong, S | 2 |
| Cipolletta, E | 1 |
| Tata, LJ | 1 |
| Abhishek, A | 2 |
| Fonseca, AC | 1 |
| Palatini, P | 4 |
| Casiglia, E | 4 |
| Tikhonoff, V | 3 |
| Parati, G | 4 |
| Salvetti, M | 3 |
| Barbagallo, CM | 3 |
| Bombelli, M | 5 |
| Dell'Oro, R | 4 |
| Bruno, B | 2 |
| Lippa, L | 3 |
| D'Elia, L | 3 |
| Masulli, M | 1 |
| Verdecchia, P | 5 |
| Reboldi, G | 3 |
| Angeli, F | 1 |
| Mallamaci, F | 3 |
| Cirillo, M | 5 |
| Rattazzi, M | 3 |
| Gesualdo, L | 4 |
| Mazza, A | 3 |
| Giannattasio, C | 5 |
| Maloberti, A | 4 |
| Volpe, M | 5 |
| Tocci, G | 3 |
| Iaccarino, G | 3 |
| Nazzaro, P | 3 |
| Galletti, F | 3 |
| Ferri, C | 8 |
| Desideri, G | 8 |
| Viazzi, F | 12 |
| Pontremoli, R | 13 |
| Muiesan, ML | 4 |
| Grassi, G | 7 |
| Niu, Y | 1 |
| Zhang, H | 5 |
| Li, XD | 1 |
| Cheng, Y | 1 |
| Wang, S | 3 |
| Krittanawong, C | 1 |
| El-Am, EA | 1 |
| Sun, T | 1 |
| Chrysant, SG | 1 |
| Kohagura, K | 1 |
| Kojima, S | 3 |
| Uchiyama, K | 3 |
| Yokota, N | 3 |
| Tokutake, E | 3 |
| Wakasa, Y | 3 |
| Hiramitsu, S | 4 |
| Waki, M | 3 |
| Jinnouchi, H | 3 |
| Kakuda, H | 3 |
| Hayashi, T | 3 |
| Kawai, N | 3 |
| Sugawara, M | 3 |
| Mori, H | 3 |
| Tsujita, K | 1 |
| Matsui, K | 3 |
| Hisatome, I | 12 |
| Ohya, Y | 3 |
| Kimura, K | 3 |
| Saito, Y | 5 |
| Ogawa, H | 3 |
| Xu, Q | 3 |
| Wang, P | 3 |
| Georgoulis, M | 1 |
| Dang, W | 1 |
| Zhao, L | 2 |
| Wang, J | 8 |
| Xu, D | 1 |
| You, L | 1 |
| Zhong, Y | 1 |
| Wu, Y | 3 |
| Chen, Y | 7 |
| Hui, R | 2 |
| Zhang, W | 7 |
| Liu, F | 2 |
| Pa, L | 1 |
| Wang, X | 10 |
| Cui, Z | 1 |
| Wang, H | 7 |
| Peng, X | 1 |
| Zhao, J | 3 |
| Yoshida, K | 1 |
| Desai, RJ | 2 |
| Glynn, RJ | 1 |
| Solomon, DH | 2 |
| Kim, SC | 2 |
| Bi, M | 1 |
| Feng, A | 1 |
| Tian, S | 1 |
| Alunno, A | 1 |
| Carubbi, F | 1 |
| Mariani, FM | 1 |
| Martini, C | 1 |
| Campanozzi, E | 1 |
| Kuwabara, M | 3 |
| Kodama, T | 1 |
| Ae, R | 1 |
| Andres-Hernando, A | 1 |
| Lanaspa, MA | 2 |
| Konan, V | 1 |
| Swamy, N | 1 |
| Zhang, SX | 1 |
| Yu, YL | 1 |
| Tang, ST | 1 |
| Lo, K | 2 |
| Feng, YQ | 2 |
| Chen, JY | 1 |
| Wu, Z | 1 |
| Cheng, C | 1 |
| Sun, X | 5 |
| Guo, D | 1 |
| Liu, X | 5 |
| Zhang, C | 1 |
| Liu, T | 1 |
| Song, J | 4 |
| Zuo, R | 1 |
| Sun, L | 1 |
| Zhu, Z | 1 |
| Wang, B | 3 |
| Lu, Z | 1 |
| Huang, CM | 1 |
| Chen, HH | 1 |
| Wang, HS | 2 |
| Mironova, OI | 1 |
| Kjeldsen, SE | 4 |
| Mariampillai, JE | 1 |
| Høieggen, A | 3 |
| Di Fusco, SA | 1 |
| Castello, L | 1 |
| Marino, G | 1 |
| Flori, M | 1 |
| Aquilani, S | 1 |
| Riccio, C | 1 |
| Nardi, F | 1 |
| Gulizia, MM | 1 |
| Gabrielli, D | 1 |
| Oliva, F | 1 |
| Colivicchi, F | 1 |
| Machnik, G | 1 |
| D, K | 1 |
| Swaminathan, K | 1 |
| Velmurugan, G | 1 |
| Ramakrishnan, A | 1 |
| Alexander, T | 1 |
| Raghupathy, AK | 1 |
| Mohanraj, S | 1 |
| Wei, X | 1 |
| Huang, S | 2 |
| Lan, X | 1 |
| Zheng, J | 3 |
| Luo, H | 2 |
| He, Y | 7 |
| Lei, W | 2 |
| Ming, J | 1 |
| Guo, Z | 1 |
| Li, X | 16 |
| Zhou, S | 1 |
| Ma, H | 3 |
| Addisu, B | 1 |
| Bekele, S | 1 |
| Wube, TB | 1 |
| Hirigo, AT | 1 |
| Cheneke, W | 1 |
| Carboni, J | 1 |
| Basalely, A | 1 |
| Singer, P | 1 |
| Castellanos, L | 1 |
| Sethna, CB | 2 |
| Fernandez-Crespo, S | 1 |
| Vazquez-Agra, N | 1 |
| Marques-Afonso, AT | 1 |
| Cruces-Sande, A | 1 |
| Martinez-Olmos, MA | 1 |
| Araujo-Vilar, D | 1 |
| Hermida-Ameijeiras, A | 1 |
| Wakabayashi, D | 1 |
| Kato, S | 1 |
| Yamakage, H | 1 |
| Kato, H | 2 |
| Kusakabe, T | 1 |
| Ozu, N | 1 |
| Kasama, S | 1 |
| Kasahara, M | 2 |
| Satoh-Asahara, N | 1 |
| Kim, JY | 2 |
| Seo, C | 1 |
| Pak, H | 1 |
| Lim, H | 1 |
| Chang, TI | 1 |
| Meng, R | 1 |
| Lian, F | 1 |
| Jiang, C | 1 |
| Hu, M | 1 |
| Cui, K | 1 |
| Song, Y | 4 |
| Yin, D | 1 |
| Song, W | 2 |
| Zhu, C | 3 |
| Feng, L | 2 |
| Fu, R | 1 |
| Lu, Y | 3 |
| Song, C | 1 |
| Dong, Q | 1 |
| Dou, K | 1 |
| Hu, J | 3 |
| Tang, L | 1 |
| Zhan, X | 3 |
| Peng, F | 2 |
| Wen, Y | 1 |
| Feng, X | 2 |
| Wu, X | 3 |
| Gao, X | 2 |
| Zhou, Q | 2 |
| Zheng, W | 3 |
| Su, N | 1 |
| Yu, B | 1 |
| Yu, W | 1 |
| Dai, S | 1 |
| Feng, C | 1 |
| Shao, Y | 3 |
| Zhao, X | 2 |
| He, T | 1 |
| Yang, Z | 2 |
| Lv, T | 1 |
| Lv, X | 1 |
| Wan, F | 1 |
| Zhou, H | 2 |
| Zhou, Y | 3 |
| Chen, M | 1 |
| Shui, X | 1 |
| Feng, J | 3 |
| Zhang, B | 5 |
| He, D | 1 |
| Zheng, D | 1 |
| Efstathiadou, A | 1 |
| Gill, D | 2 |
| McGrane, F | 1 |
| Quinn, T | 2 |
| Dawson, J | 5 |
| Shao, H | 1 |
| Sawhney, MS | 1 |
| Shi, L | 1 |
| Klauser, AS | 1 |
| Halpern, EJ | 1 |
| Strobl, S | 1 |
| Gruber, J | 1 |
| Feuchtner, G | 1 |
| Bellmann-Weiler, R | 1 |
| Weiss, G | 1 |
| Stofferin, H | 1 |
| Jaschke, W | 1 |
| Skeete, J | 1 |
| Ridley, E | 1 |
| DiPette, DJ | 1 |
| Tin, A | 1 |
| Marten, J | 1 |
| Halperin Kuhns, VL | 1 |
| Wuttke, M | 1 |
| Kirsten, H | 1 |
| Sieber, KB | 1 |
| Qiu, C | 1 |
| Gorski, M | 1 |
| Yu, Z | 1 |
| Giri, A | 1 |
| Sveinbjornsson, G | 1 |
| Li, M | 3 |
| Chu, AY | 1 |
| Hoppmann, A | 1 |
| O'Connor, LJ | 1 |
| Prins, B | 1 |
| Nutile, T | 1 |
| Noce, D | 1 |
| Akiyama, M | 1 |
| Cocca, M | 1 |
| Ghasemi, S | 1 |
| van der Most, PJ | 1 |
| Horn, K | 1 |
| Xu, Y | 4 |
| Fuchsberger, C | 1 |
| Sedaghat, S | 1 |
| Afaq, S | 1 |
| Amin, N | 1 |
| Ärnlöv, J | 1 |
| Bakker, SJL | 1 |
| Bansal, N | 1 |
| Baptista, D | 1 |
| Bergmann, S | 1 |
| Biggs, ML | 1 |
| Biino, G | 1 |
| Boerwinkle, E | 2 |
| Bottinger, EP | 1 |
| Boutin, TS | 1 |
| Brumat, M | 1 |
| Burkhardt, R | 1 |
| Campana, E | 1 |
| Campbell, A | 1 |
| Campbell, H | 2 |
| Carroll, RJ | 1 |
| Catamo, E | 1 |
| Chambers, JC | 1 |
| Ciullo, M | 1 |
| Concas, MP | 1 |
| Coresh, J | 2 |
| Corre, T | 1 |
| Cusi, D | 1 |
| Felicita, SC | 1 |
| de Borst, MH | 1 |
| De Grandi, A | 1 |
| de Mutsert, R | 1 |
| de Vries, APJ | 1 |
| Delgado, G | 2 |
| Demirkan, A | 1 |
| Devuyst, O | 1 |
| Dittrich, K | 1 |
| Eckardt, KU | 1 |
| Ehret, G | 1 |
| Endlich, K | 1 |
| Evans, MK | 1 |
| Gansevoort, RT | 2 |
| Gasparini, P | 1 |
| Giedraitis, V | 1 |
| Gieger, C | 1 |
| Girotto, G | 1 |
| Gögele, M | 1 |
| Gordon, SD | 1 |
| Gudbjartsson, DF | 1 |
| Gudnason, V | 2 |
| Haller, T | 1 |
| Hamet, P | 1 |
| Harris, TB | 3 |
| Hayward, C | 1 |
| Hicks, AA | 1 |
| Hofer, E | 1 |
| Holm, H | 1 |
| Huang, W | 2 |
| Hutri-Kähönen, N | 2 |
| Hwang, SJ | 3 |
| Ikram, MA | 1 |
| Lewis, RM | 1 |
| Ingelsson, E | 1 |
| Jakobsdottir, J | 1 |
| Jonsdottir, I | 1 |
| Jonsson, H | 1 |
| Joshi, PK | 1 |
| Josyula, NS | 1 |
| Jung, B | 1 |
| Kähönen, M | 2 |
| Kamatani, Y | 1 |
| Kanai, M | 1 |
| Kerr, SM | 1 |
| Kiess, W | 2 |
| Kleber, ME | 2 |
| Koenig, W | 4 |
| Kooner, JS | 1 |
| Körner, A | 1 |
| Kovacs, P | 1 |
| Kronenberg, F | 2 |
| Kubo, M | 1 |
| Kühnel, B | 1 |
| La Bianca, M | 1 |
| Lange, LA | 1 |
| Lehne, B | 1 |
| Lehtimäki, T | 2 |
| Loeffler, M | 1 |
| Loos, RJF | 1 |
| Lyytikäinen, LP | 2 |
| Magi, R | 1 |
| Mahajan, A | 1 |
| Martin, NG | 1 |
| März, W | 3 |
| Mascalzoni, D | 1 |
| Matsuda, K | 1 |
| Meisinger, C | 3 |
| Meitinger, T | 1 |
| Metspalu, A | 1 |
| Milaneschi, Y | 1 |
| O'Donnell, CJ | 2 |
| Wilson, OD | 1 |
| Gaziano, JM | 1 |
| Mishra, PP | 1 |
| Mohlke, KL | 1 |
| Mononen, N | 1 |
| Montgomery, GW | 1 |
| Mook-Kanamori, DO | 1 |
| Müller-Nurasyid, M | 1 |
| Nadkarni, GN | 1 |
| Nalls, MA | 1 |
| Nauck, M | 1 |
| Nikus, K | 1 |
| Ning, B | 1 |
| Nolte, IM | 1 |
| Noordam, R | 1 |
| O'Connell, JR | 1 |
| Olafsson, I | 1 |
| Padmanabhan, S | 1 |
| Penninx, BWJH | 1 |
| Perls, T | 1 |
| Peters, A | 1 |
| Pirastu, M | 1 |
| Pirastu, N | 1 |
| Pistis, G | 1 |
| Polasek, O | 1 |
| Ponte, B | 1 |
| Porteous, DJ | 1 |
| Poulain, T | 1 |
| Preuss, MH | 1 |
| Rabelink, TJ | 1 |
| Raffield, LM | 1 |
| Raitakari, OT | 2 |
| Rettig, R | 1 |
| Rheinberger, M | 1 |
| Rice, KM | 1 |
| Rizzi, F | 1 |
| Robino, A | 1 |
| Rudan, I | 1 |
| Krajcoviechova, A | 2 |
| Cifkova, R | 3 |
| Rueedi, R | 1 |
| Ruggiero, D | 1 |
| Ryan, KA | 1 |
| Saba, Y | 1 |
| Salvi, E | 1 |
| Schmidt, H | 1 |
| Schmidt, R | 1 |
| Shaffer, CM | 1 |
| Smith, AV | 2 |
| Smith, BH | 1 |
| Spracklen, CN | 1 |
| Strauch, K | 1 |
| Stumvoll, M | 1 |
| Sulem, P | 1 |
| Tajuddin, SM | 1 |
| Teren, A | 1 |
| Thiery, J | 1 |
| Thio, CHL | 1 |
| Thorsteinsdottir, U | 1 |
| Toniolo, D | 1 |
| Tönjes, A | 1 |
| Tremblay, J | 1 |
| Uitterlinden, AG | 2 |
| Vaccargiu, S | 1 |
| van der Harst, P | 1 |
| van Duijn, CM | 2 |
| Verweij, N | 1 |
| Völker, U | 1 |
| Vollenweider, P | 2 |
| Waeber, G | 2 |
| Waldenberger, M | 1 |
| Whitfield, JB | 1 |
| Wild, SH | 1 |
| Wilson, JF | 1 |
| Yang, Q | 3 |
| Zonderman, AB | 1 |
| Bochud, M | 2 |
| Wilson, JG | 1 |
| Pendergrass, SA | 1 |
| Ho, K | 1 |
| Parsa, A | 1 |
| Pramstaller, PP | 1 |
| Psaty, BM | 2 |
| Böger, CA | 1 |
| Snieder, H | 1 |
| Butterworth, AS | 1 |
| Okada, Y | 1 |
| Edwards, TL | 1 |
| Stefansson, K | 1 |
| Susztak, K | 1 |
| Scholz, M | 1 |
| Heid, IM | 1 |
| Hung, AM | 1 |
| Teumer, A | 1 |
| Pattaro, C | 1 |
| Woodward, OM | 1 |
| Vitart, V | 1 |
| Köttgen, A | 2 |
| Rahimi-Sakak, F | 1 |
| Maroofi, M | 1 |
| Rahmani, J | 1 |
| Bellissimo, N | 1 |
| Hekmatdoost, A | 1 |
| Meng, X | 2 |
| Spiliopoulou, A | 1 |
| Timofeeva, M | 1 |
| Wei, WQ | 1 |
| Gifford, A | 1 |
| Varley, T | 1 |
| Tzoulaki, I | 2 |
| Joshi, P | 1 |
| Denny, JC | 1 |
| Mckeigue, P | 1 |
| Theodoratou, E | 2 |
| Hu, L | 1 |
| Hu, G | 1 |
| Xu, BP | 1 |
| Zhu, L | 1 |
| Zhou, W | 1 |
| Wang, T | 2 |
| Bao, H | 1 |
| Cheng, X | 1 |
| Pérez Ruiz, F | 1 |
| Richette, P | 3 |
| Stack, AG | 2 |
| Karra Gurunath, R | 1 |
| García de Yébenes, MJ | 1 |
| Carmona, L | 2 |
| Fogacci, F | 1 |
| Grandi, E | 1 |
| Rizzoli, E | 1 |
| D'Addato, S | 1 |
| Qian, F | 1 |
| Liu, H | 4 |
| Schwingshackl, L | 1 |
| Neuenschwander, M | 1 |
| Hoffmann, G | 1 |
| Buyken, AE | 1 |
| Schlesinger, S | 1 |
| Palazzuoli, A | 1 |
| Landolfo, M | 2 |
| Cosentino, E | 1 |
| Chen, W | 4 |
| Lu, D | 1 |
| Huang, Z | 3 |
| Xiao, L | 1 |
| Pilemann-Lyberg, S | 3 |
| Hansen, TW | 3 |
| Rossing, P | 3 |
| Lee, SY | 1 |
| Park, W | 3 |
| Suh, YJ | 1 |
| Lim, MJ | 2 |
| Kwon, SR | 2 |
| Lee, JH | 2 |
| Joo, YB | 1 |
| Oh, YK | 1 |
| Jung, KH | 2 |
| Walrabenstein, W | 1 |
| Heslinga, M | 1 |
| de Vries, R | 1 |
| Nurmohamed, M | 1 |
| van Schaardenburg, D | 1 |
| Gerritsen, M | 2 |
| Chilunga, FP | 1 |
| Henneman, P | 1 |
| Requena-Méndez, A | 1 |
| Meeks, K | 1 |
| Beune, E | 1 |
| Mannens, MMAM | 1 |
| Agyemang, C | 1 |
| Sumpter, NA | 1 |
| Saag, KG | 5 |
| Reynolds, RJ | 1 |
| Fujita, K | 1 |
| Yamada, H | 2 |
| Iijima, M | 1 |
| Ichida, K | 2 |
| Han, QX | 1 |
| Zhao, YL | 1 |
| Zhang, F | 5 |
| Luan, FX | 1 |
| Liu, DW | 1 |
| Liu, ZS | 1 |
| Cai, GY | 1 |
| Chen, XM | 1 |
| Zhu, HY | 1 |
| Huang, JY | 1 |
| Sun, S | 1 |
| Chen, CL | 1 |
| Huang, YQ | 1 |
| Sakata, S | 1 |
| Hata, J | 1 |
| Honda, T | 1 |
| Hirakawa, Y | 1 |
| Oishi, E | 1 |
| Shibata, M | 1 |
| Yoshida, D | 1 |
| Goto, K | 1 |
| Kitazono, T | 1 |
| Ninomiya, T | 1 |
| Verma, S | 1 |
| Ji, Q | 2 |
| Bhatt, DL | 1 |
| Mazer, CD | 1 |
| Al-Omran, M | 1 |
| Ofstad, AP | 1 |
| Zwiener, I | 1 |
| George, JT | 1 |
| Fitchett, D | 1 |
| Chiu, S | 1 |
| Siri-Tarino, P | 1 |
| Bergeron, N | 1 |
| Suh, JH | 1 |
| Krauss, RM | 1 |
| Sessa, C | 1 |
| Granata, A | 1 |
| Gaudio, A | 1 |
| Xourafa, A | 1 |
| Malatino, L | 1 |
| Lentini, P | 1 |
| Fatuzzo, P | 1 |
| Rapisarda, F | 1 |
| Castellino, P | 1 |
| Zanoli, L | 1 |
| Cao, L | 1 |
| Zhao, TY | 1 |
| Yang, X | 6 |
| Zhu, XX | 1 |
| Zou, HJ | 1 |
| Wan, WG | 1 |
| Xue, Y | 1 |
| Rosei, EA | 2 |
| Facchetti, R | 2 |
| Bernardino, B | 1 |
| Pauletto, P | 1 |
| Quarti-Trevano, F | 1 |
| Yang, W | 1 |
| Wei, Z | 1 |
| Dan, X | 1 |
| Zhang, P | 2 |
| Chen, XH | 2 |
| Liang, WY | 2 |
| Liu, WW | 2 |
| Liu, ML | 2 |
| Semplicini, A | 1 |
| Arévalo-Lorido, JC | 1 |
| Carretero-Gómez, J | 1 |
| Robles, NR | 1 |
| Cao, JY | 1 |
| Waldman, B | 1 |
| O'Connell, R | 1 |
| Sullivan, DR | 1 |
| Scott, RS | 1 |
| Aryal, N | 1 |
| Gebski, V | 1 |
| Marschner, I | 1 |
| Taskinen, MR | 1 |
| Simes, JR | 1 |
| McGill, N | 1 |
| Jenkins, AJ | 3 |
| Keech, AC | 1 |
| Konta, T | 3 |
| Ichikawa, K | 3 |
| Kawasaki, R | 1 |
| Fujimoto, S | 2 |
| Iseki, K | 2 |
| Moriyama, T | 1 |
| Yamagata, K | 1 |
| Tsuruya, K | 1 |
| Narita, I | 1 |
| Kondo, M | 1 |
| Shibagaki, Y | 1 |
| Asahi, K | 1 |
| Watanabe, T | 2 |
| Wohlfahrt, P | 1 |
| Bruthans, J | 1 |
| Šulc, P | 1 |
| Lánská, V | 1 |
| Eremiášová, L | 1 |
| Pudil, J | 1 |
| Linhart, A | 2 |
| Filipovský, J | 1 |
| Mayer, O | 1 |
| Widimský, J | 1 |
| Blaha, M | 1 |
| Shibata, Y | 2 |
| Shirakabe, A | 1 |
| Okazaki, H | 1 |
| Matsushita, M | 1 |
| Goda, H | 1 |
| Shigihara, S | 1 |
| Asano, K | 1 |
| Kiuchi, K | 1 |
| Tani, K | 1 |
| Murase, T | 1 |
| Nakamura, T | 2 |
| Kobayashi, N | 1 |
| Hata, N | 1 |
| Asai, K | 1 |
| Shimizu, W | 1 |
| Ameri, P | 2 |
| Canepa, M | 2 |
| Luigi Nicolosi, G | 1 |
| Marchioli, R | 2 |
| Latini, R | 1 |
| Tavazzi, L | 2 |
| Maggioni, AP | 3 |
| Siemińska, E | 1 |
| Sobczak, P | 1 |
| Skibińska, N | 1 |
| Sikora, J | 1 |
| Russo, E | 1 |
| Leoncini, G | 6 |
| Esposito, P | 1 |
| Garibotto, G | 1 |
| Ray, EC | 1 |
| Rosas, G | 1 |
| Gaffo, A | 1 |
| Rahn, EJ | 1 |
| Dehlin, M | 1 |
| Kapetanovic, M | 1 |
| Svärd, A | 1 |
| Bengtsson Boström, K | 1 |
| Wändell, P | 1 |
| Sigurdardottir, V | 1 |
| Forsblad d'Elia, H | 1 |
| Jacobsson, L | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 5 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 2 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 2 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 3 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 7 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 2 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Zhou, L | 3 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 4 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 2 |
| Shan, A | 1 |
| Zhao, H | 4 |
| Wu, M | 2 |
| Ma, Q | 2 |
| Zhang, E | 1 |
| Zhang, J | 4 |
| Xue, F | 1 |
| Deng, L | 1 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Chen, G | 3 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 2 |
| Li, P | 2 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Zhou, X | 4 |
| Wang, W | 2 |
| Hou, J | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 4 |
| Zhu, J | 3 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 5 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 2 |
| Hu, W | 1 |
| Lu, J | 2 |
| Li, W | 3 |
| Wu, W | 4 |
| Du, F | 1 |
| Ji, H | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 2 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 2 |
| Huang, H | 2 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 2 |
| Kong, X | 1 |
| Li, S | 2 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 3 |
| Liang, C | 1 |
| Yang, H | 2 |
| Yu, K | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 2 |
| Ning, Q | 1 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 2 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 2 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Fu, D | 1 |
| Li, Z | 3 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 3 |
| Mannarino, MR | 2 |
| Pirro, M | 3 |
| Patsourakos, NG | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Xi, J | 1 |
| Wei, H | 1 |
| Wang, Z | 4 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Huang, J | 2 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 2 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 2 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 3 |
| Fan, Y | 2 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Guan, H | 1 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 3 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 2 |
| Hong, M | 1 |
| Chen, K | 3 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 2 |
| Jamil, MI | 1 |
| Cheng, D | 1 |
| Wu, CT | 2 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 2 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 4 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 2 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 2 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 3 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 2 |
| Qi, MC | 1 |
| Chang, CC | 3 |
| Dinh, TK | 1 |
| Lee, YA | 2 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 2 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 2 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Chen, B | 2 |
| Wu, J | 4 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 2 |
| Fei, P | 1 |
| Xie, Q | 2 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 2 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 2 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 2 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Li, Q | 3 |
| Cao, T | 1 |
| Guo, L | 2 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Sun, B | 2 |
| Cao, P | 1 |
| Gu, S | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 2 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 2 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Qian, Y | 1 |
| Cheng, Q | 3 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 2 |
| Situ, B | 1 |
| An, T | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 2 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Bawazier, LA | 1 |
| Sja'bani, M | 1 |
| Irijanto, F | 1 |
| Zulaela, Z | 1 |
| Widiatmoko, A | 1 |
| Kholiq, A | 1 |
| Tomino, Y | 1 |
| Gažarová, M | 1 |
| Mečiarová, L | 1 |
| Kang, HH | 1 |
| Won, KB | 1 |
| Heo, R | 1 |
| Han, D | 1 |
| Chang, HJ | 1 |
| Petreski, T | 1 |
| Ekart, R | 1 |
| Hojs, R | 1 |
| Bevc, S | 1 |
| Qualliu, E | 1 |
| Occhi, L | 1 |
| Grasso, E | 1 |
| Tognola, C | 1 |
| Tavecchia, G | 1 |
| Cartella, I | 1 |
| Milani, M | 1 |
| Vallerio, P | 1 |
| Signorini, S | 1 |
| Brambilla, P | 2 |
| Casati, M | 1 |
| D'Silva, KM | 1 |
| Yokose, C | 1 |
| Lu, N | 1 |
| McCormick, N | 1 |
| Lee, H | 1 |
| Choi, HK | 5 |
| Waheed, Y | 1 |
| Yang, F | 1 |
| Chen, Z | 3 |
| Badve, SV | 1 |
| Lv, J | 1 |
| Lin, Z | 1 |
| Kong, Y | 1 |
| Wan, Q | 1 |
| Liu, A | 1 |
| Hou, FF | 1 |
| Liang, M | 1 |
| Bento, C | 1 |
| Matos, A | 1 |
| Cordeiro, A | 1 |
| Ramalho, A | 1 |
| Mackenzie, IS | 2 |
| Ford, I | 1 |
| Nuki, G | 1 |
| Hallas, J | 3 |
| Hawkey, CJ | 1 |
| Webster, J | 2 |
| Ralston, SH | 1 |
| Walters, M | 3 |
| Robertson, M | 1 |
| De Caterina, R | 1 |
| Findlay, E | 1 |
| Perez-Ruiz, F | 4 |
| McMurray, JJV | 1 |
| MacDonald, TM | 2 |
| Liu, R | 1 |
| Peng, Y | 1 |
| Wu, H | 2 |
| Diao, X | 1 |
| Ye, H | 1 |
| Yi, C | 1 |
| Mao, H | 1 |
| Huang, F | 3 |
| Yu, X | 5 |
| Moulin-Mares, SRA | 1 |
| Oliosa, PR | 1 |
| Faria, ER | 1 |
| Zago-Gomes, MP | 1 |
| Mill, JG | 2 |
| Kobalava, ZD | 2 |
| Troitskaya, EA | 2 |
| Sandoval-Plata, G | 1 |
| Nakafero, G | 1 |
| Chakravorty, M | 1 |
| Morgan, K | 1 |
| Miake, J | 1 |
| Taufiq, F | 1 |
| Mahati, E | 1 |
| Maharani, N | 1 |
| Utami, SB | 1 |
| Bahrudin, U | 1 |
| Ninomiya, H | 1 |
| Cameron, AC | 1 |
| Burgess, S | 1 |
| Doherty, DJ | 1 |
| Karhunen, V | 1 |
| Abdul-Rahim, AH | 1 |
| Taylor-Rowan, M | 1 |
| Zuber, V | 1 |
| Tsao, PS | 1 |
| Klarin, D | 1 |
| Evangelou, E | 1 |
| Elliott, P | 2 |
| Damrauer, SM | 1 |
| Quinn, TJ | 1 |
| Dehghan, A | 2 |
| Tanaka, A | 1 |
| Node, K | 2 |
| Kobayashi, Y | 1 |
| Dimitriadis, GD | 1 |
| Marty-Ané, A | 1 |
| Norberciak, L | 2 |
| Andrès, M | 1 |
| Houvenagel, E | 2 |
| Ducoulombier, V | 2 |
| Legrand, J | 2 |
| Budzik, JF | 2 |
| Pascart, T | 2 |
| Huang, CP | 1 |
| Chen, WL | 2 |
| El-Eshmawy, MM | 1 |
| Mahsoub, N | 1 |
| Asar, M | 1 |
| Elsehely, I | 1 |
| You, H | 1 |
| Han, P | 1 |
| Yue, C | 1 |
| Teng, F | 1 |
| Qin, R | 1 |
| Geng, H | 1 |
| Xu, W | 1 |
| Lai, P | 1 |
| Liang, J | 2 |
| Pugliese, NR | 2 |
| Georgiopoulos, G | 1 |
| Han, X | 1 |
| Peng, LH | 1 |
| Xu, WD | 1 |
| Zhao, ZX | 1 |
| He, CS | 1 |
| Li, L | 3 |
| Yun, C | 1 |
| Cui, L | 2 |
| Dinu, M | 1 |
| Colombini, B | 1 |
| Pagliai, G | 1 |
| Giangrandi, I | 1 |
| Cesari, F | 1 |
| Gori, A | 1 |
| Giusti, B | 1 |
| Marcucci, R | 1 |
| Sofi, F | 1 |
| Jin, Z | 1 |
| Gigante, B | 1 |
| Savonen, K | 1 |
| Kurl, S | 1 |
| Giral, P | 2 |
| Smit, A | 1 |
| Veglia, F | 1 |
| Tremoli, E | 1 |
| Baldassarre, D | 1 |
| Morikawa, N | 1 |
| Bancks, MP | 1 |
| Yano, Y | 2 |
| Gaffo, AL | 3 |
| Duprez, DA | 1 |
| Gross, MD | 2 |
| Jacobs, DR | 5 |
| Wu, C | 1 |
| Kuang, W | 1 |
| Gulab, A | 1 |
| Torres, R | 1 |
| Pelayo, J | 1 |
| Lo, KB | 1 |
| Shahzad, A | 1 |
| Pradhan, S | 1 |
| Rangaswami, J | 1 |
| Feitosa, GS | 1 |
| Zhou, Z | 1 |
| Seki, H | 1 |
| Kaneko, H | 1 |
| Morita, H | 1 |
| Itoh, H | 1 |
| Morita, K | 1 |
| Matsuoka, S | 1 |
| Kiriyama, H | 1 |
| Kamon, T | 1 |
| Fujiu, K | 1 |
| Michihata, N | 1 |
| Jo, T | 1 |
| Takeda, N | 2 |
| Nakamura, S | 1 |
| Yasunaga, H | 1 |
| Komuro, I | 1 |
| Deng, Q | 1 |
| Zhong, L | 1 |
| Yu, Y | 2 |
| Braffett, BH | 1 |
| Basu, A | 1 |
| Bebu, I | 1 |
| Dagogo-Jack, S | 1 |
| Orchard, TJ | 2 |
| Wallia, A | 1 |
| Lopes-Virella, MF | 1 |
| Garvey, WT | 1 |
| Lachin, JM | 1 |
| Lyons, TJ | 1 |
| Huang, JH | 1 |
| Li, RH | 1 |
| Huang, SL | 1 |
| Sia, HK | 1 |
| Yu, CH | 1 |
| Tang, FC | 1 |
| Nie, Q | 1 |
| Hao, Z | 1 |
| Song, G | 1 |
| Tsuchihashi, T | 1 |
| Shi, Q | 2 |
| Wang, R | 2 |
| Shan, Y | 1 |
| Ye, M | 1 |
| Jia, B | 1 |
| Cheong, E | 1 |
| Ryu, S | 2 |
| Lee, JY | 1 |
| Lee, SH | 4 |
| Sung, JW | 1 |
| Cho, DS | 1 |
| Park, JB | 1 |
| Sung, KC | 3 |
| Caliceti, C | 1 |
| Calabria, D | 1 |
| Roda, A | 1 |
| Li, ZJ | 1 |
| Yi, CJ | 1 |
| Tang, N | 1 |
| Pagidipati, NJ | 1 |
| Hess, CN | 1 |
| Clare, RM | 1 |
| Akerblom, A | 1 |
| Tricoci, P | 1 |
| Wojdyla, D | 1 |
| Keenan, RT | 3 |
| James, S | 1 |
| Held, C | 1 |
| Mahaffey, KW | 1 |
| Klein, AB | 2 |
| Roe, MT | 1 |
| Alshahawey, M | 1 |
| Shahin, SM | 1 |
| Elsaid, TW | 1 |
| Sabri, NA | 1 |
| Perticone, M | 2 |
| Tripepi, G | 1 |
| Maio, R | 2 |
| Cimellaro, A | 2 |
| Addesi, D | 1 |
| Baggetta, R | 1 |
| Sciacqua, A | 2 |
| Sesti, G | 2 |
| Perticone, F | 2 |
| Pillinger, MH | 4 |
| Bangalore, S | 1 |
| Baumgartner, S | 3 |
| Morlock, R | 1 |
| Washburn, LK | 1 |
| Nixon, PA | 1 |
| Snively, BM | 1 |
| Russell, GB | 1 |
| Shaltout, HA | 1 |
| South, AM | 1 |
| O'Shea, TM | 1 |
| Sezai, A | 1 |
| Obata, K | 1 |
| Abe, K | 1 |
| Kanno, S | 1 |
| Sekino, H | 1 |
| Hannawi, S | 1 |
| AlSalmi, I | 1 |
| Moller, I | 1 |
| Naredo, E | 1 |
| Punzi, L | 3 |
| Cheng, YY | 1 |
| Kao, TW | 1 |
| Chang, YW | 1 |
| Wu, CJ | 1 |
| Peng, TC | 1 |
| Wu, LW | 1 |
| Yang, HF | 1 |
| Liaw, FY | 1 |
| Qiu, L | 3 |
| Cheng, XQ | 2 |
| Zeng, XJ | 1 |
| Ye, YC | 2 |
| Guo, XZ | 3 |
| Xu, CL | 2 |
| Zhu, GJ | 3 |
| Noma, K | 1 |
| Kihara, Y | 2 |
| Higashi, Y | 2 |
| Thottam, GE | 1 |
| Krasnokutsky, S | 1 |
| Zhang, JW | 1 |
| McCaffrey, TA | 1 |
| He, XQ | 1 |
| Feng, XR | 1 |
| Fu, SW | 1 |
| Genoni, G | 1 |
| Menegon, V | 1 |
| Secco, GG | 1 |
| Sonzini, M | 1 |
| Martelli, M | 1 |
| Castagno, M | 1 |
| Ricotti, R | 1 |
| Monzani, A | 1 |
| Aronici, M | 1 |
| Grossini, E | 1 |
| Di Mario, C | 1 |
| Bona, G | 1 |
| Bellone, S | 1 |
| Prodam, F | 1 |
| Zoccali, C | 1 |
| Castro-Torres, Y | 1 |
| Khan, NY | 1 |
| Carmona-Puerta, R | 1 |
| Chang, YK | 1 |
| Huang, LF | 1 |
| Shin, SJ | 1 |
| Lin, KD | 1 |
| Chong, K | 1 |
| Yen, FS | 1 |
| Chang, HY | 1 |
| Chuang, SY | 2 |
| Hsieh, TJ | 1 |
| Hsiung, CA | 1 |
| Hsu, CC | 1 |
| Ishii, T | 1 |
| Taguri, M | 1 |
| Tamura, K | 1 |
| Oyama, K | 1 |
| Sampson, AL | 1 |
| Singer, RF | 1 |
| Walters, GD | 1 |
| Butković, M | 1 |
| Watts, GF | 1 |
| Nidorf, M | 1 |
| Jelinek, M | 1 |
| Kei, A | 1 |
| Koutsouka, F | 1 |
| Makri, A | 1 |
| Elisaf, M | 2 |
| Latourte, A | 1 |
| Bardin, T | 5 |
| Carluccio, E | 1 |
| Coiro, S | 1 |
| Ambrosio, G | 1 |
| Bonaventura, A | 1 |
| Gallo, F | 1 |
| Carbone, F | 1 |
| Liberale, L | 1 |
| Maggi, D | 1 |
| Sacchi, G | 1 |
| Dallegri, F | 1 |
| Montecucco, F | 1 |
| Cordera, R | 1 |
| Isakov, VA | 1 |
| Bogdanova, AA | 1 |
| Bessonov, VV | 1 |
| Sentsova, TB | 1 |
| Tutelyan, VA | 1 |
| Lin, Y | 2 |
| Kazlova, V | 1 |
| Hong, J | 2 |
| Velliquette, RA | 1 |
| Kamei, K | 2 |
| Kayama, T | 2 |
| Kubota, I | 2 |
| Tseng, WC | 1 |
| Chen, YT | 2 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Tarng, DC | 1 |
| Jun, JE | 1 |
| Lee, YB | 1 |
| Lee, SE | 1 |
| Ahn, JY | 1 |
| Kim, G | 1 |
| Jin, SM | 1 |
| Hur, KY | 1 |
| Lee, MK | 1 |
| Kang, MR | 1 |
| Kim, JH | 1 |
| Franklin, JM | 1 |
| Spoendlin-Allen, J | 1 |
| Danaei, G | 1 |
| Montserrat-Capdevila, J | 1 |
| Seminario, MA | 1 |
| Godoy, P | 1 |
| Marsal, JR | 1 |
| Ortega, M | 1 |
| Pujol, J | 1 |
| Castañ, MT | 1 |
| Alsedà, M | 1 |
| Betriu, À | 1 |
| Lecube, A | 1 |
| Portero, M | 1 |
| Purroy, F | 1 |
| Valdivielso, JM | 1 |
| Barbé, F | 1 |
| Zheng, BK | 1 |
| Bellasi, A | 1 |
| Raggi, P | 1 |
| Wang, LX | 1 |
| Filipp, SL | 1 |
| Urbina, EM | 1 |
| Gurka, MJ | 3 |
| DeBoer, MD | 3 |
| Hu, JW | 1 |
| Chu, C | 1 |
| Yan, Y | 2 |
| Wang, K | 1 |
| Lv, YB | 1 |
| Deng, Y | 1 |
| Yan, B | 1 |
| Mu, JJ | 1 |
| Wu, CH | 1 |
| Liu, LK | 1 |
| Chou, RH | 1 |
| Kuo, CS | 1 |
| Huang, PH | 1 |
| Chen, LK | 3 |
| Lin, SJ | 1 |
| Disveld, IJM | 2 |
| Fransen, J | 3 |
| Rongen, GA | 2 |
| Kienhorst, LBE | 2 |
| Zoakman, S | 2 |
| Janssens, HJEM | 2 |
| Janssen, M | 4 |
| Persson, F | 1 |
| Theilade, S | 2 |
| Singh Ahluwalia, T | 1 |
| Frystyk, J | 1 |
| Cho, SK | 1 |
| Kim, I | 1 |
| Ndrepepa, G | 1 |
| Capon, B | 1 |
| Grandjean, A | 1 |
| Namane, N | 1 |
| Motte, M | 1 |
| Vandecandelaere, M | 1 |
| Luraschi, H | 1 |
| Godart, C | 1 |
| Zhuang, X | 1 |
| Guo, Y | 1 |
| Ni, A | 1 |
| Liao, L | 1 |
| Liao, X | 1 |
| Sun, GZ | 1 |
| Wang, HY | 2 |
| Sun, YX | 1 |
| Mancusi, C | 1 |
| Izzo, R | 1 |
| Ferrara, LA | 1 |
| Rozza, F | 1 |
| Losi, MA | 1 |
| Canciello, G | 1 |
| de Luca, N | 1 |
| Trimarco, B | 3 |
| de Simone, G | 1 |
| Torro, MI | 1 |
| Alvarez-Pitti, J | 1 |
| Redon, J | 1 |
| Redon, P | 1 |
| Yuval Bar-Asher, S | 1 |
| Shefer, A | 1 |
| Shoham-Vardi, I | 1 |
| Sergienko, R | 1 |
| Wolak, A | 1 |
| Sheiner, E | 1 |
| Wolak, T | 1 |
| Rothenbacher, D | 1 |
| Braig, S | 1 |
| Logan, CA | 1 |
| Feike, G | 1 |
| Müller, M | 1 |
| Reister, F | 1 |
| Genuneit, J | 1 |
| Park, SK | 1 |
| Rosenthal, TR | 1 |
| Williams, JS | 1 |
| Shelton, JM | 1 |
| Takahashi, M | 1 |
| Bobulescu, IA | 1 |
| Peng, LN | 2 |
| Chou, MY | 1 |
| Liang, CK | 1 |
| Lee, WJ | 3 |
| Kojima, T | 1 |
| Lin, MH | 1 |
| Loh, CH | 1 |
| Terkeltaub, R | 2 |
| Goldfarb, DS | 1 |
| Schechter, BM | 1 |
| Valiyil, R | 1 |
| Jalal, D | 3 |
| Pillinger, M | 1 |
| White, WB | 1 |
| Molino Lova, R | 1 |
| Vassalle, C | 1 |
| Masini, E | 1 |
| Del Ry, S | 1 |
| Cabiati, M | 1 |
| Pasquini, G | 2 |
| Macchi, C | 2 |
| Ashcroft, JA | 1 |
| Woźnicka-Leśkiewicz, L | 1 |
| Posadzy-Małaczyńska, A | 1 |
| Marcinkowska, J | 1 |
| Pongpanich, P | 1 |
| Pitakpaiboonkul, P | 1 |
| Takkavatakarn, K | 1 |
| Praditpornsilpa, K | 1 |
| Eiam-Ong, S | 1 |
| Susantitaphong, P | 1 |
| Maruhashi, T | 1 |
| Tykarski, A | 1 |
| Widecka, K | 1 |
| Filipiak, KJ | 1 |
| Domienik-Karłowicz, J | 1 |
| Kostka-Jeziorny, K | 1 |
| Varga, A | 1 |
| Jaguszewski, M | 1 |
| Narkiewicz, K | 1 |
| Mancia, G | 3 |
| Woerner, J | 1 |
| Lucas, T | 1 |
| Pierce, J | 1 |
| Riis, JL | 1 |
| Granger, DA | 1 |
| Ferron, AJT | 1 |
| Francisqueti, FV | 1 |
| Minatel, IO | 1 |
| Silva, CCVA | 1 |
| Bazan, SGZ | 1 |
| Kitawara, KAH | 1 |
| Garcia, JL | 1 |
| Corrêa, CR | 1 |
| Moreto, F | 3 |
| Ferreira, ALA | 1 |
| Li, DD | 1 |
| Zhao, D | 3 |
| Dong, P | 1 |
| Petruzzo, M | 1 |
| Moccia, M | 2 |
| Biyik, Z | 1 |
| Guney, I | 2 |
| Abeles, AM | 2 |
| Perez-Gomez, MV | 1 |
| Bartsch, LA | 1 |
| Castillo-Rodriguez, E | 1 |
| Fernandez-Prado, R | 1 |
| Ortiz, A | 2 |
| Gan, LM | 1 |
| Lagerström-Fermér, M | 1 |
| Ericsson, H | 1 |
| Nelander, K | 1 |
| Lindstedt, EL | 1 |
| Michaëlsson, E | 1 |
| Kjaer, M | 1 |
| Heijer, M | 1 |
| Whatling, C | 1 |
| Fuhr, R | 1 |
| Oki, Y | 1 |
| Kawai, M | 1 |
| Minai, K | 1 |
| Ogawa, K | 1 |
| Inoue, Y | 1 |
| Morimoto, S | 1 |
| Tanaka, T | 1 |
| Nagoshi, T | 1 |
| Ogawa, T | 1 |
| Yoshimura, M | 1 |
| Özalp Kızılay, D | 1 |
| Şen, S | 1 |
| Ersoy, B | 1 |
| Bailey, CJ | 1 |
| Ali, N | 1 |
| Rahman, S | 1 |
| Islam, S | 1 |
| Haque, T | 1 |
| Molla, NH | 1 |
| Sumon, AH | 1 |
| Kathak, RR | 1 |
| Asaduzzaman, M | 1 |
| Islam, F | 1 |
| Mohanto, NC | 1 |
| Hasnat, MA | 1 |
| Nurunnabi, SM | 1 |
| Ahmed, S | 1 |
| Tao, M | 1 |
| Pi, X | 1 |
| Ma, X | 1 |
| Gu, H | 2 |
| Chi, Y | 1 |
| Zhuang, S | 1 |
| Liu, N | 1 |
| Marek, B | 1 |
| Gupta, MK | 1 |
| Singh, JA | 1 |
| Mazidi, M | 1 |
| Tofte, N | 1 |
| Winther, SA | 1 |
| Ahluwalia, TS | 1 |
| Ng, DK | 1 |
| Jiang, S | 1 |
| Saland, J | 1 |
| Warady, BA | 1 |
| Furth, S | 1 |
| Meyers, KE | 1 |
| Taddei, S | 1 |
| Jansen, TLTA | 1 |
| Papandreou, C | 1 |
| Díaz-López, A | 1 |
| Becerra-Tomas, N | 2 |
| Schröder, H | 1 |
| Martínez, AJ | 1 |
| Serra-Majem, L | 2 |
| Muñoz-Garach, A | 1 |
| Lapetra, J | 1 |
| Bueno-Cavanillas, A | 1 |
| M Sánchez, V | 1 |
| Bulló, M | 1 |
| Sorli, JV | 1 |
| Quifer, M | 1 |
| Colom, A | 1 |
| Oncina-Canovas, A | 1 |
| T Sierra, L | 1 |
| Barón-López, J | 1 |
| Pérez-Farinós, N | 1 |
| Abete, I | 1 |
| Sanchez-Villegas, A | 1 |
| Casas, R | 1 |
| F García, JC | 1 |
| Corbella, E | 1 |
| Del M Bibiloni, M | 1 |
| Diez-Espino, J | 1 |
| Asensio, EM | 1 |
| Torras, L | 1 |
| Compañ-Gabucio, L | 1 |
| S Lete, I | 1 |
| Castañer, O | 1 |
| Toida, T | 1 |
| Sato, Y | 1 |
| Komatsu, H | 1 |
| Kitamura, K | 2 |
| Hashem, SG | 1 |
| Elsaady, MM | 1 |
| Afify, HG | 1 |
| Omer, WE | 1 |
| Youssef, AO | 1 |
| El-Kemary, M | 1 |
| Attia, MS | 1 |
| Persil-Ozkan, O | 1 |
| Yigit, E | 1 |
| Yigit, Z | 1 |
| Huangfu, N | 1 |
| Zhao, R | 1 |
| Henein, MY | 1 |
| Vancheri, F | 1 |
| Yuan, Y | 1 |
| Lin, F | 2 |
| Lin, M | 1 |
| Zhu, P | 1 |
| Lai, S | 1 |
| Mittherhofer, AP | 1 |
| Cianci, R | 1 |
| Riviello, L | 1 |
| Vocaturi, M | 1 |
| Mastroluca, D | 1 |
| Ciccariello, M | 1 |
| Von Heland, M | 1 |
| Ricciuti, GP | 1 |
| Salciccia, S | 1 |
| Mazzaferro, S | 1 |
| Bednarska-Czerwińska, A | 1 |
| Genovesi, S | 3 |
| Giussani, M | 3 |
| Orlando, A | 2 |
| Battaglino, MG | 1 |
| Nava, E | 1 |
| Weir, MR | 1 |
| Cortese, F | 1 |
| Giordano, P | 1 |
| Scicchitano, P | 1 |
| Faienza, MF | 1 |
| De Pergola, G | 1 |
| Calculli, G | 1 |
| Meliota, G | 1 |
| Ciccone, MM | 1 |
| Frampton, C | 1 |
| Drake, J | 1 |
| Doughty, RN | 1 |
| Troughton, RW | 1 |
| Richards, AM | 1 |
| Saladini, F | 1 |
| Pane, M | 1 |
| Beilin, LJ | 3 |
| Eguchi, K | 1 |
| Imai, Y | 1 |
| Kario, K | 1 |
| Ohkubo, T | 1 |
| Pierdomenico, SD | 1 |
| Schwartz, JE | 1 |
| Wing, L | 1 |
| Messerli, FH | 1 |
| Burnier, M | 2 |
| Brombo, G | 1 |
| Bonetti, F | 1 |
| Volpato, S | 1 |
| Morieri, ML | 1 |
| Napoli, E | 1 |
| Bandinelli, S | 2 |
| Cherubini, A | 2 |
| Maggio, M | 3 |
| Guralnik, J | 1 |
| Ferrucci, L | 4 |
| Zuliani, G | 1 |
| Shroff, RC | 1 |
| Price, KL | 1 |
| Kolatsi-Joannou, M | 1 |
| Todd, AF | 1 |
| Wells, D | 1 |
| Deanfield, J | 1 |
| Johnson, RJ | 21 |
| Rees, L | 1 |
| Woolf, AS | 1 |
| Long, DA | 1 |
| Tabara, Y | 2 |
| Kohara, K | 2 |
| Kusunoki, T | 2 |
| Abe, M | 2 |
| Miki, T | 2 |
| Jin, YL | 1 |
| Zhu, T | 1 |
| Xu, L | 2 |
| Zhang, WS | 1 |
| Liu, B | 2 |
| Jiang, CQ | 1 |
| Yu, H | 1 |
| Huang, LM | 1 |
| Cheng, KK | 1 |
| Thomas, GN | 1 |
| Lam, TH | 1 |
| Juraschek, SP | 2 |
| Kovell, LC | 1 |
| Miller, ER | 2 |
| Gelber, AC | 1 |
| Dutta, A | 2 |
| Henley, W | 1 |
| Pilling, LC | 1 |
| Wallace, RB | 2 |
| Melzer, D | 2 |
| Skak-Nielsen, H | 1 |
| Torp-Pedersen, C | 1 |
| Finer, N | 1 |
| Caterson, ID | 1 |
| Van Gaal, L | 1 |
| James, WP | 1 |
| Sharma, AM | 1 |
| Coutinho, W | 1 |
| Andersson, C | 1 |
| Hanley, A | 1 |
| Casserly, LF | 1 |
| Cronin, CJ | 1 |
| Abdalla, AA | 1 |
| Kiernan, TJ | 1 |
| Murthy, BV | 1 |
| Hegarty, A | 1 |
| Hannigan, A | 1 |
| Nguyen, HT | 1 |
| Soltani, Z | 1 |
| Rasheed, K | 1 |
| Kapusta, DR | 1 |
| Reisin, E | 1 |
| Stanhope, KL | 2 |
| Schwarz, JM | 1 |
| Havel, PJ | 2 |
| Cerecero, P | 1 |
| Hernández-Prado, B | 1 |
| Denova, E | 1 |
| Valdés, R | 1 |
| Vázquez, G | 1 |
| Camarillo, E | 1 |
| Huitrón, G | 1 |
| Larina, VN | 1 |
| Bart, BIa | 1 |
| Larin, VG | 1 |
| Donskov, AS | 1 |
| Shimodaira, M | 1 |
| Niwa, T | 1 |
| Hanyu, N | 1 |
| Nakayama, T | 1 |
| Savarese, G | 1 |
| Rosano, G | 1 |
| Dellegrottaglie, S | 1 |
| Losco, T | 1 |
| Casaretti, L | 1 |
| D'Amore, C | 1 |
| Gambardella, F | 1 |
| Prastaro, M | 1 |
| Rengo, G | 1 |
| Leosco, D | 1 |
| Perrone-Filardi, P | 1 |
| Hosoya, T | 1 |
| Ohno, I | 2 |
| Blüher, S | 1 |
| Molz, E | 1 |
| Otto, KP | 1 |
| Sergeyev, E | 1 |
| Tuschy, S | 1 |
| L'Allemand-Jander, D | 1 |
| Antolini, L | 2 |
| Galbiati, S | 1 |
| Mastriani, S | 1 |
| Stella, A | 2 |
| Valsecchi, MG | 2 |
| Molino-Lova, R | 1 |
| Prisco, D | 1 |
| Vannetti, F | 1 |
| Paperini, A | 1 |
| Zipoli, R | 1 |
| Luisi, ML | 1 |
| Cecchi, F | 1 |
| Hsia, SH | 1 |
| Chou, IJ | 2 |
| Kuo, CF | 2 |
| See, LC | 2 |
| Huang, JL | 1 |
| Yu, KH | 2 |
| Luo, SF | 2 |
| Lin, KL | 1 |
| Stojanov, M | 2 |
| Stefanovic, A | 2 |
| Dzingalasevic, G | 1 |
| Ivanisevic, J | 2 |
| Miljkovic, M | 1 |
| Mandic-Radic, S | 1 |
| Prostran, M | 2 |
| Ohara, C | 1 |
| Inoue, K | 1 |
| Kashima, S | 1 |
| Inoue, M | 1 |
| Akimoto, K | 1 |
| Yalcin, M | 1 |
| Kardesoglu, E | 1 |
| Isilak, Z | 1 |
| Uz, O | 1 |
| Atalay, M | 1 |
| Tezcan, M | 1 |
| Uzun, M | 1 |
| Sitki Cebeci, B | 1 |
| Schisterman, EF | 1 |
| Mumford, SL | 1 |
| Sjaarda, LA | 1 |
| Zheng, JS | 1 |
| Xu, XJ | 1 |
| Hu, XJ | 1 |
| Luo, M | 1 |
| Nakagawa, T | 6 |
| Sanchez-Lozada, LG | 3 |
| Shafiu, M | 1 |
| Sundaram, S | 1 |
| Le, M | 1 |
| Ishimoto, T | 1 |
| Sautin, YY | 3 |
| Uysal, Y | 1 |
| Wolters, B | 1 |
| Knop, C | 1 |
| Zhao, G | 1 |
| Huang, L | 1 |
| Song, M | 1 |
| Ishiguro, Y | 1 |
| Matsuyama, H | 1 |
| Yamada, K | 1 |
| Kato, K | 1 |
| Noba, M | 1 |
| Uemura, A | 1 |
| Matsubara, Y | 1 |
| Yoshida, S | 1 |
| Kani, A | 1 |
| Tokuda, M | 1 |
| Hasegawa, K | 1 |
| Uchiyama, T | 1 |
| Matsubara, S | 1 |
| Mori, K | 1 |
| Kimura, H | 1 |
| Shino, K | 1 |
| Kato, Y | 1 |
| Ishii, J | 1 |
| Xia, X | 2 |
| He, F | 1 |
| Qin, Y | 1 |
| Shu, F | 1 |
| Zeng, Y | 1 |
| Diao, L | 1 |
| Wan, J | 1 |
| Mi, M | 1 |
| Onat, A | 1 |
| Altuğ Çakmak, H | 1 |
| Can, G | 1 |
| Yüksel, M | 1 |
| Köroğlu, B | 1 |
| Yüksel, H | 1 |
| Karabacak, M | 2 |
| Varol, E | 1 |
| Kahraman, F | 1 |
| Ozaydin, M | 1 |
| Türkdogan, AK | 1 |
| Ersoy, IH | 1 |
| Mascarenhas-Melo, F | 1 |
| Sereno, J | 1 |
| Teixeira-Lemos, E | 1 |
| Marado, D | 1 |
| Palavra, F | 1 |
| Pinto, R | 1 |
| Rocha-Pereira, P | 1 |
| Teixeira, F | 1 |
| Reis, F | 1 |
| Shil, AB | 1 |
| Greer, JR | 1 |
| Marwaha, A | 1 |
| Dahle, DO | 1 |
| Jenssen, T | 1 |
| Holdaas, H | 1 |
| Leivestad, T | 1 |
| Vårdal, M | 1 |
| Mjøen, G | 1 |
| Reisaeter, AV | 1 |
| Toft, I | 1 |
| Hartmann, A | 1 |
| Puddu, PE | 4 |
| Bilancio, G | 1 |
| Terradura Vagnarelli, O | 1 |
| Lombardi, C | 1 |
| Mancini, M | 3 |
| Zanchetti, A | 3 |
| Menotti, A | 3 |
| Dong, J | 1 |
| Han, QF | 1 |
| Zhu, TY | 1 |
| Ren, YP | 1 |
| Chen, JH | 2 |
| Zhao, HP | 1 |
| Chen, MH | 2 |
| Xu, R | 1 |
| Hao, CM | 1 |
| Zhang, R | 3 |
| Zhang, XH | 1 |
| Tian, N | 1 |
| Zalawadiya, SK | 1 |
| Veeranna, V | 1 |
| Mallikethi-Reddy, S | 1 |
| Bavishi, C | 1 |
| Lunagaria, A | 1 |
| Kottam, A | 1 |
| Afonso, L | 1 |
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 1 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Roddy, E | 1 |
| Mallen, CD | 1 |
| Doherty, M | 2 |
| Yokoyama, H | 1 |
| Sone, H | 1 |
| Honjo, J | 1 |
| Okizaki, S | 1 |
| Yamada, D | 1 |
| Shudo, R | 1 |
| Shimizu, H | 1 |
| Moriya, T | 1 |
| Haneda, M | 1 |
| Gouri, A | 2 |
| Dekaken, A | 2 |
| Bentorki, AA | 2 |
| Touaref, A | 2 |
| Yekhlef, A | 1 |
| Sekkache, F | 1 |
| Kouicem, N | 2 |
| Dohmen, K | 1 |
| Tanaka, H | 1 |
| Haruno, M | 1 |
| Tunstall-Pedoe, H | 1 |
| Woodward, M | 1 |
| Fenech, G | 1 |
| Rajzbaum, G | 1 |
| Mazighi, M | 1 |
| Blacher, J | 1 |
| Qin, L | 1 |
| Lu, S | 1 |
| Xing, Y | 1 |
| Li, R | 1 |
| Ning, G | 1 |
| Cong, L | 1 |
| Zhan, JQ | 1 |
| Yang, L | 1 |
| Li, SG | 1 |
| Chen, C | 3 |
| Zhang, HY | 1 |
| Ma, ZP | 1 |
| Hao, XL | 1 |
| Simayi, D | 1 |
| Tao, L | 1 |
| Amanguli, A | 1 |
| Mohemaiti, M | 1 |
| Jing, MX | 1 |
| Saimaiti, A | 1 |
| Zou, XG | 1 |
| Gu, Y | 1 |
| Wang, YH | 1 |
| Zhang, WJ | 1 |
| Salem, S | 1 |
| Mehrsai, A | 1 |
| Heydari, R | 1 |
| Pourmand, G | 1 |
| Ho, CS | 2 |
| Chen, YM | 2 |
| Woo, J | 2 |
| Bjornstad, P | 1 |
| Paul Wadwa, R | 1 |
| Sirota, JC | 1 |
| Snell-Bergeon, JK | 1 |
| McFann, K | 4 |
| Rewers, M | 1 |
| Rivard, CJ | 1 |
| Chonchol, MB | 1 |
| Maahs, DM | 1 |
| Zhang, JX | 1 |
| Zhang, YP | 1 |
| Wu, QN | 1 |
| Garneri, D | 1 |
| Gonnella, A | 1 |
| Ambrosioni, E | 1 |
| Costa, FV | 1 |
| Leonetti, G | 1 |
| Pessina, AC | 1 |
| Agabiti Rosei, E | 1 |
| Deferrari, G | 3 |
| Ronchi, I | 1 |
| Carugo, S | 1 |
| Cuspidi, C | 1 |
| de Carvalho Vidigal, F | 1 |
| de Lima Rosado, LE | 1 |
| Paixão Rosado, G | 1 |
| Lanes Ribeiro, Rde C | 1 |
| Castro Franceschini, Sdo C | 1 |
| Kawada, T | 1 |
| Du, T | 2 |
| Lin, X | 1 |
| Huo, R | 1 |
| Sarmento, PL | 1 |
| Plavnik, FL | 1 |
| Scaciota, A | 1 |
| Lima, JO | 1 |
| Miranda, RB | 1 |
| Ajzen, SA | 1 |
| Picillo, M | 1 |
| Erro, R | 1 |
| Vitale, C | 2 |
| Longo, K | 1 |
| Amboni, M | 1 |
| Santangelo, G | 1 |
| Spina, E | 1 |
| De Rosa, A | 1 |
| De Michele, G | 1 |
| Santoro, L | 1 |
| Barone, P | 1 |
| Pellecchia, MT | 1 |
| Scheven, L | 1 |
| Joosten, MM | 1 |
| de Jong, PE | 1 |
| Bakker, SJ | 1 |
| Kanbay, A | 1 |
| Inonu, H | 1 |
| Solak, Y | 3 |
| Erden, A | 2 |
| Uslu, E | 1 |
| Yuksel, SA | 1 |
| Ozturk, MA | 1 |
| Yakhlef, A | 1 |
| Joo, K | 1 |
| Joo, H | 1 |
| Meek, IL | 1 |
| Vonkeman, HE | 1 |
| van de Laar, MA | 1 |
| Odden, MC | 1 |
| Amadu, AR | 1 |
| Smit, E | 1 |
| Lo, L | 1 |
| Peralta, CA | 1 |
| Wijnands, JM | 2 |
| Boonen, A | 2 |
| Dagnelie, PC | 2 |
| van Greevenbroek, MM | 1 |
| van der Kallen, CJ | 2 |
| Ferreira, I | 1 |
| Schalkwijk, CG | 1 |
| Feskens, EJ | 1 |
| Stehouwer, CD | 2 |
| van der Linden, S | 2 |
| Arts, IC | 2 |
| Massy, ZA | 1 |
| Maizel, J | 1 |
| Yuan, G | 1 |
| Jeon, JS | 1 |
| Chung, SH | 1 |
| Han, DC | 1 |
| Noh, H | 1 |
| Kwon, SH | 1 |
| Lindholm, B | 1 |
| Lee, HB | 1 |
| Badeĭnikova, KK | 1 |
| Mazaev, AP | 1 |
| Toguzova, ZA | 1 |
| Mamedov, MN | 1 |
| Didigova, RT | 1 |
| Verardi, FM | 1 |
| Pareo, I | 1 |
| Bentivenga, C | 1 |
| Cicero, AF | 2 |
| Yilmaz, BA | 1 |
| Caliskan, Y | 1 |
| Yilmaz, A | 1 |
| Ozkok, A | 1 |
| Bilge, AK | 1 |
| Deniz, G | 1 |
| Sariyar, M | 1 |
| Yildiz, A | 2 |
| Kienhorst, LB | 1 |
| Janssens, HJ | 1 |
| Xia, K | 2 |
| de Oliveira, A | 1 |
| Hermsdorff, HHM | 1 |
| Guedes Cocate, P | 1 |
| Bressan, J | 1 |
| Azevedo Novello, A | 1 |
| Cardoso dos Santos, E | 1 |
| José Natali, A | 1 |
| Barbieri, L | 1 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Cassetti, E | 1 |
| Marino, P | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Němec, P | 1 |
| Marotta, T | 2 |
| Liccardo, M | 2 |
| Schettini, F | 2 |
| Verde, F | 2 |
| Ferrara, AL | 2 |
| Li, LX | 2 |
| Dong, XH | 1 |
| Li, MF | 1 |
| Li, TT | 2 |
| Bao, YQ | 2 |
| Jia, WP | 2 |
| Doumas, M | 1 |
| Athyros, VG | 5 |
| Karagiannis, A | 4 |
| Franchi, C | 1 |
| Salerno, F | 1 |
| Conca, A | 1 |
| Djade, CD | 1 |
| Tettamanti, M | 1 |
| Pasina, L | 1 |
| Corrao, S | 1 |
| Marengoni, A | 1 |
| Marcucci, M | 1 |
| Mannucci, PM | 1 |
| Nobili, A | 1 |
| Battelli, MG | 1 |
| Polito, L | 1 |
| Bolognesi, A | 1 |
| Recondo, J | 1 |
| Ortega-Calvo, M | 1 |
| Fitó, M | 1 |
| Basora, J | 1 |
| Mehta, T | 1 |
| Nuccio, E | 1 |
| Madero, M | 3 |
| Sarnak, MJ | 2 |
| Zhan, Y | 2 |
| Tang, Z | 1 |
| Hu, D | 3 |
| Yu, J | 2 |
| Gonçalves, JP | 1 |
| Ramos, E | 1 |
| Severo, M | 1 |
| Wong, MC | 1 |
| Ong, KK | 1 |
| Dunger, DB | 1 |
| Lopes, C | 1 |
| Goicoechea, M | 2 |
| Garcia de Vinuesa, S | 1 |
| Verdalles, U | 2 |
| Verde, E | 1 |
| Macias, N | 1 |
| Santos, A | 1 |
| Pérez de Jose, A | 1 |
| Cedeño, S | 1 |
| Linares, T | 1 |
| Luño, J | 2 |
| Lytvyn, Y | 1 |
| Perkins, BA | 1 |
| Cherney, DZ | 1 |
| Escudero-López, B | 1 |
| Berná, G | 1 |
| Ortega, Á | 1 |
| Herrero-Martín, G | 1 |
| Cerrillo, I | 1 |
| Martín, F | 1 |
| Fernández-Pachón, MS | 1 |
| Qiu, Q | 1 |
| Gong, Y | 1 |
| Dou, L | 2 |
| Bozec, E | 1 |
| Girerd, N | 1 |
| Aykas, F | 1 |
| Bulut, K | 1 |
| Dogan, S | 1 |
| Sarli, B | 1 |
| Acmaz, G | 1 |
| Afsar, B | 4 |
| Siriopol, D | 2 |
| Covic, A | 4 |
| Sharma, S | 1 |
| Yigit, M | 1 |
| Turkdogan, KA | 1 |
| Sert, M | 1 |
| De Giorgi, A | 1 |
| Fabbian, F | 1 |
| Pala, M | 1 |
| Tiseo, R | 1 |
| Parisi, C | 1 |
| Misurati, E | 1 |
| Manfredini, R | 1 |
| Park, M | 1 |
| Jung, SJ | 1 |
| Yoon, S | 1 |
| Yun, JM | 1 |
| Yoon, HJ | 1 |
| Grammer, TB | 2 |
| Silbernagel, G | 2 |
| Ritz, E | 1 |
| Cao, H | 1 |
| Zou, R | 1 |
| Molshatzki, N | 1 |
| Weinstein, G | 1 |
| Streifler, JY | 1 |
| Goldbourt, U | 1 |
| Tanne, D | 1 |
| Kopel, E | 2 |
| Wysokiński, A | 1 |
| Kłoszewska, I | 1 |
| Peluso, I | 1 |
| Teichner, A | 1 |
| Manafikhi, H | 1 |
| Palmery, M | 1 |
| Sertoglu, E | 1 |
| Uyanik, M | 1 |
| Zhu, W | 1 |
| Mai, L | 1 |
| Fang, L | 1 |
| Ying, K | 1 |
| Galassi, FM | 1 |
| Liao, XP | 1 |
| Zhu, HW | 1 |
| Zeng, F | 1 |
| Tang, ZH | 1 |
| Medici, V | 1 |
| Bremer, AA | 1 |
| Lee, V | 1 |
| Lam, HD | 1 |
| Nunez, MV | 1 |
| Chen, GX | 1 |
| Keim, NL | 1 |
| Kanji, T | 1 |
| Gandhi, M | 1 |
| Clase, CM | 1 |
| Trepiccione, F | 1 |
| Perna, AF | 1 |
| Santoro, A | 1 |
| Mandreoli, M | 1 |
| Zhu, CS | 1 |
| Lin, ZJ | 1 |
| Wang, XJ | 1 |
| Sun, XX | 1 |
| Xiao, ML | 1 |
| Yanai, H | 1 |
| Hirowatari, Y | 1 |
| Rob, D | 1 |
| Nakamura, Y | 1 |
| Ueshima, H | 4 |
| Okuda, N | 1 |
| Miura, K | 3 |
| Kita, Y | 1 |
| Miyagawa, N | 1 |
| Yoshita, K | 1 |
| Nakagawa, H | 1 |
| Sakata, K | 2 |
| Saitoh, S | 1 |
| Okamura, T | 3 |
| Okayama, A | 2 |
| Choudhry, SR | 1 |
| Rodriguez, B | 1 |
| Masaki, KH | 1 |
| Chan, Q | 1 |
| Stamler, J | 3 |
| van Sloten, TT | 1 |
| Schram, MT | 1 |
| Sep, SJ | 1 |
| Koster, A | 1 |
| Henry, RM | 1 |
| Dominiczak, A | 2 |
| Kielstein, JT | 1 |
| Manolis, AJ | 1 |
| Tassone, EJ | 1 |
| Miceli, S | 1 |
| Gilowski, W | 2 |
| Tian, Y | 1 |
| Fang, Y | 1 |
| Nie, Y | 1 |
| Mu, Y | 2 |
| Guo, X | 2 |
| Yu, S | 1 |
| Jiang, M | 1 |
| Sun, G | 1 |
| Uslu, S | 1 |
| Ozcelik, E | 1 |
| Kebapci, N | 1 |
| Temel, HE | 1 |
| Demirci, F | 1 |
| Ergun, B | 1 |
| Demirustu, C | 1 |
| Ciarla, S | 1 |
| Giorgini, P | 1 |
| Struglia, M | 1 |
| Striuli, R | 1 |
| Necozione, S | 1 |
| Properzi, G | 2 |
| Weissgerber, TL | 1 |
| Milic, NM | 1 |
| Turner, ST | 1 |
| Asad, RA | 1 |
| Mosley, TH | 1 |
| Kardia, SL | 1 |
| Hanis, CL | 1 |
| Garovic, VD | 1 |
| Nam, SH | 1 |
| Kang, SG | 1 |
| Song, SW | 1 |
| Rho, JS | 1 |
| Hu, HY | 1 |
| Chou, YJ | 1 |
| Huang, N | 1 |
| Chou, YC | 1 |
| Lee, MS | 1 |
| Li, CP | 1 |
| Stewart Coats, AJ | 1 |
| Shewan, LG | 1 |
| Maiuolo, J | 1 |
| Oppedisano, F | 1 |
| Gratteri, S | 1 |
| Muscoli, C | 1 |
| Mollace, V | 1 |
| Wu, AH | 1 |
| Gladden, JD | 1 |
| Ahmed, M | 1 |
| Ahmed, A | 1 |
| Filippatos, G | 1 |
| Castejon, R | 1 |
| Jimenez-Ortiz, C | 1 |
| Rosado, S | 1 |
| Tutor-Ureta, P | 1 |
| Mellor-Pita, S | 1 |
| Yebra-Bango, M | 1 |
| Su, P | 1 |
| Hong, L | 1 |
| Goff, DC | 1 |
| Carr, JJ | 1 |
| Rodríguez-Arias, JJ | 1 |
| Coll-de-Tuero, G | 1 |
| Volterrani, M | 1 |
| Iellamo, F | 1 |
| Sposato, B | 1 |
| Romeo, F | 1 |
| Gondouin, B | 1 |
| Jourde-Chiche, N | 1 |
| Sallee, M | 1 |
| Cerini, C | 1 |
| Loundou, A | 1 |
| Morange, S | 1 |
| Berland, Y | 1 |
| Burtey, S | 1 |
| Brunet, P | 1 |
| Guieu, R | 1 |
| Dussol, B | 1 |
| Bassols, J | 1 |
| Martínez-Calcerrada, JM | 1 |
| Prats-Puig, A | 1 |
| Carreras-Badosa, G | 1 |
| Díaz-Roldán, F | 1 |
| Osiniri, I | 1 |
| Riera-Pérez, E | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| López-Bermejo, A | 1 |
| Larsen, KS | 1 |
| Pottegård, A | 2 |
| Lindegaard, H | 1 |
| Rajan, S | 1 |
| Zalpuri, I | 1 |
| Harrington, A | 1 |
| Cimpeanu, C | 1 |
| Song, X | 1 |
| Fan, X | 1 |
| Sloop, GD | 1 |
| Bialczak, JK | 1 |
| Weidman, JJ | 1 |
| St Cyr, JA | 1 |
| Hsieh, YP | 1 |
| Wen, YK | 1 |
| Chiu, PF | 1 |
| Lin, CC | 3 |
| Peng, FF | 1 |
| Luo, QM | 1 |
| Lin, ZC | 1 |
| Yu, XQ | 1 |
| Huang, FX | 1 |
| Meng, L | 2 |
| Gao, J | 1 |
| Zhang, G | 1 |
| Zheng, X | 1 |
| Søltoft Larsen, K | 1 |
| Lindegaard, HM | 1 |
| Balog, M | 1 |
| Mlinarević, D | 1 |
| Šerić, V | 1 |
| Miljanović, M | 1 |
| Blažeković, R | 1 |
| Degmečić, IV | 1 |
| Blažetić, S | 1 |
| Oršolić, I | 1 |
| Vari, SG | 1 |
| Heffer, M | 1 |
| Sato, H | 1 |
| Suzuki, N | 1 |
| Kabasawa, A | 1 |
| Suzuki, K | 1 |
| Hirayama, A | 1 |
| Kato, T | 1 |
| Ueno, Y | 1 |
| Kastorini, CM | 1 |
| Georgousopoulou, EN | 1 |
| Laskaris, A | 1 |
| Skourlis, N | 1 |
| Zana, A | 1 |
| Chatzinikolaou, C | 1 |
| Tousoulis, D | 1 |
| Stefanadis, C | 2 |
| Lei, H | 1 |
| Ma, J | 1 |
| Ortega-Cortes, R | 1 |
| Trujillo, X | 1 |
| Hurtado López, EF | 1 |
| López Beltrán, AL | 1 |
| Colunga Rodríguez, C | 1 |
| Barrera-de Leon, JC | 1 |
| Tlacuilo-Parra, A | 1 |
| Murakami, Y | 2 |
| Nagai, M | 2 |
| Sugiyama, D | 2 |
| Nansseu, JR | 1 |
| Moor, VJ | 1 |
| Nouaga, ME | 1 |
| Zing-Awona, B | 1 |
| Tchanana, G | 1 |
| Ketcha, A | 1 |
| Dohi, Y | 1 |
| Satirapoj, B | 1 |
| Wirajit, O | 1 |
| Burata, A | 1 |
| Supasyndh, O | 1 |
| Ruangkanchanasetr, P | 1 |
| Unal, HU | 2 |
| Karaman, M | 1 |
| Saglam, M | 2 |
| Eyileten, T | 1 |
| Gezer, M | 1 |
| Verim, S | 2 |
| Oguz, Y | 2 |
| Vural, A | 1 |
| Yilmaz, MI | 2 |
| Maiolino, G | 1 |
| Pagnin, E | 1 |
| Plebani, M | 1 |
| Davis, PA | 1 |
| Calò, LA | 1 |
| Rebora, P | 1 |
| Acevedo, A | 1 |
| Benavides, J | 1 |
| Chowdhury, M | 1 |
| Lopez, M | 1 |
| Pena, L | 1 |
| Montenegro, A | 1 |
| Lievano, M | 1 |
| Lombo, B | 1 |
| Beberashvili, I | 1 |
| Erlich, A | 1 |
| Azar, A | 1 |
| Sinuani, I | 1 |
| Feldman, L | 1 |
| Gorelik, O | 1 |
| Stav, K | 1 |
| Efrati, S | 1 |
| Perna, L | 1 |
| Mons, U | 1 |
| Schöttker, B | 1 |
| Brenner, H | 1 |
| Aloia, E | 1 |
| Sciaccaluga, C | 1 |
| Harada, M | 1 |
| Izawa, A | 1 |
| Hidaka, H | 1 |
| Nakanishi, K | 1 |
| Terasawa, F | 1 |
| Motoki, H | 1 |
| Yazaki, Y | 1 |
| Ikeda, U | 1 |
| Hongo, M | 1 |
| Metoki, H | 1 |
| Kawasaki, M | 1 |
| Castaldo, G | 1 |
| Monaco, L | 1 |
| Castaldo, L | 1 |
| Galdo, G | 1 |
| Cereda, E | 1 |
| Safiri, S | 1 |
| Qorbani, M | 1 |
| Heshmat, R | 1 |
| Tajbakhsh, R | 1 |
| Eslami Shahr Babaki, A | 1 |
| Djalalinia, S | 1 |
| Motlagh, ME | 1 |
| Tajadini, MH | 1 |
| Asayesh, H | 1 |
| Safari, O | 1 |
| Kelishadi, R | 1 |
| Musacchio, E | 1 |
| Perissinotto, E | 1 |
| Sartori, L | 1 |
| Veronese, N | 1 |
| Zambon, S | 1 |
| Manzato, E | 2 |
| Baggio, G | 1 |
| Corti, MC | 1 |
| Crepaldi, G | 1 |
| Ramonda, R | 1 |
| Yeung, PK | 1 |
| Kolathuru, SS | 1 |
| Agu, RU | 1 |
| Schils, R | 1 |
| Krzesinski, JM | 1 |
| Cheung, YT | 1 |
| Edelmann, MN | 1 |
| Mulrooney, DA | 1 |
| Green, DM | 1 |
| Chemaitilly, W | 1 |
| John, N | 1 |
| Robison, LL | 1 |
| Hudson, MM | 1 |
| Krull, KR | 1 |
| Moulin, SR | 1 |
| Baldo, MP | 1 |
| Souza, JB | 1 |
| Luchi, WM | 1 |
| Capingana, DP | 1 |
| Magalhães, P | 1 |
| Kırça, M | 1 |
| Oğuz, N | 1 |
| Çetin, A | 1 |
| Uzuner, F | 1 |
| Yeşilkaya, A | 1 |
| Robinson, PC | 1 |
| Do, R | 1 |
| Altay, M | 1 |
| Karakoç, MA | 1 |
| Çakır, N | 1 |
| Yılmaz Demirtaş, C | 1 |
| Cerit, ET | 1 |
| Aktürk, M | 1 |
| Ateş, İ | 1 |
| Bukan, N | 1 |
| Arslan, M | 1 |
| Chenglong, Z | 1 |
| Jing, L | 1 |
| Chiou, ST | 1 |
| Barger, SD | 1 |
| Cribbet, MR | 1 |
| Muldoon, MF | 1 |
| Dalama, B | 1 |
| Mesa, J | 1 |
| Ding, Z | 1 |
| Yang, XL | 1 |
| Kim, TJ | 1 |
| Jung, S | 1 |
| Kim, CK | 1 |
| Gluba-Brzozka, A | 1 |
| Franczyk, B | 1 |
| Bartnicki, P | 1 |
| Rysz-Gorzyn Ska, M | 1 |
| Rysz, J | 1 |
| Jin, N | 1 |
| Hong, T | 1 |
| Ji, L | 1 |
| Khanna, PP | 1 |
| Kopicko, J | 1 |
| Fung, M | 1 |
| Bhakta, N | 1 |
| Adler, S | 1 |
| Storgard, C | 1 |
| So, A | 1 |
| Winter, WE | 1 |
| Okafor, ON | 1 |
| Farrington, K | 1 |
| Gorog, DA | 1 |
| Ranjith, N | 1 |
| Myeni, NN | 1 |
| Sartorius, B | 1 |
| Mayise, C | 1 |
| Strait, JB | 1 |
| Brunelli, C | 1 |
| Studenski, S | 1 |
| Lakatta, EG | 1 |
| AlGhatrif, M | 1 |
| Nossent, J | 1 |
| Raymond, W | 1 |
| Divitini, M | 1 |
| Knuiman, M | 1 |
| Klisic, A | 1 |
| Kotur-Stevuljevic, J | 1 |
| Kavaric, N | 1 |
| Matic, M | 1 |
| Kang, YS | 1 |
| Jeong, YJ | 1 |
| Yoon, YS | 1 |
| Kwack, WG | 1 |
| Oh, JY | 1 |
| Luciano, R | 1 |
| Shashaj, B | 1 |
| Spreghini, M | 1 |
| Del Fattore, A | 1 |
| Rustico, C | 1 |
| Wietrzykowska Sforza, R | 1 |
| Morino, GS | 1 |
| Dallapiccola, B | 1 |
| Manco, M | 1 |
| Chen, MY | 1 |
| Zhao, CC | 1 |
| Yu, TP | 1 |
| Ticinesi, A | 1 |
| Lauretani, F | 2 |
| Ceda, GP | 1 |
| Ruggiero, C | 2 |
| Aloe, R | 1 |
| Larsson, A | 1 |
| Cederholm, T | 1 |
| Lind, L | 1 |
| Meschi, T | 1 |
| Sucher, S | 1 |
| Markova, M | 1 |
| Hornemann, S | 1 |
| Pivovarova, O | 1 |
| Rudovich, N | 1 |
| Thomann, R | 1 |
| Schneeweiss, R | 1 |
| Rohn, S | 1 |
| Pfeiffer, AFH | 1 |
| Lambert, EA | 1 |
| Hachem, M | 1 |
| Hemmes, R | 1 |
| Straznicky, NE | 1 |
| Eikelis, N | 1 |
| Sari, CI | 1 |
| Schlaich, MP | 1 |
| Lambert, GW | 1 |
| Dixon, JB | 1 |
| Lee, AM | 1 |
| Yazici, R | 1 |
| Altintepe, L | 1 |
| Yazici, M | 1 |
| Sunnetcioglu, A | 1 |
| Gunbatar, H | 1 |
| Yıldız, H | 1 |
| Gagliardi, AC | 1 |
| Miname, MH | 1 |
| Santos, RD | 3 |
| Puig, JG | 2 |
| Martínez, MA | 1 |
| Mora, M | 1 |
| Fraile, JM | 1 |
| Montoya, F | 1 |
| Torres, RJ | 1 |
| Todd, DJ | 1 |
| Lippi, G | 3 |
| Targher, G | 8 |
| Montagnana, M | 3 |
| Salvagno, GL | 1 |
| Guidi, GC | 1 |
| Gersch, C | 1 |
| Palii, SP | 1 |
| Kim, KM | 2 |
| Angerhofer, A | 1 |
| Henderson, GN | 2 |
| Anzai, N | 2 |
| Jutabha, P | 1 |
| Kimura, T | 1 |
| Babu, E | 1 |
| Jin, CJ | 1 |
| Srivastava, S | 1 |
| Endou, H | 2 |
| Sakurai, H | 1 |
| De Vera, MA | 1 |
| Krishnan, E | 5 |
| Sierra, C | 1 |
| Coca, A | 1 |
| Edwards, NL | 3 |
| Mora-Fernández, C | 1 |
| Jarque, A | 1 |
| Getino, MA | 1 |
| Sánchez, R | 2 |
| Lozano, L | 1 |
| Navarro, JF | 1 |
| Feig, DI | 5 |
| Kang, DH | 9 |
| Voruganti, VS | 2 |
| Nath, SD | 2 |
| Cole, SA | 1 |
| Thameem, F | 2 |
| Jowett, JB | 1 |
| Bauer, R | 2 |
| MacCluer, JW | 2 |
| Blangero, J | 2 |
| Comuzzie, AG | 2 |
| Abboud, HE | 2 |
| Arar, NH | 2 |
| Navaneethan, SD | 1 |
| Beddhu, S | 1 |
| Euser, SM | 1 |
| Hofman, A | 3 |
| Westendorp, RG | 1 |
| Breteler, MM | 2 |
| Brown, CM | 1 |
| Dulloo, AG | 1 |
| Montani, JP | 1 |
| Kim, BS | 2 |
| Lee, JE | 1 |
| Huh, JK | 1 |
| Kim, BJ | 2 |
| Kang, JH | 2 |
| Lee, MH | 2 |
| Park, JR | 2 |
| Rhee, EJ | 2 |
| Oh, KW | 1 |
| Lee, WY | 2 |
| Park, CY | 1 |
| Park, SW | 1 |
| Kim, SW | 2 |
| Huang, RC | 2 |
| Mori, TA | 2 |
| Burke, V | 1 |
| Newnham, J | 1 |
| Stanley, FJ | 2 |
| Landau, LI | 2 |
| Kendall, GE | 1 |
| Oddy, WH | 2 |
| López Suárez, A | 1 |
| Chen, HJ | 1 |
| Yeh, WT | 1 |
| Pan, WH | 2 |
| Leow, MK | 1 |
| Parmar, MS | 1 |
| Bueno, C | 1 |
| Hebert, LA | 1 |
| Rovin, B | 1 |
| Oh, J | 1 |
| Won, HY | 1 |
| Kang, SM | 1 |
| Titov, VN | 1 |
| Dmitriev, VA | 1 |
| Oshchepkova, EV | 1 |
| Nilsson, PM | 1 |
| Bandukwala, F | 1 |
| Huang, M | 1 |
| Zaltzman, JS | 1 |
| Nash, MM | 1 |
| Prasad, GV | 1 |
| Daoussis, D | 2 |
| Panoulas, VF | 2 |
| Antonopoulos, I | 1 |
| John, H | 1 |
| Toms, TE | 1 |
| Wong, P | 1 |
| Nightingale, P | 2 |
| Douglas, KM | 2 |
| Kitas, GD | 3 |
| Greene, T | 1 |
| Beck, GJ | 1 |
| Kusek, JW | 1 |
| Collins, AJ | 1 |
| Levey, AS | 1 |
| Menon, V | 1 |
| Okura, T | 1 |
| Higaki, J | 2 |
| Kurata, M | 1 |
| Irita, J | 1 |
| Miyoshi, K | 1 |
| Yamazaki, T | 1 |
| Hayashi, D | 1 |
| Kohro, T | 1 |
| Nagai, R | 1 |
| Marasini, B | 1 |
| Massarotti, M | 1 |
| Héroux, M | 1 |
| Janssen, I | 1 |
| Lam, M | 1 |
| Lee, DC | 1 |
| Hebert, JR | 1 |
| Sui, X | 1 |
| Blair, SN | 1 |
| Tavares, NR | 1 |
| Moreira, PA | 1 |
| Amaral, TF | 1 |
| Egert, S | 1 |
| Bosy-Westphal, A | 1 |
| Seiberl, J | 1 |
| Kürbitz, C | 1 |
| Settler, U | 1 |
| Plachta-Danielzik, S | 1 |
| Wagner, AE | 1 |
| Frank, J | 1 |
| Schrezenmeir, J | 1 |
| Rimbach, G | 1 |
| Wolffram, S | 1 |
| Müller, MJ | 1 |
| Muntoni, S | 2 |
| Atzori, L | 1 |
| Mereu, R | 1 |
| Manca, A | 1 |
| Satta, G | 1 |
| Gentilini, A | 1 |
| Bianco, P | 1 |
| Baule, A | 1 |
| Baule, GM | 1 |
| Borges, RL | 2 |
| Hirota, AH | 1 |
| Quinto, BM | 1 |
| Ribeiro, AB | 2 |
| Zanella, MT | 2 |
| Batista, MC | 2 |
| Zoppini, G | 3 |
| Negri, C | 1 |
| Stoico, V | 1 |
| Perrone, F | 1 |
| Muggeo, M | 5 |
| Bonora, E | 5 |
| Turgut, F | 1 |
| Kasapoğlu, B | 1 |
| Croymans, DM | 1 |
| Sanchez, A | 1 |
| Barth, JD | 1 |
| Roberts, CK | 1 |
| Bahorun, T | 1 |
| Luximon-Ramma, A | 1 |
| Gunness, TK | 1 |
| Sookar, D | 1 |
| Bhoyroo, S | 1 |
| Jugessur, R | 1 |
| Reebye, D | 1 |
| Googoolye, K | 1 |
| Crozier, A | 1 |
| Aruoma, OI | 1 |
| Indraratna, PL | 1 |
| Williams, KM | 1 |
| Graham, GG | 1 |
| Day, RO | 1 |
| Wasserman, A | 1 |
| Shnell, M | 1 |
| Boursi, B | 1 |
| Guzner-Gur, H | 1 |
| Friedman, JH | 1 |
| Sachs, L | 1 |
| Batra, KL | 1 |
| Zimmermann, B | 1 |
| Li, NF | 1 |
| Wang, HM | 1 |
| Yao, XG | 1 |
| Luca Salvagno, G | 1 |
| Cesare Guidi, G | 1 |
| Mizuta, E | 1 |
| Hamada, T | 2 |
| Igawa, O | 3 |
| Shigemasa, C | 3 |
| Brandstätter, A | 1 |
| Lamina, C | 1 |
| Kiechl, S | 1 |
| Hunt, SC | 1 |
| Coassin, S | 1 |
| Paulweber, B | 1 |
| Kramer, F | 1 |
| Summerer, M | 1 |
| Willeit, J | 1 |
| Kedenko, L | 1 |
| Adams, TD | 1 |
| Olivero, JJ | 2 |
| Nguyen, PT | 1 |
| Fan, AZ | 1 |
| Yesupriya, A | 1 |
| Chang, MH | 1 |
| House, M | 1 |
| Ned, R | 1 |
| Hayes, D | 1 |
| Dowling, NF | 1 |
| Mokdad, AH | 1 |
| Palmer, IM | 1 |
| Schutte, AE | 1 |
| Huisman, HW | 1 |
| Guo, K | 1 |
| Uchiyama, S | 1 |
| Ueno, T | 1 |
| Su, Y | 1 |
| White, JS | 1 |
| Kramer, CK | 1 |
| von Mühlen, D | 1 |
| Jassal, SK | 1 |
| Barrett-Connor, E | 1 |
| Ong, G | 1 |
| Davis, WA | 2 |
| Davis, TM | 2 |
| Heo, NJ | 1 |
| Ahn, JM | 1 |
| Lee, TW | 1 |
| Chin, HJ | 1 |
| Na, KY | 1 |
| Chae, DW | 1 |
| Kim, S | 1 |
| Steenland, K | 2 |
| Fletcher, T | 1 |
| Savitz, DA | 1 |
| Mascitelli, L | 1 |
| Pezzetta, F | 1 |
| Goldstein, MR | 1 |
| Yamaoka-Tojo, M | 1 |
| Tojo, T | 1 |
| Takahira, N | 1 |
| Matsunaga, A | 1 |
| Aoyama, N | 1 |
| Masuda, T | 1 |
| Izumi, T | 1 |
| Cain, L | 1 |
| Shankar, A | 1 |
| Ducatman, AM | 1 |
| de Vinuesa, SG | 1 |
| Ruiz-Caro, C | 1 |
| Ampuero, J | 1 |
| Rincón, A | 1 |
| Arroyo, D | 1 |
| Eliseev, MS | 2 |
| Barskova, VG | 2 |
| Wen, CP | 1 |
| David Cheng, TY | 1 |
| Chan, HT | 1 |
| Tsai, MK | 1 |
| Chung, WS | 1 |
| Tsai, SP | 1 |
| Wahlqvist, ML | 2 |
| Yang, YC | 1 |
| Wu, SB | 1 |
| Chiang, PH | 1 |
| Wen, SF | 1 |
| Tangri, N | 1 |
| Weiner, DE | 1 |
| Tang, LJ | 1 |
| Jiang, JJ | 1 |
| Chen, XF | 1 |
| Wang, JA | 1 |
| Lin, XF | 1 |
| Du, YX | 1 |
| Fang, CF | 1 |
| Pu, ZX | 1 |
| Heo, SH | 1 |
| Shih, CY | 1 |
| Chen, CY | 1 |
| Wen, CJ | 1 |
| Liu, HM | 1 |
| Kuo, HK | 1 |
| de Klerk, N | 1 |
| Newnham, JP | 1 |
| Hands, B | 1 |
| Wu, YQ | 1 |
| Xu, YX | 1 |
| Wang, YL | 1 |
| Luo, YY | 1 |
| Hu, DY | 1 |
| Liu, WJ | 1 |
| Pi, L | 1 |
| Wang, MS | 1 |
| Wang, JY | 1 |
| Zhao, SM | 1 |
| Li, MJ | 1 |
| Chung, BH | 1 |
| Kang, SH | 1 |
| Hwang, HS | 1 |
| Choi, BS | 1 |
| Park, CW | 1 |
| Kim, YS | 1 |
| Kim, JI | 1 |
| Moon, IS | 1 |
| Yang, CW | 1 |
| Bhansing, KJ | 1 |
| van Bon, L | 1 |
| Radstake, TR | 1 |
| Glazer, NL | 1 |
| Chasman, DI | 1 |
| Aspelund, T | 1 |
| Eiriksdottir, G | 1 |
| Launer, L | 1 |
| Nalls, M | 1 |
| Hernandez, D | 1 |
| Arking, DE | 1 |
| Grove, ML | 1 |
| Linda Kao, WH | 1 |
| Chonchol, M | 1 |
| Haritunians, T | 1 |
| Lumley, T | 1 |
| Shlipak, M | 1 |
| Larson, MG | 2 |
| Upadhyay, A | 1 |
| Rivadeneira, F | 1 |
| Stricker, B | 1 |
| Paré, G | 1 |
| Parker, AN | 1 |
| Ridker, PM | 1 |
| Siscovick, DS | 1 |
| Witteman, JC | 2 |
| Fox, CS | 2 |
| Codoñer-Franch, P | 1 |
| Ballester-Asensio, E | 1 |
| Martínez-Pons, L | 1 |
| Vallecillo-Hernández, J | 1 |
| Navarro-Ruíz, A | 1 |
| del Valle-Pérez, R | 1 |
| Levine, DA | 1 |
| Lewis, CE | 1 |
| Williams, OD | 1 |
| Safford, MM | 1 |
| Liu, K | 1 |
| Calhoun, DA | 1 |
| Kiefe, CI | 1 |
| Widerøe, TE | 1 |
| Sokolove, J | 1 |
| Meotti, FC | 1 |
| Jameson, GN | 1 |
| Turner, R | 1 |
| Harwood, DT | 1 |
| Stockwell, S | 1 |
| Rees, MD | 1 |
| Thomas, SR | 1 |
| Kettle, AJ | 1 |
| Barbosa, MC | 1 |
| Brandão, AA | 1 |
| Pozzan, R | 1 |
| Magalhães, ME | 1 |
| Campana, EM | 1 |
| Fonseca, FL | 1 |
| Pizzi, OL | 1 |
| Freitas, EV | 1 |
| Brandão, AP | 1 |
| Dzhergeniia, SL | 1 |
| Ushakov, IB | 1 |
| Ho, SC | 1 |
| Ho, YP | 1 |
| Nery, AB | 1 |
| Mesquita, ET | 1 |
| Lugon, JR | 1 |
| Kang, HC | 1 |
| de Miranda, VA | 1 |
| de Souza, BG | 1 |
| Andrade, JA | 1 |
| Rosa, ML | 1 |
| Adeva, MM | 1 |
| Souto, G | 1 |
| Jung, CH | 1 |
| Yu, JH | 1 |
| Bae, SJ | 1 |
| Koh, EH | 1 |
| Kim, MS | 1 |
| Park, JY | 2 |
| Kim, HK | 1 |
| Riegersperger, M | 1 |
| Goldsmith, D | 1 |
| Ford, ES | 1 |
| Lai, X | 1 |
| Huang, B | 1 |
| Yao, L | 1 |
| Qiao, Y | 1 |
| Zhu, S | 1 |
| Wen, J | 1 |
| Hurtes, X | 1 |
| Meria, P | 1 |
| Fassett, RG | 1 |
| Venuthurupalli, SK | 1 |
| Gobe, GC | 1 |
| Coombes, JS | 1 |
| Cooper, MA | 1 |
| Hoy, WE | 1 |
| Hoffmann, MM | 1 |
| Boehm, BO | 1 |
| Bloomgarden, ZT | 1 |
| Ganotakis, ES | 1 |
| Paletas, K | 1 |
| Nicolaou, V | 1 |
| Bacharoudis, G | 1 |
| Tziomalos, K | 1 |
| Alexandrides, T | 1 |
| Liberopoulos, EN | 2 |
| Skoumas, J | 1 |
| Masoura, C | 1 |
| Siasos, G | 1 |
| Galiatsatos, N | 1 |
| Psaltopoulou, T | 1 |
| Mylonakis, C | 1 |
| Margazas, A | 1 |
| Kyvelou, S | 1 |
| Mamatas, S | 1 |
| Panagiotakos, D | 1 |
| Neri, L | 1 |
| Rocca Rey, LA | 1 |
| Lentine, KL | 1 |
| Hinyard, LJ | 1 |
| Pinsky, B | 1 |
| Xiao, H | 1 |
| Dukes, J | 1 |
| Schnitzler, MA | 1 |
| Martí del Moral, L | 1 |
| Agil, A | 1 |
| Navarro-Alarcón, M | 1 |
| López-Ga de la Serrana, H | 1 |
| Palomares-Bayo, M | 1 |
| Oliveras-López, MJ | 1 |
| Ogbera, OA | 1 |
| Okeoghene, OA | 1 |
| Azenabor, A | 1 |
| Masue, T | 1 |
| Wada, K | 1 |
| Hayashi, M | 1 |
| Yasuda, K | 1 |
| Deguchi, T | 1 |
| Nagata, C | 1 |
| Dei Cas, A | 1 |
| Spigoni, V | 1 |
| Franzini, L | 1 |
| Preti, M | 1 |
| Ardigò, D | 1 |
| Derlindati, E | 1 |
| Metra, M | 1 |
| Monti, LD | 1 |
| Dell'Era, P | 1 |
| Gnudi, L | 1 |
| Zavaroni, I | 1 |
| Stellato, D | 1 |
| Morrone, LF | 1 |
| Di Giorgio, C | 1 |
| Latif, W | 1 |
| Karaboyas, A | 1 |
| Tong, L | 1 |
| Winchester, JF | 1 |
| Arrington, CJ | 1 |
| Pisoni, RL | 1 |
| Marshall, MR | 1 |
| Kleophas, W | 1 |
| Levin, NW | 1 |
| Sen, A | 1 |
| Robinson, BM | 1 |
| Saran, R | 1 |
| Alvarez-Lario, B | 1 |
| Macarrón-Vicente, J | 1 |
| McIntyre, NJ | 1 |
| Fluck, RJ | 1 |
| McIntyre, CW | 1 |
| Taal, MW | 1 |
| Chrzczanowicz, J | 1 |
| Gawron-Skarbek, A | 1 |
| Kostka, J | 1 |
| Nowak, D | 1 |
| Drygas, W | 1 |
| Jegier, A | 1 |
| Kostka, T | 1 |
| Yan, WH | 1 |
| Chen, XQ | 1 |
| Xia, LY | 1 |
| Qin, XZ | 1 |
| Liu, YH | 1 |
| Ding, HT | 1 |
| Han, SM | 1 |
| Doehner, W | 1 |
| Landmesser, U | 1 |
| Katsuren, K | 1 |
| Nakamura, K | 1 |
| Ohta, T | 2 |
| Chohan, S | 1 |
| Becker, MA | 1 |
| MacDonald, PA | 1 |
| Chefo, S | 1 |
| Jackson, RL | 1 |
| Leiva, E | 1 |
| Mujica, V | 1 |
| Brito, K | 1 |
| Palomo, I | 1 |
| Orrego, R | 1 |
| Moore-Carrasco, R | 1 |
| Vásquez, M | 1 |
| Guzmán, L | 1 |
| Nuñez, S | 1 |
| Díaz, N | 1 |
| Icaza, G | 1 |
| Arredondo, M | 1 |
| Iseki, C | 1 |
| Kinjo, K | 1 |
| Suzuki, S | 1 |
| Sagara, K | 1 |
| Otsuka, T | 1 |
| Matsuno, S | 1 |
| Funada, R | 1 |
| Uejima, T | 1 |
| Oikawa, Y | 1 |
| Koike, A | 1 |
| Nagashima, K | 1 |
| Kirigaya, H | 1 |
| Yajima, J | 1 |
| Sawada, H | 1 |
| Aizawa, T | 1 |
| Yamashita, T | 1 |
| Håglin, L | 2 |
| Bäckman, L | 1 |
| Törnkvist, B | 1 |
| Panero, F | 1 |
| Gruden, G | 1 |
| Perotto, M | 1 |
| Fornengo, P | 1 |
| Barutta, F | 1 |
| Greco, E | 1 |
| Runzo, C | 1 |
| Ghezzo, G | 1 |
| Cavallo-Perin, P | 1 |
| Bruno, G | 1 |
| Levantesi, G | 1 |
| Marfisi, RM | 1 |
| Franzosi, MG | 1 |
| Nicolosi, GL | 1 |
| Schweiger, C | 1 |
| Silletta, MG | 1 |
| Tognoni, G | 1 |
| Heras, M | 1 |
| Fernández-Reyes, MJ | 1 |
| Molina, Á | 1 |
| Rodríguez, A | 1 |
| Álvarez-Ude, F | 1 |
| Liu, WC | 1 |
| Hung, CC | 1 |
| Chen, SC | 1 |
| Yeh, SM | 1 |
| Lin, MY | 1 |
| Chiu, YW | 1 |
| Kuo, MC | 1 |
| Chang, JM | 1 |
| Chen, HC | 1 |
| Loeffler, LF | 1 |
| Navas-Acien, A | 1 |
| Brady, TM | 1 |
| Fadrowski, JJ | 1 |
| Isik, T | 1 |
| Ayhan, E | 1 |
| Ergelen, M | 1 |
| Uyarel, H | 1 |
| Takagi, H | 1 |
| Umemoto, T | 1 |
| Pasalic, D | 1 |
| Marinkovic, N | 1 |
| Feher-Turkovic, L | 1 |
| Puddu, P | 1 |
| Puddu, GM | 1 |
| Cravero, E | 1 |
| Vizioli, L | 1 |
| Muscari, A | 1 |
| Luczak, A | 1 |
| Knevel, R | 1 |
| Huizinga, TW | 1 |
| van Nies, JA | 1 |
| van der Helm-van Mil, A | 1 |
| De Vries-Bouwstra, JK | 1 |
| Shatat, IF | 1 |
| Abdallah, RT | 1 |
| Sas, DJ | 1 |
| Hailpern, SM | 1 |
| D'Marco, L | 1 |
| García, I | 1 |
| Vega, C | 1 |
| Moutzouri, E | 1 |
| Florentin, M | 1 |
| Liamis, G | 1 |
| Elisaf, MS | 2 |
| Bazrgar, M | 1 |
| Karimi, M | 1 |
| Kim, BT | 1 |
| Park, SB | 1 |
| Cho, DY | 1 |
| Je, SH | 1 |
| Kim, KN | 1 |
| Kaya, Z | 1 |
| Buscemi, S | 1 |
| Maniaci, V | 1 |
| Barile, AM | 1 |
| Rosafio, G | 1 |
| Mattina, A | 1 |
| Canino, B | 1 |
| Verga, S | 1 |
| Rini, GB | 1 |
| Holmar, J | 1 |
| Fridolin, I | 1 |
| Uhlin, F | 1 |
| Lauri, K | 1 |
| Luman, M | 1 |
| Kawai, T | 1 |
| Ohishi, M | 1 |
| Takeya, Y | 1 |
| Onishi, M | 1 |
| Ito, N | 1 |
| Yamamoto, K | 1 |
| Kamide, K | 2 |
| Rakugi, H | 2 |
| Oikonen, M | 1 |
| Wendelin-Saarenhovi, M | 1 |
| Siitonen, N | 1 |
| Loo, BM | 1 |
| Jula, A | 1 |
| Seppälä, I | 1 |
| Saarikoski, L | 1 |
| Juonala, M | 1 |
| Huupponen, R | 1 |
| Viikari, JS | 1 |
| Atar, AI | 1 |
| Yilmaz, OC | 1 |
| Akin, K | 1 |
| Selcoki, Y | 1 |
| Er, O | 1 |
| Eryonucu, B | 1 |
| Ma, W | 1 |
| Qi, LT | 1 |
| Zhao, F | 1 |
| Zhang, BW | 1 |
| Li, JP | 1 |
| Zhu, SN | 1 |
| Wang, SY | 1 |
| Huo, Y | 1 |
| Antunovic, T | 1 |
| Ratkovic, M | 1 |
| Gledovic, B | 1 |
| Gligorovic-Barhanovic, N | 1 |
| Bozovic, D | 1 |
| de Oliveira, EP | 2 |
| Manda, RM | 1 |
| Torezan, GA | 1 |
| Teixeira, O | 1 |
| Michelin, E | 1 |
| Burini, RC | 2 |
| Chiou, MJ | 1 |
| Longo-Mbenza, B | 1 |
| Nsenga, JN | 1 |
| Mokondjimobe, E | 1 |
| Gombet, T | 1 |
| Assori, IN | 1 |
| Ibara, JR | 1 |
| Ellenga-Mbolla, B | 1 |
| Vangu, DN | 1 |
| Fuele, SM | 1 |
| Rock, KL | 1 |
| Kataoka, H | 1 |
| Lai, JJ | 1 |
| Hu, SL | 1 |
| Liu, CS | 2 |
| Lin, CH | 1 |
| Davidson, LE | 1 |
| Li, CI | 2 |
| Li, TC | 3 |
| Lin, WY | 1 |
| Sonmez, A | 1 |
| Cakir, E | 1 |
| Arslan, E | 1 |
| Caglar, K | 1 |
| Thornley, S | 1 |
| Marshall, RJ | 1 |
| Jackson, R | 1 |
| Gentles, D | 1 |
| Crengle, S | 1 |
| Kerr, A | 1 |
| Wells, S | 1 |
| de Onis, M | 1 |
| Martínez-Costa, C | 1 |
| Núñez, F | 1 |
| Nguefack-Tsague, G | 1 |
| Montal, A | 1 |
| Brines, J | 1 |
| Park, JS | 1 |
| Kang, S | 1 |
| Ahn, CW | 1 |
| Cha, BS | 1 |
| Kim, KR | 1 |
| Lee, HC | 1 |
| Ioannou, GN | 1 |
| Boyko, EJ | 1 |
| Grassi, D | 1 |
| Ferri, L | 1 |
| Di Giosia, P | 1 |
| Cheli, P | 1 |
| Del Pinto, R | 1 |
| Kawamoto, O | 1 |
| Michiue, T | 1 |
| Ishikawa, T | 1 |
| Maeda, H | 1 |
| Kong, AP | 1 |
| Choi, KC | 1 |
| Chan, MH | 1 |
| Ozaki, R | 1 |
| Chan, CW | 1 |
| Chan, JC | 1 |
| Papanas, N | 1 |
| Fonseca, VA | 1 |
| Maltezos, E | 1 |
| Rosendorff, C | 1 |
| Jogendra, MR | 1 |
| Boelaert, J | 1 |
| Lynen, F | 1 |
| Glorieux, G | 1 |
| Eloot, S | 1 |
| Van Landschoot, M | 1 |
| Waterloos, MA | 1 |
| Sandra, P | 1 |
| Vanholder, R | 1 |
| Silveira, LV | 1 |
| Martínez-Indart, L | 1 |
| Herrero-Beites, AM | 1 |
| Pijoan, JI | 1 |
| Segal, M | 2 |
| Rodriguez-Iturbe, B | 2 |
| Abu-Bachar, F | 1 |
| Sidi, Y | 1 |
| Olchovsky, D | 1 |
| Mangge, H | 2 |
| Zelzer, S | 1 |
| Puerstner, P | 1 |
| Schnedl, WJ | 1 |
| Reeves, G | 1 |
| Postolache, TT | 1 |
| Bruckert, E | 1 |
| Ratziu, V | 1 |
| Poynard, T | 1 |
| Chapman, MJ | 1 |
| Opolon, P | 1 |
| Turpin, G | 1 |
| Dincer, HE | 1 |
| Dincer, AP | 1 |
| Levinson, DJ | 1 |
| Watanabe, S | 2 |
| Kanellis, J | 3 |
| Lan, H | 1 |
| Mazzali, M | 3 |
| Wasada, T | 2 |
| Iwatani, M | 2 |
| Waring, WS | 3 |
| Maxwell, SR | 3 |
| Webb, DJ | 3 |
| Invitti, C | 2 |
| Guzzaloni, G | 1 |
| Gilardini, L | 2 |
| Morabito, F | 2 |
| Viberti, G | 1 |
| Ben-Noun, L | 1 |
| Laor, A | 1 |
| Miyazaki, H | 1 |
| Matsumoto, Y | 1 |
| Hakoda, M | 2 |
| Feig, D | 2 |
| Kivlighn, S | 2 |
| Tuttle, KR | 3 |
| Herrera-Acosta, J | 2 |
| KOHN, PM | 1 |
| PROZAN, GB | 1 |
| LOVERING, EF | 1 |
| LONGOBARDI, A | 1 |
| LAL, HB | 1 |
| LAL, H | 1 |
| Denzer, C | 1 |
| Muche, R | 1 |
| Mayer, H | 1 |
| Heinze, E | 1 |
| Debatin, KM | 1 |
| Wabitsch, M | 1 |
| Gavin, AR | 1 |
| Adwani, SH | 1 |
| Breukels, O | 1 |
| Campo, C | 1 |
| Ruilope, LM | 2 |
| Segura, J | 1 |
| Rodicio, JL | 1 |
| García-Robles, R | 1 |
| Garcia-Puig, J | 2 |
| Alderman, MH | 6 |
| Julius, S | 1 |
| Devereux, RB | 1 |
| De Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Dahlöf, B | 1 |
| Alderman, M | 2 |
| Aiyer, KJ | 1 |
| Conen, D | 1 |
| Wietlisbach, V | 1 |
| Bovet, P | 1 |
| Shamlaye, C | 1 |
| Riesen, W | 1 |
| Paccaud, F | 1 |
| Wdowczyk, M | 1 |
| Bednarska-Chabowska, D | 1 |
| Adamiec, R | 1 |
| Hong, YS | 1 |
| Lee, MJ | 1 |
| Kim, KH | 1 |
| Lee, YH | 1 |
| Kim, BG | 1 |
| Jeong, B | 1 |
| Yoon, HR | 1 |
| Nishio, H | 1 |
| Srinivas, TR | 2 |
| Segal, MS | 2 |
| Sousa, T | 1 |
| Morato, M | 1 |
| Fernandes, E | 1 |
| Carvalho, F | 1 |
| Albino-Teixeira, A | 1 |
| Nasonov, EL | 1 |
| Iakunina, IA | 1 |
| Zilov, AV | 1 |
| Il'inykh, EV | 1 |
| Wong, W | 1 |
| Tolkoff-Rubin, N | 1 |
| Delmonico, FL | 1 |
| Cardarelli, F | 1 |
| Saidman, SL | 1 |
| Farrell, ML | 1 |
| Shih, V | 1 |
| Winkelmayer, WC | 1 |
| Cosimi, AB | 1 |
| Pascual, M | 1 |
| Niskanen, LK | 1 |
| Laaksonen, DE | 1 |
| Nyyssönen, K | 1 |
| Alfthan, G | 1 |
| Lakka, HM | 1 |
| Lakka, TA | 1 |
| Salonen, JT | 1 |
| Daskalopoulou, SS | 1 |
| Mikhailidis, D | 1 |
| Mercuro, G | 1 |
| Cerquetani, E | 1 |
| Zoncu, S | 1 |
| Deidda, M | 1 |
| Fini, M | 1 |
| Rosano, GM | 1 |
| Szeto, YT | 1 |
| Kwok, TC | 1 |
| Benzie, IF | 1 |
| Redfern, JS | 1 |
| Hohage, H | 1 |
| Welling, U | 1 |
| Heck, M | 1 |
| Zeh, M | 1 |
| Gerhardt, U | 1 |
| Suwelack, BM | 1 |
| Kornberg, A | 1 |
| Küpper, B | 1 |
| Hommann, M | 1 |
| Scheele, J | 1 |
| Short, RA | 1 |
| Desai, MY | 1 |
| Dalal, D | 1 |
| Carvalho, JA | 1 |
| Martin, DR | 1 |
| Flynn, JA | 1 |
| Nasir, K | 1 |
| Blumenthal, RS | 1 |
| Ratto, E | 3 |
| Vaccaro, V | 2 |
| Parodi, D | 1 |
| Parodi, A | 2 |
| Falqui, V | 2 |
| Tomolillo, C | 2 |
| Masunari, N | 1 |
| Yamada, M | 1 |
| Fujiwara, S | 1 |
| Suzuki, G | 1 |
| Kodama, K | 1 |
| Kasagi, F | 1 |
| Kuo, SC | 1 |
| Yang, YH | 1 |
| Huang, CC | 1 |
| Peng, MC | 1 |
| Tsai, WC | 1 |
| Chang, YY | 1 |
| Chen, WH | 1 |
| Chen, SS | 1 |
| Liu, JS | 1 |
| Os, I | 2 |
| Wu, CW | 1 |
| Kurata, A | 1 |
| Shigematsu, Y | 1 |
| Yoo, TW | 1 |
| Shin, HS | 1 |
| Ryu, SH | 1 |
| Keum, DG | 1 |
| Baker, JF | 1 |
| Schumacher, HR | 1 |
| Kahn, HS | 1 |
| Mount, DB | 1 |
| Reginato, AM | 1 |
| Calberg, MJ | 1 |
| Kjøller, E | 1 |
| Guo, CY | 1 |
| Cupples, LA | 1 |
| Levy, D | 2 |
| Wilson, PW | 1 |
| Kato, M | 1 |
| Tomikura, Y | 1 |
| Kotani, K | 1 |
| Kinugawa, T | 1 |
| Ogino, K | 2 |
| Ishida, K | 1 |
| Somers, VK | 1 |
| Masseoud, D | 1 |
| Rott, K | 1 |
| Liu-Bryan, R | 1 |
| Agudelo, C | 1 |
| Iwashima, Y | 1 |
| Horio, T | 1 |
| Ogihara, T | 1 |
| Kawano, Y | 2 |
| Zanolin, ME | 1 |
| Tosi, F | 3 |
| Castello, R | 1 |
| Spiazzi, G | 1 |
| Dorizzi, R | 1 |
| Moghetti, P | 1 |
| Mikuls, TR | 1 |
| Siriamornpun, S | 1 |
| Price, K | 1 |
| Kannelis, J | 1 |
| Pontiggia, B | 1 |
| Mazzilli, G | 1 |
| Girola, A | 1 |
| Sartorio, A | 1 |
| Viberti, GC | 1 |
| Sautin, Y | 2 |
| Ejaz, AA | 1 |
| Sheu, WH | 1 |
| Tseng, YH | 1 |
| Corry, DB | 1 |
| Tuck, ML | 1 |
| Bos, MJ | 1 |
| Koudstaal, PJ | 1 |
| Tomita, H | 1 |
| Oka, Y | 1 |
| Ohtsuka, N | 1 |
| Tanaci, N | 1 |
| Ertugrul, DT | 1 |
| Sahin, M | 1 |
| Yucel, M | 1 |
| Olcay, I | 1 |
| Demirag, NG | 1 |
| Gursoy, A | 1 |
| Choo, KE | 1 |
| Lau, KB | 1 |
| Chew, PH | 1 |
| Matayoshi, T | 1 |
| Aksnes, TA | 1 |
| Reims, HM | 1 |
| Guptha, S | 1 |
| Moan, A | 1 |
| Chizyński, K | 1 |
| Rózycka, M | 1 |
| Patel, DA | 1 |
| Srinivasan, SR | 2 |
| Xu, JH | 1 |
| Berenson, GS | 2 |
| Delfini, E | 1 |
| Petramala, L | 1 |
| Caliumi, C | 1 |
| Cotesta, D | 1 |
| De Toma, G | 1 |
| Cavallaro, G | 1 |
| Panzironi, G | 1 |
| Diacinti, D | 1 |
| Minisola, S | 1 |
| D' Erasmo, E | 1 |
| Mazzuoli, GF | 1 |
| Letizia, C | 1 |
| Bonita, JS | 1 |
| Mandarano, M | 1 |
| Shuta, D | 1 |
| Vinson, J | 1 |
| Jacobs, JW | 1 |
| Bijlsma, JW | 1 |
| Zharikov, S | 1 |
| Conti, N | 1 |
| Miller, E | 1 |
| Najjar, SS | 1 |
| Senin, U | 1 |
| Sun, K | 1 |
| Strazzullo, P | 2 |
| Milionis, HJ | 1 |
| Kita, MD | 1 |
| Klocke, R | 1 |
| Caliskan, M | 1 |
| Erdogan, D | 1 |
| Gullu, H | 1 |
| Yildirim, I | 1 |
| Ozer, I | 1 |
| Yildirir, A | 1 |
| Muderrisoglu, H | 1 |
| Kutzing, MK | 1 |
| Firestein, BL | 1 |
| Gersch, MS | 1 |
| Benner, S | 1 |
| Lopez-Alvarenga, JC | 1 |
| Strasak, A | 1 |
| Ruttmann, E | 2 |
| Brant, L | 1 |
| Kelleher, C | 1 |
| Klenk, J | 1 |
| Concin, H | 2 |
| Diem, G | 2 |
| Pfeiffer, K | 1 |
| Ulmer, H | 2 |
| Omura, Y | 1 |
| Lu, DP | 1 |
| Shimotsura, Y | 1 |
| Ohki, M | 1 |
| Duvvi, H | 1 |
| Toschi, V | 1 |
| Cronstein, BN | 1 |
| Wallace, C | 1 |
| Newhouse, SJ | 1 |
| Braund, P | 1 |
| Tobin, M | 1 |
| Falchi, M | 1 |
| Ahmadi, K | 1 |
| Dobson, RJ | 1 |
| Marçano, AC | 1 |
| Hajat, C | 1 |
| Burton, P | 1 |
| Deloukas, P | 1 |
| Brown, M | 1 |
| Connell, JM | 1 |
| Lathrop, GM | 1 |
| Farrall, M | 1 |
| Spector, T | 1 |
| Samani, NJ | 1 |
| Caulfield, MJ | 1 |
| Munroe, PB | 1 |
| Perry, ME | 1 |
| Sturrock, RD | 1 |
| Strasak, AM | 1 |
| Kelleher, CC | 1 |
| Brant, LJ | 1 |
| Rapp, K | 1 |
| Pfeiffer, KP | 1 |
| Ioachimescu, AG | 1 |
| Brennan, DM | 1 |
| Hoar, BM | 1 |
| Hazen, SL | 1 |
| Hoogwerf, BJ | 1 |
| Gaucher, EA | 1 |
| Angerhofer, AJ | 1 |
| Benner, SA | 1 |
| Franchini, M | 1 |
| Favaloro, EJ | 1 |
| Baumert, J | 1 |
| Döring, A | 2 |
| Pilz, S | 1 |
| Haj-Yahya, S | 1 |
| Almer, G | 1 |
| Fujimori, S | 1 |
| Yamasaki, T | 1 |
| Tomita, K | 1 |
| Neogi, T | 1 |
| George, J | 1 |
| Erem, C | 1 |
| Kocak, M | 1 |
| Hacihasanoglu, A | 1 |
| Yilmaz, M | 1 |
| Saglam, F | 1 |
| Ersoz, HO | 1 |
| Svendsen, K | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Kuller, LH | 1 |
| Saker, BM | 1 |
| Tofler, OB | 1 |
| Burvill, MJ | 1 |
| Reilly, KA | 1 |
| Carel, RS | 1 |
| Shoenfeld, Y | 1 |
| Eldar, M | 1 |
| Silverberg, DS | 1 |
| Eldar, Z | 1 |
| Pinkhas, J | 1 |
| Mor, G | 1 |
| Takkunen, H | 3 |
| Reunanen, A | 3 |
| Aromaa, A | 2 |
| Knekt, P | 2 |
| Heule, H | 1 |
| Keusch, G | 1 |
| Uhlschmid, G | 1 |
| Largiadèr, F | 1 |
| Binswanger, U | 1 |
| Suarez, BK | 1 |
| Harlan, WR | 1 |
| Hull, AL | 1 |
| Schmouder, RP | 1 |
| Thompson, FE | 1 |
| Larkin, FA | 1 |
| Landis, JR | 1 |
| Rodgers, M | 1 |
| Hedley, AJ | 1 |
| Mitchell, JR | 1 |
| Rapado, A | 1 |
| Woolliscroft, JO | 1 |
| Colfer, H | 1 |
| Fox, IH | 1 |
| Godin, M | 1 |
| Schneider, H | 5 |
| Pastow, A | 1 |
| Rafnsson, V | 1 |
| Bengtsson, C | 2 |
| Degoulet, P | 1 |
| Legrain, M | 1 |
| Réach, I | 1 |
| Aimé, F | 1 |
| Devriés, C | 1 |
| Rojas, P | 1 |
| Jacobs, C | 1 |
| Cooper, KH | 1 |
| Berndt, H | 1 |
| Sankalé, M | 1 |
| Prebis, JW | 1 |
| Gruskin, AB | 1 |
| Polinsky, MS | 1 |
| Baluarte, HJ | 1 |
| Kinner, B | 1 |
| Sauer, I | 1 |
| Kirsch, JJ | 1 |
| Müller, J | 1 |
| Pitule-Schödel, H | 1 |
| Ziegelasch, HJ | 4 |
| Duffy, WB | 1 |
| Senekjian, HO | 1 |
| Knight, TF | 1 |
| Weinman, EJ | 1 |
| Lorant, P | 1 |
| Kremeier, E | 1 |
| Fessel, WJ | 1 |
| Dowse, GK | 3 |
| Gareeboo, H | 2 |
| Alberti, KG | 2 |
| Zimmet, P | 1 |
| Tuomilehto, J | 2 |
| Purran, A | 1 |
| Fareed, D | 1 |
| Chitson, P | 2 |
| Collins, VR | 2 |
| Grunstein, RR | 1 |
| Stenlöf, K | 1 |
| Hedner, J | 1 |
| Sjöström, L | 1 |
| Yamazaki, K | 1 |
| Murata, M | 1 |
| O'Reilly, S | 1 |
| Jenkins, DJ | 1 |
| Khan, A | 1 |
| Jenkins, AL | 1 |
| Illingworth, R | 1 |
| Pappu, AS | 1 |
| Wolever, TM | 1 |
| Vuksan, V | 1 |
| Buckley, G | 1 |
| Rao, AV | 1 |
| Cunnane, SC | 1 |
| Swaminathan, R | 1 |
| Cockram, C | 1 |
| Lau, E | 1 |
| Chan, A | 1 |
| Folsom, AR | 2 |
| Rao, X | 1 |
| Cen, R | 1 |
| Zhang, K | 1 |
| He, L | 1 |
| Irving, S | 1 |
| Dennis, BH | 1 |
| Cappuccio, FP | 1 |
| Farinaro, E | 1 |
| Trevisan, M | 1 |
| Hodge, AM | 1 |
| Zimmet, PZ | 2 |
| Cullen, KJ | 1 |
| Knuiman, MW | 1 |
| Ward, NJ | 1 |
| Tobita, Y | 1 |
| Otaki, H | 1 |
| Kusaka, Y | 1 |
| Iki, M | 1 |
| Kajita, E | 1 |
| Sato, K | 1 |
| Caballero Oliver, A | 1 |
| Stiefel García-Junco, P | 1 |
| García-Donas López, MA | 1 |
| Villar Ortiz, J | 1 |
| Carneado de la Fuente, J | 1 |
| Kawamura, T | 2 |
| Yamamoto, R | 2 |
| WaKai, K | 2 |
| Ichihara, Y | 2 |
| Mizuno, Y | 2 |
| Kojima, M | 1 |
| Aoki, R | 1 |
| Tamakoshi, A | 1 |
| Ohno, Y | 2 |
| Elbagir, MN | 1 |
| Eltom, MA | 1 |
| Mahadi, EO | 1 |
| Berne, C | 1 |
| Brestrich, M | 1 |
| Claus, J | 1 |
| Blümchen, G | 1 |
| Shah, DM | 1 |
| Reed, G | 1 |
| Zenere, MB | 3 |
| Saggiani, F | 3 |
| Cacciatori, V | 2 |
| Travia, D | 2 |
| Zenti, MG | 2 |
| Branzi, P | 3 |
| Santi, L | 2 |
| Katsumori, K | 1 |
| Saeki, A | 1 |
| Drabo, PY | 1 |
| Kabore, J | 1 |
| Lengani, A | 1 |
| Ilboudo, PD | 1 |
| C-Soriguer, FJ | 1 |
| González-Ruiz, A | 1 |
| Ruano, TJ | 1 |
| Pareja, A | 1 |
| Collantes, E | 1 |
| Folsom, A | 1 |
| Tao, S | 1 |
| Rathmann, W | 1 |
| Funkhouser, E | 1 |
| Dyer, AR | 2 |
| Roseman, JM | 1 |
| Adachi, H | 1 |
| Hashimoto, R | 1 |
| Tsuruta, M | 1 |
| Imaizumi, T | 1 |
| Valdemarsson, S | 1 |
| Lindblom, P | 1 |
| Bergenfelz, A | 1 |
| Torun, M | 1 |
| Yardim, S | 1 |
| Simsek, B | 1 |
| Burgaz, S | 1 |
| Kivlighn, SD | 1 |
| Kim, YG | 1 |
| Suga, S | 1 |
| Fogo, AB | 1 |
| Anno, T | 1 |
| Yokoi, M | 1 |
| Iguchi, A | 1 |
| Vaccarino, V | 1 |
| Krumholz, HM | 1 |
| Culleton, BF | 2 |
| Kannel, WB | 1 |
| Liese, AD | 1 |
| Hense, HW | 1 |
| Löwel, H | 1 |
| Tietze, M | 1 |
| Keil, U | 1 |
| Cohen, H | 1 |
| Madhavan, S | 1 |
| Rosell, M | 1 |
| Regnström, J | 1 |
| Kallner, A | 1 |
| Hellénius, ML | 1 |
| de la Serna, G | 1 |
| Cadarso, C | 1 |
| Sumino, H | 1 |
| Ichikawa, S | 1 |
| Kanda, T | 1 |
| Sakamaki, T | 1 |
| Alberiche, MP | 1 |
| Yeh, CJ | 1 |
| Chan, P | 1 |
| Dobson, A | 1 |
| Ovalle, F | 1 |
| Bell, DS | 1 |
| Kashyap, AS | 1 |
| Kashyap, S | 1 |
| Lussier-Cacan, S | 1 |
| Xhignesse, M | 1 |
| Kessling, AM | 1 |
| Davignon, J | 1 |
| Sing, CF | 1 |
| Lai, SW | 2 |
| Tan, CK | 1 |
| Ng, KC | 2 |
| Lai, MM | 1 |
| Silla, J | 1 |
| Ordovás, JM | 1 |
| Sabater, A | 1 |
| Ruiz de la Fuente, S | 1 |
| Portolés, O | 1 |
| González, JI | 1 |
| Saiz, C | 1 |
| Poullis, M | 1 |
| Rich, MW | 1 |
| Chu, NF | 1 |
| Wang, DJ | 1 |
| Liou, SH | 1 |
| Shieh, SM | 1 |
| Shirom, A | 1 |
| Melamed, S | 1 |
| Nir-Dotan, M | 1 |
| Stiefel, P | 1 |
| Montilla, C | 1 |
| García-Morillo, S | 1 |
| Pamies, E | 1 |
| Miranda, ML | 1 |
| Villar, J | 1 |
| Hainer, V | 1 |
| Stunkard, AJ | 1 |
| Kunesová, M | 1 |
| Parízková, J | 1 |
| Stich, V | 1 |
| Allison, DB | 1 |
| Franse, LV | 1 |
| Pahor, M | 1 |
| Di Bari, M | 1 |
| Shorr, RI | 1 |
| Wan, JY | 1 |
| Somes, GW | 1 |
| Applegate, WB | 1 |
| Clermont, G | 1 |
| Lecour, S | 1 |
| Lahet, J | 1 |
| Siohan, P | 1 |
| Vergely, C | 1 |
| Chevet, D | 1 |
| Rifle, G | 1 |
| Rochette, L | 1 |
| Pilotto, L | 1 |
| Schillaci, G | 1 |
| Santeusanio, F | 1 |
| Porcellati, C | 1 |
| Brunetti, P | 1 |
| Mizuno, S | 1 |
| Yamanaka, H | 1 |
| Hosoda, Y | 1 |
| Sakuma, K | 1 |
| Matuoka, Y | 1 |
| Odaka, M | 1 |
| Yamaguchi, M | 1 |
| Yosida, H | 1 |
| Morisawa, H | 1 |
| Murayama, T | 1 |
| Wang, JG | 1 |
| Staessen, JA | 1 |
| Fagard, RH | 1 |
| Birkenhäger, WH | 1 |
| Gong, L | 1 |
| Löcsey, L | 1 |
| Asztalos, L | 1 |
| Dán, A | 1 |
| Kinces, Z | 1 |
| Berczi, C | 1 |
| Sziki, G | 1 |
| Tatsuno, I | 1 |
| Peixoto , MR | 1 |
| Monego, ET | 1 |
| Jardim, PC | 1 |
| Carvalho, MM | 1 |
| Sousa, AL | 1 |
| Oliveira, JS | 1 |
| Balestra Neto, O | 1 |
| García Puig, J | 1 |
| Miguel Ruilope, L | 1 |
| Capuano, V | 1 |
| Bambacaro, A | 1 |
| Lanzara, C | 1 |
| Fortunato, I | 1 |
| D'Arminio, T | 1 |
| Del Regno, B | 1 |
| D'Antonio, V | 1 |
| Lanti, M | 2 |
| Angeletti, M | 2 |
| Panarelli, W | 1 |
| Gueli, N | 1 |
| Del Nero, A | 1 |
| Zia, N | 1 |
| Carmenini, E | 1 |
| Cacciafesta, M | 1 |
| Maxwell, AJ | 1 |
| Bruinsma, KA | 1 |
| Hu, P | 1 |
| Seeman, TE | 1 |
| Reuben, DB | 1 |
| Aboa Eboule, AC | 1 |
| De Smet, P | 1 |
| Dramaix, M | 1 |
| De Backer, G | 1 |
| Kornitzer, M | 1 |
| Hashimoto, T | 1 |
| Valle, M | 1 |
| Gascón, F | 1 |
| Martos, R | 1 |
| Ruz, FJ | 1 |
| Bermudo, F | 1 |
| Morales, R | 1 |
| Cañete, R | 1 |
| Wortmann, RL | 1 |
| Fernández-Andrade, C | 1 |
| Zazgornik, J | 1 |
| Balcke, P | 1 |
| Schmidt, P | 1 |
| Kopsa, H | 1 |
| Tweeddale, MG | 1 |
| Fodor, JG | 1 |
| Oberwittler, W | 1 |
| Schulte, H | 1 |
| Berchtold, P | 2 |
| Berger, M | 2 |
| Greiser, E | 1 |
| Dohse, M | 1 |
| Irmscher, K | 1 |
| Gries, FA | 2 |
| Zimmermann, H | 2 |
| Laaser, U | 1 |
| Bulpitt, CJ | 1 |
| Hodes, C | 1 |
| Everitt, MG | 1 |
| Shoshkes, M | 1 |
| Hedstrand, H | 1 |
| Marktl, W | 1 |
| Rudas, B | 1 |
| Marangoni, R | 1 |
| Savino, R | 1 |
| Colombo, R | 1 |
| Cimino, R | 1 |
| Civardi, F | 1 |
| Zwiauer, KF | 1 |
| Pakosta, R | 1 |
| Mueller, T | 1 |
| Widhalm, K | 1 |
| Agamah, ES | 1 |
| Webber, LS | 1 |
| Staessen, J | 1 |
| Vogel, H | 1 |
| Schirmer, F | 1 |
| Flechsig, R | 1 |
| Koch, R | 1 |
| Schröder, HE | 1 |
| Richter, HG | 1 |
| Burke, GL | 1 |
| Ballew, C | 1 |
| Haskell, WL | 1 |
| Donahue, RP | 1 |
| Liu, KA | 1 |
| Hilner, JE | 1 |
| Levine, W | 1 |
| Shekelle, RB | 1 |
| Schoenberger, JA | 1 |
| Moser, M | 1 |
| Lapidus, L | 1 |
| Stendahl, C | 1 |
| Waldenström, J | 1 |
| Scott, JT | 1 |
| Gerhard, W | 2 |
| Hempel, WE | 2 |
| Gaber, E | 1 |
| Richter, K | 2 |
| Wagenknecht, CU | 2 |
| Gillum, RF | 1 |
| Hermann, K | 1 |
| Docolomanský, A | 1 |
| Kvasnovský, S | 1 |
| Schlapbach, P | 1 |
| Friedrich, G | 1 |
| Bertoli, L | 1 |
| Busnardo, I | 1 |
| Zagnoni, P | 1 |
| Burack, RC | 1 |
| Keller, JB | 1 |
| Higgins, MW | 1 |
| Nishizawa, T | 1 |
| Jouve, A | 1 |
| Sommer, A | 1 |
| Avierinos, C | 1 |
| Fondarai, J | 1 |
| de Gennes, JL | 1 |
| Thomopoulos, P | 1 |
| Truffert, J | 1 |
| Labrousse de Tregomain, B | 1 |
| Matzkies, F | 1 |
| Brunner, C | 1 |
| Berg, G | 1 |
| Prior, IA | 1 |
| Klein, R | 1 |
| Klein, BE | 1 |
| Cornoni, JC | 1 |
| Maready, J | 1 |
| Cassel, JC | 1 |
| Tyroler, HA | 1 |
| Kuntzinger, H | 1 |
| Debray, JR | 1 |
| Chrétien, J | 1 |
| Gueniot, M | 1 |
| Hardouin, JP | 1 |
| Himbert, J | 2 |
| Pichot, P | 1 |
| Richet, G | 1 |
| Roussel, C | 2 |
| Ryckewaert, AR | 1 |
| Harvengt, C | 1 |
| Lavenne, F | 1 |
| Bensaid, J | 1 |
| Láhoda, F | 1 |
| Ross, A | 1 |
| Nikolov, GS | 1 |
| Levi, J | 1 |
| Bicher, HI | 1 |
| Rosenfeld, J | 1 |
| Wekka, Z | 1 |
| Bozyk, Z | 1 |
| Rürup, B | 1 |
| Schulz, J | 1 |
| Boden, C | 1 |
| Boden, U | 1 |
| Schulz, HJ | 1 |
| Heyden, S | 1 |
| Ravera, M | 1 |
| Ugo, C | 1 |
| Knappe, J | 1 |
| Knappe, G | 1 |
| Strube, G | 1 |
| Dück, KD | 1 |
| Relke, W | 1 |
| Di Stefano, A | 1 |
| Pennisi, S | 1 |
| Terranova, R | 1 |
| Turri, C | 1 |
| Martelli, GC | 1 |
| Hood, B | 1 |
| Olander, R | 1 |
| Orndahl, G | 1 |
| Holländer, E | 1 |
| Schwarczmann, P | 1 |
| Lavicka, J | 1 |
| Chaloupková, E | 1 |
| Steigmann, F | 1 |
| Oz, R | 1 |
| Dubin, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovas[NCT01131676] | Phase 3 | 7,064 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Study of Novel Approaches for Prevention[NCT01183689] | 599 participants (Actual) | Interventional | 2010-08-31 | Completed | |||
| Diabetes Control and Complications Trial (DCCT)[NCT00360815] | 1,441 participants | Interventional | 1983-08-31 | Completed | |||
| Epidemiology of Diabetes Interventions and Complications (EDIC)[NCT00360893] | 1,441 participants (Actual) | Observational | 1994-04-30 | Active, not recruiting | |||
| Randomized Intervention Study to Assess the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease and Its Impact on Morbidity and Mortality: The ILERVAS Project[NCT03228459] | 16,660 participants (Actual) | Interventional | 2015-01-15 | Active, not recruiting | |||
| The Bogalusa Heart Study[NCT00005129] | 11,737 participants (Actual) | Observational | 1972-06-30 | Active, not recruiting | |||
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases[NCT02211365] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2014-02-28 | Recruiting | |||
| A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia[NCT01984749] | 1,000 participants (Anticipated) | Interventional | 2013-11-30 | Active, not recruiting | |||
| Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)[NCT00327860] | 1,100 participants (Actual) | Observational | 2003-10-31 | Active, not recruiting | |||
| Paediatric Obesity and Cardiovascular Dysfunction: Searching for Early Markers of Damage[NCT03169257] | 100 participants (Actual) | Interventional | 2015-01-15 | Completed | |||
| The Effect of Acute Fructose Load in Patients With Chronic Kidney Disease and Patients With Type 2 Diabetes Compared to Healthy Subjects[NCT03157960] | 20 participants (Actual) | Interventional | 2012-02-01 | Completed | |||
| Adverse Metabolic Effects of Dietary Sugar: Ad Libitum vs Energy-balanced Diets[NCT02548767] | 36 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Genetic-specific Effects of Fructose on Liver Lipogenesis[NCT03783195] | 15 participants (Actual) | Interventional | 2019-01-25 | Completed | |||
| "Evaluation of the Intervention Program Obeldicks for Obese Children and Adolescents"[NCT00435734] | 4,000 participants (Actual) | Observational | 1999-07-31 | Active, not recruiting | |||
| A Double-blind Randomized Controlled Trial on Whole Soy and Daidzein Supplementation on Reduction of Blood Pressure in Prehypertensive Postmenopausal Chinese Women[NCT01270737] | 270 participants (Anticipated) | Interventional | 2011-03-31 | Not yet recruiting | |||
| The Effects of Soy Protein and/or Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors-a Six Months RCT Among Postmenopausal Women[NCT00856882] | 0 participants | Interventional | 2007-10-31 | Completed | |||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Genetic, Environment and Its Interaction Analysis for Cardiovascular Autonomic Neuropathy in Chinese Population[NCT02461342] | 2,100 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| The Risk Analysis for Cardiovascular Autonomic Neuropathy in General Chinese Population[NCT02462616] | 2,100 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| A Community-based, Family Navigator Intervention to Improve Cardiometabolic Health of Medicaid-insured Youth Identified Through an Antipsychotic Medication Preauthorization Program[NCT02877823] | 302 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| The Effects of Orange Juice Compared With Sugar-sweetened Beverage on Risk Factors and Metabolic Processes Associated With the Development of Cardiovascular Disease and Type 2 Diabetes[NCT03527277] | 56 participants (Actual) | Interventional | 2018-06-01 | Completed | |||
| Effects of 2-weeks Fructose & HFCS Consumption on Dyslipidemia & Insulin Resistance[NCT01103921] | 214 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| A Single-arm Trial to Evaluate the Efficacy of an Aggressive Weight Loss Program With a Ketogenic Induction Phase for the Treatment of Chronic Plaque Psoriasis[NCT03531528] | 37 participants (Actual) | Interventional | 2018-05-21 | Completed | |||
| A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response t[NCT01493531] | Phase 3 | 610 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| [NCT02797028] | Phase 4 | 320 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention[NCT03425708] | Phase 4 | 400 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| Evaluation of Quercetin in Type 2 Diabetes: Impact on Glucose Tolerance and Postprandial Endothelial Function.[NCT01839344] | Phase 2 | 19 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Vascular Health and Risk Factors in Children With Down Syndrome[NCT04735874] | 55 participants (Actual) | Observational | 2021-02-02 | Completed | |||
| Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases[NCT01248143] | Phase 2/Phase 3 | 300 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Alkaline Diet for Insulin Sensitivity[NCT02501343] | 32 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)[NCT00416741] | 2,000 participants (Actual) | Observational | 2005-02-28 | Completed | |||
| Randomized Controlled Clinical Trial for Assessing Tolerability and Effectiveness of Formula Coleosoma 29 in Patients With Dyslipidemia[NCT03027336] | Phase 2 | 39 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.[NCT00174915] | Phase 3 | 1,072 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.[NCT00430248] | Phase 3 | 2,269 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout[NCT00102440] | Phase 3 | 760 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| The Effect of Allopurinol on Malondialdehyde, Nitric Oxide, Kidney Injury Molecule-1 Urine Levels, Resistive Index and Renal Elastography in Kidney Stone Patients After Extra Corporeal Shockwave Lithotripsy[NCT05414669] | Phase 4 | 35 participants (Actual) | Interventional | 2020-08-06 | Completed | ||
| Effect of a Cold Water Immersion (CWI) on Pain in People With Gouty Arthritis: A Community Based Randomized Controlled Trial[NCT04587544] | 76 participants (Actual) | Interventional | 2019-07-01 | Completed | |||
| Study for the Investigation of New Individual Risk Profiles and Therapeutic Strategies in Obesity Related Cardiovascular and Metabolic Disorders.[NCT00482924] | 1,500 participants (Anticipated) | Observational | 2003-01-31 | Recruiting | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia[NCT06084585] | 180 participants (Anticipated) | Interventional | 2023-10-23 | Recruiting | |||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)[NCT00237588] | Phase 4 | 25 participants | Interventional | 2004-12-31 | Completed | ||
| Influence of Food Liking of Adding Spices to Replace Dietary Sugar Using Sequential Monadic CLT Methodology[NCT03139552] | 150 participants (Actual) | Interventional | 2016-10-17 | Completed | |||
| Influence on Food Liking of Adding Spices to Replace Dietary Sugar[NCT03134079] | 160 participants (Actual) | Interventional | 2015-09-10 | Completed | |||
| [NCT00000487] | Phase 3 | 0 participants | Interventional | 1972-06-30 | Completed | ||
| Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout[NCT02600780] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients[NCT04554069] | 280 participants (Anticipated) | Observational | 2021-06-01 | Not yet recruiting | |||
| [NCT00005140] | 0 participants | Observational | 1977-09-30 | Completed | |||
| [NCT00005122] | 0 participants | Observational | 1958-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Heart failure requiring hospitalisation (adjudicated). Percentage of patients with the event are presented. (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 4.1 |
| Empagliflozin 10 mg | 2.6 |
| Empagliflozin 25 mg | 2.8 |
| All Empagliflozin | 2.7 |
"New onset albuminuria defined as urine albumin / creatinine ratio (UACR) ≥30 mg/g.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 51.2 |
| Empagliflozin 10 mg | 51.5 |
| Empagliflozin 25 mg | 51.5 |
| All Empagliflozin | 51.5 |
New onset macroalbuminuria defined as UACR >300 mg/g. Percentage of patients with the event are presented. (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16.2 |
| Empagliflozin 10 mg | 10.9 |
| Empagliflozin 25 mg | 11.5 |
| All Empagliflozin | 11.2 |
"Silent MI; defined as presence in the ECG of:~Any Q-wave in leads V2-V3 ≥0.02 seconds or QS complex in leads V2 and V3~Q-wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF)~R-wave ≥0.04 seconds in V1-V2 and R/S ≥1 with a concordant positive T-wave in the absence of a conduction defect.~It was also required that there had been no adjudicated and confirmed event of either acute MI, hospitalisation for unstable angina, coronary revascularisation procedures or stent thrombosis following randomisation up to and including the date of the specified ECG measurement.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.2 |
| Empagliflozin 10 mg | 1.6 |
| Empagliflozin 25 mg | 1.6 |
| All Empagliflozin | 1.6 |
"Composite microvascular outcome defined as:~Initiation of retinal photocoagulation~Vitreous haemorrhage~Diabetes-related blindness, or~New or worsening nephropathy defined as:~New onset of macroalbuminuria; or~Doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) ≤45 mL/min/1.73m2; or~Initiation of continuous renal replacement therapy, or~Death due to renal disease. Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.5 |
| Empagliflozin 10 mg | 13.9 |
| Empagliflozin 25 mg | 14.1 |
| All Empagliflozin | 14.0 |
"The composite of all events adjudicated (4-point MACE): cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction (excluding silent MI), non-fatal stroke and hospitalization for unstable angina pectoris.This is a key secondary endpoint of the trial.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 14.3 |
| Empagliflozin 10 mg | 12.8 |
| Empagliflozin 25 mg | 12.8 |
| All Empagliflozin | 12.8 |
"Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), and non-fatal stroke.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 12.1 |
| Empagliflozin 10 mg | 10.4 |
| Empagliflozin 25 mg | 10.5 |
| All Empagliflozin | 10.5 |
Waist circumference will be measured using a Gulik tape measure and following a standardized protocol. Two measures of waist circumference will be taken; if the difference exceeds 1.0 cm, a third measure will be taken. Changes are measured from baseline to year 2. (NCT01183689)
Timeframe: Change from baseline to 2 years
| Intervention | centimeters (Mean) |
|---|---|
| Control Group | 0.21 |
| Small Behavior Changes | -1.06 |
| Large Behavior Changes | -2.21 |
Mean changes in the Center for Epidemiologic Studies Depression (CES-C) Scale. Reference: Turvey, C. L., Wallace, R. B., & Herzog, R. (1999). A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr, 11(2), 139-148. 20 item questionnaire with a possible range of scores is zero to 60, and higher scores indicating the presence of more symptomatology. (NCT01183689)
Timeframe: 2 years
| Intervention | units on a scale (Mean) |
|---|---|
| Control Group | 1.68 |
| Small Behavior Changes | 0.60 |
| Large Behavior Changes | 1.73 |
"The Eating Inventory (Stunkard, 1988) is a 51-item self-report instrument, was used to assess the subscale of dietary restraint (e.g., degree of conscious control exerted over eating behaviors; range from 0-21 with higher scores reflecting greater levels of restraint).~Reference: Stunkard, A. J. M., S. (1988). Eating Inventory Manual. New York: Psychological Corporation." (NCT01183689)
Timeframe: 2 years
| Intervention | Units on a scale (Mean) |
|---|---|
| Control Group | 0.39 |
| Small Behavior Changes | 0.59 |
| Large Behavior Changes | 1.27 |
"The Eating Inventory (TFEQ(Stunkard, 1988), a 51-item self-report instrument, was used to assess the subscale of disinhibition (e.g., susceptibility to loss of control over eating; range 0-16, with higher scores reflecting greater levels of disinhibition).~REF: Stunkard, A. J. M., S. (1988). Eating Inventory Manual. New York: Psychological Corporation." (NCT01183689)
Timeframe: Changes at 2 years
| Intervention | Units on a scale (Mean) |
|---|---|
| Control Group | 0.07 |
| Small Behavior Changes | -0.78 |
| Large Behavior Changes | -0.03 |
"Flexible control is characterized by a balanced approach to eating (e.g., taking smaller portions to control weight, engaging in healthy compensation) and is associated with better weight management outcomes (Westenhoefer, Stunkard, & Pudel, 1999). Scores range from 0 to 12 with higher scores reflecting greater levels of flexible control.~REF: Westenhoefer, J., Stunkard, A. J., & Pudel, V. (1999). Validation of the flexible and rigid control dimensions of dietary restraint. Int J Eat Disord, 26(1), 53-64." (NCT01183689)
Timeframe: Changes from baseline to 2 years
| Intervention | units on a scale (Mean) |
|---|---|
| Control Group | 0.39 |
| Small Behavior Changes | 0.59 |
| Large Behavior Changes | 1.27 |
"The General Health Index, a one-item question from the CDC's Health-Related Quality of Life measure (Measuring Healthy Days, 2000) required participants to report whether in general their health is excellent (1), very good (2), good (3), fair (4), or poor (5). Lower scores denotes better outcomes.~Ref: Measuring Healthy Days. (2000). Atlanta, Georgia: Centers for Disease Control and Prevention" (NCT01183689)
Timeframe: Changes from baseline to 2 years
| Intervention | 2 year changes in units on a scale (Mean) |
|---|---|
| Control Group | 0.04 |
| Small Behavior Changes | -0.04 |
| Large Behavior Changes | -0.11 |
We calculated homeostatic model assessment insulin resistance (HOMA-IR): fasting glucose in (mg/dl) * fasting insulin in (uU/mL). (NCT01183689)
Timeframe: Change from baseline to 2 years
| Intervention | HOMA-IR (Mean) |
|---|---|
| Control Group | -0.03 |
| Small Behavior Changes | -0.15 |
| Large Behavior Changes | -0.33 |
Mean change in fasting glucose from baseline to 2 years in mg/dl for all participants with year 2 measures (NCT01183689)
Timeframe: 2 years
| Intervention | Mean change from baseline in mg/dl (Mean) |
|---|---|
| Control Group | 1.48 |
| Small Behavior Changes | 0.40 |
| Large Behavior Changes | -0.18 |
Mean change in fasting insulin (uU/ml) from baseline to 2 years (NCT01183689)
Timeframe: 2 years
| Intervention | Mean changes at 2 years in uU/ml (Mean) |
|---|---|
| Control Group | -0.27 |
| Small Behavior Changes | -0.73 |
| Large Behavior Changes | -1.48 |
Change from baseline to 2 years in diastolic blood pressure (NCT01183689)
Timeframe: 2 years
| Intervention | mmHg (Mean) |
|---|---|
| Control Group | -0.41 |
| Small Behavior Changes | -2.14 |
| Large Behavior Changes | -1.33 |
Mean changes from baseline to 2 years in total cholesterol among participants with Year 2 measurements (mg/dl) (NCT01183689)
Timeframe: 2 years
| Intervention | mg/dl (Mean) |
|---|---|
| Control Group | -0.56 |
| Small Behavior Changes | 0.74 |
| Large Behavior Changes | 1.33 |
Mean changes in HDL-C from baseline to year 2 in (mg/dl) for compared among the 3 arms using analysis of variance (NCT01183689)
Timeframe: 2 years
| Intervention | Mean Change from Baseline in mg/dl (Mean) |
|---|---|
| Control Group | -0.09 |
| Small Behavior Changes | 1.43 |
| Large Behavior Changes | 2.12 |
Mean changes between baseline and 2 years in low density lipoprotein cholesterol: LDL-c (mg/dl) (NCT01183689)
Timeframe: 2 years
| Intervention | Mean change in LDL-C in mg/dl (Mean) |
|---|---|
| Control Group | -0.01 |
| Small Behavior Changes | 0.16 |
| Large Behavior Changes | 1.43 |
Compare changes in systolic blood pressure across the three intervention groups (NCT01183689)
Timeframe: Measured at 2 Years
| Intervention | mmHg (Mean) |
|---|---|
| Control Group | 1.73 |
| Small Behavior Changes | -3.72 |
| Large Behavior Changes | -2.66 |
Mean differences in weight changes among intervention groups at 24 months post-randomization (NCT01183689)
Timeframe: 2 years
| Intervention | kilograms (Mean) |
|---|---|
| Control Group | 0.54 |
| Self-regulation With Small Behavior Changes | -0.77 |
| Self-regulation With Large Behavior Changes | -1.50 |
Percentage of those participants whose body mass index at baseline was less than 30 kg/m2 who subsequently transitioned to a body mass index of 30 kg/m2 or more (i.e. met criteria for obesity) sometime during 3 years of follow-up (i.e. at least one visit). Percentages will be compared among the three arms of the trial and summarized with odds ratios Participants were assigned values of 0 or 1 at each exam depending on their obesity level. Inference is based on generalized estimating equations. (NCT01183689)
Timeframe: 3 years
| Intervention | percentage of participants (Mean) |
|---|---|
| Control Group | 16.9 |
| Self-regulation With Small Behavior Changes | 7.9 |
| Self-regulation With Large Behavior Changes | 8.6 |
"Rigid control is characterized by an all-or-nothing inflexibility around dietary rules (e.g., strict calorie counting, with guilt following if calorie-dense foods are consumed) that is associated with poor weight outcomes and more binge eating (Westenhoefer, Stunkard, & Pudel, 1999). Scores range from 0 to 16 with higher scores reflecting greater rigid control.~REF: Stunkard, A. J. M., S. (1988). Eating Inventory Manual. New York: Psychological Corporation." (NCT01183689)
Timeframe: Changes from baseline to 2 years
| Intervention | 2 year changes in units on a scale (Mean) |
|---|---|
| Control Group | 0.35 |
| Small Behavior Changes | 0.22 |
| Large Behavior Changes | 1.75 |
Number of days per week the participant reports weighing themselves. This is divided into two groups: 1) more than once per week and 2) no more than once per week (NCT01183689)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 30 |
| Small Behavior Changes | 44 |
| Large Behavior Changes | 56 |
"Dietary intake was assessed using the 2005 Block Food Frequency Questionnaire (Block FFQ) at baseline and 2 years. This validated, quantitative 110-food item questionnaire is designed to assess relative intake of energy.~REF: Block G, Woods M, Potosky A, Clifford C. Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 1990; 43:1327-1335." (NCT01183689)
Timeframe: Changes from baseline to 2 years in kilocalories
| Intervention | kilocalories (Mean) |
|---|---|
| Control Group | -134 |
| Small Behavior Changes | -186 |
| Large Behavior Changes | -185 |
Mean weight change from baseline across an average planned follow-up of three years. These mean changes will be compared among the three arms of the trial. (NCT01183689)
Timeframe: 3 years
| Intervention | kilograms (Mean) |
|---|---|
| Control Group | 0.26 |
| Self-regulation With Small Behavior Changes | -0.56 |
| Self-regulation With Large Behavior Changes | -2.37 |
Average over time (average follow-up of 3 years) of the percent of participants within each arm of the trial who gain 1 pound or more at each visit. These percentages will be compared among the three arms generalized estimating equations. Note that weight changes in units of pounds were used to define this outcome so that it may be more clear to participants. Elsewhere in the protocol, weight is reported in kilograms. Percentages at each visit are the percent who gained 1 pound or more from baseline among all who were weighed at that visit. Participants were assigned values of 0 or 1 at each visit depending on their weight gain status. (NCT01183689)
Timeframe: 3 years
| Intervention | percentage gaining 1 pound or more among (Mean) |
|---|---|
| Control Group | 40.8 |
| Self-regulation With Small Behavior Changes | 32.5 |
| Self-regulation With Large Behavior Changes | 23.6 |
Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12. (NCT01493531)
Timeframe: 12 Months
| Intervention | Gout Flares (Mean) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.7 |
| Lesinurad 400 mg + Allopurinol | 0.8 |
| Placebo + Allopurinol | 0.9 |
Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01493531)
Timeframe: 12 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.314 |
| Lesinurad 400 mg + Allopurinol | 0.276 |
| Placebo + Allopurinol | 0.333 |
Proportion of subjects with an sUA level that is < 6.0 mg/dL by Month 6. (NCT01493531)
Timeframe: 6 months
| Intervention | Proportion of Subjects (Number) |
|---|---|
| Lesinurad 200 mg + Allopurinol | 0.554 |
| Lesinurad 400 mg + Allopurinol | 0.665 |
| Placebo + Allopurinol | 0.233 |
Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
The percent change in serum urate from baseline to the Final visit was summarized. The percent change in serum urate was calculated as [(Final visit - baseline levels)/baseline]*100. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -45.2 |
| Febuxostat 120 mg QD | -51.9 |
| Febuxostat 240 mg QD | -66.3 |
| Allopurinol QD | -33.7 |
| Placebo QD | -3.0 |
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(Week 28 - baseline levels)/baseline]*100 and summarized. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.6 |
| Febuxostat 120 mg QD | -54.9 |
| Febuxostat 240 mg QD | -67.8 |
| Allopurinol QD | -34.4 |
| Placebo QD | -3.6 |
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -33.8 |
| Febuxostat 120 mg QD | -42.4 |
| Febuxostat 240 mg QD | -47.0 |
| Allopurinol QD | -22.6 |
| Placebo QD | -40.3 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -45.6 |
| Febuxostat 120 mg QD | -54.2 |
| Febuxostat 240 mg QD | -53.2 |
| Allopurinol QD | -31.5 |
| Placebo QD | -52.0 |
Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00174915)
Timeframe: Weeks 8 through 28
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 55 |
| Febuxostat 120 mg QD | 54 |
| Febuxostat 240 mg QD | 57 |
| Allopurinol QD | 46 |
| Placebo QD | 52 |
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00174915)
Timeframe: Last 3 visits (any last 3 visits up to week 28)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 48 |
| Febuxostat 120 mg QD | 65 |
| Febuxostat 240 mg QD | 69 |
| Allopurinol QD | 22 |
| Placebo QD | 0 |
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected and may have differed by subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks).
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 79 |
| Febuxostat 240 mg QD | 92 |
| Allopurinol QD | 39 |
| Placebo QD | 1 |
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00174915)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 87 |
| Febuxostat 240 mg QD | 94 |
| Allopurinol QD | 41 |
| Placebo QD | 1 |
The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Baseline and Last Visit on treatment (up to 6 months)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -33.1 |
| Febuxostat 80 mg QD | -40.6 |
| Allopurinol 200 mg or 300 mg QD | -31.3 |
Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 2
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.1 |
| Febuxostat 80 mg QD | -44.5 |
| Allopurinol 200 mg or 300 mg QD | -33.8 |
Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 4
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -34.9 |
| Febuxostat 80 mg QD | -45.5 |
| Allopurinol 200 mg or 300 mg QD | -34.5 |
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 6
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.6 |
| Febuxostat 80 mg QD | -45.1 |
| Allopurinol 200 mg or 300 mg QD | -34.4 |
The percentage of subjects with mild-to-moderate renal impairment whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.7 |
| Febuxostat 80 mg QD | 71.6 |
| Allopurinol 200 mg or 300 mg QD | 42.3 |
The percentage of subjects whose serum urate level was <6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 45.2 |
| Febuxostat 80 mg QD | 67.1 |
| Allopurinol 200 mg or 300 mg QD | 42.1 |
The percentage of subjects whose serum urate level was <4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.5 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.1 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.0 |
| Febuxostat 80 mg QD | 18.6 |
| Allopurinol 200 mg or 300 mg QD | 1.4 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 3.1 |
| Febuxostat 80 mg QD | 20.3 |
| Allopurinol 200 mg or 300 mg QD | 1.8 |
The percentage of subjects whose serum urate level was <5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 16.5 |
| Febuxostat 80 mg QD | 44.0 |
| Allopurinol 200 mg or 300 mg QD | 13.2 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.4 |
| Febuxostat 80 mg QD | 45.9 |
| Allopurinol 200 mg or 300 mg QD | 11.7 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.0 |
| Febuxostat 80 mg QD | 51.6 |
| Allopurinol 200 mg or 300 mg QD | 13.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 19.3 |
| Febuxostat 80 mg QD | 49.7 |
| Allopurinol 200 mg or 300 mg QD | 14.8 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.1 |
| Febuxostat 80 mg QD | 74.1 |
| Allopurinol 200 mg or 300 mg QD | 43.2 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 47.1 |
| Febuxostat 80 mg QD | 75.2 |
| Allopurinol 200 mg or 300 mg QD | 45.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 48.9 |
| Febuxostat 80 mg QD | 75.3 |
| Allopurinol 200 mg or 300 mg QD | 46.6 |
Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | -1.0 |
| Allopurinol 300 mg QD | 0.0 |
The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -44.7 |
| Febuxostat 120 mg QD | -51.5 |
| Allopurinol 300 mg QD | -33.0 |
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -46.3 |
| Febuxostat 120 mg QD | -53.5 |
| Allopurinol 300 mg QD | -34.8 |
Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.7 |
| Febuxostat 120 mg QD | -53.0 |
| Allopurinol 300 mg QD | -34.8 |
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -51.7 |
| Febuxostat 120 mg QD | -43.8 |
| Allopurinol 300 mg QD | -39.6 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -29.5 |
| Febuxostat 120 mg QD | -49.5 |
| Allopurinol 300 mg QD | -28.6 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -83.4 |
| Febuxostat 120 mg QD | -65.5 |
| Allopurinol 300 mg QD | -49.7 |
The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00102440)
Timeframe: Weeks 8 through 52
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 64 |
| Febuxostat 120 mg QD | 70 |
| Allopurinol 300 mg QD | 64 |
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Final Visit (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 74 |
| Febuxostat 120 mg QD | 80 |
| Allopurinol 300 mg QD | 36 |
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00102440)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 42 |
Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 52 visit was summarized. (NCT00102440)
Timeframe: Week 52
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 81 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 39 |
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00102440)
Timeframe: Last 3 Visits (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 53 |
| Febuxostat 120 mg QD | 62 |
| Allopurinol 300 mg QD | 21 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
Overall liking of apple crisp with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: Day of taste testing
| Intervention | score on likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 7.31 |
| Reduced Sugar Recipe | 6.83 |
| Reduced Sugar Plus Spice Recipe | 7.22 |
Overall liking of oatmeal with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.84 |
| Reduced Sugar Recipe | 5.70 |
| Reduced Sugar Plus Spice Recipe | 6.15 |
Overall liking of tea with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.00 |
| Reduced Sugar Recipe | 5.62 |
| Reduced Sugar Plus Spice Recipe | 5.85 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 54 |
| Second Place Ranking | 63 |
| Third Place Ranking | 33 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 88 |
| Second Place Ranking | 39 |
| Third Place Ranking | 21 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 66 |
| Second Place Ranking | 41 |
| Third Place Ranking | 42 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 48 |
| Second Place Ranking | 60 |
| Third Place Ranking | 40 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 63 |
| Second Place Ranking | 44 |
| Third Place Ranking | 43 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 49 |
| Second Place Ranking | 50 |
| Third Place Ranking | 50 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 33 |
| Second Place Ranking | 43 |
| Third Place Ranking | 74 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 12 |
| Second Place Ranking | 49 |
| Third Place Ranking | 87 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: Day of taste testings
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 34 |
| Second Place Ranking | 58 |
| Third Place Ranking | 57 |
192 reviews available for uric acid and Cardiovascular Diseases
| Article | Year |
|---|---|
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Tr | 2021 |
Relationship between serum uric acid, all-cause mortality and cardiovascular mortality in peritoneal dialysis patients: systematic review and meta-analysis of cohort studies.
Topics: Cardiovascular Diseases; Cohort Studies; Humans; Peritoneal Dialysis; Prospective Studies; Retrospec | 2021 |
Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Renal Insufficiency, | 2022 |
SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Renal Insuf | 2022 |
Serum uric acid level and all-cause and cardiovascular mortality in peritoneal dialysis patients: A systematic review and dose-response meta-analysis of cohort studies.
Topics: Cardiovascular Diseases; Humans; Mortality; Peritoneal Dialysis; Renal Insufficiency, Chronic; Uric | 2022 |
Early life exposure to the Chinese Famine of 1959 - 1961 is an independent risk factor of adulthood elevated homocysteine, hyperuricemia, high LDL, and hypertension.
Topics: Adult; Cardiovascular Diseases; Child; Child, Preschool; China; Cross-Sectional Studies; Famine; Fem | 2022 |
Uric acid in metabolic syndrome: Does uric acid have a definitive role?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2022 |
Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk.
Topics: Adolescent; Animals; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Hypertension; Hype | 2022 |
Serum uric acid and the risk of ventricular arrhythmias: a systematic review.
Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2022 |
Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Nutrition Surveys; Prospective Studies; Risk Fac | 2023 |
Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Nutrition Surveys; Prospective Studies; Risk Fac | 2023 |
Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Nutrition Surveys; Prospective Studies; Risk Fac | 2023 |
Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Nutrition Surveys; Prospective Studies; Risk Fac | 2023 |
Association of hyperuricemia with cardiovascular diseases: current evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hyperuricemia; Mal | 2023 |
Are serum uric acid levels predictors of cardiovascular risk? An update.
Topics: Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2023 |
Update in uric acid, hypertension, and cardiovascular diseases.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Prospective Studies; | 2023 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; | 2023 |
Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases.
Topics: Antioxidants; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Uric Acid | 2023 |
Insights into the relationship between serum uric acid and pulmonary hypertension (Review).
Topics: Cardiovascular Diseases; Humans; Hypertension; Hypertension, Pulmonary; Hyperuricemia; Risk Factors; | 2024 |
Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: Meta-analysis of correlational evidence.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Diabetes Complications; Diabetes Mellitus, Type 2; Hu | 2019 |
Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants.
Topics: Biomarkers; Cardiovascular Diseases; Cause of Death; Female; Humans; Hyperuricemia; Male; Middle Age | 2019 |
Dietary sugars and cardiometabolic risk factors: a network meta-analysis on isocaloric substitution interventions.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Dietary Sugars; Fructo | 2020 |
Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Disease Progression; Gout; Gout Su | 2020 |
Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Dietary Supplement | 2019 |
Comorbidities in gout and hyperuricemia: causality or epiphenomena?
Topics: Cardiovascular Diseases; Comorbidity; Gout; Humans; Hyperuricemia; Prevalence; Renal Insufficiency, | 2020 |
[Vascular dysfunction in Cardiorenal Syndrome type 4].
Topics: Aorta; Arginine; Autonomic Nervous System Diseases; Bone Diseases, Metabolic; Cardio-Renal Syndrome; | 2020 |
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Humans; Hyperuricemia; Risk Assessment; Uric Acid | 2020 |
Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Italy; Male; Middle | 2020 |
Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age.
Topics: Cardiovascular Diseases; Child; Diabetes Mellitus; Fructose; Humans; Hypertension; Insulin Resistanc | 2020 |
Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance.
Topics: Animals; Cardiovascular Diseases; Diabetes Complications; Heart; Humans; Kidney; Kidney Diseases; Ma | 2020 |
Cardiovascular safety risks associated with gout treatments.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Colchicine; Gout; Gout Suppressants; Heart Disease Ri | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney; Myocardium; Renal Insufficiency, Chron | 2020 |
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uri | 2021 |
Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis.
Topics: Blood Pressure; Cardiovascular Diseases; Disease Progression; Glomerular Filtration Rate; Gout Suppr | 2020 |
[Asymptomatic Hyperuricemia and Risk Of Cardiovascular and Renal Diseases].
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Disease Progression; Humans; Hyperuricemia; Kidney D | 2020 |
Urate, Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials.
Topics: Blood Pressure; Cardiovascular Diseases; Genetic Predisposition to Disease; Humans; Mendelian Random | 2021 |
Uric acid and cardiovascular disease: A clinical review.
Topics: Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypo | 2021 |
[Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Carotid intima-media thickness in patients with hyperuricemia: a systematic review and meta-analysis.
Topics: Blood Pressure; Cardiovascular Diseases; Carotid Intima-Media Thickness; Humans; Hyperuricemia; Uric | 2021 |
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Humans; Hypertension; Prognosis; Risk Factors; Str | 2021 |
Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights.
Topics: Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Kidney Diseases; Uric Acid | 2021 |
An update of genetics, co-morbidities and management of hyperuricaemia.
Topics: Cardiovascular Diseases; Comorbidity; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; Re | 2021 |
The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Topics: Allopurinol; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppr | 2021 |
Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review.
Topics: Cardiovascular Diseases; Diet; Feeding Behavior; Female; Fructose; Humans; Hyperuricemia; Male; Meta | 2017 |
Change gout: the need for a new approach.
Topics: Biomarkers; Body Mass Index; Cardiovascular Diseases; Diet Therapy; Disease Progression; Evidence-Ba | 2017 |
Gout and Metabolic Syndrome: a Tangled Web.
Topics: Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Gout; Humans; Hyperlipide | 2017 |
The challenge of Mendelian randomization approach.
Topics: Cardiovascular Diseases; Disease Progression; Gout; Humans; Kidney Diseases; Randomized Controlled T | 2017 |
The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney Diseas | 2017 |
Effects of serum uric acid on blood-pressure lowering treatment.
Topics: Blood Pressure; Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Ris | 2017 |
Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
Topics: Cardiovascular Diseases; Creatinine; Disease Progression; Glomerular Filtration Rate; Humans; Hyperu | 2017 |
[URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].
Topics: Biomarkers; Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal I | 2016 |
Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Topics: Allopurinol; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endothelial Cells; Humans; R | 2018 |
Uric acid and cardiovascular risk: What genes can say.
Topics: Biomarkers; Cardiovascular Diseases; Genetic Predisposition to Disease; Humans; Hyperuricemia; Mende | 2018 |
Cardiac and renal protective effects of urate-lowering therapy.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Uric acid and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Humans; Uric Acid | 2018 |
The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2018 |
Hyperuricemia and endothelial function: From molecular background to clinical perspectives.
Topics: Antioxidants; Atherosclerosis; Cardiovascular Diseases; Catalysis; Endothelium, Vascular; Humans; Hy | 2018 |
Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk.
Topics: Cardiovascular Diseases; Consensus; Global Health; Humans; Hyperuricemia; Morbidity; Risk Factors; U | 2018 |
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Disease | 2019 |
Gout and cardiovascular disease: crystallized confusion.
Topics: Biomarkers; Cardiovascular Diseases; Colchicine; Global Health; Gout; Gout Suppressants; Humans; Mor | 2019 |
Potential Dangers of Serum Urate-Lowering Therapy.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Oxidative Stress; Polyethylene Glycols; Thioglyc | 2019 |
Uric acid and the cardio-renal effects of SGLT2 inhibitors.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Heart; Humans; Hypoglycemic Agents; Kidney | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppr | 2019 |
Hyperuricemia and Cardiovascular Disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2019 |
Prevention of Cardiovascular Diseases in Children and Adolescents.
Topics: Adolescent; Age of Onset; Arterial Pressure; Biomarkers; Blood Glucose; Cardiovascular Diseases; Chi | 2019 |
Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Gout Suppressants; Humans; Hyperuricemia; Mutation; Ri | 2019 |
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?
Topics: Animals; Cardiovascular Diseases; Humans; Hypertension; Kidney; Kidney Diseases; Metabolic Syndrome; | 2013 |
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?
Topics: Animals; Cardiovascular Diseases; Humans; Hypertension; Kidney; Kidney Diseases; Metabolic Syndrome; | 2013 |
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?
Topics: Animals; Cardiovascular Diseases; Humans; Hypertension; Kidney; Kidney Diseases; Metabolic Syndrome; | 2013 |
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?
Topics: Animals; Cardiovascular Diseases; Humans; Hypertension; Kidney; Kidney Diseases; Metabolic Syndrome; | 2013 |
Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Child; Clinical Trials as Topic; Diabetes Mellitus, | 2013 |
[Hyperuricemia and cardiovascular continuum].
Topics: Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2013 |
Changes in serum uric acid levels and cardiovascular events: a meta-analysis.
Topics: Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic; Regression Analysis; Risk Fa | 2013 |
[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 8. Asymptomatic hyperuricemia].
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Metabolic Syndrome; Renal Insuffi | 2013 |
Undiagnosed diabetes has poorer profiles for cardiovascular and metabolic markers than known diabetes: The Yuport Medical Checkup Center Study.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Pressure; Cardiovascular Diseases; C | 2013 |
Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Female; Gonadal Steroid Horm | 2014 |
Sugar, uric acid, and the etiology of diabetes and obesity.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Sucrose; Disease Models, Animal | 2013 |
Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies.
Topics: Cardiovascular Diseases; Female; Humans; Male; Prospective Studies; Uric Acid | 2013 |
Definition of hyperuricemia and gouty conditions.
Topics: Cardiovascular Diseases; Crystallization; Female; Gout; Humans; Hyperuricemia; Male; Risk Factors; U | 2014 |
Gout.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Colchicine; Comorbidi | 2013 |
Serum uric acid and cardiovascular risk: state of the art and perspectives.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2014 |
[Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].
Topics: Animals; Bone Remodeling; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Disease Mode | 2014 |
Hyperuricemia and cardiovascular disease risk.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase | 2014 |
[Gout and cardiovascular risk].
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2014 |
Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Topics: Adipocytes; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Differentiation; Cell Movement; | 2014 |
Uric acid as a biomarker and a therapeutic target in diabetes.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Nephropathies; Enzyme Inhibitors; H | 2015 |
Uric acid: friend or foe? Uric acid and cognitive function "Gout kills more wise men than simple".
Topics: Animals; Antioxidants; Cardiovascular Diseases; Cognition; Female; Gout; Humans; Hyperuricemia; Male | 2015 |
Camellia sinensis in asymptomatic hyperuricemia: A meta-analysis of tea or tea extract effects on uric acid levels.
Topics: Antioxidants; Asymptomatic Diseases; Camellia sinensis; Cardiovascular Diseases; Dietary Supplements | 2017 |
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Creatinine; Disease Progression; Glomerular Filtration Rate; Gout Suppressa | 2015 |
[Uric acid, the kidney and cardiovascular mortality].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Risk Factors; | 2015 |
[The role of uric acid and allopurinol therapy in cardiovascular disease].
Topics: Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Uric Acid | 2015 |
Serum uric acid and the risk of cardiovascular and renal disease.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; | 2015 |
Regulation of uric acid metabolism and excretion.
Topics: 5'-Nucleotidase; Adenosine Deaminase; Cardiovascular Diseases; Humans; Metabolic Networks and Pathwa | 2016 |
Relation of serum uric acid to cardiovascular disease.
Topics: Cardiovascular Diseases; Female; Humans; Male; Risk Factors; Severity of Illness Index; Uric Acid | 2016 |
Uric acid lowering therapy in cardiovascular diseases.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatmen | 2016 |
[Kidney diseases and metabolic disorders--basics and applications required for general physicians. Topics: IV. Uric acid metabolic disorder (relationship between liyperuricemia and CKD-CVD)].
Topics: Age Factors; Animals; Cardiovascular Diseases; General Practitioners; Humans; Kidney Diseases; Metab | 2015 |
[Studies on association between nonalcoholic fatty liver disease and hyperuricemia: current status and future prospects].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Non-alcoholic Fatty | 2016 |
[The First Step Aiming at the Prevention of Hypertension and Atherosclerosis. Identification of Individuals at High Risk of Hypertension].
Topics: Albuminuria; Ankle Brachial Index; Atherosclerosis; Biomarkers; Blood Pressure; Cardiovascular Disea | 2015 |
Low acid uric in primary prophylaxis: worthy?
Topics: Allopurinol; Cardiovascular Diseases; Early Diagnosis; Humans; Oxypurinol; Primary Prevention; Risk | 2016 |
[HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES].
Topics: Aged; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male | 2016 |
Insight into rheumatological cause and effect through the use of Mendelian randomization.
Topics: Bone Density; Cardiovascular Diseases; Genetic Variation; Glycosylation; Humans; Immunoglobulin G; I | 2016 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Dise | 2016 |
Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis.
Topics: Aged; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Mortality | 2016 |
Allopurinol as a therapeutic option in cardiovascular disease.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Enzyme Inhibitors; Free Radical Scavengers; Humans; H | 2017 |
Uric acid: A marker of increased cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Coronary Artery Disease; Female; Heart | 2009 |
The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Cor | 2008 |
The role of hyperuricemia and gout in kidney and cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Incidence; Kidney Diseases; Risk Factors; Uric Acid | 2008 |
[Novelties in the field of progression factors in chronic kidney disease].
Topics: Adult; Amidohydrolases; Animals; Arginine; Carbon; Cardiovascular Diseases; Chronic Disease; Clinica | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2008 |
Sugary drinks in the pathogenesis of obesity and cardiovascular diseases.
Topics: Adiposity; Animals; Beverages; Caffeine; Cardiovascular Diseases; Dietary Sucrose; Dogs; Fructose; H | 2008 |
The role of hyperuricemia in vascular disorders.
Topics: Animals; Biological Evolution; Cardiovascular Diseases; Disease Models, Animal; Humans; Hypertension | 2009 |
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Uric Acid | 2009 |
Medical implications of hyperuricemia.
Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabo | 2009 |
[Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].
Topics: Anaerobiosis; Calcium Channel Blockers; Cardiovascular Diseases; Depression, Chemical; Gout; Humans; | 2010 |
Chronic kidney disease: a marker of cardiovascular disease.
Topics: Albuminuria; Anemia; Biomarkers; Blood Urea Nitrogen; Cardiovascular Diseases; Creatinine; Glomerula | 2009 |
Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA).
Topics: Caprylates; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Mellitus; Environmental Mon | 2010 |
Uric acid as a factor in the metabolic syndrome.
Topics: Biomarkers; Brazil; Cardiovascular Diseases; Female; Global Health; Humans; Hyperuricemia; Insulin R | 2010 |
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?
Topics: Animals; Antioxidants; Cardiovascular Diseases; Cells, Cultured; Clinical Trials as Topic; Comorbidi | 2010 |
Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles.
Topics: Animals; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Glomerular Filtration Rate; Hu | 2010 |
Gout: a clinical syndrome illustrated and discussed.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2010 |
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors.
Topics: Cardiovascular Diseases; Coronary Disease; Female; Genetic Loci; Genome-Wide Association Study; Gout | 2010 |
[Impact of serum uric acid level on the cardiovascular system as a risk factor].
Topics: Adipokines; Benzbromarone; Cardiovascular Diseases; Hyperuricemia; Kidney; Organic Anion Transporter | 2010 |
Uric acid in heart disease: a new C-reactive protein?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk; Uric Acid | 2011 |
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?
Topics: Cardiovascular Diseases; Chronic Disease; Evidence-Based Medicine; Fatty Liver; Humans; Hyperuricemi | 2011 |
Diet-induced metabolic acidosis.
Topics: Acid-Base Equilibrium; Acidosis; Bicarbonates; Biomarkers; Cardiovascular Diseases; Citric Acid; Die | 2011 |
Allopurinol, uric acid, and oxidative stress in cardiorenal disease.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Oxidative S | 2011 |
Uric acid as a cardiometabolic risk factor: to be or not to be.
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Kidney Diseases; Metabolic Syndrome; R | 2011 |
[Hyperuricemia and uro-nephrological disorders].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diagnosis, Differential; Humans; Hypertension; H | 2011 |
Biomarkers in chronic kidney disease: a review.
Topics: Acetylglucosaminidase; Acute-Phase Proteins; Biomarkers; C-Reactive Protein; Cardiovascular Diseases | 2011 |
Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage?
Topics: Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Progno | 2012 |
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Losartan; Risk Factors; Uric Acid; Xanthine Oxidase | 2006 |
Is there anything good in uric acid?
Topics: Age Factors; Brain Diseases; Cardiovascular Diseases; Female; Gout; Humans; Hypertension; Hyperurice | 2011 |
Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options.
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Reactive Oxygen Species; | 2011 |
Cardiovascular and renal effects of hyperuricaemia and gout.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Disease Progression; Evidence-Based Med | 2012 |
The role of serum uric acid in cardiovascular disease in type 2 diabetic and non-diabetic subjects: a narrative review.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypertension; Risk | 2011 |
Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Randomized Con | 2012 |
Uric acid as one of the important factors in multifactorial disorders--facts and controversies.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Uric A | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Topics: Allopurinol; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2012 |
Uric acid as a danger signal in gout and its comorbidities.
Topics: Biomarkers; Cardiovascular Diseases; Comorbidity; Crystallization; Diabetes Mellitus; Gout; Humans; | 2013 |
Hyperuricaemia: more than just a cause of gout?
Topics: Animals; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Inflammation; Kid | 2013 |
Chronic hyperuricemia, uric acid deposit and cardiovascular risk.
Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2013 |
Uric acid and diabetes: Is there a link?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2013 |
The role of uric acid in the pathogenesis of human cardiovascular disease.
Topics: Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperuricemia; Oxidative Stress; Uric Acid; | 2013 |
Asymptomatic hyperuricemia: to treat or not to treat.
Topics: Age Factors; Allopurinol; Cardiovascular Diseases; Clinical Trials as Topic; Gout; Gout Suppressants | 2002 |
[Uric acid metabolism and insulin resistance in type 2 diabetes].
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resista | 2002 |
[Identification of a novel urate transporter URAT1 and current status on urate research].
Topics: Animals; Cardiovascular Diseases; Carrier Proteins; Cloning, Molecular; Free Radical Scavengers; Gal | 2003 |
[Sleep apnea syndrome].
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Life Style; Sleep Apnea Syndromes; Uric Acid | 2003 |
[Association of serum uric acid level with cardiovascular mortality].
Topics: Analysis of Variance; Cardiovascular Diseases; Cohort Studies; Follow-Up Studies; Humans; Japan; Ris | 2003 |
Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?
Topics: Animals; Antioxidants; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hypertension; Hy | 2003 |
Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
Topics: Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Uric Acid; Xanthine | 2003 |
Uric acid: role in cardiovascular disease and effects of losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hyperuri | 2004 |
[Role of uric acid in cardiovascular diseases].
Topics: Biomarkers; Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2003 |
[Serum uric acid--a cardiovasular risk factor?].
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; | 2004 |
Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: a statistical modeling perspective.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Kidney Diseases; Models, St | 2005 |
Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed.
Topics: Animals; Cardiovascular Diseases; Humans; Hyperuricemia; Kidney Diseases; Muscle, Smooth, Vascular; | 2004 |
[Uric acid--more deleterious than we thought?].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Female; H | 2005 |
Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2005 |
Pathogenesis of gout.
Topics: Cardiovascular Diseases; Crystallization; Diet; Gout; Humans; Hyperuricemia; Inflammation; Insulin R | 2005 |
[Uric acid as a marker of pathophysiological mechanisms in patients with cardiovascular disease].
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Myocardial Ischemia; Prognosis; Uric Aci | 2005 |
Overview of hyperuricaemia and gout.
Topics: Antioxidants; Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Prevalence; Uric Acid | 2005 |
New insights into gout epidemiology.
Topics: Cardiovascular Diseases; Comorbidity; Feeding Behavior; Female; Gout; Humans; Male; Prevalence; Risk | 2006 |
Serum uric acid: a risk factor and a target for treatment?
Topics: Adolescent; Adult; Animals; Blood Pressure; Cardiovascular Diseases; Child; Clinical Trials as Topic | 2006 |
Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Humans; Kidney Diseases; Uric Acid | 2006 |
Uric acid and the vasculature.
Topics: Blood Vessels; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperuricemia; Myocytes, Smoo | 2006 |
Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperuricemia; Kidney Diseases; Risk Fact | 2006 |
[Lifestyle modification for patients with hypertension: alcohol restriction].
Topics: Alcohol Drinking; Animals; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypertension; L | 2006 |
[Is hyperuricemia a cardiovascular risk factor?].
Topics: Cardiovascular Diseases; Comorbidity; Female; Gout; Humans; Hyperuricemia; Obesity; Risk Factors; Se | 2006 |
Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies.
Topics: Animals; Antioxidants; Blood Pressure; Caffeine; Cardiovascular Diseases; Clinical Trials as Topic; | 2007 |
Uric acid: an old actor for a new role.
Topics: Cardiovascular Diseases; Humans; Uric Acid | 2007 |
Uric acid reduction: a new paradigm in the management of cardiovascular risk?
Topics: Animals; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Risk Reduction Behavior; Uric Acid; Xan | 2007 |
Uric acid and oxidative stress: relative impact on cardiovascular risk?
Topics: Atherosclerosis; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Oxidative Stress; React | 2007 |
Altered uric acid levels and disease states.
Topics: Animals; Cardiovascular Diseases; Gout; Humans; Hypertension; Hyperuricemia; Inflammation; Kidney Di | 2008 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Update on gout: pathophysiology and potential treatments.
Topics: Animals; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Immu | 2007 |
Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Dyslipidemias; Female; Genome, Human; Humans; Lipids; Mal | 2008 |
Gout is a risk factor for cardiovascular disease.
Topics: Acute Disease; Algorithms; Cardiovascular Diseases; Gout; Harm Reduction; Humans; Recurrence; Risk A | 2007 |
The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease.
Topics: Animals; Antioxidants; Ascorbic Acid; Biological Evolution; Blood Pressure; Cardiovascular Diseases; | 2008 |
The paradoxical relationship between serum uric acid and cardiovascular disease.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Heart Failure; Humans; Hypertension; Hyperuricemia; | 2008 |
[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; | 2008 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
[Relationship between hyperuricemia and metabolic syndrome].
Topics: Adipocytes; Cardiovascular Diseases; Cell Differentiation; Humans; Hyperuricemia; Metabolic Syndrome | 2008 |
The role of urate and xanthine oxidase inhibitors in cardiovascular disease.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Uric Acid; Xanthine Oxidas | 2008 |
[Uric acid and arterial hypertension].
Topics: Carbohydrate Metabolism; Cardiovascular Diseases; Endocrine System Diseases; Female; Gout; Humans; H | 1981 |
[Complication of childhood obesity].
Topics: Body Mass Index; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Fatty Liver; Female; Hum | 1995 |
[Hyperuricemia and insulin resistance].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Humans | 1996 |
Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hypertension; Kidney Diseases; Risk Factors; Uric Acid | 1999 |
Uric acid: is it a risk factor for cardiovascular disease?
Topics: Animals; Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2000 |
Uric acid as a risk factor for cardiovascular disease.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Female; Humans; Insulin Resistance; Ischemia; Male; Midd | 2000 |
Uric acid and cardiovascular disease: a renal-cardiac relationship?
Topics: Cardiovascular Diseases; Humans; Kidney Diseases; Risk Factors; Uric Acid | 2001 |
Hyperuricemia and renal function.
Topics: Cardiovascular Diseases; Humans; Hypertension, Renal; Kidney; Renal Insufficiency; Uric Acid | 2001 |
[Hyperuricemia in hypertension].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diuretics; Drug Therapy, Combination; Humans; Hype | 2001 |
Uric acid and cardiovascular risk.
Topics: Animals; Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2002 |
Gout and hyperuricemia.
Topics: Africa; Arthritis, Gouty; Asia; Cardiovascular Diseases; Diet Therapy; Gout; Humans; Prevalence; Uri | 2002 |
[Renal markers and predictors, and renal and cardiovascular risk factors].
Topics: Age Factors; Alcohol Drinking; Biomarkers; Blood Pressure; Cardiovascular Diseases; Fatty Acids; Hum | 2002 |
Gout.
Topics: Arthritis; Cardiovascular Diseases; Diabetes Complications; Environment; Gout; Humans; Hyperlipidemi | 1987 |
[Hyperuricemia: is treatment necessary or not?].
Topics: Cardiovascular Diseases; Diuretics; Gout; Humans; Kidney Calculi; Uric Acid | 1985 |
57 trials available for uric acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypogl | 2022 |
Uric acid as a predictor of weight gain and cardiometabolic health in the Study of Novel Approaches to Weight Gain Prevention (SNAP) study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Obesity; Risk Factors; Uric Acid; | 2022 |
Effects of elevated serum urate on cardiometabolic and kidney function markers in a randomised clinical trial of inosine supplementation.
Topics: Biomarkers; Cardiovascular Diseases; Creatinine; Dietary Supplements; Double-Blind Method; Female; G | 2022 |
Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Dietary Su | 2022 |
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Topics: Aged; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment | 2023 |
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Hum | 2020 |
A Randomized Study of the Effect of Replacing Sugar-Sweetened Soda by Reduced Fat Milk on Cardiometabolic Health in Male Adolescent Soda Drinkers.
Topics: Adolescent; Animals; Blood Pressure; Carbonated Beverages; Cardiovascular Diseases; Drinking; Dyslip | 2020 |
Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial.
Topics: Administration, Oral; Aged; Asian People; Aspirin; Cardiovascular Diseases; China; Dose-Response Rel | 2020 |
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Heart Disease Risk Factors; | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Denmark; Febuxostat; Female; Gout; Gout Suppressants; Ho | 2020 |
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk | 2022 |
Effects of vegetarian versus Mediterranean diet on kidney function: Findings from the CARDIVEG study.
Topics: Adult; Aged; Blood Urea Nitrogen; Cardiovascular Diseases; Creatinine; Cross-Over Studies; Diet, Med | 2021 |
Serum urate and cardiovascular events in the DCCT/EDIC study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Heart Disease Risk Factors; Human | 2021 |
Serum urate and cardiovascular events in the DCCT/EDIC study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Heart Disease Risk Factors; Human | 2021 |
Serum urate and cardiovascular events in the DCCT/EDIC study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Heart Disease Risk Factors; Human | 2021 |
Serum urate and cardiovascular events in the DCCT/EDIC study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Heart Disease Risk Factors; Human | 2021 |
Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study.
Topics: Administration, Oral; Adult; Alanine Transaminase; Arginine; Aspartate Aminotransferases; C-Reactive | 2017 |
Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Topics: Adult; Aged; Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Cross-Over Studies; Fe | 2017 |
Effects of Multivitamin, Multimineral and Phytonutrient Supplementation on Nutrient Status and Biomarkers of Heart Health Risk in a Russian Population: A Randomized, Double Blind, Placebo Controlled Study.
Topics: Adult; Aged; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; | 2018 |
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Cardiovascular Diseases; Drug Administration Schedule | 2019 |
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Febuxostat; Female; Gou | 2019 |
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Feb | 2014 |
Daidzein supplementation decreases serum triglyceride and uric acid concentrations in hypercholesterolemic adults with the effect on triglycerides being greater in those with the GA compared with the GG genotype of ESR-β RsaI.
Topics: Adult; Aged; Asian People; Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; Energy | 2014 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Can soy intake affect serum uric acid level? Pooled analysis from two 6-month randomized controlled trials among Chinese postmenopausal women with prediabetes or prehypertension.
Topics: Aged; Aging; Cardiovascular Diseases; China; Dietary Supplements; Double-Blind Method; Female; Human | 2015 |
Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Creatinine; Disease Progression; Fema | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Topics: Adolescent; Adult; Apolipoprotein C-III; Apolipoproteins B; Beverages; Blood Glucose; Body Mass Inde | 2015 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; D | 2015 |
Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
Topics: Aged; Allopurinol; Biological Availability; Blood Pressure; Cardiovascular Diseases; Enzyme Inhibito | 2015 |
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Topics: Aged; Aged, 80 and over; Brain Diseases; Cardiovascular Diseases; Cause of Death; Febuxostat; Female | 2017 |
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Creatinine; Double | 2017 |
Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes: A randomized clinical trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cohort Studies; Dairy Products; Diabe | 2017 |
Uric acid and long-term outcomes in CKD.
Topics: Cardiovascular Diseases; Cause of Death; Confidence Intervals; Female; Follow-Up Studies; Glomerular | 2009 |
Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly.
Topics: Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Dietary Supplement | 2009 |
Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study.
Topics: Adult; Aged; Anthropometry; Antioxidants; Blood Glucose; Blood Pressure; Body Composition; Body Weig | 2009 |
Black tea reduces uric acid and C-reactive protein levels in humans susceptible to cardiovascular diseases.
Topics: Adult; C-Reactive Protein; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Myocardial Is | 2010 |
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
Topics: Aged; Allopurinol; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chi-Square Distribution; | 2010 |
The effects of isoflavones combined with soy protein on lipid profiles, C-reactive protein and cardiovascular risk among postmenopausal Chinese women.
Topics: Aged; Asian People; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2012 |
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Glomer | 2011 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Female; Follow-Up Studies; Human | 2013 |
Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combinatio | 2013 |
Hyperuricaemia does not impair cardiovascular function in healthy adults.
Topics: Acetylcholine; Adolescent; Adult; Baroreflex; Blood Pressure; Cardiovascular Diseases; Endothelium, | 2004 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; End | 2004 |
Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction.
Topics: Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cyclosporine; Female; Graft Surv | 2004 |
Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Creatinine; Cyclosporine; Female; Glomerular Filtration | 2005 |
Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction.
Topics: Adult; Aged; Blood Pressure; Calcineurin Inhibitors; Cardiovascular Diseases; Cholesterol; Creatinin | 2005 |
Postprandial lipemia as a risk factor for cardiovascular disease in patients with hypothyroidism.
Topics: Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholestero | 2006 |
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2006 |
Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cohort | 2007 |
Effect of nibbling versus gorging on cardiovascular risk factors: serum uric acid and blood lipids.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Circadian Rhythm; Creatinine; Cross-Over Studies; Diu | 1995 |
[Lactovegetarian diet: effect on changes in body weight, lipid status, fibrinogen and lipoprotein (a) in cardiovascular patients during inpatient rehabilitation treatment].
Topics: Adult; Aged; Body Weight; Cardiac Rehabilitation; Cardiovascular Diseases; Cholesterol; Cholesterol, | 1996 |
Serum urate determines antioxidant capacity in middle-aged men - a controlled, randomized diet and exercise intervention study.
Topics: Adult; Antioxidants; Blood Pressure; Body Constitution; Body Mass Index; Cardiovascular Diseases; Ch | 1999 |
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; | 1999 |
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Cardiovascular Dis | 2000 |
Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2001 |
Diet and medication in the treatment of hyperuricemia in hypertensive patients.
Topics: Allopurinol; Benzothiadiazines; Cardiovascular Diseases; Diet; Diuretics; Energy Intake; Ethanol; Ex | 2001 |
The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial.
Topics: Aged; Arthritis, Gouty; Blood Glucose; Cardiovascular Diseases; Cholesterol; Creatinine; Drug Therap | 1991 |
In defense of traditional antihypertensive therapy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1988 |
[Influence of aluminum nicotinate on serum lipids].
Topics: Adult; Alkaline Phosphatase; Aluminum; Arteriosclerosis; Blood Glucose; Cardiovascular Diseases; Cho | 1969 |
710 other studies available for uric acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Distribution characteristics and influencing factors of homocyteine in an apparently healthy examined population.
Topics: Adult; Age Factors; Aged; Biomarkers; Cardiovascular Diseases; China; Cholesterol, HDL; Creatinine; | 2021 |
Low density lipoprotein cholesterol and all-cause mortality rate: findings from a study on Japanese community-dwelling persons.
Topics: Age Factors; Aged; Alcohol Drinking; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Cho | 2021 |
The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study.
Topics: Cardiovascular Diseases; Female; Humans; Incidence; Male; Prospective Studies; Risk Factors; Uric Ac | 2021 |
Gout, urate-lowering drugs, and risk of cardiovascular disease: can we clinically trust in the adjusted real-life data?
Topics: Cardiovascular Diseases; Gout; Humans; Pharmaceutical Preparations; Trust; Uric Acid | 2021 |
Serum uric acid level and all-cause and cardiovascular mortality in Chinese elderly: A community-based cohort study in Shanghai.
Topics: Aged; Cardiovascular Diseases; Cause of Death; China; Cohort Studies; Female; Humans; Male; Uric Aci | 2021 |
Uric Acid and Risk of Cardiovascular Disease: A Question of Start and Finish.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Cross-Sectional St | 2021 |
High-level uric acid in asymptomatic hyperuricemia could be an isolated risk factor of cardio-cerebrovascular diseases: A prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Disease Risk Fact | 2021 |
Cardiometabolic risk in adolescents with normal weight obesity.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Male; | 2022 |
Metabolic Factors Mediate the Association Between Serum Uric Acid to Serum Creatinine Ratio and Cardiovascular Disease.
Topics: Cardiometabolic Risk Factors; Cardiovascular Diseases; Creatinine; Humans; Prospective Studies; Uric | 2021 |
Uric Acid Variability and All-Cause Mortality: A Prospective Cohort Study in Northern China.
Topics: Cardiovascular Diseases; China; Cohort Studies; Humans; Prospective Studies; Risk Factors; Uric Acid | 2021 |
Body mass index was linked with multi-cardiometabolic abnormalities in Chinese children and adolescents: a community-based survey.
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Child; Child, Preschool; Humans; Hypert | 2022 |
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Cardiovascular Diseases; Gout; Heart Disease Risk Factors; Humans; Lupus | 2022 |
The Association between Serum Uric Acid Levels and 10-Year Cardiovascular Disease Risk in Non-Alcoholic Fatty Liver Disease Patients.
Topics: Cardiovascular Diseases; Humans; Non-alcoholic Fatty Liver Disease; Nutrition Surveys; Risk Factors; | 2022 |
Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Huma | 2022 |
Uric acid and cardiovascular risk stratification in the acute coronary syndromes: a friend we should mind.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Friends; Humans; Risk Factors; Uric Acid | 2022 |
Uricaemia and associated health determinants in a paediatric population in Mexico.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Child; Cholesterol, HDL; Female; Humans; Male; | 2022 |
Uric acid, xanthine oxidase, and vascular damage: potential of xanthine oxidoreductase inhibitors to prevent cardiovascular diseases.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxid | 2022 |
[Association of serum uric acid with cardiovascular risk factors and their clustering among children and adolescents in Yinchuan City].
Topics: Adolescent; Cardiovascular Diseases; Child; Cluster Analysis; Female; Heart Disease Risk Factors; Hu | 2022 |
Hyperuricemia is Related to the Risk of Cardiovascular Diseases in Ethnic Chinese Elderly Women.
Topics: Adult; Aged; Cardiovascular Diseases; China; Cross-Sectional Studies; Ethnicity; Female; Humans; Hyp | 2022 |
Dietary patterns and cardiovascular risk factors among Brazilians: A population-based study in Viçosa, Minas Gerais.
Topics: Adult; Body Mass Index; Brazil; Cardiovascular Diseases; Catalase; Cholesterol; Cholesterol, HDL; Cr | 2022 |
Cardiovascular risk factors, ethnicity and infection stone are independent factors associated with reduced renal function in renal stone formers.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Ethnicity; Female; Gout; Heart | 2022 |
Pararenal Fat and Renal Dysfunction in Patients without Significant Cardiovascular Disease.
Topics: Aged; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Overweight; | 2022 |
Cardiovascular protection conferred by glucagon-like peptide-1 receptor agonists: A role for serum uric acid reduction?
Topics: Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; | 2022 |
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout | 2022 |
A Clinical Profile of Patients with Hyperuricemia and the Relationship between Hyperuricemia and Metabolic Syndrome: A Cross-sectional Study at a Tertiary Hospital in the Indian Population.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hypertriglyceridemia; Hyperuricemi | 2022 |
The significance of follow-up serum uric acid levels in predicting all-cause mortality and cardiovascular mortality in peritoneal dialysis patients.
Topics: Cardiovascular Diseases; Follow-Up Studies; Humans; Peritoneal Dialysis; Prognosis; Risk Factors; Ur | 2023 |
Association of Hyperuricemia with 10-Year Atherosclerotic Cardiovascular Disease Risk among Chinese Adults and Elders.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; China; Cross-Sectional Studies; Female; Human | 2022 |
Association between serum uric acid and arterial stiffness in a large-aged 40-70 years old population.
Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hypertension; Male; M | 2022 |
Sex-specific cardiometabolic risk markers of left ventricular mass in physically active young adults: the CHIEF heart study.
Topics: Adolescent; Adult; Body Mass Index; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholester | 2022 |
[Ocena związku stężenia kwasu moczowego z przebiegiem zakażenia SARS-CoV-2].
Topics: C-Reactive Protein; Cardiovascular Diseases; COVID-19; Humans; Hyperuricemia; Retrospective Studies; | 2022 |
Uric acid and cardiometabolic risk by gender in youth with type 1 diabetes.
Topics: Adolescent; Blood Pressure; Cardiovascular Diseases; Child; Cholesterol, HDL; Diabetes Mellitus, Typ | 2022 |
Cardiometabolic profile of young women with hypoprolactinemia.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Carotid Intima-Media Thickness; Female; Fi | 2022 |
Should Low Serum Urate Be Exonerated? Untangling the Influence of Sarcopenia in Observational Studies.
Topics: Cardiovascular Diseases; Gout; Humans; Sarcopenia; Uric Acid | 2023 |
The uric acid value of 4.8 mg/dl may not be an ideal prognostic threshold for cardiovascular disease mortality.
Topics: Biomarkers; Cardiovascular Diseases; Cardiovascular System; Cause of Death; Humans; Prognosis; Risk | 2022 |
Reply to 'The uric acid value of 4.8 mg/dl may not be an ideal prognostic threshold for cardiovascular disease mortality'.
Topics: Cardiovascular Diseases; Cardiovascular System; Cause of Death; Humans; Prognosis; Uric Acid | 2022 |
Association of hyperuricemia with apolipoprotein AI and atherogenic index of plasma in healthy Chinese people: a cross-sectional study.
Topics: Apolipoprotein A-I; Cardiovascular Diseases; China; Cross-Sectional Studies; Humans; Hyperuricemia; | 2022 |
Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease.
Topics: Cardiovascular Diseases; Humans; Non-alcoholic Fatty Liver Disease; Nutrition Surveys; Uric Acid | 2023 |
Gout Flares and Intercritical Gout: Do they Play a Significant Role in Predicting Cardiovascular Events?
Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Symptom Flare Up; Uric Acid | 2022 |
Uric Acid Induces a Proatherothrombotic Phenotype in Human Endothelial Cells by Imbalancing the Tissue Factor/Tissue Factor Pathway Inhibitor Pathway.
Topics: Cardiovascular Diseases; Fibrinolytic Agents; Human Umbilical Vein Endothelial Cells; Humans; Inflam | 2023 |
The Association Between Uric Acid and Symmetric Dimethylarginine Levels in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis.
Topics: Arginine; Cardiovascular Diseases; Female; Humans; Lactation; Peritoneal Dialysis, Continuous Ambula | 2022 |
Associations between serum perfluoroalkyl acid (PFAA) concentrations and health related biomarkers in firefighters.
Topics: Alkanesulfonates; Alkanesulfonic Acids; Australia; Biomarkers; Caprylates; Cardiovascular Diseases; | 2022 |
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinoge | 2022 |
Association Among Polyphenol Intake, Uric Acid, and Hyperuricemia: A Cross-Sectional Analysis in a Population at High Cardiovascular Risk.
Topics: Cardiovascular Diseases; Coumaric Acids; Cross-Sectional Studies; Female; Heart Disease Risk Factors | 2022 |
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Topics: Alopecia; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Fibrinogen; | 2023 |
Uric acid could be a marker of cardiometabolic risk and disease severity in children with juvenile idiopathic arthritis.
Topics: Adult; Arthritis, Juvenile; Cardiovascular Diseases; Child; Humans; Patient Acuity; Retrospective St | 2023 |
Hyperuricaemia and its association with other risk factors for cardiovascular diseases: A population-based study.
Topics: Adolescent; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hypertension; Hyperuri | 2022 |
The Presence of Hyperhomocysteinemia Does Not Aggravate the Cardiometabolic Risk Imposed by Hyperuricemia in Young Individuals: A Retrospective Analysis of a Cross-Sectional Study.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Hom | 2022 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Dise | 2023 |
Changes in cardiovascular disease risk factors during menopausal transition in Japanese women: the Circulatory Risk in Communities Study (CIRCS).
Topics: Alanine Transaminase; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; East Asian People; Fem | 2023 |
Uric acid and gamma-glutamyl-transferase in children and adolescents with obesity: Association to anthropometric measures and cardiometabolic risk markers depending on pubertal stage, sex, degree of weight loss and type of patient care: Evaluation of the
Topics: Adiposity; Adolescent; Body Mass Index; Cardiovascular Diseases; Child; Female; Follow-Up Studies; g | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Serum uric acid significantly improves the accuracy of cardiovascular risk score models.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Dise | 2023 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Longitudinal Studies; Middl | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Development of a prediction model to estimate the 5-year risk of cardiovascular events and all-cause mortality in haemodialysis patients: a retrospective study.
Topics: Cardiovascular Diseases; Humans; Male; Renal Dialysis; Retrospective Studies; Risk Factors; Uric Aci | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hyperuricem | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Novel sedentary cage induced sedentariness in rats: evidence from relevant biomarkers.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Endothelin-1; Glucose; Insulin; Male; Nitric Oxide; Ra | 2022 |
Gout Flare and Cardiovascular Events-Reply.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid | 2023 |
Gout Flare and Cardiovascular Events.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid | 2023 |
Hyperuricemia increases the risk of cardiovascular mortality associated with very high HdL-cholesterol level.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Hy | 2023 |
Uric Acid Is Associated with Worsening of Diastolic Function and Adverse Outcomes in Patients with Coronary Slow Flow.
Topics: Aged; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Regre | 2023 |
Serum uric acid variation and the risk of cardiovascular disease: A prospective cohort study.
Topics: Aged; Bayes Theorem; Biomarkers; Cardiovascular Diseases; Humans; Inflammation; Prospective Studies; | 2023 |
Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross-sectional analysis.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Gout; Humans; Hyperuricemia; Kidney Diseas | 2023 |
Association of MPPED2 gene variant rs10767873 with kidney function and risk of cardiovascular disease in patients with hypertension.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Hypertension; | 2023 |
Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis.
Topics: Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol | 2023 |
Temporal relationship between hyperuricemia and hypertension and its impact on future risk of cardiovascular disease.
Topics: Blood Pressure; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Aci | 2023 |
The association between muscle-to-fat ratio and cardiometabolic risks: The China National Health Survey.
Topics: Body Mass Index; Cardiovascular Diseases; Female; Health Surveys; Humans; Male; Muscles; Obesity; Ov | 2023 |
Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach.
Topics: Aged; Cardiovascular Diseases; Gout; Humans; Male; Medicare; United States; Uric Acid | 2023 |
U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults.
Topics: Adult; Aged; Cardiovascular Diseases; China; Cross-Sectional Studies; East Asian People; Female; Hum | 2023 |
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Cholesterol; Creatinine; Female; Fibrinoge | 2023 |
The Interplay between Cardiovascular Risk, Cardiovascular Events, and Disease Activity in Primary Sjögren's Syndrome: Is Uric Acid the Missing Link?
Topics: Cardiovascular Diseases; Female; Heart Disease Risk Factors; Humans; Lung Diseases, Interstitial; Re | 2023 |
Endocrinology.
Topics: Body Mass Index; C-Peptide; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Typ | 2023 |
Association of serum uric acid levels with cardiovascular and all-cause mortality in hypertensive patients in China: a cohort study.
Topics: Cardiovascular Diseases; China; Cohort Studies; Female; Humans; Hypertension; Male; Prospective Stud | 2023 |
The synergistic effect of the triglyceride-glucose index and serum uric acid on the prediction of major adverse cardiovascular events after coronary artery bypass grafting: a multicenter retrospective cohort study.
Topics: Bayes Theorem; Biomarkers; Blood Glucose; Cardiovascular Diseases; Coronary Artery Bypass; Female; G | 2023 |
The effects of cardiometabolic factors on the association between serum uric acid and risk of all-cause mortality in adults with congestive heart failure.
Topics: Adult; Cardiovascular Diseases; Heart Failure; Humans; Hyperglycemia; Hypertension; Nutrition Survey | 2023 |
Serum Uric Acid and Clinical Cardiovascular Diseases in Men and Women: A Perspective for the Drug Target and the Effect of Sex.
Topics: Cardiovascular Diseases; Drug Delivery Systems; Female; Humans; Male; Risk Factors; Sex Factors; Uri | 2023 |
Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome.
Topics: Androgens; Body Mass Index; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Disease | 2023 |
Uric acid and left ventricular mass in prediction of cardiovascular risk-New insight from the URRAH study.
Topics: Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Hypertension; Hypertrophy, Left Ventric | 2023 |
Association of Normal Serum Uric Acid Level and Cardiovascular Disease in People Without Risk Factors for Cardiac Diseases in China.
Topics: Biomarkers; Cardiovascular Diseases; China; Heart Diseases; Humans; Hyperuricemia; Risk Factors; Uri | 2023 |
[ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach].
Topics: Allopurinol; Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2023 |
Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Glucose; Humans; Hyper | 2023 |
Association between serum uric acid levels and cardiovascular risk factors among adults in India.
Topics: Adult; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Female; Glycated Hemoglo | 2023 |
Association of serum uric acid with anemia in U.S. adults: a cross-sectional study using secondary data.
Topics: Adult; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Male; Nutrition Surveys; Ri | 2023 |
Safety update: febuxostat and CVD.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome | 2023 |
Dyslipidemia and its associated factors among adult cardiac patients at Ambo university referral hospital, Oromia region, west Ethiopia.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies; Dyslipidemias; Ethiopia; Hospi | 2023 |
Association Between Dietary Fiber Intake and Cardiometabolic Risk Factors in Adolescents in the United States.
Topics: Adolescent; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cross-Sectional Studies; Diet; Di | 2023 |
The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; | 2023 |
The value of waist circumference as a preditor of cardiovascular risk in adult patients with classic phenylketonuria.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Cholesterol, HDL; Female; Hea | 2023 |
Novel pathological implications of serum uric acid with cardiovascular disease risk in obesity.
Topics: Cardiovascular Diseases; Cohort Studies; Female; Humans; Hyperuricemia; Male; Obesity; Prospective S | 2023 |
Uric Acid and Risk of Cardiovascular Disease and Mortality: A Longitudinal Cohort Study.
Topics: Adult; Cardiovascular Diseases; Cohort Studies; Gout; Humans; Longitudinal Studies; Uric Acid | 2023 |
Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in southeastern China.
Topics: Cardiovascular Diseases; China; Female; Humans; Hyperglycemia; Hypertension; Hyperuricemia; Male; Re | 2023 |
Uric Acid Levels, Number of Standard Modifiable Cardiovascular Risk Factors, and Prognosis in Patients With Coronary Artery Disease: A Large Cohort Study in Asia.
Topics: Asia; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Heart Disease Risk Factors; | 2023 |
Serum uric acid to creatinine ratio as a risk factor for mortality among patients on continuous ambulatory peritoneal dialysis: a multi-center retrospective study.
Topics: Adult; Cardiovascular Diseases; Creatinine; Female; Humans; Male; Middle Aged; Peritoneal Dialysis, | 2023 |
Development and validation of an age-sex-ethnicity-specific metabolic syndrome score in the Chinese adults.
Topics: Adult; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; East | 2023 |
Association of serum uric acid with all-cause and cardiovascular mortality in obstructive sleep apnea.
Topics: Cardiovascular Diseases; Humans; Nutrition Surveys; Prospective Studies; Risk Factors; Sleep Apnea, | 2023 |
Serum uric acid levels and risk of cardiovascular disease in type 2 diabetes: results from a cross-sectional study and Mendelian randomization analysis.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Genome-Wide Association | 2023 |
Genetically Determined Uric Acid and the Risk of Cardiovascular and Neurovascular Diseases: A Mendelian Randomization Study of Outcomes Investigated in Randomized Trials.
Topics: Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cognition; Genome-Wide Association S | 2019 |
Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cadaver; Cardiovascular Diseases; Coronary Vessels; Fema | 2019 |
Could uric acid reduction by specific xanthine oxidase inhibition improve vascular function and reduce cardiovascular risk?
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Nitriles; Pyridines; Risk Factors; Uri | 2019 |
Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascular Diseases; Cohort Studies; Ge | 2019 |
Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study.
Topics: Adult; Aged; Bayes Theorem; Biological Specimen Banks; Cardiovascular Diseases; Cohort Studies; Como | 2019 |
U-Shaped Association of Serum Uric Acid With All-Cause and Cause-Specific Mortality in US Adults: A Cohort Study.
Topics: Adult; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Hyperuricemia; Male; | 2020 |
Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Comorbidity; Female; Follow-Up Studies; Gout; Humans; Hyp | 2019 |
Arterial Stiffness, Sugar-Sweetened Beverages and Fruits Intake in a Rural Population Sample: Data from the Brisighella Heart Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Cardiovascular Diseases; Diet; Eating; Fa | 2019 |
Elevated Uric Acid Levels Promote Vascular Smooth Muscle Cells (VSMC) Proliferation via an Nod-Like Receptor Protein 3 (NLRP3)-Inflammasome-Dependent Mechanism.
Topics: Actins; Animals; Cardiovascular Diseases; Carrier Proteins; Cell Line; Cell Proliferation; China; Hu | 2019 |
Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088-1094.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Risk Factors; | 2019 |
Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088-1094.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Risk Factors; | 2019 |
Association of Serum Uric Acid with Cardiovascular Disease Risk Scores in Koreans.
Topics: Adult; Aged; Alcohol Drinking; Body Mass Index; Cardiovascular Diseases; Creatinine; Cross-Sectional | 2019 |
Hyperuricaemia and its association with 10-year risk of cardiovascular disease among migrant and non-migrant African populations: the RODAM study.
Topics: Adult; Aged; Cardiovascular Diseases; Emigrants and Immigrants; Europe; Female; Ghana; Humans; Hyper | 2020 |
Electrochemical analysis of uric acid excretion to the intestinal lumen: Effect of serum uric acid-lowering drugs and 5/6 nephrectomy on intestinal uric acid levels.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascular Diseases; Disease M | 2019 |
Risk Factors For Hyperuricemia In Chinese Centenarians And Near-Centenarians.
Topics: Age Factors; Aged, 80 and over; Alcohol Drinking; Biomarkers; Cardiovascular Diseases; China; Choles | 2019 |
Relationship between serum uric acid level and all-cause and cardiovascular mortality in population with obesity.
Topics: Body Mass Index; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Confounding | 2020 |
Serum uric acid levels and cardiovascular mortality in a general Japanese population: the Hisayama Study.
Topics: Aged; Cardiovascular Diseases; Female; Humans; Japan; Male; Middle Aged; Risk Factors; Survival Rate | 2020 |
ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population.
Topics: Aged; Aged, 80 and over; Aging; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascu | 2020 |
Mild Hyperuricemia: To Treat, or Not to Treat, That is the Question. Suggestions form the URRAH Study.
Topics: Biomarkers; Cardiovascular Diseases; Clinical Decision-Making; Clinical Trials as Topic; Gout Suppre | 2020 |
Cardiovascular risk assessment after one-year acute ischemic stroke based on uric acid levels and renal dysfunction. A clinical study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Ischemic Stroke | 2021 |
Association between serum uric acid levels and mortality: a nationwide community-based cohort study.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Female; Health Surveys; Humans; Ja | 2020 |
Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?
Topics: Adult; Cardiovascular Diseases; Cross-Sectional Studies; Female; Heart Disease Risk Factors; Humans; | 2020 |
Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
Topics: Aged; Aged, 80 and over; APACHE; Biomarkers; Cardiovascular Diseases; Emergency Service, Hospital; F | 2020 |
Cancer in chronic heart failure patients in the GISSI-HF trial.
Topics: Aged; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol; Chronic Disease; Creatin | 2020 |
The differential role of uric acid - The purpose or cause of cardiovascular diseases?
Topics: Antioxidants; Biomarkers; Cardiovascular Diseases; Female; Humans; Hypertension; Oxidative Stress; R | 2020 |
[Consequences of Gout and Hyperuricemia].
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2020 |
Association of serum uric acid, morning home blood pressure and cardiovascular risk factors in a population with previous prehypertension: a cross-sectional study.
Topics: Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Female; Heart Disease Risk Factors | 2020 |
Uric acid alterations by consumption of gluten-free bakery products in relation to cardiovascular and metabolic syndrome risk factors.
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diet, Gluten-Free; Female; Human | 2020 |
Independent association of serum uric acid levels with arterial stiffness in the absence of established cardiovascular disorders.
Topics: Adult; Ankle Brachial Index; Blood Pressure; Cardiovascular Diseases; Female; Humans; Male; Pulse Wa | 2021 |
Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cross-Sectional Stu | 2021 |
Hypouricemia and Mortality Risk in the US General Population.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Fem | 2021 |
Relationship between Serum Uric Acid and Mortality Risk in Hemodialysis Patients: A Multicenter Prospective Cohort Study.
Topics: Adult; Aged; C-Reactive Protein; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Hyperur | 2020 |
Serum concentration of vitamin A and its relationship with body adiposity, oxidative stress, and cardiovascular risk in women with recommended dietary intake of vitamin A.
Topics: Adiposity; beta Carotene; Blood Glucose; Body Mass Index; Cardiometabolic Risk Factors; Cardiovascul | 2020 |
Uric acid to high-density lipoprotein cholesterol ratio predicts cardiovascular mortality in patients on peritoneal dialysis.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Female; Humans; Kidney Diseases; Male; | 2021 |
Association of uric acid with cardiovascular risk in Brazilian children and adolescents.
Topics: Adolescent; Age Factors; Biomarkers; Brazil; Cardiometabolic Risk Factors; Cardiovascular Diseases; | 2021 |
Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
Topics: Adult; Aged; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Diabetes Mellitus; Female; | 2021 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans | 2021 |
Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout.
Topics: Aged; Cardiovascular Diseases; Gout; Humans; Risk Factors; Tomography, X-Ray Computed; Uric Acid | 2021 |
Relevance of Physical Fitness and Cardiovascular Disease Risk.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Corticotropin-Releasing Hormone; Female; Humans; M | 2021 |
Association Between Total Bilirubin Levels and Cardio-Metabolic Risk Factors Related to Obesity.
Topics: Adult; Bilirubin; Body Mass Index; Cardiometabolic Risk Factors; Cardiovascular Diseases; Case-Contr | 2022 |
U-Shaped Relationship Between Cardiovascular Mortality and Serum Uric Acid May Be Attributed to Stroke- and Heart-Specific Mortality, Respectively, Among Hypertensive Patients: A Nationally Representative Cohort Study.
Topics: Cardiovascular Diseases; Cardiovascular System; Cause of Death; Cohort Studies; Female; Follow-Up St | 2021 |
Interaction between the rs9356744 polymorphism and metabolic risk factors in relation to type 2 diabetes mellitus: The Cardiometabolic Risk in Chinese (CRC) Study.
Topics: Asian People; Cardiovascular Diseases; China; Diabetes Mellitus, Type 2; Humans; Lipids; Pulse Wave | 2021 |
The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk.
Topics: Biomarkers; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Humans; Italy; Male; | 2021 |
Changes in serum uric acid and the risk of cardiovascular disease and all-cause mortality in the general population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi | 2021 |
Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; China; Follow-Up Studies; Humans; Hyperur | 2021 |
Association Between Uric Acid, Carotid Intima-Media Thickness, and Cardiovascular Events: Prospective Results From the IMPROVE Study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Carotid Arteries; Carotid Intima-Media Thickness; Europe; | 2021 |
Serum Urate Trajectory in Young Adulthood and Incident Cardiovascular Disease Events by Middle Age: CARDIA Study.
Topics: Adolescent; Adult; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypertension; Inciden | 2021 |
Correlation analysis of low-level serum uric acid and cardiovascular events in patients on peritoneal dialysis.
Topics: Adult; Cardiovascular Diseases; Cohort Studies; Correlation of Data; Female; Humans; Male; Middle Ag | 2021 |
Still Trying to Understand the Role of Uric Acid in Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2021 |
Relation of Serum Uric Acid and Cardiovascular Events in Young Adults Aged 20-49 Years.
Topics: Adult; Atrial Fibrillation; Cardiovascular Diseases; Female; Heart Failure; Humans; Hyperuricemia; I | 2021 |
Gender Difference in the Relationships between Inflammatory Markers, Serum Uric Acid and Framingham Risk Score.
Topics: Biomarkers; Cardiovascular Diseases; Female; Humans; Male; Risk Factors; Sex Factors; Uric Acid | 2021 |
Impact of Serum Uric Acid Concentration on the Risk of Cardiovascular Disease: A Cohort Study Conducted in Northern China.
Topics: Cardiovascular Diseases; China; Cohort Studies; Humans; Middle Aged; Risk Factors; Uric Acid | 2021 |
Which is more important, xanthine oxidase activity or uric acid itself, in the risk for cardiovascular disease?
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine | 2021 |
Association between serum uric acid and cardiovascular disease risk factors in adolescents in America: 2001-2018.
Topics: Adolescent; Blood Pressure; Cardiovascular Diseases; Child; Cholesterol; Cholesterol, HDL; Female; G | 2021 |
Association between serum uric acid and cardiovascular mortality and all-cause mortality: a cohort study.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Humans; Male; Middl | 2017 |
Serum uric acid level as a cardio-cerebrovascular event risk factor in middle-aged and non-obese Chinese men.
Topics: Adult; Age Factors; Asian People; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Ch | 2017 |
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cause of Death; Female; Gout; Humans; Male; | 2017 |
Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Essential Hypertension; Female; Fo | 2017 |
Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization.
Topics: Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Logistic Models; Male; Middle Aged; Pa | 2017 |
Antenatal corticosteroids and cardiometabolic outcomes in adolescents born with very low birth weight.
Topics: Adolescent; Adrenal Cortex Hormones; Biomarkers; Birth Weight; Blood Pressure; Body Composition; C-R | 2017 |
Uric acid is independent cardiovascular risk factor, as manifested by increased carotid intima-media thickness in rheumatoid arthritis patients.
Topics: Adult; Arthritis, Rheumatoid; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Carotid Intima-M | 2017 |
Examining the gender difference in the association between metabolic syndrome and the mean leukocyte telomere length.
Topics: Adult; Aged; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Female; Human | 2017 |
Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; China; Cluster Analysis; Cross-Sectional Studies; | 2017 |
Is Serum Uric Acid a Biomarker, but not a Mediator in Patients With Lifestyle and Cardiovascular Diseases?
Topics: Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hypertrophy, Left Ventricular; Hyperurice | 2017 |
Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; | 2017 |
Insulin resistance, serum uric acid and metabolic syndrome are linked to cardiovascular dysfunction in pediatric obesity.
Topics: Adolescent; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Child; Female; Humans; Insuli | 2017 |
The problem of cardio-renal diseases in patients with gout.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Ur | 2017 |
Levels of uric acid and increased diastolic blood pressure: Risk factors for atrial fibrillation in patients older than 60 years.
Topics: Aged; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Hum | 2017 |
A Point-based Mortality Prediction System for Older Adults with Diabetes.
Topics: Aged; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; | 2017 |
Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants | 2017 |
Serum uric acid and acute coronary syndrome: Is there a role for functional markers of residual cardiovascular risk?
Topics: Acute Coronary Syndrome; Biomarkers; Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2018 |
Serendipity: How the search for meaning of serum uric acid might lead to the repurposing of an old drug in patients with cardiovascular disease.
Topics: Cardiovascular Diseases; Drug Repositioning; Heart Valves; Humans; Myocardial Revascularization; Ris | 2018 |
Unraveling the relationship between serum uric acid levels and cardiovascular risk.
Topics: Cardiovascular Diseases; Cardiovascular System; Humans; Risk Factors; Uric Acid | 2018 |
Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Diabet | 2018 |
The Association between Serum Uric Acid and Renal Damage: The Takahata Study - New Insights.
Topics: Albuminuria; beta 2-Microglobulin; Cardiovascular Diseases; Creatinine; Female; Glomerular Filtratio | 2018 |
Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Italy; Prognosis; Research Design; Retro | 2018 |
U-Shaped Association Between Serum Uric Acid Levels With Cardiovascular and All-Cause Mortality in the Elderly: The Role of Malnourishment.
Topics: Age Factors; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Female; Geriatric Assessment | 2018 |
Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors.
Topics: Calcinosis; Cardiovascular Diseases; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up St | 2018 |
An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout.
Topics: Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Gout; Humans; Kidney; Longitudin | 2018 |
Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors.
Topics: Age Factors; Aged; Cardiovascular Diseases; Female; Glycated Hemoglobin; Humans; Logistic Models; Ma | 2018 |
Association of serum uric acid levels and cardiovascular risk score.
Topics: Cardiovascular Diseases; Cardiovascular System; Humans; Risk Factors; Uric Acid | 2018 |
Reply to: Serum uric acid levels positively correlates with 10-year cardiovascular risk score in the general population from China.
Topics: Cardiovascular Diseases; China; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase | 2018 |
Among markers of risk, uric acid remains a two-faced Janus awaiting definitive framing.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2018 |
Longitudinal Associations of Metabolic Syndrome Severity Between Childhood and Young Adulthood: The Bogalusa Heart Study.
Topics: Adolescent; Adult; Aging; Alabama; Black People; Cardiovascular Diseases; Child; Cross-Sectional Stu | 2018 |
The Relationships of the Fractional Excretion of Uric Acid with Brachial-Ankle Pulse Wave Velocity and Ankle Brachial Index in Chinese Young Adults.
Topics: Ankle Brachial Index; Asian People; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans | 2018 |
Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan Longitudinal Aging Study.
Topics: Age Factors; Aged; Aging; Body Mass Index; Cardiovascular Diseases; Carotid Intima-Media Thickness; | 2018 |
Crystal-proven Gout and Characteristic Gout Severity Factors Are Associated with Cardiovascular Disease.
Topics: Adult; Aged; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Female; Gout; Humans; Ma | 2018 |
Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes.
Topics: Biomarkers; Blood Pressure Determination; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes | 2019 |
U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study.
Topics: Adult; Cardiovascular Diseases; Cause of Death; Female; Humans; Hyperuricemia; Male; Middle Aged; Pr | 2018 |
The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient.
Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Female; Gout; Humans; Male; Middle Ag | 2018 |
Toward a panoramic perspective of the association between environmental factors and cardiovascular disease: An environment-wide association study from National Health and Nutrition Examination Survey 1999-2014.
Topics: Area Under Curve; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Environme | 2018 |
Serum uric acid levels positively correlates with 10-year cardiovascular risk score in the general population from China.
Topics: Cardiovascular Diseases; Cardiovascular System; China; Humans; Risk Factors; Uric Acid | 2018 |
Is increased uric acid a risk factor or a defensive response? The Campania Salute Network.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Arterial Pressure; Biomarkers; | 2018 |
Uric acid is linked to cardiometabolic risk factors in overweight and obese youths.
Topics: Adolescent; Anthropometry; Blood Pressure; Blood Pressure Determination; Body Mass Index; Cardiovasc | 2018 |
Routine blood tests during pregnancy for predicting future increases in risk of cardiovascular morbidity.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Creatinine; Female | 2018 |
Association of maternal uric acid and cystatin C serum concentrations with maternal and neonatal cardiovascular risk markers and neonatal body composition: The Ulm SPATZ Health Study.
Topics: Adult; Birth Weight; Body Composition; Body Mass Index; Cardiovascular Diseases; Cystatin C; Female; | 2018 |
Metabolic and cardiovascular effects of chronic mild hyperuricemia in rodents.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Chronic Disease; Fasti | 2018 |
Association between serum activin A and metabolic syndrome in older adults: Potential of activin A as a biomarker of cardiometabolic disease.
Topics: Absorptiometry, Photon; Activins; Aged; Aged, 80 and over; Aging; Biomarkers; Body Mass Index; C-Rea | 2018 |
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Clinical Trials, Phase III as T | 2019 |
Relationship between inflammatory parameters and cardiovascular and lifestyle factors in the Mugello study oldest old.
Topics: Aged, 80 and over; Biomarkers; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Cytokin | 2018 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiov | 2018 |
Gender, subclinical organ damage and cardiovascular risk stratification in hypertensive patients.
Topics: Adult; Ankle Brachial Index; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Carotid In | 2019 |
Salivary uric acid: Associations with resting and reactive blood pressure response to social evaluative stress in healthy African Americans.
Topics: Adult; Black or African American; Blood Pressure; Cardiovascular Diseases; Female; Healthy Volunteer | 2019 |
Association between Cardiac Remodeling and Metabolic Alteration in an Experimental Model of Obesity Induced by Western Diet.
Topics: Animals; Atrial Remodeling; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cho | 2018 |
Serum Gamma-Glutamyltransferase Levels are Associated with Cardiovascular Risk Factors in China: A Nationwide Population-Based Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Child; Ch | 2018 |
Time to reconsider urate: Neuroprotective potential may prevail on cardiovascular risk in animal models and clinical trials.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Disease Models, Animal; Humans; Mice, Tr | 2018 |
Relationship Between Uric Acid, Proteinuria, and Atherogenic Index of Plasma in Renal Transplant Patients.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cohort Studies; Female; Glomerular Filtration | 2018 |
High Serum Uric Acid is Highly Associated with a Reduced Left Ventricular Ejection Fraction Rather than Increased Plasma B-type Natriuretic Peptide in Patients with Cardiovascular Diseases.
Topics: Aged; Aging; Biomarkers; Cardiac Catheterization; Cardiovascular Diseases; Female; Humans; Male; Mid | 2019 |
Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children
Topics: Adolescent; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Female; Follow-Up Studies; | 2019 |
The relationship between serum uric acid and lipid profile in Bangladeshi adults.
Topics: Adult; Bangladesh; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Fema | 2019 |
Relationship between serum uric acid and clustering of cardiovascular disease risk factors and renal disorders among Shanghai population: a multicentre and cross-sectional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; China; Cluster Analysis; Cross- | 2019 |
Cardiometabolic risk factors in young women with macroprolactinaemia.
Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Female; Fibrinogen; Humans; Insulin Resistance; Mi | 2019 |
Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey.
Topics: Adult; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Female | 2019 |
Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mel | 2019 |
Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study.
Topics: Adolescent; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Carotid Intima-Media Thi | 2019 |
Hyperuricaemia and vascular risk: the debate continues.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid; Xanthine Oxidase | 2019 |
The difficult relationship between uric acid and cardiovascular disease.
Topics: Aged; Allopurinol; Atrial Fibrillation; Cardiovascular Diseases; Febuxostat; Humans; Medicare; Risk | 2019 |
Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Communicable Diseases; Female; Gout; Humans; Hyperuri | 2019 |
Sleep Duration is Inversely Associated with Serum Uric Acid Concentrations and Uric Acid to Creatinine Ratio in an Elderly Mediterranean Population at High Cardiovascular Risk.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Creatinine; Cross-Sectional Studies; Female; Humans; Male | 2019 |
Pre- and Postdialysis Uric Acid Difference and Risk of Long-Term All-Cause and Cardiovascular Mortalities in Japanese Hemodialysis Patients; Miyazaki Dialysis Cohort Study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Ki | 2019 |
Determination of uric acid in serum using an optical sensor based on binuclear Pd(II) 2-pyrazinecarboxamide-bipyridine doped in a sol gel matrix.
Topics: 2,2'-Dipyridyl; Carcinoma, Hepatocellular; Cardiovascular Diseases; Coordination Complexes; Gels; Hu | 2019 |
Does weight loss affect the parameters that are metabolically related to cardiovascular diseases?
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Chi-Square Distribution; Ch | 2019 |
Carotid arterial stiffness and intima-media thickness: A little impact of uric acid.
Topics: Cardiovascular Diseases; Carotid Arteries; Carotid Intima-Media Thickness; Clinical Decision-Making; | 2019 |
Association of High Serum Uric Acid and Increased Arterial Stiffness is Dependent on Cardiovascular Risk Factors in Female Population.
Topics: Ankle Brachial Index; Biomarkers; Cardiovascular Diseases; China; Female; Humans; Hypercholesterolem | 2019 |
Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Aged; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Carotid Intima-Media Thickness; C | 2019 |
The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study.
Topics: Adrenal Hyperplasia, Congenital; Adult; Androgens; Atorvastatin; C-Reactive Protein; Cardiovascular | 2019 |
Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular | 2019 |
Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease; | 2019 |
Added predictive value of high uric acid for cardiovascular events in the Ambulatory Blood Pressure International Study.
Topics: Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Cohort Studies; Correlation of Data; | 2019 |
Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?
Topics: Cardiovascular Diseases; Drug Labeling; Febuxostat; Humans; Thiazoles; Uric Acid | 2019 |
Uric acid within the "normal" range predict 9-year cardiovascular mortality in older individuals. The InCHIANTI study.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cause of Death; Female; H | 2019 |
Circulating angiopoietin-2 is a marker for early cardiovascular disease in children on chronic dialysis.
Topics: Adolescent; Angiopoietin-2; Arteries; Biomarkers; Cardiovascular Diseases; Cell Adhesion Molecules; | 2013 |
Synergistic influence of age and serum uric acid on blood pressure among community-dwelling Japanese women.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Blood Pressure; C-Reactive Protein; Cardi | 2013 |
Uric acid levels, even in the normal range, are associated with increased cardiovascular risk: the Guangzhou Biobank Cohort Study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; China; Female; Humans; Male; Middle Aged; Prevalen | 2013 |
Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, | 2013 |
Uric acid measurement improves prediction of cardiovascular mortality in later life.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Female; Humans; Iowa; Kaplan-Meier Est | 2013 |
Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals.
Topics: Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Ob | 2013 |
Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality.
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Female; Gout; Humans; Hyperuricemia; Incide | 2013 |
Uric acid as a cross-over between rheumatology and cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Rheumatic Diseases; Risk Factors; Uric Acid | 2013 |
Association between serum uric acid levels and cardiovascular risk among university workers from the State of Mexico: a nested case-control study.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cohort Studies; | 2013 |
Gender differences in the relationship between serum uric acid and mean platelet volume in a Japanese general population.
Topics: Blood Platelets; Cardiovascular Diseases; Female; Humans; Japan; Male; Mean Platelet Volume; Middle | 2014 |
Body mass index, waist circumference, and waist-to-height ratio as predictors of cardiometabolic risk in childhood obesity depending on pubertal development.
Topics: Adolescent; Body Height; Body Mass Index; Cardiovascular Diseases; Child; Female; gamma-Glutamyltran | 2013 |
Serum uric acid and blood pressure in children at cardiovascular risk.
Topics: Adolescent; Age Factors; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Child; Cohort Stu | 2013 |
Higher uric acid levels are associated with better functional recovery in elderly patients receiving cardiac rehabilitation.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Cardiac Rehabilitation; Cardiovascular Diseases; Exerc | 2013 |
Survival impact of serum uric acid levels in children and adolescents.
Topics: Adolescent; Cardiovascular Diseases; Cause of Death; Child; Female; Humans; Hyperuricemia; Kidney Di | 2013 |
Total bilirubin in young men and women: association with risk markers for cardiovascular diseases.
Topics: Bilirubin; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Fast | 2013 |
The association between plasma uric acid level and cardiovascular events in patients with stable coronary artery disease: a short-term follow-up study.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Follow-Up Studies; Humans; Risk Factors; Uric Acid | 2013 |
Postprandial effects of two Chinese liquors on selected cardiovascular disease risk factors in young men.
Topics: Adult; Alcoholic Beverages; C-Reactive Protein; Cardiovascular Diseases; Cross-Over Studies; Humans; | 2013 |
Components of the metabolic syndrome are negative predictors of weight loss in obese children with lifestyle intervention.
Topics: Adolescent; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Child; Female; | 2014 |
Interaction between serum uric acid and triglycerides in relation to prehypertension in community-dwelling Japanese adults.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Blood Pressure; Body Mass Index; Cardio | 2014 |
Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hyper | 2014 |
Serum total and high-density lipoprotein phospholipids: independent predictive value for cardiometabolic risk.
Topics: Apolipoproteins; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Follo | 2014 |
Low high-density lipoprotein cholesterol is characterized by elevated oxidative stress.
Topics: Biomarkers; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Female; Humans; Lipoprot | 2014 |
Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin.
Topics: Adiponectin; Adult; Aged; Aryldialkylphosphatase; Biomarkers; Blood Glucose; Blood Pressure; Body Ma | 2013 |
Response letter to Shil and colleagues.
Topics: Cardiovascular Diseases; Female; Humans; Male; Uric Acid | 2013 |
Uric acid for prediction of cardiovascular mortality in older adults.
Topics: Cardiovascular Diseases; Female; Humans; Male; Uric Acid | 2013 |
Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Child; Child, Presc | 2014 |
Serum uric acid and eGFR_CKDEPI differently predict long-term cardiovascular events and all causes of deaths in a residential cohort.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Follow-Up | 2014 |
The associations of uric acid, cardiovascular and all-cause mortality in peritoneal dialysis patients.
Topics: Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Peritoneal Dialysis; Prognosis; Risk Fac | 2014 |
Uric acid and cardiovascular disease risk reclassification: findings from NHANES III.
Topics: Adult; Aged; Area Under Curve; Biomarkers; Cardiovascular Diseases; Discriminant Analysis; Female; H | 2015 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Relationship between a low ankle brachial index and all-cause death and cardiovascular events in subjects with and without diabetes.
Topics: Aged; Ankle Brachial Index; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Complic | 2014 |
Serum uric acid level and cardiovascular risks in hemodialysis patients: an Algerian cohort study.
Topics: Adult; Aged; Algeria; Biomarkers; Cardiovascular Diseases; Comorbidity; Female; Humans; Male; Middle | 2013 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort S | 2013 |
Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish Heart Health Extended Cohort Study.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Dyslipidemias; Female; Foll | 2014 |
Association between serum uric acid levels and cardiovascular disease in middle-aged and elderly Chinese individuals.
Topics: Age Factors; Aged; Asian People; Biomarkers; Cardiovascular Diseases; China; Cross-Sectional Studies | 2014 |
Overweight and obesity among low-income Muslim Uyghur women in far western China: correlations of body mass index with blood lipids and implications in preventive public health.
Topics: Adult; Aged; Apolipoproteins; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular Disea | 2014 |
Serum uric acid as a risk predictor for erectile dysfunction.
Topics: Biomarkers; Cardiovascular Diseases; Case-Control Studies; Confidence Intervals; Erectile Dysfunctio | 2014 |
Serum uric acid and hypertension in adults: a paradoxical relationship in type 1 diabetes.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Case-Control Studies; Cross-Sectional Studies; Diabe | 2014 |
Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2015 |
Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study.
Topics: Aged; Albuminuria; Biomarkers; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti | 2014 |
Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality.
Topics: Adult; Aged; Anthropometry; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, | 2014 |
Serum uric acid can predict higher C-reactive protein levels in apparently healthy men.
Topics: Adult; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Humans; Male; Middle Ag | 2014 |
Validity of U-shaped risk of estimated glomerular filtration rate for all-cause mortality.
Topics: Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Male; Renal Insufficiency, Chro | 2014 |
Associations of serum uric acid levels with cardiovascular health factors: differences by sex, age and body mass index in Chinese participants.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; China; Cross- | 2014 |
Relationship between cardiovascular risk factors and the echogenicity and pattern of the carotid intima-media complex in men.
Topics: Adult; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Carotid Artery, Common; Carotid | 2014 |
Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Male; Men | 2014 |
The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort.
Topics: Absorption; Adult; Albuminuria; Cardiovascular Diseases; Chi-Square Distribution; Disease Progressio | 2014 |
Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome.
Topics: Cardiovascular Diseases; Cohort Studies; Humans; Hyperuricemia; Risk Factors; Sleep Apnea, Obstructi | 2014 |
Serum uric acid level and cardiovascular risks in hemodialysis patients: an Algerian cohort study.
Topics: Adult; Aged; Algeria; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Kidney Failure, Chroni | 2014 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M | 2014 |
Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort.
Topics: Aged; Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Cohort Studies; Cross-Sectional St | 2014 |
Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Confounding Factors, Epidemiologic; Creatinine | 2014 |
The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: the CODAM study.
Topics: Adult; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cross-S | 2014 |
Nontraditional risk factors for cardiovascular disease and visceral adiposity index among different body size phenotypes.
Topics: Adiposity; Adolescent; Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Body Mass Index; Cardiova | 2015 |
Mortality predictive role of serum uric acid in diabetic hemodialysis patients.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Follow-Up Studies | 2014 |
[Detection of early markers of atherosclerosis in men with various levels of risk of cardiovascular complications].
Topics: Adult; Ankle Brachial Index; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Carotid Arteries; | 2014 |
Cardiovascular-renal changes after kidney donation: one-year follow-up study.
Topics: Adult; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Female; Follow-Up Studies; Glomerular Fi | 2015 |
The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study.
Topics: Aged; Cardiovascular Diseases; Decision Support Techniques; Erythema; Female; Gout; Humans; Hyperten | 2015 |
Retinol-binding protein 4 as a novel risk factor for cardiovascular disease in patients with coronary artery disease and hyperinsulinemia.
Topics: Aged; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies | 2014 |
The impact of serum uric acid on the diagnostic of metabolic syndrome in apparently healthy brazilian middle-aged men.
Topics: Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Humans; Male; Metabolic Syndrome; Middle A | 2014 |
Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Choleste | 2015 |
Association of hyperuricemia with conventional cardiovascular risk factors in elderly patients.
Topics: Age Factors; Aged; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; | 2015 |
Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes.
Topics: Aged; Asian People; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cross- | 2015 |
Hyperuricemia as a risk factor for cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Uric Acid | 2015 |
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Chronic Disease; Comorbi | 2014 |
In response: hyperuricemia as a risk factor for cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Uric Acid | 2015 |
Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study.
Topics: Aged; Aged, 80 and over; Asian People; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; C | 2015 |
Association of Uric Acid With Vascular Stiffness in the Framingham Heart Study.
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Comorbidity; Cross-Sectional Studies; Femal | 2015 |
Serum Uric Acid, Gender, and Low Ankle Brachial Index in Adults With High Cardiovascular Risk.
Topics: Aged; Ankle Brachial Index; Biomarkers; Cardiovascular Diseases; China; Female; Humans; Male; Periph | 2015 |
Serum uric acid and cardiovascular risk among Portuguese adolescents.
Topics: Adolescent; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cross-Sectional Stu | 2015 |
Consumption of orange fermented beverage reduces cardiovascular risk factors in healthy mice.
Topics: Alcoholic Beverages; Animals; Antioxidants; Bilirubin; Biomarkers; C-Reactive Protein; Cardiovascula | 2015 |
Serum Uric Acid and Impaired Glucose Tolerance: The Cardiometabolic Risk in Chinese (CRC) Study.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; China; Cholesterol, LDL; Female; Glucose In | 2015 |
Carotid-Femoral Pulse Wave Velocity: An Urgent Need for a Harmonization of Denominations.
Topics: Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Uric Acid; Vascular Stiffness | 2015 |
Persistence of cardiovascular risk factors in women with previous preeclampsia: a long-term follow-up study.
Topics: Adult; Albuminuria; Cardiovascular Diseases; Carotid Intima-Media Thickness; Case-Control Studies; F | 2015 |
The relationship between vascular inflammation and target organ damage in hypertensive crises.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chemokine CCL2; Emergency Service, Ho | 2015 |
Association between the markers of metabolic acid load and higher all-cause and cardiovascular mortality in a general population with preserved renal function.
Topics: Adult; Bicarbonates; Biomarkers; Cardiovascular Diseases; Female; Humans; Hydrogen-Ion Concentration | 2015 |
Hyperuricemia starts at 360 micromoles (6 mg/dL).
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
Uric Acid and Cardiovascular Events: A Mendelian Randomization Study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Coronary Disease; Cross-Sectional Studies; Female; Follow | 2015 |
Serum uric acid as a predictor for cardiovascular and all-cause mortality in women versus men.
Topics: Cardiovascular Diseases; Cause of Death; Female; Global Health; Humans; Male; Meta-Analysis as Topic | 2015 |
Serum uric acid and subsequent cognitive performance in patients with pre-existing cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Cognition Disorders; Female; Humans; Male; | 2015 |
Serum uric acid and cardiovascular risk: an early wake-up call.
Topics: Cardiovascular Diseases; Female; Humans; Male; Uric Acid | 2015 |
Uric acid levels in patients with schizophrenia on clozapine monotherapy.
Topics: Adult; Anthropometry; Cardiovascular Diseases; Case-Control Studies; Clozapine; Female; Humans; Insu | 2015 |
Importance of Uric Acid Levels and Comorbidities Affecting Renal Function.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Female; Humans; Male; Peripheral Vascular Diseases; U | 2015 |
The association of metabolic syndrome and its components with brachial-ankle pulse wave velocity in south China.
Topics: Adolescent; Adult; Aged; Ankle Brachial Index; Biomarkers; Blood Glucose; Blood Pressure; Cardiovasc | 2015 |
A brief history of uric acid: From gout to cardiovascular risk factor.
Topics: Cardiovascular Diseases; Gout; History, 18th Century; History, 19th Century; History, 20th Century; | 2015 |
The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Blood Glucose; Blood Pressure; Ca | 2015 |
The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Blood Glucose; Blood Pressure; Ca | 2015 |
The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Blood Glucose; Blood Pressure; Ca | 2015 |
The association and interaction analysis of hypertension and uric acid on cardiovascular autonomic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Blood Glucose; Blood Pressure; Ca | 2015 |
Uric Acid and Peripheral Arterial Disease.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Female; Humans; Male; Peripheral Vascular Diseases; U | 2015 |
Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations.
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Cartilage; Gout; Humans; Hyperuricemia; Kidney Disea | 2015 |
[Hyperuricemia and cardiovascular diseases: from phylogenesys to patogenetic mechanisms].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Phylogeny; Risk Factors; Uric Acid | 2015 |
Relationship between High-Performance Liquid Chromatography Fingerprints and Uric Acid-Lowering Activities of Cichorium intybus L.
Topics: Animals; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Cichorium intybus; Hyperuric | 2015 |
Reply to "Association of Serum Uric Acid Concentration With Metabolic Risk Factors in Patients With Type 2 Diabetes".
Topics: Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Uric Acid | 2015 |
Association of Serum Uric Acid Concentration With Metabolic Risk Factors in Patients With Type 2 Diabetes.
Topics: Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Uric Acid | 2015 |
Relationship of three different types of low-carbohydrate diet to cardiometabolic risk factors in a Japanese population: the INTERMAP/INTERLIPID Study.
Topics: Adult; Asian People; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; | 2016 |
Does skin microcirculation represent a faithful mirror of uric acid alterations?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Male; Uric Acid; Vascular Stiffn | 2015 |
Association between serum uric acid, aortic, carotid and femoral stiffness among adults aged 40-75 years without and with type 2 diabetes mellitus: The Maastricht Study.
Topics: Adult; Aged; Aorta; Blood Glucose; Cardiovascular Diseases; Carotid Arteries; Compliance; Cross-Sect | 2015 |
Uric acid is an independent predictor of cardiovascular events in post-menopausal women.
Topics: Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Middle Aged; Postmenopau | 2015 |
The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study.
Topics: Aged; Cardiovascular Diseases; China; Cohort Studies; Coronary Disease; Dyslipidemias; Female; Human | 2015 |
Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: a cross-sectional study.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Blood Pressure; Body Mass Index; Cardiovascular Dise | 2015 |
Effects of serum uric acid levels on the arginase pathway in women with metabolic syndrome.
Topics: Adult; Arginase; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Chol | 2016 |
Associations between low levels of serum uric acid and cardiometabolic parameters.
Topics: Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardium; Uric Acid | 2015 |
Uric Acid: A Missing Link Between Hypertensive Pregnancy Disorders and Future Cardiovascular Disease?
Topics: Adult; Biomarkers; Black People; Cardiovascular Diseases; Causality; Comorbidity; Cross-Sectional St | 2015 |
Association of Metabolic Syndrome with the Cardioankle Vascular Index in Asymptomatic Korean Population.
Topics: Alanine Transaminase; Ankle; Aspartate Aminotransferases; Blood Glucose; Blood Pressure; Blood Urea | 2015 |
High Serum Uric Acid Levels Are Associated with All-Cause and Cardiovascular, but Not Cancer, Mortality in Elderly Adults.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Male; Neoplasms; Risk | 2015 |
Consensus Meeting on "Uric Acid and Cardiovascular Risk" held at University Magna Graecia, Catanzaro, Italy, May 2014. Publication of the Proceedings as a special issue in the International Journal of Cardiology.
Topics: Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2016 |
Metabolic syndrome is associated with decreased circulating endothelial progenitor cells and increased arterial stiffness in systemic lupus erythematosus.
Topics: Adult; Aged; Arteries; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies | 2016 |
Relationship Between Hyperuricemia and Cardiovascular Disease Risk Factors in a Chinese Population: A Cross-Sectional Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Ma | 2015 |
Serum Urate and Incident Cardiovascular Disease: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Topics: Adolescent; Adult; Biomarkers; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Cor | 2015 |
Could Uric Acid Be Considered a Cardiovascular Risk Factor?
Topics: Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
The role of uric acid in the development of cardiovascular disease.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2015 |
Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Kaplan-M | 2015 |
Uric acid, carotid intima-media thickness and body composition in prepubertal children.
Topics: Biomarkers; Blood Pressure; Body Composition; Body Mass Index; C-Reactive Protein; Cardiovascular Di | 2016 |
Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.
Topics: Cardiovascular Diseases; Cohort Studies; Crystallization; Denmark; Female; Gout; Humans; Hyperuricem | 2015 |
Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cross-Sectional Stu | 2016 |
Uric acid increases erythrocyte aggregation: Implications for cardiovascular disease.
Topics: Blood Viscosity; Cardiovascular Diseases; Erythrocyte Aggregation; Humans; Hyperuricemia; Risk Facto | 2016 |
The role of uric acid in chronic kidney disease patients.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Female; Glomerular Filtration Rate; Hospitalization; | 2017 |
Serum uric acid predicts cardiovascular mortality in male peritoneal dialysis patients with diabetes.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi-Square Distribution; China; Di | 2016 |
Ideal Cardiovascular Health Metrics and Incident Hyperuricemia.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; China; Cholesterol; | 2016 |
The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism.
Topics: Aged; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Drug Th | 2016 |
Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Case-Control Studies; Denmark; | 2016 |
Plasma Content of Glucose, C-reactive Protein, Uric Acid and Cholesterol in Male, Female and Ovariectomized Rats upon Acute and Chronic Stress--a Path for Development of Cardiovascular Diseases.
Topics: Animals; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Female; Male; Ovar | 2015 |
Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Female; Humans; Hyperuricemia; Japan; Male; Middle Ag | 2016 |
Metabolic syndrome and 10-year cardiovascular disease incidence: The ATTICA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Mass Index; Body Wei | 2016 |
[Correlation between waist circumference and organ damage in patients with cardiovascular disease after cardiac rehabilitation program].
Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Humans; Middle Aged; Prognosis; Uric Acid; | 2016 |
Models Predictive of Metabolic Syndrome Components in Obese Pediatric Patients.
Topics: Adolescent; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Child; Cross-Sectional Studies; | 2016 |
Serum Uric Acid and Mortality Form Cardiovascular Disease: EPOCH-JAPAN Study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Female; Humans; Male; Middle Ag | 2016 |
Atherogenic index of plasma and risk of cardiovascular disease among Cameroonian postmenopausal women.
Topics: Aged; Atherosclerosis; Blood Glucose; Blood Pressure; Cameroon; Cardiovascular Diseases; Cholesterol | 2016 |
Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
Topics: Academic Medical Centers; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Cause of Death; Cohor | 2016 |
Uric acid and cardiovascular-renal disease risk. Insights from a human model opposite to hypertension.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Female; Humans; Hypert | 2016 |
Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk.
Topics: Anthropometry; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Determination; Bo | 2016 |
Hyperuricemia and Cardiovascular Disease in Patients with Hypertension.
Topics: Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Colombia; Cross-Sectio | 2016 |
Longitudinal Study of Serum Uric Acid, Nutritional Status, and Mortality in Maintenance Hemodialysis Patients.
Topics: Aged; Anthropometry; Cardiovascular Diseases; Cause of Death; Female; Humans; Kidney Failure, Chroni | 2016 |
Association of cognitive function and serum uric acid: Are cardiovascular diseases a mediator among women?
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cognitive Dysfunction; Cohort Studies; Cross-Secti | 2016 |
Importance of cystatin C and uric acid levels in the association of cardiometabolic risk factors in Japanese junior high school students.
Topics: Adolescent; Biomarkers; Cardiovascular Diseases; Child; Cholesterol, HDL; Creatinine; Cystatin C; Fe | 2017 |
Large-Scale Pooled Data and Beyond.
Topics: Cardiovascular Diseases; Computational Biology; Gene Expression Profiling; Genetic Variation; Genomi | 2016 |
Tissue Characterization of Coronary Plaques as a Key to Relationship between Serum Uric Acid Level and Cardiovascular Disease: A Direct Risk or an Indirect Marker?
Topics: Biomarkers; Cardiovascular Diseases; Humans; Plaque, Atherosclerotic; Tissue Distribution; Ultrasono | 2016 |
An observational study of sequential protein-sparing, very low-calorie ketogenic diet (Oloproteic diet) and hypocaloric Mediterranean-like diet for the treatment of obesity.
Topics: Adult; Blood Glucose; Blood Urea Nitrogen; Caloric Restriction; Cardiovascular Diseases; Creatinine; | 2016 |
Association of Serum Uric Acid With Cardiometabolic Risk Factors and Metabolic Syndrome in Iranian Adolescents: the CASPIAN-III Study.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Child; Cross-Sectional S | 2016 |
Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study.
Topics: Aged; Anthropometry; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Female; Humans; Hyp | 2017 |
Effect of Cardiovascular Injury on Catabolism of Adenosine and Adenosine 5-'Triphosphate in Systemic Blood in a Freely Moving Rat Model In Vivo.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Cardiova | 2016 |
Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.
Topics: Adolescent; Adult; Antineoplastic Agents; Biomarkers; Cancer Survivors; Cardiovascular Diseases; Cog | 2016 |
Distribution of Serum Uric Acid in Black Africans and Its Association With Cardiovascular Risk Factors.
Topics: Adult; Aged; Angola; Black People; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; | 2017 |
Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ.
Topics: Angiotensin II; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Gene Expressi | 2017 |
Serum Total Sialic Acid Level is Elevated in Hypothyroid Patients as an Atherosclerotic Risk Factor.
Topics: Adolescent; Adult; Atherosclerosis; Autoantibodies; Biomarkers; C-Reactive Protein; Cardiovascular D | 2017 |
Association of hemoglobin with ankle-brachial index in general population.
Topics: Adult; Ankle Brachial Index; Blood Cell Count; Body Mass Index; Cardiovascular Diseases; Cholesterol | 2016 |
Relative Handgrip Strength Is a Simple Indicator of Cardiometabolic Risk among Middle-Aged and Older People: A Nationwide Population-Based Study in Taiwan.
Topics: Aged; Anthropometry; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholestero | 2016 |
Participant-Reported Health Status Predicts Cardiovascular and All-Cause Mortality Independent of Established and Nontraditional Biomarkers: Evidence From a Representative US Sample.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Fem | 2016 |
Association of serum uric acid and cardioembolic stroke in patients with acute ischemic stroke.
Topics: Aged; Biomarkers; Brain Ischemia; Cardiovascular Diseases; Female; Humans; Intracranial Embolism; Lo | 2016 |
Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients.
Topics: Aged; Area Under Curve; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Female; Humans; K | 2017 |
Interactive effect of serum uric acid and total bilirubin for cardiovascular disease in Chinese patients with type 2 diabetes.
Topics: Aged; Asian People; Bilirubin; Cardiovascular Diseases; China; Cross-Sectional Studies; Diabetes Mel | 2016 |
Hyperuricemia and Cardiovascular Disease: What is Left to Prove?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2017 |
Serum Uric Acid and Mortality Form Cardiovascular Disease: EPOCH-JAPAN Study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cohort Studies; Female; Humans; | 2016 |
Association Between Hyperuricemia and Major Adverse Cardiac Events in Patients with Acute Myocardial Infarction.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Complications; Female; Heart Failure; Humans; Hyperte | 2017 |
Longitudinal Association Between Serum Uric Acid and Arterial Stiffness: Results From the Baltimore Longitudinal Study of Aging.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Baltimore; Biomarkers; Blood Pressure; Cardiovas | 2017 |
Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study.
Topics: Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Female; Forecasting; Health Surveys; Hum | 2016 |
Relationship between Cystatin C, Retinol-binding Protein 4 and Framingham Risk Score in Healthy Postmenopausal Women.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; C-Reactive Protein; Cardiovascular Disea | 2016 |
Relationship between FEV1 and Cardiovascular Risk Factors in General Population without Airflow Limitation.
Topics: Adult; Age Factors; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Carotid Artery Dise | 2016 |
Percentiles of serum uric acid and cardiometabolic abnormalities in obese Italian children and adolescents.
Topics: Adolescent; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Child, Preschool; Cross-Sec | 2017 |
Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes.
Topics: Asian People; Cardiovascular Diseases; Cerebrovascular Disorders; China; Cross-Sectional Studies; Di | 2017 |
Uric acid and endothelial function in elderly community-dwelling subjects.
Topics: Acetylcholine; Aged; Aging; Biomarkers; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascu | 2017 |
Serum uric acid and the relationship with subclinical organ damage in adults.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Cholesterol; Female; Humans; Male; Obesity; Triglyceride | 2017 |
Correlation of metabolic syndrome severity with cardiovascular health markers in adolescents.
Topics: Adolescent; Apolipoproteins B; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Child; Cross | 2017 |
Does the serum uric acid level have any relation to arterial stiffness or blood pressure in adults with congenital renal agenesis and/or hypoplasia?
Topics: Adult; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Congenital Abnormaliti | 2017 |
Red cell distribution width and uric acid in patients with obstructive sleep apnea.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Erythrocyte Indices; Female; Humans; H | 2018 |
Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study.
Topics: Adult; Aged; C-Reactive Protein; Cardiovascular Diseases; Female; Humans; Male; Metabolic Syndrome; | 2008 |
Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; H | 2008 |
Hyperuricaemia is associated with increased C-reactive protein concentrations in a large cohort of unselected outpatients.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cohort Studies; Humans; Hyperuricemia; Pred | 2008 |
Inactivation of nitric oxide by uric acid.
Topics: Cardiovascular Diseases; Chromatography, Liquid; Endothelial Cells; Glutathione; Humans; Hydrogen Pe | 2008 |
Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
Topics: Animals; Cardiovascular Diseases; Female; Gene Expression; Glucose Transport Proteins, Facilitative; | 2008 |
Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Epidemiologic Meth | 2008 |
Genetics of variation in serum uric acid and cardiovascular risk factors in Mexican Americans.
Topics: Adult; Cardiovascular Diseases; Chromosomes, Human, Pair 3; Female; Genetic Predisposition to Diseas | 2009 |
Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease.
Topics: Cardiovascular Diseases; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards | 2009 |
Serum uric acid and cognitive function and dementia.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cognition Disorders; Dementia; Female; Follow-Up Studies; | 2009 |
Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword.
Topics: Adult; Body Mass Index; Calcium; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Female; Hum | 2009 |
Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents.
Topics: Adolescent; Alanine Transaminase; Australia; C-Reactive Protein; Cardiovascular Diseases; Cholestero | 2009 |
[Uric acid, appreciated by all accepted by anyone].
Topics: Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2009 |
Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study.
Topics: Adult; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Middle Aged; Proportional Hazar | 2009 |
Uric acid and cardiovascular risk.
Topics: Animals; Biological Evolution; Cardiovascular Diseases; Hominidae; Humans; Hyperuricemia; Mutation; | 2009 |
Uric acid and cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Purines; Risk Factors; Uric Acid; Xanthi | 2009 |
Uric acid and cardiovascular risk.
Topics: Cardiovascular Diseases; Chromosomes, Human; Humans; Polymorphism, Genetic; Risk Factors; Uric Acid | 2009 |
Uric acid and cardiovascular risk.
Topics: Allopurinol; Antimetabolites; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Kidney Dis | 2009 |
Uric acid and cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Hyperuricemia; Prognosis; Risk Factors; | 2009 |
[Uric acid. Biology, biochemistry, and diagnostic value in the role of an integral test (a lecture)].
Topics: Animals; Cardiovascular Diseases; Female; Gout; Humans; Male; Portraits as Topic; Uric Acid | 2009 |
Statins and hypertension.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Creatinine; Female; Glomerular Filtration Ra | 2009 |
Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk.
Topics: Adult; C-Reactive Protein; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Hype | 2009 |
Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Dyslipidemias; Epidemiologic Methods; Fe | 2010 |
Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Coronary Stenosis; Female; Follow-Up Studies; Humans; Hyp | 2009 |
What rheumatologists should know about gout and cardiovascular disease.
Topics: Cardiovascular Diseases; Gout; Humans; Metabolic Syndrome; Physicians; Rheumatology; Uric Acid | 2009 |
Dietary patterns and the risk of mortality: impact of cardiorespiratory fitness.
Topics: Adult; Age Factors; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular | 2010 |
Risk factors for cardiovascular disease in Sardinia from 1978 to 2001: a comparative study with Italian mainland.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Apolipoproteins A; Blood Glucose; Cardiovascular D | 2009 |
Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Creatinine; Cross-Se | 2009 |
Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Kaplan-Meier Estim | 2009 |
Uric acid, cardiovascular mortality, and long-term outcomes in CKD.
Topics: Cardiovascular Diseases; Humans; Kidney Failure, Chronic; Time Factors; Treatment Outcome; Uric Acid | 2009 |
Uric acid and cardiovascular disease: how to solve another chicken or egg puzzle.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Renal Insufficiency; Uric Acid | 2009 |
Carotid intima-media thickness, dietary intake, and cardiovascular phenotypes in adolescents: relation to metabolic syndrome.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Carotid Arteries; Diet; Female; Humans; Male; | 2010 |
Hyperuricemia, cardiovascular disease, and the metabolic syndrome.
Topics: Angiotensin II; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Ob | 2009 |
Prognostic significance of serum uric acid in patients admitted to the Department of Medicine.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Female; Hospital Departments; Hosp | 2010 |
Medication trials in an imperfect world: gout and Parkinson's disease.
Topics: Antiparkinson Agents; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug-R | 2009 |
Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population.
Topics: Adult; Aged; Cardiovascular Diseases; China; Cross-Sectional Studies; Dyslipidemias; Ethnicity; Fema | 2009 |
Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol; | 2010 |
Sex and age interaction with genetic association of atherogenic uric acid concentrations.
Topics: Age Factors; Aged; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bin | 2010 |
Gene polymorphisms in association with emerging cardiovascular risk markers in adult women.
Topics: Adolescent; Adult; Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Demography; Female | 2010 |
Uric acid and the cardiovascular profile of African and Caucasian men.
Topics: Adult; Biomarkers; Black People; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; H | 2010 |
Potential role of uric Acid as a risk factor for cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2010 |
Daidzein-metabolising phenotypes in relation to serum lipids and uric acid in adults in Guangzhou, China.
Topics: Adult; Cardiovascular Diseases; China; Cholesterol, HDL; Cross-Sectional Studies; Diet Records; Equo | 2010 |
Sugar-sweetened beverage effect on cardiovascular risk factors lacks significance.
Topics: Adolescent; Animals; Beverages; Blood Pressure; Cardiovascular Diseases; Dietary Sucrose; Fructose; | 2010 |
A prospective study of uric acid by glucose tolerance status and survival: the Rancho Bernardo Study.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose | 2010 |
Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Kaplan-Meier Estimate; Mal | 2010 |
Very low-grade albuminuria reflects susceptibility to chronic kidney disease in combination with cardiovascular risk factors.
Topics: Adult; Albuminuria; Cardiovascular Diseases; Chronic Disease; Cohort Studies; Creatinine; Cross-Sect | 2010 |
Comment on: Gout: an independent risk factor for all-cause and cardiovascular mortality.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Iron; Risk Factors; Uric Acid | 2010 |
[Uric acid: a benchwarmer risk factor for cardiovascular disease].
Topics: Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2010 |
Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Chi-Square Distribution; Cholestero | 2010 |
The relationship between serum uric acid and chronic kidney disease among Appalachian adults.
Topics: Adult; Appalachian Region; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Female; Glomer | 2010 |
[Carbohydrate metabolic disorders in gout: incidence and clinical features].
Topics: Anthropometry; Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Cholesterol; Diabete | 2010 |
Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Hyp | 2010 |
Relation of uric acid levels to aortic root dilatation in hypertensive patients with and without metabolic syndrome.
Topics: Aged; Aortic Diseases; Blood Pressure; Cardiovascular Diseases; Dilatation, Pathologic; Echocardiogr | 2010 |
High levels of serum uric acid are associated with silent brain infarction.
Topics: Adult; Aged; Analysis of Variance; Brain; Brain Infarction; C-Reactive Protein; Cardiovascular Disea | 2010 |
Ability among adolescents for the metabolic syndrome to predict elevations in factors associated with type 2 diabetes and cardiovascular disease: data from the national health and nutrition examination survey 1999-2006.
Topics: Adolescent; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, | 2010 |
Relationship between serum uric acid and cerebral white matter lesions in the elderly.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Brain; Cardiovascular Diseases; Cerebrum; Cross-Sec | 2012 |
The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial.
Topics: Body Weight; Cardiovascular Diseases; Cohort Studies; Follow-Up Studies; Gout; Humans; Hypertension; | 2010 |
Differential relationships between anthropometry measures and cardiovascular risk factors in boys and girls.
Topics: Adolescent; Age Factors; Analysis of Variance; Anthropometry; Biomarkers; Blood Pressure; Body Heigh | 2011 |
Predictive value of serum uric acid on cardiovascular disease and all-cause mortality in urban Chinese patients.
Topics: Aged; Aged, 80 and over; Asian People; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; R | 2010 |
Clinical significance of early-onset hyperuricemia in renal transplant recipients.
Topics: Adult; Cardiovascular Diseases; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; | 2011 |
Cystatin C, cardiometabolic risk, and body composition in severely obese children.
Topics: Adolescent; Alanine Transaminase; Analysis of Variance; Blood Glucose; Blood Pressure; Body Composit | 2011 |
Uric acid and cardiovascular risk in rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Cardiovascular Diseases; Disease Models, Animal; Humans; Hypertensio | 2011 |
Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antihypertensive Agents; Black People; Body Mass I | 2011 |
Did The Captain only have gout?
Topics: Cardiovascular Diseases; Cartoons as Topic; Fructose; Gout; History, 19th Century; History, 20th Cen | 2010 |
Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation.
Topics: Allantoin; Cardiovascular Diseases; Humans; Hydrogen Peroxide; Hyperuricemia; Inflammation; NADPH Ox | 2011 |
Association between uric acid and cardiovascular risk variables in a non-hospitalized population.
Topics: Adult; Age Factors; Biomarkers; Blood Pressure; Body Mass Index; Brazil; Cardiovascular Diseases; Cr | 2011 |
[Results of experimental study of psychophysiological state and hematological characteristics in servicemen presenting with hyperuricemia].
Topics: Adult; Aged; Cardiovascular Diseases; Cognitive Behavioral Therapy; Humans; Hyperuricemia; Male; Mid | 2010 |
Impact of allopurinol use on urate concentration and cardiovascular outcome.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cohort Studies; Female; Gout; Gout Su | 2011 |
[Hyperuricemia].
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hypertension; Hyperuricemia; Uric Acid | 2011 |
Prehypertension and cardiovascular risk factors in adults enrolled in a primary care programme.
Topics: Adult; Alcohol Drinking; Biomarkers; Body Mass Index; Brazil; Cardiovascular Diseases; Cross-Section | 2011 |
Serum gamma-glutamyltransferase is associated with arterial stiffness in healthy individuals.
Topics: Adult; Ankle Brachial Index; Blood Glucose; Blood Pressure; Body Mass Index; C-Reactive Protein; Car | 2011 |
Uric acid and mortality from all-causes and cardiovascular disease among adults with and without diagnosed diabetes: findings from the National Health and Nutrition Examination Survey III Linked Mortality Study.
Topics: Adult; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus; Humans; Mortality; Proporti | 2011 |
Association among serum uric acid, cardiovascular risk, and arterial stiffness: a cross-sectional study in She ethnic minority group of Fujian Province in China.
Topics: Adult; Aged; Blood Flow Velocity; Blood Pressure; Cardiovascular Diseases; China; Female; Humans; Hy | 2012 |
Uric acid is predictive of cardiovascular mortality and sudden cardiac death in subjects referred for coronary angiography.
Topics: Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; Death, Sudden, Cardiac; Fema | 2013 |
World congress on insulin resistance, diabetes, and cardiovascular disease: Part 1.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, T | 2011 |
Long-term adherence to the Mediterranean diet reduces the prevalence of hyperuricaemia in elderly individuals, without known cardiovascular disease: the Ikaria study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cross-Sectional Studies; Diet, Mediterranean; Fema | 2011 |
Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Creatinine; Databases, Factual; F | 2011 |
Altered serum selenium and uric acid levels and dyslipidemia in hemodialysis patients could be associated with enhanced cardiovascular risk.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Female; Humans; Kidney Failure, Chro | 2011 |
Glycaemic indices and non-traditional biochemical cardiovascular disease markers in a diabetic population in Nigeria.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Chi-Square Distribution; Cro | 2011 |
Associations of urinary 6-sulfatoxymelatonin with biomarkers related to cardiovascular disease in Japanese women.
Topics: Asian People; Biomarkers; Body Composition; Body Mass Index; C-Reactive Protein; Cardiovascular Dise | 2012 |
Lower endothelial progenitor cell number, family history of cardiovascular disease and reduced HDL-cholesterol levels are associated with shorter leukocyte telomere length in healthy young adults.
Topics: Adult; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cr | 2013 |
Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population.
Topics: Adult; Aged; Australia; Biomarkers; Canada; Cardiovascular Diseases; Chronic Disease; Cluster Analys | 2011 |
Risk profile in chronic kidney disease stage 3: older versus younger patients.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Atherosclerosis; Cardiovascular Diseases; Diabeti | 2011 |
Physical activity and total antioxidant capacity across an adult lifespan of men.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cardiovascular Diseases; Humans; Lipids; Longevity; M | 2012 |
High prevalence of coexisting prehypertension and prediabetes among healthy adults in northern and northeastern China.
Topics: Adolescent; Adult; Anthropometry; Blood Glucose; Blood Pressure; Cardiovascular Diseases; China; Cho | 2011 |
Effect of body mass index-z score on adverse levels of cardiovascular disease risk factors.
Topics: Adiponectin; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Child; Female; Humans; Hy | 2012 |
High levels of hsCRP are associated with carbohydrate metabolism disorder.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; C-Reactive Protein; Carbohydrate Metabo | 2011 |
Elevated resting heart rate is associated with white blood cell count in middle-aged and elderly individuals without apparent cardiovascular disease.
Topics: Age Factors; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Choleste | 2012 |
Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence.
Topics: Adult; Aged; Atrial Fibrillation; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Mid | 2012 |
[Contribution of the CoLaus study to decipher the determinants of serum uric acid].
Topics: Biomarkers; Cardiovascular Diseases; Cohort Studies; Glucose Transport Proteins, Facilitative; Gout; | 2011 |
A structural equation model for assessment of links between changes in serum triglycerides, -urate, and -glucose and changes in serum calcium, -magnesium and -phosphate in type 2 diabetes and non-diabetes metabolism.
Topics: Adult; Biomarkers; Blood Glucose; Calcium; Cardiovascular Diseases; Case-Control Studies; Chi-Square | 2011 |
Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi-Square Distribution; Diabetes Complic | 2012 |
Serum uric acid as a marker of all-cause mortality in an elderly patient cohort.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female | 2012 |
Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Glomerular F | 2012 |
Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006.
Topics: Adolescent; Biomarkers; Blood Pressure; Cardiovascular Diseases; Child; Cohort Studies; Cross-Sectio | 2012 |
Uric acid: a novel prognostic marker for cardiovascular disease.
Topics: Biomarkers; Cardiovascular Diseases; Female; Humans; Male; Oxidative Stress; Prognosis; Uric Acid | 2012 |
No impact of serum uric acid on the outcome of recent-onset arthritis.
Topics: Arthritis, Rheumatoid; Arthrography; Biomarkers; Cardiovascular Diseases; Comorbidity; Disease Progr | 2012 |
Serum uric acid in U.S. adolescents: distribution and relationship to demographic characteristics and cardiovascular risk factors.
Topics: Adolescent; Age Distribution; Age Factors; Biomarkers; Body Mass Index; Cardiovascular Diseases; Fem | 2012 |
[Uric acid, atherosclerosis and vascular calcifications in chronic kidney disease].
Topics: Adolescent; Adult; Aged; Atherosclerosis; Calcinosis; Cardiovascular Diseases; Chronic Disease; Como | 2012 |
Is the apolipoprotein E4 allele always hazardous? Serum uric acid level as a conflict.
Topics: Adult; Alleles; Apolipoprotein E4; Cardiovascular Diseases; Genetic Predisposition to Disease; Human | 2012 |
Joint association of ankle-brachial index and serum uric acid on the outcomes of six-year all-cause mortality and cardiovascular mortality in Chinese patients.
Topics: Adult; Ankle Brachial Index; Asian People; Cardiovascular Diseases; Cause of Death; Female; Humans; | 2012 |
Serum total bilirubin concentration is inversely correlated with Framingham risk score in Koreans.
Topics: Adult; Aged; Aged, 80 and over; Bilirubin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardi | 2012 |
Uric acid: a crucial marker of cardiovascular diseases?
Topics: Biomarkers; Cardiovascular Diseases; Humans; Uric Acid | 2012 |
Endothelial function and other biomarkers of cardiovascular risk in frequent consumers of street food.
Topics: Adult; Biomarkers; Body Composition; Brachial Artery; Cardiovascular Diseases; Cholesterol; Endothel | 2012 |
Optical method for cardiovascular risk marker uric acid removal assessment during dialysis.
Topics: Biomarkers; Cardiovascular Diseases; Dialysis Solutions; Female; Humans; Male; Middle Aged; Prognosi | 2012 |
Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients.
Topics: Biomarkers; Cardiovascular Diseases; Cohort Studies; Essential Hypertension; Female; Follow-Up Studi | 2012 |
Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study.
Topics: Adult; Age Factors; Asymptomatic Diseases; Atherosclerosis; Biomarkers; Body Mass Index; Cardiovascu | 2012 |
Response letter to 'Uric acid: a crucial marker of coronary artery calcium score?'.
Topics: Cardiovascular Diseases; Humans; Uric Acid | 2013 |
[Association between serum uric acid and brachial ankle pulse wave velocity in Beijing community residents].
Topics: Aged; Ankle; Blood Pressure; Brachial Artery; Cardiovascular Diseases; China; Female; Humans; Male; | 2012 |
High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confidence Intervals; Enz | 2013 |
Pathological and behavioral risk factors for higher serum C-reactive protein concentrations in free-living adults--a Brazilian community-based study.
Topics: Abdominal Fat; Adult; Aged; Aged, 80 and over; Anthropometry; Blood Glucose; Body Mass Index; Brazil | 2013 |
Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cause of Death; Female; Heart Failure; Huma | 2013 |
Helicobacter pylori infection is identified as a cardiovascular risk factor in Central Africans.
Topics: Antibodies, Bacterial; Biomarkers; Black People; Blood Glucose; Body Mass Index; Cardiovascular Dise | 2012 |
Uric acid and mortality in elderly Chinese: a 10-year population-based cohort study.
Topics: Aged; Anthropometry; Cardiovascular Diseases; Cause of Death; Female; Humans; Male; Proportional Haz | 2012 |
Serum uric acid independently predicts cardiovascular events in advanced nephropathy.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Endothelium, Vascular; Female; | 2012 |
Is serum urate causally associated with incident cardiovascular disease?
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Databases, Factual; Female; Humans; Inciden | 2013 |
Association between WHO cut-offs for childhood overweight and obesity and cardiometabolic risk.
Topics: Adolescent; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Child; Choleste | 2013 |
Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Female; Humans; I | 2012 |
Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality.
Topics: Adult; Cardiovascular Diseases; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Hype | 2013 |
Comprehensive evaluation of pericardial biochemical markers in death investigation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Alcoholic Intoxication; Asphyxia; Biomarkers; | 2013 |
Associations of uric acid and gamma-glutamyltransferase (GGT) with obesity and components of metabolic syndrome in children and adolescents.
Topics: Adolescent; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Cross-Sectional Studies; Fe | 2013 |
Uric acid: where are we?
Topics: Animals; Biomarkers; Cardiovascular Diseases; Causality; Circadian Rhythm; Humans; Hypertension; Rat | 2013 |
A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients.
Topics: Cardiovascular Diseases; Case-Control Studies; Chromatography, High Pressure Liquid; Cresols; Female | 2013 |
Dietary, anthropometric, and biochemical determinants of uric acid in free-living adults.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Blood Pressure; Body Composition; Body Ma | 2013 |
Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; | 2014 |
Association of serum uric acid and cardiovascular disease in healthy adults.
Topics: Analysis of Variance; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Female; Humans; | 2013 |
Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults.
Topics: Adiponectin; Adiposity; Adolescent; Adult; Age Factors; Cardiovascular Diseases; Case-Control Studie | 2013 |
Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults.
Topics: Adiponectin; Adiposity; Adolescent; Adult; Age Factors; Cardiovascular Diseases; Case-Control Studie | 2013 |
Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults.
Topics: Adiponectin; Adiposity; Adolescent; Adult; Age Factors; Cardiovascular Diseases; Case-Control Studie | 2013 |
Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults.
Topics: Adiponectin; Adiposity; Adolescent; Adult; Age Factors; Cardiovascular Diseases; Case-Control Studie | 2013 |
A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Cardiovascular Dise | 2002 |
Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Cell Division; Cells, Cultured; Developed Countrie | 2002 |
Uric acid concentrations and the mechanisms of cardiovascular disease.
Topics: Allopurinol; Antimetabolites; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Risk Factors; Urat | 2002 |
Prevalence and concomitants of glucose intolerance in European obese children and adolescents.
Topics: Adolescent; Birth Weight; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases | 2003 |
Relationship of neck circumference to cardiovascular risk factors.
Topics: Adolescent; Adult; Blood Glucose; Body Constitution; Body Mass Index; Cardiovascular Diseases; Chole | 2003 |
Hyperuricemia; relationship to hypercholesteremia and acute myocardial infarction.
Topics: Anterior Wall Myocardial Infarction; Cardiovascular Diseases; Cholesterol; Humans; Hypercholesterole | 1959 |
Hyperuricemia in myocardial infarction.
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Myocardial Infarction; Uric Acid | 1961 |
Serum uric acid in myocardial infarction.
Topics: Cardiovascular Diseases; Humans; Myocardial Infarction; Probenecid; Uric Acid | 1963 |
Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome.
Topics: Adolescent; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Child; Cholesterol, HDL; Cohor | 2003 |
Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension.
Topics: Adult; Arteries; Cardiovascular Diseases; Creatine; Cross-Sectional Studies; Humans; Hypertension; H | 2003 |
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country.
Topics: Adult; Age Distribution; Alcohol Drinking; Blood Pressure; Body Height; Body Mass Index; Cardiovascu | 2004 |
The C677 mutation in methylene tetrahydrofolate reductase gene: correlation with uric acid and cardiovascular risk factors in elderly Korean men.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Genetic Predisposition to Disease; Genotype | 2004 |
Diuretic-induced hyperuricemia does not decrease cardiovascular risk.
Topics: Antioxidants; Cardiovascular Diseases; Diuretics; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2004 |
Xanthine oxidase inhibition by 1,3-dipropyl-8-sulfophenylxanthine (DPSPX), an antagonist of adenosine receptors.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Free Radical Scavengers; Hypertension; Oxidants; O | 2004 |
[Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease].
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Gout; Humans; | 2004 |
Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.
Topics: Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Finland; Follow-Up Studies; | 2004 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension, Renal; Losartan; Uric Acid | 2004 |
Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk.
Topics: Aged; Allopurinol; Biomarkers; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Enzy | 2004 |
Effects of a long-term vegetarian diet on biomarkers of antioxidant status and cardiovascular disease risk.
Topics: Adult; Antioxidants; Ascorbic Acid; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Case-Co | 2004 |
Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men.
Topics: Adult; Age Factors; Brazil; Cardiovascular Diseases; Cholesterol, HDL; Cross-Sectional Studies; Huma | 2005 |
Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients.
Topics: Albuminuria; Analysis of Variance; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Carotid | 2005 |
Serum uric acid concentration as a risk factor for cardiovascular mortality: a longterm cohort study of atomic bomb survivors.
Topics: Adult; Age Distribution; Cardiovascular Diseases; Cohort Studies; Female; Humans; Japan; Male; Middl | 2005 |
Confounders of uric acid levels.
Topics: Alcohol Drinking; Cardiovascular Diseases; Gout; Humans; Male; Middle Aged; Uric Acid | 2005 |
The serum uric acid and related cardiovascular risk factors in south Taiwan.
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Diet; Female; Humans; Hyperuricemia; Life Style; | 2005 |
What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death?
Topics: Biomarkers; Cardiovascular Diseases; Cause of Death; Follow-Up Studies; Humans; Hyperuricemia; Male; | 2005 |
Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Female; Humans; Hypertension; Hypertrophy, Left | 2005 |
Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Female; Humans; Hypertension; Insulin Resistance; Male; | 2005 |
The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison.
Topics: Adolescent; Adult; Body Mass Index; Body Size; Cardiovascular Diseases; Female; Heart Rate; Humans; | 2005 |
Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study.
Topics: Adult; Cardiovascular Diseases; Chromosomes, Human; Chromosomes, Human, Pair 15; Chromosomes, Human, | 2005 |
Status of endothelial dependent vasodilation in patients with hyperuricemia.
Topics: Adult; Blood Flow Velocity; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Humans; | 2005 |
Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension.
Topics: Cardiovascular Diseases; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Hype | 2006 |
Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Fe | 2006 |
Uric acid status and its correlates in Hangzhou urban population.
Topics: Body Mass Index; Cardiovascular Diseases; China; Creatinine; Cross-Sectional Studies; Feces; Female; | 2006 |
Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors.
Topics: Adolescent; Albuminuria; Blood Glucose; Cardiovascular Diseases; Child; Female; Glucose Tolerance Te | 2006 |
Uric acid: an additional component of metabolic syndrome?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2006 |
Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study.
Topics: Aged; Brain Ischemia; Cardiovascular Diseases; Case-Control Studies; Cerebral Hemorrhage; Cohort Stu | 2006 |
Association between risk factors and carotid enlargement.
Topics: Adaptation, Physiological; Aged; Alcohol Drinking; Body Mass Index; Cardiovascular Diseases; Carotid | 2006 |
Cardiovascular risk factors in pre-pubertal Malays: effects of diabetic parentage.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Case-Control Studies | 2007 |
Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study.
Topics: Adiponectin; Adiposity; Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseas | 2006 |
Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Mass Index; Calcium | 2007 |
[Gout and diuretics; still an issue].
Topics: Cardiovascular Diseases; Case-Control Studies; Diuretics; Gout; Humans; Hypertension; Incidence; Uri | 2007 |
Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Antioxidants; Cardiovascular Diseases; Cell Differentiation; Enzy | 2007 |
Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension.
Topics: Albuminuria; Arteries; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Cardiovascular Dis | 2007 |
Prevalence of and risk factors for peripheral arterial disease in the patients with hypertension among Han Chinese.
Topics: Adult; Aged; Asian People; Blood Pressure; Cardiovascular Diseases; Case-Control Studies; China; Cho | 2007 |
Association of serum uric acid with cardiovascular disease in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Female; H | 2007 |
Podagra, uric acid, and cardiovascular disease.
Topics: Cardiovascular Diseases; Gout; Humans; Prevalence; Uric Acid | 2007 |
Association between serum uric acid levels and coronary flow reserve in hypertensive patients without concomitant risk factors.
Topics: Adult; Cardiovascular Diseases; Cohort Studies; Coronary Circulation; Coronary Vessels; Echocardiogr | 2007 |
Genome scan for determinants of serum uric acid variability.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Chromosome Mapping; Diabetes Mellitus, Type 2; Femal | 2007 |
Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Austria; Biomarkers; Cardiovascular Diseases; Coronary D | 2008 |
Anatomical relationship between traditional acupuncture point ST 36 and Omura's ST 36 (True ST 36) with their therapeutic effects: 1) inhibition of cancer cell division by markedly lowering cancer cell telomere while increasing normal cell telomere, 2) im
Topics: Acupuncture; Acupuncture Points; Blood Cell Count; Blood Glucose; C-Reactive Protein; Cardiovascular | 2007 |
Elevated uric acid and cardiovascular disease. How strong is the evidence of a pathogenetic link?
Topics: C-Reactive Protein; Cardiovascular Diseases; Humans; Hyperuricemia; Inflammation; Risk Factors; Uric | 2007 |
Uric acid, type 2 diabetes, and cardiovascular diseases: fueling the common soil hypothesis?
Topics: Asian People; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Multivariate A | 2008 |
Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Stud | 2008 |
Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Female; Humans | 2008 |
Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cohort Studies; Dyslipidemias; Follow-Up Studies; | 2008 |
Uric acid indicates a high cardiovascular risk profile but is not closely associated with insulin resistance in obese adolescents.
Topics: Adolescent; Cardiovascular Diseases; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Risk F | 2008 |
Asymptomatic hyperuricemia: perhaps not so benign?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney Diseases; Risk Factors; Uric Acid | 2008 |
Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Topics: Adult; Blood Coagulation; Blood Pressure; Calcium; Cardiovascular Diseases; Factor IX; Factor VII; F | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Alcohol consumption and gout.
Topics: Adult; Alcoholic Beverages; Beer; Blood Pressure; Cardiovascular Diseases; Gout; Humans; Male; Middl | 1967 |
Casual blood pressure: its relationship to several cardiovascular risk factors in middle-aged men.
Topics: Blood Glucose; Body Weight; Cardiomegaly; Cardiovascular Diseases; Cholesterol; Cross-Sectional Stud | 1984 |
Raised serum urate concentration as risk factor for premature mortality in middle aged men.
Topics: Adult; Aged; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Neoplasms; Risk; Uric Acid | 1984 |
[Cardiovascular diseases after kidney transplantation: an analysis of predisposing factors].
Topics: Cardiomegaly; Cardiovascular Diseases; Cholesterol; Female; Humans; Hyperparathyroidism; Hypertensio | 1981 |
Honolulu Heart Study: review of genetic analyses.
Topics: Adult; Aged; Asian; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Female; Hawaii; Humans; | 1984 |
Dietary intake and cardiovascular risk factors, Part II. Serum urate, serum cholesterol, and correlates.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Cholesterol; Diet; Female; Humans; Male; Middle Ag | 1983 |
Hyperuricemia as a risk factor for cardiovascular mortality.
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Disease; Female; Finland; Humans; Male; Middle Aged; | 1982 |
Changes in blood lipids and blood pressure during adolescence.
Topics: Adolescent; Blood Pressure; Cardiovascular Diseases; Contraceptives, Oral; Cross-Sectional Studies; | 1980 |
Hyperuricemia in acute illness: a poor prognostic sign.
Topics: Acute Disease; Adult; Aged; Blood Pressure; Cardiovascular Diseases; Creatinine; Female; Heart Rate; | 1982 |
[Hypertension and hyperuricemia: how are they related?].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Renal Circulat | 1982 |
[The cardiovascular risk profile of the long-term diabetic].
Topics: Cardiovascular Diseases; Diabetes Complications; Humans; Hypercholesterolemia; Hypertension; Middle | 1982 |
Erythrocyte sedimentation rate and cardiovascular disease. Results from a population study of women in Göteborg, Sweden.
Topics: Adult; Angina Pectoris; Blood Sedimentation; Cardiovascular Diseases; Cerebrovascular Disorders; Cho | 1982 |
Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study.
Topics: Adolescent; Adult; Age Factors; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disorders; | 1982 |
Physical training programs for mass scale use: effects on cardiovascular disease--facts and theories.
Topics: Adult; Body Weight; Cardiovascular Diseases; Cholesterol; Female; Humans; Male; Middle Aged; Models, | 1982 |
[Asymptomatic hyperuricemia-when should it be treated?].
Topics: Arthritis; Cardiovascular Diseases; Gout; Humans; Kidney Calculi; Kidney Diseases; Patient Care Plan | 1982 |
[Cardiovascular risk factors among African populations. Gout].
Topics: Africa; Black or African American; Black People; Cardiovascular Diseases; Female; Gout; Humans; Male | 1980 |
Uric acid in childhood essential hypertension.
Topics: Adolescent; Adult; Cardiovascular Diseases; Child; Child, Preschool; Diet, Sodium-Restricted; Female | 1981 |
[Metabolic risk factors in the very old].
Topics: Aged; Aging; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Female; Humans; Hype | 1981 |
[Secondary diseases complicating cancer].
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Female; Heart Failure; Humans; Li | 1981 |
[The cardiovascular risk profile in patients with disorders of glucose tolerance (borderline diabetes) dependent on the heredity of the diabetes].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Glucose Tolerance Test; Humans; | 1981 |
Management of asymptomatic hyperuricemia.
Topics: Acute Disease; Cardiovascular Diseases; Decision Making; Gout; Humans; Kidney Calculi; Risk; Uric Ac | 1981 |
[The influence of diabetes heredity on cardiovasculary risk profile in patients with high age diabetes (author's transl)].
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Female; Humans; Hypertension; Male; R | 1981 |
[The cardiovascular risk profile in persons with normal glucose tolerance with reference to the familial occurrence of diabetes mellitus].
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus; Female; Glucose Tolerance Test; | 1981 |
[Cardiovascular diseases in Vienna. Epidemiological results of the "Vienna Health Study 1979"].
Topics: Adult; Austria; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol; Coronary Disease; F | 1981 |
High uric acid as an indicator of cardiovascular disease. Independence from obesity.
Topics: Aged; Body Weight; Cardiovascular Diseases; Coronary Disease; Female; Follow-Up Studies; Gout; Human | 1980 |
Changes in population cholesterol concentrations and other cardiovascular risk factor levels after five years of the non-communicable disease intervention programme in Mauritius. Mauritius Non-communicable Disease Study Group.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cross-Sectional | 1995 |
Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study.
Topics: Adult; Anthropometry; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Female | 1995 |
Missed opportunity following diagnosis of gout.
Topics: Adult; Allopurinol; Beer; Cardiovascular Diseases; Gout; Humans; Lipoproteins; Male; Risk Factors; U | 1995 |
Association between serum uric acid and some cardiovascular risk factors in a Chinese population.
Topics: Adult; Aging; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Female; Hong Kong; Humans; Male | 1994 |
Body mass, fat distribution and cardiovascular risk factors in a lean population of south China.
Topics: Abdomen; Adipose Tissue; Adult; Aged; Alcohol Drinking; Anthropometry; Blood Glucose; Blood Pressure | 1994 |
Uric acid metabolism and tubular sodium handling. Results from a population-based study.
Topics: Adult; Aged; Analysis of Variance; Cardiovascular Diseases; Cross-Sectional Studies; Humans; Kidney | 1993 |
Association of body mass index and waist-hip circumference ratio with cardiovascular disease risk factors in Micronesian Nauruans.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anthropometry; Blood Glucose; Blood P | 1993 |
Alcohol and mortality in Busselton, Western Australia.
Topics: Adult; Alcohol Drinking; Alcoholism; Cardiovascular Diseases; Cause of Death; Comorbidity; Diabetes | 1993 |
[A cross-sectional analysis on relationships between maximum oxygen uptake and risk factors for cardiovascular diseases].
Topics: Adult; Age Factors; Alcohol Drinking; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular | 1995 |
[Transmembrane Na+ transport kinetics in arterial hypertension: relations with vascular risk parameters].
Topics: Adult; Biological Transport, Active; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Creat | 1995 |
Newly developed ST-T abnormalities on the electrocardiogram and chronologic changes in cardiovascular risk factors.
Topics: Blood Pressure; Cardiovascular Diseases; Cholesterol; Electrocardiography; Female; Heart Conduction | 1996 |
Pattern of long-term complications in Sudanese insulin-treated diabetic patients.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disord | 1995 |
Parameters associated with adverse perinatal outcome in hypertensive pregnancies.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Disease Progression; Ductus Arteriosus, Patent; Female; | 1996 |
Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study.
Topics: Adipose Tissue; Adolescent; Alcohol Drinking; Arteriosclerosis; Blood Pressure; Body Composition; Bo | 1996 |
[Diabetes mellitus at the National Hospital Center of Ouagadougou (Burkina Faso)].
Topics: Adult; Burkina Faso; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Me | 1996 |
[Lipoprotein profile in patients with isolated hyperuricemia].
Topics: Apolipoproteins; Cardiovascular Diseases; Cholesterol; Humans; Hyperlipidemias; Lipoproteins; Microv | 1996 |
Relationship between fasting insulin and cardiovascular risk factors is already present in young men: the Verona Young Men Atherosclerosis Risk Factors Study.
Topics: Adolescent; Arteriosclerosis; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cross-Sectio | 1997 |
Serum uric acid and its correlates in Chinese adult populations, urban and rural, of Beijing. The PRC-USA Collaborative Study in Cardiovascular and Cardiopulmonary Epidemiology.
Topics: Adult; Age Distribution; Body Mass Index; Cardiovascular Diseases; China; Cross-Sectional Studies; D | 1997 |
Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults.
Topics: Adult; Black People; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Cross-Sectional Stu | 1998 |
Clustering of cardiovascular risk factors in hyperinsulinemia in Japanese without diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hyperinsulinism; Hypertensio | 1998 |
Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Disea | 1998 |
Serum uric acid levels in cardiovascular diseases.
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; Lipoproteins; Male; M | 1998 |
Favorable life-style modification and attenuation of cardiovascular risk factors.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL | 1999 |
Risk factors for cardiovascular disease: one down, many more to evaluate.
Topics: Biomarkers; Cardiovascular Diseases; Disease Progression; Epidemiologic Methods; Humans; Risk Factor | 1999 |
Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.
Topics: Age Distribution; Aging; Boston; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; | 1999 |
Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Cause of Death; Cohort Studies; Germany; Humans; Male; Middle Aged; Mortali | 1999 |
Serum uric acid and cardiovascular events in successfully treated hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Cardiovascular Diseases; Cohort Studies; Di | 1999 |
Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia.
Topics: Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Postmenopause; U | 1999 |
Obesity worsens cardiovascular risk profiles independently of hyperinsulinaemia.
Topics: Adult; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Female; Glucose Tolerance Test; Human | 1997 |
Relationship between hemostatic factors and known cardiovascular disease correlates in two suburban populations in Taiwan.
Topics: Apolipoproteins; Blood Coagulation Factors; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 1999 |
Is raised serum uric acid a cause of cardiovascular disease or death?
Topics: Cardiovascular Diseases; Female; Humans; Male; Risk Factors; Uric Acid | 1999 |
Hormone replacement therapy and serum uric acid.
Topics: Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Hyperinsulinism; Middle Aged; | 1999 |
Hormone replacement therapy and serum uric acid.
Topics: Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Postmenopause; R | 1999 |
Sources of variation in plasma lipid and lipoprotein traits in a sample selected for health.
Topics: Adult; Age Factors; Alcohol Drinking; Apolipoproteins B; Blood Glucose; Cardiovascular Diseases; Cho | 1999 |
Association between serum uric acid and cardiovascular risk factors among elderly people in Taiwan.
Topics: Age Factors; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Male; Risk Fact | 1999 |
[Association of blood uric acid with other cardiovascular risk factors in the male working population in Valencia].
Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Humans; Male; Middle Aged; Occupation | 1999 |
Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease.
Topics: Cardiovascular Diseases; Confounding Factors, Epidemiologic; Humans; Multivariate Analysis; Risk Fac | 2000 |
Serum uric acid and cardiovascular disease risk.
Topics: Cardiovascular Diseases; Female; Humans; Risk Factors; Uric Acid | 2000 |
Serum uric acid and cardiovascular disease risk.
Topics: Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2000 |
Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan.
Topics: Adult; Age Factors; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cholesterol; Humans; M | 2000 |
Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey.
Topics: Adult; Aged; Analysis of Variance; Black or African American; Cardiovascular Diseases; Cross-Section | 2000 |
The relationships among objective and subjective environmental stress levels and serum uric acid: the moderating effect of perceived control.
Topics: Adult; Age Factors; Body Mass Index; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Cr | 2000 |
[Prevalence of dyslipidemia and its phenotypes in recently diagnosed essential arterial hypertension].
Topics: Adult; Alcohol Drinking; Algorithms; Blood Glucose; Cardiovascular Diseases; Female; Humans; Hyperli | 2000 |
Intrapair resemblance in very low calorie diet-induced weight loss in female obese identical twins.
Topics: Adipose Tissue; Adult; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Choleste | 2000 |
Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients.
Topics: Aged; Analysis of Variance; Antioxidants; Ascorbic Acid; Cardiovascular Diseases; Case-Control Studi | 2000 |
[Serum uric acid and cardiovascular mortality].
Topics: Cardiovascular Diseases; Humans; Risk Factors; Uric Acid | 2000 |
Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study.
Topics: Antihypertensive Agents; Biomarkers; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Mi | 2000 |
Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers.
Topics: Adult; Cardiovascular Diseases; Cause of Death; Cohort Studies; Humans; Japan; Life Expectancy; Male | 2000 |
[Changes in cardiovascular risk factors after renal transplantation].
Topics: Adult; Blood Pressure; Body Composition; Body Mass Index; Cardiovascular Diseases; Creatinine; Cysta | 2001 |
Hypophosphataemia: cause of the disturbed metabolism in the metabolic syndrome.
Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, | 2001 |
[Hyperuricemia as a cardiovascular risk factor].
Topics: Biomarkers; Cardiovascular Diseases; Humans; Hypertension; Risk Factors; Uric Acid | 2001 |
[Distribution and correlation of uric acid with classic cardiovascular risk factors in an adult population in Campania. VIP project data].
Topics: Adult; Aged; Cardiovascular Diseases; Female; Humans; Italy; Male; Middle Aged; Risk Factors; Uric A | 2001 |
Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population Study.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Female; Humans; Incidence; Italy; Male; Middle | 2001 |
An assessment of the main metabolic variables of cardiovascular risk in a sample population of workers in Rome.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cardiovascular Diseases; Cholesterol; Female; Hu | 2001 |
Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease.
Topics: Adult; Aged; Arginine; Brachial Artery; Cardiovascular Diseases; Clinical Trials as Topic; Dietary S | 2001 |
Hyperuricaemia and its related factors in Taiwanese middle-aged adults.
Topics: Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Risk Factors; Taiwan; Uric Acid | 2002 |
Is serum uric acid level associated with all-cause mortality in high-functioning older persons: MacArthur studies of successful aging?
Topics: Aged; Aging; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Life Style; Ma | 2001 |
[Relation between uricemia and total, cardiovascular and coronary mortality in both genders of non-selected sample of the Belgium population].
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Belgium; Cardiovascular Diseases; Chi-Square Distributio | 2001 |
Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Female; Humans; Japan; Linear Models; Male; Mi | 2001 |
Metabolic cardiovascular syndrome in obese prepubertal children: the role of high fasting insulin levels.
Topics: Alanine Transaminase; Apolipoproteins; Aspartate Aminotransferases; Blood Pressure; Cardiovascular D | 2002 |
Red blood cell count in short-term prediction of cardiovascular disease incidence in the Gubbio population study.
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Disease; Erythrocyte Count; Female; Follow-Up Studies | 2002 |
[Frequency of cardiovascular risk factors in renal transplant patients (author's transl)].
Topics: Adolescent; Adult; Cardiovascular Diseases; Cholesterol; Diabetes Complications; Female; Humans; Hyp | 1978 |
Elevated serum uric acid. A cardiovascular risk factor?
Topics: Adolescent; Cardiovascular Diseases; Coronary Disease; Diuretics; Female; Humans; Hypertension; Male | 1979 |
[The cardiovascular risk profile of the borderline diabetic].
Topics: Adult; Aged; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Humans; Hypercholest | 1979 |
[Studies on late mortality of myocardial infarct. Part II].
Topics: Adult; Age Factors; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Follow-Up Studies; Germa | 1977 |
Cardiovascular risk factors in gross obesity.
Topics: Adult; Age Factors; Blood Glucose; Cardiovascular Diseases; Cholesterol; Female; Follow-Up Studies; | 1977 |
[Obesity and cardiovascular risk].
Topics: Adult; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hyp | 1978 |
[Risk factors in juveniles. Indications of cardiovascular risk in higher-grade school children of Cologne].
Topics: Adolescent; Adult; Age Factors; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; F | 1977 |
Hyperuricemia and other cardiovascular risk factors.
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Female; Finland; Humans; Male; Mass Screening; Mi | 1977 |
The relationship between blood pressure and biochemical risk factors in a general population.
Topics: Adult; Blood Glucose; Blood Pressure; Body Height; Body Weight; Calcium; Cardiovascular Diseases; Ch | 1976 |
Systolic hypertension, hyperuricemia, and hyperglycemia as risk factors in cardiovascular disease.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Hyperglycemia; | 1976 |
A study of middle-aged men with particular reference to risk factors for cardiovascular disease.
Topics: Blood Pressure; Body Weight; Cardiovascular Diseases; Electrocardiography; Glucose Tolerance Test; H | 1975 |
Screening for risks of cardiovascular disease in children. A preliminary report.
Topics: Austria; Cardiovascular Diseases; Child; Cholesterol; Humans; Mass Screening; Obesity; Risk; Triglyc | 1976 |
Short time treatment with high-efficiency paired filtration dialysis for chronic renal failure.
Topics: Adult; Aged; Anuria; beta 2-Microglobulin; Cardiovascular Diseases; Creatinine; Hemofiltration; Huma | 1992 |
Cardiovascular risk factors in obese children in relation to weight and body fat distribution.
Topics: Adipose Tissue; Adolescent; Analysis of Variance; Anthropometry; Apolipoproteins; Blood Glucose; Blo | 1992 |
Serum uric acid and its relation to cardiovascular disease risk factors in children and young adults from a biracial community: the Bogalusa Heart Study.
Topics: Adolescent; Adult; Age Factors; Black People; Cardiovascular Diseases; Child; Child, Preschool; Chol | 1991 |
The relation of physical activity to cardiovascular disease risk factors in Mauritians. Mauritius Noncommunicable Disease Study Group.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cholesterol, H | 1991 |
[Type A behavior--a uniform construct?].
Topics: Adult; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Occupational Diseases; Psychophys | 1990 |
Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites. The role of insulin.
Topics: Adipose Tissue; Adolescent; Adult; Anthropometry; Black People; Body Composition; Cardiovascular Dis | 1989 |
Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry.
Topics: Adult; Cardiovascular Diseases; Coronary Disease; Female; Humans; Male; Middle Aged; Mortality; Neop | 1989 |
Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden.
Topics: Adult; Aged; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middl | 1988 |
[Correlation of pathologic laboratory values in patients with cardiovascular diseases--consequences for diagnosis in general practice].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Chemical Analysis; | 1987 |
The association of the ratio of waist to hip girth with blood pressure, serum cholesterol and serum uric acid in children and youths aged 6-17 years.
Topics: Abdomen; Adipose Tissue; Adolescent; Age Factors; Anthropometry; Blood Pressure; Cardiovascular Dise | 1987 |
[Value and rank of diagnostic laboratory parameters in cardiovascular diseases. Results of multivariant and discriminant analyses of the Berlin EBMO-Cor population study].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Blood Chemical Analysis; Blood Glucose; Blood Sedimen | 1987 |
[Hyperuricemia in a rural population group].
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Czechoslovakia; Female; Humans; Male; Middl | 1987 |
[Etiology and pathogenesis of sudden deafness].
Topics: Adult; Cardiovascular Diseases; Female; Hearing Loss, Sudden; Humans; Hyperglycemia; Hyperlipidemias | 1985 |
Sulphinpyrazone dose schedule in hyperuricemic patients with cardiovascular diseases: tolerability assessment.
Topics: Allopurinol; Cardiovascular Diseases; Creatinine; Drug Tolerance; Female; Humans; Kidney Function Te | 1985 |
Cardiovascular risk factors and obesity: are baseline levels of blood pressure, glucose, cholesterol and uric acid elevated prior to weight gain?
Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Dis | 1985 |
[Secondary hyperuricemia].
Topics: Cardiovascular Diseases; Diuretics; Endocrine System Diseases; Ethanol; Fructose; Gout; Hematologic | 1985 |
[Ist results of a prospective survey on cardiovascular diseases in a large enterprise].
Topics: Adult; Age Factors; Angina Pectoris; Arteriosclerosis; Cardiovascular Diseases; Cholesterol; France; | 1973 |
[Hyperlipemias due to alcohol].
Topics: Adult; Alcoholism; Body Weight; Cardiovascular Diseases; Cholesterol; Dietary Carbohydrates; Ethanol | 1972 |
[Concentration of uric acid in the serum. Interrelationship between uric acid and age, weight, height, serum lipids, liver function, glucose tolerance as well as basic disorders].
Topics: Adult; Age Factors; Aged; Body Height; Body Weight; Cardiovascular Diseases; Female; Gastrointestina | 1974 |
Cardiovascular epidemiology in New Zealand and the Pacific.
Topics: Adult; Aged; Anthropometry; Blood Pressure; Cardiovascular Diseases; Cholesterol; Coronary Disease; | 1974 |
Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia.
Topics: Adolescent; Adult; Age Factors; Black People; Blood Glucose; Blood Pressure; Body Height; Body Weigh | 1973 |
[What sould be done for a high concentration of blood urea?].
Topics: Acute Kidney Injury; Anemia; Bone Diseases; Calcium; Cardiovascular Diseases; Creatinine; Gastrointe | 1974 |
[A new concept of preventive medicine using automatic data processing by computer. II. Application to diseases and risks of the digestive apparatus and to cardiovascular diseases and risks].
Topics: Alcoholism; Blood Glucose; Body Height; Body Weight; Cardiovascular Diseases; Cholesterol; Computers | 1969 |
[First results of the application to cardiovascular diseases of a new preventive medicine concept using automatic treatment of the information by computer].
Topics: Adult; Aged; Angina Pectoris; Body Weight; Cardiovascular Diseases; Computers; Diabetes Mellitus; El | 1971 |
[Neurological complications in uricopathy].
Topics: Adult; Athetosis; Cardiovascular Diseases; Chorea; Compulsive Behavior; Female; Humans; Intellectual | 1972 |
[Podagric arthropathy].
Topics: Adolescent; Adult; Albuminuria; Algeria; Cardiovascular Diseases; Child; Child, Preschool; Cholester | 1971 |
Platelet aggregation in several cardiovascular diseases determined with a modified screen filtration pressure method.
Topics: Adenine Nucleotides; Adolescent; Adult; Blood Platelets; Cardiovascular Diseases; Cell Aggregation; | 1970 |
[Blood cholesterol, glucose and uric acid levels in men and women born in 1927, 1912 and 1897].
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Cholesterol; Epidemiologic Methods; Female; Hum | 1969 |
[Risk factors for heart and circulatory diseases in an aged population. Pilot study in a home for the aged].
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol; Diet; Electrocardiography; Female; Geriatrics; He | 1969 |
[Dietary management of hazard factors in cardiovascular diseases].
Topics: Aged; Cardiovascular Diseases; Diabetes Complications; Diet Therapy; Humans; Hypercholesterolemia; H | 1970 |
[Benziodarone therapy in hyperuricemia in the aged].
Topics: Age Factors; Aged; Cardiovascular Diseases; Gout; Humans; Kidney Failure, Chronic; Respiratory Insuf | 1970 |
[Ischemic heart disease and so-called risk factors--results of an epidemiological study in Erfurt].
Topics: Angina Pectoris; Blood Glucose; Cardiovascular Diseases; Computers; Coronary Disease; Fatty Acids, E | 1971 |
[Contribution to the study of the ratio between blood cholesterol and blood uric acid in a group of arteriopathic patients].
Topics: Aged; Cardiovascular Diseases; Cholesterol; Female; Humans; Male; Middle Aged; Uric Acid | 1967 |
[Clinico-statistical considerations on the behavior of blood uric acid in subjects over 60].
Topics: Age Factors; Aged; Body Height; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Sex Fact | 1968 |
[Uric acid, hypertension, blood vessels and serum lipids].
Topics: Cardiovascular Diseases; Cholesterol; Diuretics; Humans; Hyperglycemia; Hypertension; Kidney Disease | 1968 |
[Gout in advanced age].
Topics: Age Factors; Aged; Allopurinol; Bone and Bones; Cardiovascular Diseases; Colchicine; Female; Gout; H | 1968 |
[Hyperuricemia in internal diseases].
Topics: Anemia; Cardiovascular Diseases; Gout; Hematologic Diseases; Humans; Hydrochlorothiazide; Kidney Dis | 1969 |
Newer diuretics in the treatment of cardiac or hepatic disease in elderly patients.
Topics: Ascites; Benzothiadiazines; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cardiovascular Diseases | 1966 |